Dokumentvorlage, Version vom 21.02.2019

Dossier zur Nutzenbewertung gemäß § 35a SGB V

Obinutuzumab (Gazyvaro®)

Roche Pharma AG

Modul 4 B - Anhang G

Patienten mit follikulärem Lymphom, die auf eine Behandlung mit Rituximab oder einem Rituximab-haltigen Regime nicht angesprochen haben oder während bzw. bis zu sechs Monate nach der Behandlung progredient wurden

Medizinischer Nutzen und
medizinischer Zusatznutzen,
Patientengruppen mit therapeutisch
bedeutsamem Zusatznutzen

Stand: 10.05.2021

Inhaltsverzeichnis

Seite

Anhang 4-G: Statistische Analysen

Anhang 4-G1: Subgruppenanalysen für Gesamtüberleben (OS), Progressionsfreies Überleben (PFS) (Bewertung durch IRC), Gesundheitszustand (EQ-5D-VAS) und Gesundheitsbezogene Lebensqualität (FACT-Lym).....1

1 (Anhang): Ergebnisse für OS - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel – Datenschnitt 30.11.2018 1

2 (Anhang): Ergebnisse für OS - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel – Datenschnitt 01.09.2014 6

3 (Anhang): Ergebnisse für PFS (Bewertung durch IRC) - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel 12

4 (Anhang): Ergebnisse für EQ-5D-VAS - Verbesserung des Gesundheitszustands um MID zehn - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel 18

5 (Anhang): Ergebnisse für EQ-5D-VAS - Verschlechterung des Gesundheitszustands um MID zehn - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel 22

6 (Anhang): Ergebnisse für FACT-G - Verbesserung der Gesundheitsbezogenen Lebensqualität um MID sechs - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel..... 26

7 (Anhang): Ergebnisse für FACT-G - Verschlechterung der Gesundheitsbezogenen Lebensqualität um MID sechs - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel..... 30

8 (Anhang): Ergebnisse für FACT-LymS - Verbesserung der Gesundheitsbezogenen Lebensqualität um MID fünf - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel..... 34

9 (Anhang): Ergebnisse für FACT-LymS - Verschlechterung der Gesundheitsbezogenen Lebensqualität um MID fünf - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel..... 38

Anhang 4-G2: Weitere Analysen zu Gesundheitszustand (EQ-5D-VAS) und Gesundheitsbezogene Lebensqualität (FACT-Lym): MMRM-Analysen und Mittelwerte pro Visite..... 42

10 (Anhang): Ergebnisse für EQ-5D-VAS MMRM - Hauptanalysen aus RCT mit dem zu bewertenden Arzneimittel 42

11 (Anhang): Ergebnisse für FACT-G MMRM - Hauptanalysen aus RCT mit dem zu bewertenden Arzneimittel 43
12 (Anhang): Ergebnisse für FACT-LymS MMRM - Hauptanalysen aus RCT mit dem zu bewertenden Arzneimittel 44
13 (Anhang): Ergebnisse für EQ-5D-VAS Mittelwerte pro Visite aus RCT mit dem zu bewertenden Arzneimittel 45
14 (Anhang): Ergebnisse für FACT-G Mittelwerte pro Visite aus RCT mit dem zu bewertenden Arzneimittel 46
15 (Anhang): Ergebnisse für FACT-LymS Mittelwerte pro Visite aus RCT mit dem zu bewertenden Arzneimittel 47
16 (Anhang): Ergebnisse für EQ-5D-VAS Mittelwerte pro Visite - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel 51
17 (Anhang): Ergebnisse für FACT-G Mittelwerte pro Visite - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel 60
18 (Anhang): Ergebnisse für FACT-LymS Mittelwerte pro Visite - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel 68
Anhang 4-G3: Generelle Verträglichkeit (Induktionsphase) 133
19 (Anhang): Ergebnisse für Patienten mit UE aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) - Subgruppenanalysen 133
20 (Anhang): Ergebnisse für Patienten mit SUE aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) - Subgruppenanalysen 134
21 (Anhang): Ergebnisse für Patienten mit Behandlungsabbruch wegen UE aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) - Subgruppenanalysen 135
22 (Anhang): Ergebnisse für Patienten mit nicht schwerem UE (Grad 1 - 2) aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) – Subgruppenanalysen 136
23 (Anhang): Ergebnisse für Patienten mit schwerem UE (Grad ≥ 3) aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) - Subgruppenanalysen 137
24 (Anhang): Ergebnisse für Patienten mit UE Grad 1 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) – Subgruppenanalysen 138
25 (Anhang): Ergebnisse für Patienten mit UE Grad 2 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) – Subgruppenanalysen 139
26 (Anhang): Ergebnisse für Patienten mit UE Grad 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) - Subgruppenanalysen 140
27 (Anhang): Ergebnisse für Patienten mit UE Grad 4 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) - Subgruppenanalysen 141
28 (Anhang): Ergebnisse für Patienten mit UE Grad 5 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) - Subgruppenanalysen 142
Anhang 4-G3: Generelle Verträglichkeit (gesamte Studiendauer) 143
29 (Anhang): Ergebnisse für Patienten mit UE aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen 143

30 (Anhang): Ergebnisse für Patienten mit SUE aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen 145

31 (Anhang): Ergebnisse für Patienten mit Behandlungsabbruch wegen UE aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen 146

32 (Anhang): Ergebnisse für Patienten mit nicht schweren UE (Grad 1 - 2) aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen 148

33 (Anhang): Ergebnisse für Patienten mit schweren UE (Grad ≥ 3) aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen 150

34 (Anhang): Ergebnisse für Patienten mit UE Grad 1 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) – Subgruppenanalysen 152

35 (Anhang): Ergebnisse für Patienten mit UE Grad 2 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen 154

36 (Anhang): Ergebnisse für Patienten mit UE Grad 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen 156

37 (Anhang): Ergebnisse für Patienten mit UE Grad 4 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen 157

38 (Anhang): Ergebnisse für Patienten mit UE Grad 5 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen 160

Anhang 4-G4: Spezifische Verträglichkeit: Unerwünschte Ereignisse von besonderem Interesse (AESI) – (Induktionsphase) 162

39 (Anhang): Ergebnisse für Akute Thrombozytopenie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 162

40 (Anhang): Ergebnisse für Gastrointestinale Perforation nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 165

41 (Anhang): Ergebnisse für Infektionen nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 168

42 (Anhang): Ergebnisse für Infusionsbedingte Reaktionen (IRR) nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 171

43 (Anhang): Ergebnisse für Neoplasie nach UE, SUE, Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 174

44 (Anhang): Ergebnisse für Neutropenie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 176

45 (Anhang): Ergebnisse für Progressive multifokale Leukenzephalopathie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 179

46 (Anhang): Ergebnisse für Thrombozytopenie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 182

47 (Anhang): Ergebnisse für Tumorlyse-Syndrom (TLS) nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 185

48 (Anhang): Ergebnisse für Kardiale Ereignisse nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 188

49 (Anhang): Ergebnisse für Zweitmalignom nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)..... 191

Anhang 4-G4: Spezifische Verträglichkeit: Unerwünschte Ereignisse von besonderem Interesse (AESI) –Time-to-event-Analysen (gesamte Studiendauer)..... 194

50 (Anhang): Ergebnisse für Akute Thrombozytopenie nach UE, SUE, UE Grad ≥ 3 mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 194

51 (Anhang): Ergebnisse für Gastrointestinale Perforation nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 202

52 (Anhang): Ergebnisse für Infektionen nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 210

53 (Anhang): Ergebnisse für Infusionsbedingte Reaktionen (IRR) nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 214

54 (Anhang): Ergebnisse für Neoplasien nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 222

55 (Anhang): Ergebnisse für Neutropenie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)..... 226

56 (Anhang): Ergebnisse für Progressive multifokale Leukenzephalopathie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 230

57 (Anhang): Ergebnisse für Thrombozytopenie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 238

58 (Anhang): Ergebnisse für Tumorlyse-Syndrom (TLS) nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 244

59 (Anhang): Ergebnisse für Kardiale Ereignisse nach UE, SUE, UE Grad ≥ 3 mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 251

60 (Anhang): Ergebnisse für Zweitmalignom nach UE, SUE, UE Grad ≥ 3 mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)..... 255

61 (Anhang): Ergebnisse für Hepatitis-B (HBV) Reaktivierung nach UE aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)..... 261

62 (Anhang): Ergebnisse für verlängerte Neutropenie nach UE aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)..... 262

63 (Anhang): Ergebnisse für spät einsetzende Neutropenie nach UE aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 263

Anhang 4-G5: Spezifische Verträglichkeit: UE nach SOC/PT (Induktionsphase)..... 264

64 (Anhang): Ergebnisse für UE bei ≥ 10 % der Patienten in einem Studienarm nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 264

65 (Anhang): Ergebnisse für UE bei ≥ 10 % der Patienten in einem Studienarm nach SOC/PT und mit statistisch signifikantem Ergebnis für die Gesamtpopulation nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 266

66 (Anhang): Ergebnisse für SUE bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 269

67 (Anhang): Ergebnisse SUE bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT und mit statistisch signifikantem Ergebnis für die Gesamtpopulation nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 270

68 (Anhang): Ergebnisse für UE Grad ≥ 3 bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 271

69 (Anhang): Ergebnisse für UE Grad ≥ 3 bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT und mit statistisch signifikantem Ergebnis für die Gesamtpopulation nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 272

70 (Anhang): Ergebnisse für Abbruchgründe (UE) nach SOC aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 274

71 (Anhang): Ergebnisse für Abbruchgründe (UE) nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 275

72 (Anhang): Ergebnisse für Abbruchgründe (UE) nach SOC/PT nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) 277

Anhang 4-G5: Spezifische Verträglichkeit: UE nach SOC/PT (gesamte Studiendauer) 321

73 (Anhang): Ergebnisse für UE bei ≥ 10 % der Patienten in einem Studienarm nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 321

74 (Anhang): Ergebnisse für UE bei ≥ 10 % der Patienten in einem Studienarm nach SOC/PT und mit statistisch signifikantem Ergebnis für die Gesamtpopulation nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 323

75 (Anhang): Ergebnisse für SUE bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 372

76 (Anhang): Ergebnisse für SUE bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT und mit statistisch signifikantem Ergebnis für die Gesamtpopulation nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 373

77 (Anhang): Ergebnisse für UE Grad ≥ 3 bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 383

78 (Anhang): Ergebnisse für UE Grad ≥ 3 bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT und mit statistisch signifikantem Ergebnis für die Gesamtpopulation nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 384

79 (Anhang): Ergebnisse für Abbruchgründe (UE) nach SOC aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 401

80 (Anhang): Ergebnisse für Abbruchgründe (UE) nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 402

81 (Anhang): Ergebnisse für Abbruchgründe (UE) nach SOC/PT nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) 407

Anhang 4-G: Statistische Analysen

Anhang 4-G1: Subgruppenanalysen für Gesamtüberleben (OS), Progressionsfreies Überleben (PFS) (Bewertung durch IRC), Gesundheitszustand (EQ-5D-VAS) und Gesundheitsbezogene Lebensqualität (FACT-Lym)

1 (Anhang): Ergebnisse für OS - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel – Datenschnitt 30.11.2018

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: Overall Survival
MODEL: Unstratified Analysis STUDY: GO01297
Time to Event Analysis by Subgroups (Efficacy)

		G-Benda (N=164)												Benda (N=171)										G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	66	40,2	98	59,8	32,9	22,7	50,2	NE	67,7	NE	171	100,0	85	49,7	86	50,3	25,0	16,1	31,2	60,3	47,8	87,8	0,0371	0,71	0,52	0,98		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	36	39,6	55	60,4	38,3	24,0	53,3	NE	60,3	NE	98	57,3	44	44,9	54	55,1	26,5	15,4	34,2	65,9	42,2	NE	0,1507	0,72	0,47	1,13		Convergence criterion (GCONV=1E-8) satisfied.	0,8689
	Female	73	44,5	30	41,1	43	58,9	23,7	11,9	56,8	88,3	60,6	NE	73	42,7	41	56,2	32	43,8	21,9	10,9	32,5	56,5	34,3	87,8	0,1312	0,70	0,43	1,12		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	17	27,4	45	72,6	57,1	16,3	NE	NE	NE	NE	63	36,8	16	25,4	47	74,6	56,5	26,5	NE	NE	NE	NE	0,8713	1,06	0,53	2,09		Convergence criterion (GCONV=1E-8) satisfied.	0,1712
	>= 60 years	102	62,2	49	48,0	53	52,0	31,3	20,3	43,4	71,3	51,1	NE	108	63,2	69	63,9	39	36,1	17,9	10,9	25,3	42,2	30,9	60,1	0,0080	0,61	0,42	0,88		Convergence criterion (GCONV=1E-8) satisfied.	
Race/ethnicity	White	144	87,8	59	41,0	85	59,0	38,3	21,9	51,4	88,3	67,7	NE	148	86,5	71	48,0	77	52,0	26,5	17,9	31,8	64,6	45,9	92,0	0,1170	0,76	0,54	1,07		Convergence criterion (GCONV=1E-8) satisfied.	0,0535
	Other	8	4,9	2	25,0	6	75,0	NE	2,8	NE	NE	2,8	NE	8	4,7	6	75,0	2	25,0	14,0	9,6	25,0	25,0	9,6	60,1	0,0285	0,19	0,04	0,98		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	12	7,3	5	41,7	7	58,3	32,4	22,1	NE	NE	31,3	NE	15	8,8	8	53,3	7	46,7	25,3	6,5	65,9	65,9	10,1	79,5	0,6702	0,78	0,26	2,40		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	37	47,4	41	52,6	25,3	19,6	39,8	62,1	44,3	NE	79	46,2	39	49,4	40	50,6	18,5	11,6	28,8	65,9	32,5	NE	0,7052	0,92	0,58	1,44		Convergence criterion (GCONV=1E-8) satisfied.	0,0005
	North America	67	40,9	16	23,9	51	76,1	75,0	27,4	NE	NE	88,3	NE	74	43,3	40	54,1	34	45,9	25,0	14,0	34,0	56,5	34,2	79,3	<.0001	0,33	0,18	0,59		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	13	68,4	6	31,6	12,0	0,9	57,1	60,3	12,0	71,3	18	10,5	6	33,3	12	66,7	40,9	5,0	NE	NE	40,9	NE	0,0777	2,33	0,88	6,16		Convergence criterion (GCONV=1E-8) satisfied.	
Body mass index	Underweight (< 18.5)													1	0,6	1	100,0			13,7	NE	NE	13,7	NE	NE		NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,4120

	Normal weight (18.5 -< 25)	55	33,5	23	41,8	32	58,2	24,0	6,3	51,1	88,3	51,1	NE	51	29,8	25	49,0	26	51,0	28,8	14,0	53,9	69,3	48,2	NE	0,6251	0,87	0,49	1,53		Convergence criterion (GCONV=1E-8) satisfied.	
	Overweight (25 - < 30)	60	36,6	29	48,3	31	51,7	38,3	20,2	51,4	71,3	51,4	NE	58	33,9	29	50,0	29	50,0	21,4	9,3	30,9	42,2	27,9	NE	0,2574	0,74	0,44	1,25		Convergence criterion (GCONV=1E-8) satisfied.	
	Obese (>= 30)	46	28,0	13	28,3	33	71,7	63,3	15,1	NE	NE	67,7	NE	55	32,2	27	49,1	28	50,9	28,1	14,6	39,8	64,3	39,8	NE	0,0392	0,50	0,26	0,98		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	3	1,8	1	33,3	2	66,7	34,9	34,9	NE	NE	34,9	NE	6	3,5	3	50,0	3	50,0	26,5	7,4	60,1	60,1	7,4	NE	0,4061	0,39	0,04	3,89		Convergence criterion (GCONV=1E-8) satisfied.	
Baseline ECOG Performance Status score	0-1	156	95,1	63	40,4	93	59,6	34,6	23,7	51,1	88,3	67,7	NE	162	94,7	80	49,4	82	50,6	26,5	16,1	31,8	64,6	47,8	87,8	0,0570	0,73	0,52	1,01		Convergence criterion (GCONV=1E-8) satisfied.	0,2649
	2	8	4,9	3	37,5	5	62,5	2,8	0,9	NE	NE	0,9	NE	7	4,1	5	71,4	2	28,6	14,7	1,8	25,0	25,0	1,8	NE	0,3366	0,50	0,12	2,12		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing													2	1,2			2	100,0	NE	NE	NE	NE	NE	NE			NE	NE	NE			
Independence status (Katz ADL)	Independent (5-6)	70	42,7	25	35,7	45	64,3	27,4	20,3	57,1	NE	57,6	NE	72	42,1	37	51,4	35	48,6	18,5	11,6	30,9	55,5	31,8	NE	0,0446	0,60	0,36	0,99		Convergence criterion (GCONV=1E-8) satisfied.	0,6664
	Very dependent (0-2)	3	1,8	1	33,3	2	66,7	5,4	5,4	NE	NE	5,4	NE	1	0,6			1	100,0	NE	NE	NE	NE	NE	NE	0,5637	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	

	Missing	91	55,5	40	44,0	51	56,0	40,2	20,2	56,8	88,3	60,6	NE	98	57,3	48	49,0	50	51,0	25,3	15,8	39,8	79,3	48,2	NE	0,2747	0,79	0,52	1,21		Convergence criterion (GCONV=1E-8) satisfied.	
Best response to prior therapy	CR/PR	135	82,3	58	43,0	77	57,0	32,4	21,8	45,8	88,3	60,6	NE	138	80,7	65	47,1	73	52,9	26,5	18,5	34,0	69,3	48,2	92,0	0,2691	0,82	0,57	1,17		Convergence criterion (GCONV=1E-8) satisfied.	0,1415
	SD	22	13,4	7	31,8	15	68,2	47,4	5,6	NE	NE	47,4	NE	20	11,7	10	50,0	10	50,0	27,9	6,9	34,3	55,5	12,0	NE	0,1721	0,52	0,20	1,36		Convergence criterion (GCONV=1E-8) satisfied.	
	PD	7	4,3	1	14,3	6	85,7	NE	14,3	NE	NE	14,3	NE	8	4,7	6	75,0	2	25,0	12,8	7,1	42,2	28,4	7,1	NE	0,0649	0,17	0,02	1,43		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing (UE)													5	2,9	4	80,0	1	20,0	21,9	4,0	83,4	47,8	4,0	83,4			NE	NE	NE			
FLIPI Histologic Tumor Grade	1	67	34,8	22	38,6	35	61,4	47,4	26,8	71,1	NE	62,1	NE	64	31,6	28	51,9	26	48,1	12,0	8,3	30,9	42,2	27,9	NE	0,0404	0,56	0,32	0,98		Convergence criterion (GCONV=1E-8) satisfied.	0,2606
	2	73	44,5	30	41,1	43	58,9	27,4	19,6	51,4	88,3	56,8	NE	70	40,9	31	44,3	39	55,7	31,8	23,4	47,8	79,3	48,0	NE	0,7519	0,92	0,56	1,52		Convergence criterion (GCONV=1E-8) satisfied.	
	3													5	2,9	4	80,0	1	20,0	18,5	14,0	22,3	19,4	14,0	NE			NE	NE	NE			
	3a	26	15,9	10	38,5	16	61,5	14,1	5,6	56,8	NE	16,3	NE	35	20,5	21	60,0	14	40,0	21,6	7,4	34,0	55,5	25,0	87,8	0,1355	0,56	0,26	1,21		Convergence criterion (GCONV=1E-8) satisfied.	
	Unknown	5	3,0	3	60,0	2	40,0	57,6	14,3	NE	60,6	14,3	NE	6	3,5	1	16,7	5	83,3	60,2	60,2	NE	NE	60,2	NE	0,4748	2,24	0,23	21,71		Convergence criterion (GCONV=1E-8) satisfied.	
	Variants	3	1,8	1	33,3	2	66,7	2,8	2,8	NE	NE	2,8	NE	1	0,6			1	100,0	NE	NE	NE	NE	NE	NE	0,5637	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	12	28,6	30	71,4	57,6	20,3	NE	NE	88,3	NE	35	20,5	13	37,1	22	62,9	42,2	9,6	79,3	NE	60,1	NE	0,4484	0,74	0,34	1,62		Convergence criterion (GCONV=1E-8) satisfied.	0,9673

	Intermediate (2)	51	31,1	19	37,3	32	62,7	23,8	14,9	67,7		NE	47,4		NE	60	35,1	28	46,7	32	53,3	23,4	14,1	34,0	57,2	32,5		NE	0,3103	0,74	0,41	1,33		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	32	50,0	32	50,0	32,9	15,1	51,4	71,3		53,3		NE	69	40,4	41	59,4	28	40,6	18,5	10,1	29,1	53,4	30,9	65,9		0,0865	0,67	0,42	1,06		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	3	42,9	4	57,1	31,3	14,3		NE	NE	14,3		NE	7	4,1	3	42,9	4	57,1	25,3	22,3		NE		NE	22,3		NE	0,7635	0,78	0,16	3,90		Convergence criterion (GCONV=1E-8) satisfied.	
Fc gamma receptor IIa	131HH	43	26,2	17	39,5	26	60,5	39,8	22,7	60,6		NE	44,3		NE	37	21,6	16	43,2	21	56,8	39,8	14,6	60,2	83,4	47,8		NE	0,8954	0,96	0,48	1,89		Convergence criterion (GCONV=1E-8) satisfied.	0,5539
	131HR	70	42,7	27	38,6	43	61,4	34,9	20,2	57,6	88,3		71,1		NE	81	47,4	40	49,4	41	50,6	26,5	14,1	34,2	64,6	37,5		NE	0,0852	0,65	0,40	1,07		Convergence criterion (GCONV=1E-8) satisfied.	
	131RR	35	21,3	14	40,0	21	60,0	51,4	4,8	57,7		NE	57,1		NE	35	20,5	20	57,1	15	42,9	16,1	6,3	31,8	56,5	25,3		NE	0,1313	0,59	0,30	1,18		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	16	9,8	8	50,0	8	50,0	15,6	4,6	32,9		NE	14,9		NE	18	10,5	9	50,0	9	50,0	14,7	7,4	21,6	34,3	14,0		NE	0,6462	0,80	0,31	2,08		Convergence criterion (GCONV=1E-8) satisfied.	
Fc gamma receptor IIIa	158VV	20	12,2	13	65,0	7	35,0	22,1	11,1	40,2	51,1		22,1	62,8		30	17,5	20	66,7	10	33,3	13,7	8,5	31,2	34,0	14,6	55,5		0,5402	0,80	0,40	1,63		Convergence criterion (GCONV=1E-8) satisfied.	0,5657
	158VF	68	41,5	23	33,8	45	66,2	44,3	23,8	71,3		NE	71,3		NE	69	40,4	32	46,4	37	53,6	25,3	10,1	33,3	65,9	33,3		NE	0,0551	0,59	0,35	1,02		Convergence criterion (GCONV=1E-8) satisfied.	
	158FF	60	36,6	22	36,7	38	63,3	51,4	14,3	62,1		NE	62,1		NE	54	31,6	24	44,4	30	55,6	39,8	19,4	60,1	83,4	60,1		NE	0,5742	0,85	0,47	1,51		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	16	9,8	8	50,0	8	50,0	15,6	4,6	32,9		NE	14,9		NE	18	10,5	9	50,0	9	50,0	14,7	7,4	21,6	34,3	14,0		NE	0,6462	0,80	0,31	2,08		Convergence criterion (GCONV=1E-8) satisfied.	
Fc gamma receptor IIb/IIc	232II	107	65,2	40	37,4	67	62,6	45,8	23,8	60,3		NE	71,1		NE	111	64,9	56	50,5	55	49,5	23,4	11,6	34,0	64,6	47,8	92,0		0,0300	0,64	0,43	0,96		Convergence criterion (GCONV=1E-8) satisfied.	0,1702
	232IT	39	23,8	18	46,2	21	53,8	34,6	9,9	51,1	60,6		40,2		NE	38	22,2	17	44,7	21	55,3	28,8	14,6	42,2	83,4	30,9		NE	0,9143	1,04	0,53	2,01		Convergence criterion (GCONV=1E-8) satisfied.	
	232TT	1	0,6			1	100,0		NE	NE		NE		NE	NE	4	2,3	3	75,0	1	25,0	25,0	25,0	79,3	34,2	25,0	79,3		0,1823	<0,01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	17	10,4	8	47,1	9	52,9	16,3	4,6	32,9		NE	14,9		NE	18	10,5	9	50,0	9	50,0	14,7	7,4	21,6	34,3	14,0		NE	0,5263	0,73	0,28	1,91		Convergence criterion (GCONV=1E-8) satisfied.	
Absolute lymphocyte count	>= median	76	46,3	25	32,9	51	67,1	51,4	22,1	71,1		NE	74,0		NE	86	50,3	38	44,2	48	55,8	27,9	19,4	37,5	79,3	53,4		NE	0,1094	0,66	0,40	1,10		Convergence criterion (GCONV=1E-8) satisfied.	0,8177
	< median	88	53,7	41	46,6	47	53,4	31,3	19,6	44,3	75,0		51,1		NE	82	48,0	46	56,1	36	43,9	21,4	10,1	31,2	48,2	34,2	79,5		0,1252	0,72	0,47	1,10		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing															3	1,8	1	33,3	2	66,7		9,6	0,6		NE		NE	9,6		NE		NE	NE	NE		
Time from initial NHL diagnosis to randomization	< 6 months	6	3,7	1	16,7	5	83,3		NE	62,1		NE	62,1		NE	6	3,5	4	66,7	2	33,3		6,5	4,0	64,3	38,0	4,0		NE	0,0763	0,17	0,02	1,55		Convergence criterion (GCONV=1E-8) satisfied.	0,2119
	6-12 months	11	6,7	4	36,4	7	63,6	38,3	3,9		NE		NE	3,9		NE	19	11,1	8	42,1	11	57,9	27,5	7,4	34,3		NE	27,5		NE	0,9458	0,96	0,29	3,21		Convergence criterion (GCONV=1E-8) satisfied.	
	> 12 months	147	89,6	61	41,5	86	58,5	32,4	22,1	47,4	88,3		62,8		NE	146	85,4	73	50,0	73	50,0	25,3	16,1	32,5	60,3	47,8	87,8		0,0772	0,74	0,52	1,04		Convergence criterion (GCONV=1E-8) satisfied.	


Beta 2 microglobulin	>= 3.5 mg/L	30	18,3	18	60,0	12	40,0	19,6	4,8	31,3	50,2	21,8	71,1	34	19,9	23	67,6	11	32,4	15,8	7,1	21,4	34,2	19,4	55,5	0,6353	0,86	0,46	1,60		Convergence criterion (GCONV=1E-8) satisfied.	0,6484
	< 3.5 mg/L	128	78,0	47	36,7	81	63,3	39,8	24,0	57,1	NE	74,0	NE	124	72,5	56	45,2	68	54,8	28,8	21,6	42,2	79,3	56,5	92,0	0,1076	0,73	0,49	1,07		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	6	3,7	1	16,7	5	83,3	NE	60,6	NE	NE	60,6	NE	13	7,6	6	46,2	7	53,8	8,3	1,0	60,3	60,3	7,4	NE	0,1110	0,21	0,02	1,75		Convergence criterion (GCONV=1E-8) satisfied.	
Prior therapies	<= 2	134	81,7	53	39,6	81	60,4	38,3	24,0	51,4	NE	62,1	NE	133	77,8	64	48,1	69	51,9	27,5	17,9	33,3	64,3	48,0	NE	0,0764	0,72	0,50	1,04		Convergence criterion (GCONV=1E-8) satisfied.	0,9800
	> 2	30	18,3	13	43,3	17	56,7	23,7	5,4	74,0	88,3	23,8	NE	38	22,2	21	55,3	17	44,7	16,1	9,6	27,9	48,2	26,5	92,0	0,4711	0,77	0,39	1,55		Convergence criterion (GCONV=1E-8) satisfied.	
Refractory Type	Rituximab + Chemotherapy	139	84,8	60	43,2	79	56,8	32,4	20,3	44,3	88,3	60,3	NE	129	75,4	65	50,4	64	49,6	25,0	14,7	31,8	60,3	47,8	87,8	0,1838	0,79	0,56	1,12		Convergence criterion (GCONV=1E-8) satisfied.	0,1042
	Rituximab Monotherapy	25	15,2	6	24,0	19	76,0	74,0	0,9	NE	NE	74,0	NE	42	24,6	28	47,6	22	52,4	26,9	13,7	34,0	64,3	29,1	NE	0,8255	0,36	0,14	0,92		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical cut-off:
30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_eff_tte.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_eff_tte_sg_OS_FOLY_IT_30NOV2018_01297.xls 07OCT2019 14:22

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: Overall Survival
STUDY: GO01297

Geographic region (N=335)



Patients at risk											
G-Benda, Western Europe	78	68	62	53	46	40	30	21	11	2	
G-Benda, North America	67	62	59	50	48	43	37	32	20	9	
G-Benda, Other	19	15	13	12	12	12	9	6	2	2	
Benda, Western Europe	79	66	55	46	41	36	32	20	11	2	
Benda, North America	74	60	52	42	35	31	24	19	14	6	1
Benda, Other	18	17	17	15	15	11	9	6	3		

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_sg_OS_FOLY_IT_30NOV2018_01297.pdf
07OCT2019 15:12

2 (Anhang): Ergebnisse für OS - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel – Datenschnitt 01.09.2014

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: Overall Survival
MODEL: Unstratified Analysis
STUDY: GO01207
Time to Event Analysis by Subgroups (Efficacy)

		G-Benda (N=155)												Benda (N=166)												G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	155	100,0	25	16,1	130	83,9	NE	22,1	NE	NE	NE	NE	166	100,0	36	21,7	130	78,3	25,3	19,4	39,8	NE	39,8	NE	0,1662	0,70	0,42	1,16		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	85	54,8	12	14,1	73	85,9	NE	21,8	NE	NE	NE	NE	95	57,2	18	18,9	77	81,1	29,1	17,9	NE	NE	34,3	NE	0,2564	0,66	0,32	1,36		Convergence criterion (GCONV=1E-8) satisfied.	0,8151
	Female	70	45,2	13	18,6	57	81,4	NE	11,9	NE	NE	NE	NE	71	42,8	18	25,4	53	74,6	21,9	10,9	39,8	39,8	37,5	NE	0,4102	0,74	0,36	1,52		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	59	38,1	7	11,9	52	88,1	NE	15,1	NE	NE	NE	NE	61	36,7	6	9,8	55	90,2	39,8	37,5	NE	NE	39,8	NE	0,7058	1,23	0,41	3,68		Convergence criterion (GCONV=1E-8) satisfied.	0,2096
	>= 60 years	96	61,9	18	18,8	78	81,3	NE	20,2	NE	NE	NE	NE	105	63,3	30	28,6	75	71,4	19,6	12,0	25,3	42,2	25,3	NE	0,0611	0,58	0,32	1,03		Convergence criterion (GCONV=1E-8) satisfied.	
Race/ethnicity	White	139	89,7	23	16,5	116	83,5	NE	21,8	NE	NE	NE	NE	143	86,1	32	22,4	111	77,6	25,3	17,9	39,8	NE	39,8	NE	0,2029	0,71	0,41	1,21		Convergence criterion (GCONV=1E-8) satisfied.	0,8700
	Other	7	4,5	1	14,3	6	85,7	NE	2,8	NE	NE	2,8	NE	8	4,8	1	12,5	7	87,5	NE	9,6	NE	NE	9,6	NE	0,8995	1,20	0,07	19,12		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	9	5,8	1	11,1	8	88,9	NE	22,1	NE	NE	22,1	NE	15	9,0	3	20,0	12	80,0	25,3	6,5	NE	NE	25,3	NE	0,6000	0,55	0,06	5,35		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	72	46,5	14	19,4	58	80,6	22,7	14,6	NE	NE	NE	NE	78	47,0	20	25,6	58	74,4	19,4	10,9	42,2	42,2	34,3	NE	0,5747	0,82	0,41	1,64		Convergence criterion (GCONV=1E-8) satisfied.	0,0184
	North America	65	41,9	7	10,8	58	89,2	NE	26,8	NE	NE	NE	NE	73	44,0	16	21,9	57	78,1	25,3	19,6	39,8	NE	37,5	NE	0,0401	0,41	0,17	0,99		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	18	11,6	4	22,2	14	77,8	23,8	0,9	NE	NE	23,8	NE	15	9,0			15	100,0	NE	NE	NE	NE	NE	NE	0,0677	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Body mass index	Underweight (< 18.5)													1	0,6			1	100,0	NE	NE	NE	NE	NE	NE		NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,2665
	Normal weight (18.5 -< 25)	54	34,8	12	22,2	42	77,8	22,7	9,9	NE	NE	NE	NE	50	30,1	9	18,0	41	82,0	NE	10,9	NE	NE	NE	NE	0,6272	1,24	0,52	2,94		Convergence criterion (GCONV=1E-8) satisfied.	
	Overweight (25 - < 30)	53	34,2	7	13,2	46	86,8	NE	20,2	NE	NE	NE	NE	56	33,7	14	25,0	42	75,0	21,6	9,3	42,2	42,2	34,3	NE	0,1209	0,49	0,20	1,23		Convergence criterion (GCONV=1E-8) satisfied.	
	Obese (>= 30)	46	29,7	6	13,0	40	87,0	NE	15,1	NE	NE	NE	NE	52	31,3	12	23,1	40	76,9	29,1	14,6	39,8	39,8	37,5	NE	0,1802	0,52	0,19	1,38		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	2	1,3			2	100,0	NE	NE	NE	NE	NE	NE	7	4,2	1	14,3	6	85,7	NE	7,4	NE	NE	7,4	NE	0,5637	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Baseline ECOG Performance Status Score	0-1	147	94,8	23	15,6	124	84,4	NE	22,1	NE	NE	NE	NE	NE	157	94,6	34	21,7	123	78,3	25,3	19,6	39,8	NE	39,8	NE	0,1522	0,68	0,40	1,16		Convergence criterion (GCONV=1E-8) satisfied.	0,8072
	2	8	5,2	2	25,0	6	75,0	NE	0,9	NE	NE	0,9	NE	NE	7	4,2	2	28,6	5	71,4	19,4	1,8	NE	NE	1,8	NE	0,9387	1,08	0,15	7,72		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing														2	1,2			2	100,0	NE	NE	NE	NE	NE	NE		NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Independence status (Katz ADL)	Independent (5-6)	64	41,3	9	14,1	55	85,9	22,7	19,6	NE	NE	NE	NE	NE	67	40,4	11	16,4	56	83,6	19,6	12,0	NE	NE	NE	NE	0,4917	0,73	0,30	1,78		Convergence criterion (GCONV=1E-8) satisfied.	NE
	Very dependent (0-2)	3	1,9	1	33,3	2	66,7	5,4	NE	NE	5,4	NE	NE	NE	1	0,6			1	100,0	NE	NE	NE	NE	NE	NE		NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	88	56,8	15	17,0	73	83,0	NE	21,8	NE	NE	NE	NE	NE	88	59,0	25	25,5	73	74,5	29,1	15,8	39,8	NE	39,8	NE	0,1441	0,62	0,33	1,18		Convergence criterion (GCONV=1E-8) satisfied.	
Best response to prior therapy	CR/PR	126	81,3	21	16,7	105	83,3	NE	20,3	NE	NE	NE	NE	NE	133	80,1	29	21,8	104	78,2	25,3	17,9	39,8	NE	37,5	NE	0,3008	0,74	0,42	1,31		Convergence criterion (GCONV=1E-8) satisfied.	0,9007
	SD	22	14,2	3	13,6	19	86,4	NE	5,6	NE	NE	NE	NE	NE	20	12,0	4	20,0	16	80,0	34,3	7,4	NE	NE	34,3	NE	0,4401	0,56	0,12	2,51		Convergence criterion (GCONV=1E-8) satisfied.	
	PD	7	4,5	1	14,3	6	85,7	NE	14,3	NE	NE	14,3	NE	NE	8	4,8	1	12,5	7	87,5	42,2	NE	NE	42,2	NE	NE	0,3711	>999,99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing (UE)														5	3,0	2	40,0	3	60,0	21,9	4,0	NE	NE	4,0	NE		NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Histologic grade (follicular)	1	54	34,8	7	13,0	47	87,0	NE	21,8	NE	NE	NE	NE	NE	61	30,7	14	27,5	37	72,5	12,0	8,3	42,2	42,2	NE	NE	0,0289	0,38	0,15	0,94		Convergence criterion (GCONV=1E-8) satisfied.	0,0919
	2	69	44,5	11	15,9	58	84,1	NE	15,1	NE	NE	NE	NE	NE	68	41,0	13	19,1	55	80,9	34,3	21,4	39,8	39,8	37,5	NE	0,8332	0,92	0,41	2,05		Convergence criterion (GCONV=1E-8) satisfied.	
	3														5	3,0	1	20,0	4	80,0	19,4	19,4	NE	NE	19,4	NE		NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	3a	24	15,5	5	20,8	19	79,2	NE	5,6	NE	NE	NE	NE	NE	35	21,1	8	22,9	27	77,1	25,3	7,4	NE	NE	25,3	NE	0,7220	0,82	0,27	2,50		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown/Variants	8	5,2	2	25,0	6	75,0	14,3	2,8	NE	NE	2,8	NE	NE	7	4,2			7	100,0	NE	NE	NE	NE	NE	NE	0,2457	>999,99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	27,1	6	14,3	36	85,7	NE	11,9	NE	NE	NE	NE	NE	34	20,5	8	23,5	26	76,5	39,8	9,5	42,2	42,2	39,8	NE	0,5076	0,70	0,24	2,03		Convergence criterion (GCONV=1E-8) satisfied.	0,9742
	Intermediate (2)	47	30,3	8	17,0	39	83,0	23,8	14,6	NE	NE	23,8	NE	NE	58	34,9	13	22,4	45	77,6	21,9	14,1	NE	NE	37,5	NE	0,5411	0,76	0,31	1,84		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	60	38,7	10	16,7	50	83,3	NE	15,1	NE	NE	NE	NE	NE	67	40,4	14	20,9	53	79,1	25,3	14,6	NE	NE	NE	NE	0,3519	0,68	0,30	1,54		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	6	3,9	1	16,7	5	83,3	14,3	14,3	NE	NE	14,3	NE	NE	7	4,2	1	14,3	6	85,7	25,3	25,3	NE	NE	25,3	NE	0,9191	1,15	0,07	18,59		Convergence criterion (GCONV=1E-8) satisfied.	
Fc gamma receptor IIa	131HH	42	27,1	6	14,3	36	85,7	NE	20,3	NE	NE	NE	NE	NE	36	21,7	4	11,1	32	88,9	39,8	14,6	NE	NE	39,8	NE	0,5307	1,50	0,42	5,33		Convergence criterion (GCONV=1E-8) satisfied.	0,2163
	131HR	66	42,6	12	18,2	54	81,8	NE	14,6	NE	NE	NE	NE	NE	78	47,0	17	21,8	61	78,2	23,4	14,1	42,2	42,2	37,5	NE	0,3657	0,71	0,34	1,49		Convergence criterion (GCONV=1E-8) satisfied.	

	131RR	34	21,9	4	11,8	30	88,2		NE	4,8	NE		NE		NE	34	20,5	11	32,4	23	67,6	25,3	6,3	34,3		NE	25,3		NE	0,0759	0,37	0,12	1,16			Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	13	8,4	3	23,1	10	76,9	19,6		4,6	NE		NE	11,9	NE	18	10,8	4	22,2	14	77,8	20,6	7,4		NE		NE	17,9		NE	0,8924	1,11	0,24	5,05			Convergence criterion (GCONV=1E-8) satisfied.	
Fc gamma receptor IIIa	158VV	19	12,3	5	26,3	14	73,7	21,8		11,1	NE		NE	20,3	NE	30	18,1	10	33,3	20	66,7	14,6	8,5	42,2		42,2	23,4		NE	0,7867	0,86	0,28	2,59			Convergence criterion (GCONV=1E-8) satisfied.	0,7207
	158VF	65	41,9	8	12,3	57	87,7		NE	22,7	NE		NE		NE	65	39,2	12	18,5	53	81,5	25,3	10,1		NE		NE		NE	0,2301	0,58	0,24	1,42			Convergence criterion (GCONV=1E-8) satisfied.	
	158FF	58	37,4	9	15,5	49	84,5		NE	14,3	NE		NE		NE	53	31,9	10	18,9	43	81,1	37,5	19,4		NE		NE	37,5		NE	0,7381	0,86	0,35	2,11			Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	13	8,4	3	23,1	10	76,9	19,6		4,6	NE		NE	11,9	NE	18	10,8	4	22,2	14	77,8	20,6	7,4		NE		NE	17,9		NE	0,8924	1,11	0,24	5,05			Convergence criterion (GCONV=1E-8) satisfied.	
Fc gamma receptor IIb/IIc	232II	104	67,1	15	14,4	89	85,6		NE	22,1	NE		NE		NE	107	64,5	25	23,4	82	76,6	23,4	12,0	37,5		NE	37,5		NE	0,0591	0,54	0,29	1,03			Convergence criterion (GCONV=1E-8) satisfied.	0,4460
	232IT	36	23,2	7	19,4	29	80,6	26,8		9,9	NE		NE	26,8	NE	37	22,3	7	18,9	30	81,1	39,8	14,6	42,2		39,8	39,8		42,2	0,8100	1,14	0,40	3,28			Convergence criterion (GCONV=1E-8) satisfied.	
	232TT	1	0,6			1	100,0		NE	NE	NE		NE		NE	4	2,4			4	100,0		NE	NE		NE		NE	NE		NE	NE	NE	NE	NE			Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	14	9,0	3	21,4	11	78,6	19,6		4,6	NE		NE	19,6	NE	18	10,8	4	22,2	14	77,8	20,6	7,4		NE		NE	17,9		NE	0,9594	0,96	0,21	4,35			Convergence criterion (GCONV=1E-8) satisfied.	
Absolute lymphocyte count	>= median	72	46,5	9	12,5	63	87,5		NE	22,1	NE		NE		NE	84	50,6	13	15,5	71	84,5	37,5	19,6		NE		NE	37,5		NE	0,3841	0,69	0,29	1,61			Convergence criterion (GCONV=1E-8) satisfied.	0,9849
	< median	83	53,5	16	19,3	67	80,7		NE	14,3	NE		NE		NE	79	47,6	22	27,8	57	72,2	25,3	10,9	39,8		39,8	34,3		NE	0,2915	0,71	0,37	1,35			Convergence criterion (GCONV=1E-8) satisfied.	
	Missing															3	1,8	1	33,3	2	66,7		9,6	9,6		NE		NE	9,6		NE			NE		NE			Convergence criterion (GCONV=1E-8) satisfied.	
Time from initial NHL diagnosis to randomization	< 6 months	6	3,9			6	100,0		NE	NE	NE		NE		NE	6	3,6	2	33,3	4	66,7		6,5	4,0		NE		NE	4,0		NE	0,1385	<0,01	0,00		NE		Convergence criterion (GCONV=1E-8) satisfied.	0,0479
	6-12 months	11	7,1			11	100,0		NE	NE	NE		NE		NE	18	10,8	4	22,2	14	77,8	34,3	7,4		NE	34,3	34,3		NE	0,1628	<0,01	0,00		NE		Convergence criterion (GCONV=1E-8) satisfied.	
	> 12 months	138	89,0	25	18,1	113	81,9		NE	20,3	NE		NE		NE	142	85,5	30	21,1	112	78,9	25,3	19,4	42,2		NE	39,8		NE	0,4522	0,82	0,48	1,39			Convergence criterion (GCONV=1E-8) satisfied.	
Beta 2 microglobulin	>= 3.5 mg/L	28	18,1	9	32,1	19	67,9	15,1		3,8	22,7		NE	21,8	NE	35	21,1	10	28,6	25	71,4	19,4	10,1		NE		NE	19,6		NE	0,7068	1,19	0,48	2,93			Convergence criterion (GCONV=1E-8) satisfied.	0,3069
	< 3.5 mg/L	121	78,1	16	13,2	105	86,8		NE	26,8	NE		NE		NE	118	71,1	22	18,6	96	81,4	34,3	23,4	42,2		NE	39,8		NE	0,2217	0,67	0,35	1,28			Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	6	3,9			6	100,0		NE	NE	NE		NE		NE	13	7,8	4	30,8	9	69,2		8,3	1,0		NE		NE	7,4		NE	0,1324	<0,01	0,00		NE		Convergence criterion (GCONV=1E-8) satisfied.	
Prior therapies	<= 2	125	80,6	17	13,6	108	86,4		NE	22,7	NE		NE		NE	130	78,3	26	20,0	104	80,0	29,1	21,4	39,8		42,2	37,5		NE	0,1090	0,61	0,33	1,12			Convergence criterion (GCONV=1E-8) satisfied.	0,4279
	> 2	30	19,4	8	26,7	22	73,3	20,2		2,3	NE		NE	23,8	NE	36	21,7	10	27,8	26	72,2	16,1	9,5		NE		NE	23,4		NE	0,9620	0,98	0,39	2,48			Convergence criterion (GCONV=1E-8) satisfied.	


Refractory Type	Rituximab + Chemotherapy	130	83,9	23	17,7	107	82,3	NE	20,2	NE	NE	NE	NE	127	76,5	27	21,3	100	78,7	25,3	19,4	39,8	NE	37,5	NE	0,4704	0,82	0,47	1,42		Convergence criterion (GCONV=1E-8) satisfied.	0,1313
	Rituximab Monotherapy	25	16,1	2	8,0	23	92,0	NE	9,9	NE	NE	NE	NE	39	23,5	9	23,1	30	76,9	23,4	14,1	NE	42,2	29,1	NE	0,0638	0,26	0,06	1,20		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical cut-off:
01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/t_eff_tte.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_eff_tte_sg_OS_FOLY_IT_01SEP2014_01297.xls 07OCT2019 15:46

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: Overall Survival
STUDY: GO01297

Time from initial NHL diagnosis to randomization (N=321)



Patients at risk


G-Benda, < 6 months	6	6	6	5	5	4	4	2			
G-Benda, 6-12 months	11	8	7	5	4	4	2	1	1	1	
G-Benda, > 12 months	138	123	110	93	77	53	36	18	14	4	
Benda, < 6 months	6	5	3	3	3	2					
Benda, 6-12 months	18	17	12	11	10	5	3	1	1		
Benda, > 12 months	142	124	108	91	73	55	35	22	9	5	1

Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_km_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_km_sg_OS_FOLY_IT_01SEP2014_01297.pdf
07OCT2019 15:54

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: Overall Survival
STUDY: GO01297

Geographic region (N=321)



Patients at risk											
G-Benda, Western Europe	72	62	53	44	33	20	14	4	2		
G-Benda, North America	65	60	56	48	43	34	23	15	11	4	
G-Benda, Other	18	15	14	11	10	7	5	2	2	1	
Benda, Western Europe	78	71	58	49	38	27	14	7	3		
Benda, North America	73	62	52	44	39	28	19	15	7	5	1
Benda, Other	15	13	13	12	9	7	5	1			

Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_km_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_km_sg_OS_FOLY_IT_01SEP2014_01297.pdf
07OCT2019 15:54

3 (Anhang): Ergebnisse für PFS (Bewertung durch IRC) - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: Progression-Free Survival (PFS) - IRC
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Efficacy)

		G-Benda (N=155)												Benda (N=166)												G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	155	100,0	54	34,8	101	65,2	10,7	7,7	12,5	NE	22,5	NE	166	100,0	90	54,2	76	45,8	8,8	7,6	10,2	13,8	11,4	16,2	<.0001	0,49	0,35	0,68		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	85	54,8	28	32,9	57	67,1	11,6	8,2	22,5	29,2	22,5	NE	95	57,2	47	49,5	48	50,5	10,1	7,7	11,0	14,9	11,4	16,6	0,0024	0,49	0,30	0,78		Convergence criterion (GCONV=1E-8) satisfied.	0,8923
	Female	70	45,2	26	37,1	44	62,9	9,2	6,3	12,1	NE	12,1	NE	71	42,8	43	60,6	28	39,4	8,0	5,7	10,2	13,7	10,4	16,6	0,0054	0,50	0,31	0,82		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	59	38,1	18	30,5	41	69,5	11,5	7,7	14,3	NE	13,1	NE	61	36,7	32	52,5	29	47,5	8,5	6,7	10,6	13,7	10,4	19,4	0,0370	0,54	0,31	0,97		Convergence criterion (GCONV=1E-8) satisfied.	0,7741
	>= 60 years	96	61,9	36	37,5	60	62,5	10,5	6,8	13,6	29,2	22,5	NE	105	63,3	58	55,2	47	44,8	8,9	7,5	10,6	14,2	11,3	16,6	0,0001	0,44	0,29	0,68		Convergence criterion (GCONV=1E-8) satisfied.	
Race/ethnicity	White	139	89,7	49	35,3	90	64,7	10,7	7,7	12,5	NE	20,5	NE	143	86,1	77	53,8	66	46,2	8,9	7,6	10,6	14,9	11,5	16,6	0,0002	0,51	0,36	0,74		Convergence criterion (GCONV=1E-8) satisfied.	0,1555
	Other	7	4,5	2	28,6	5	71,4	6,8	2,8	NE	NE	2,8	NE	8	4,8	6	75,0	2	25,0	7,2	6,4	8,8	8,5	6,4	13,8	0,1557	0,32	0,06	1,66		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	9	5,8	3	33,3	6	66,7	17,5	0,6	NE	22,5	0,6	NE	15	9,0	7	46,7	8	53,3	10,1	2,4	11,3	11,3	8,5	NE	0,1960	0,40	0,10	1,67		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	72	46,5	28	38,9	44	61,1	10,7	6,8	12,1	22,5	11,9	NE	78	47,0	42	53,8	36	46,2	8,7	6,4	10,6	14,2	10,8	19,4	0,0612	0,63	0,39	1,03		Convergence criterion (GCONV=1E-8) satisfied.	0,0095
	North America	65	41,9	16	24,6	49	75,4	19,5	7,7	NE	NE	28,3	NE	73	44,0	41	56,2	32	43,8	8,3	6,5	10,4	13,7	10,4	16,2	<.0001	0,26	0,14	0,47		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	18	11,6	10	55,6	8	44,4	6,1	0,9	0,2	11,5	6,1	NE	15	9,0	7	46,7	8	53,3	10,6	7,6	13,7	15,9	9,7	NE	0,6250	1,28	0,48	3,40		Convergence criterion (GCONV=1E-8) satisfied.	
Body mass index	Underweight (< 18.5)													1	0,6	1	100,0			10,6		NE		10,6		NE	NE		NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,2894
	Normal weight (18.5 -< 25)	54	34,8	24	44,4	30	55,6	10,5	3,3	11,9	22,5	11,5	NE	50	30,1	27	54,0	23	46,0	8,7	6,4	11,5	13,8	11,0	19,4	0,2398	0,72	0,41	1,25		Convergence criterion (GCONV=1E-8) satisfied.	
	Overweight (25 - < 30)	53	34,2	16	30,2	37	69,8	10,2	6,6	NE	NE	14,3	NE	56	33,7	33	58,9	23	41,1	8,9	6,3	10,8	13,3	10,2	16,2	0,0017	0,40	0,22	0,72		Convergence criterion (GCONV=1E-8) satisfied.	
	Obese (>= 30)	46	29,7	13	28,3	33	71,7	13,1	8,0	29,2	NE	23,8	NE	52	31,3	25	48,1	27	51,9	9,3	6,7	11,5	16,2	10,6	24,3	0,0105	0,42	0,21	0,83		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	2	1,3	1	50,0	1	50,0	7,7	7,7	NE	NE	7,7	NE	7	4,2	4	57,1	3	42,9	6,2	0,8	13,0	8,8	0,8	13,0	0,4819	0,46	0,05	4,24		Convergence criterion (GCONV=1E-8) satisfied.	
Baseline ECOG Performance Status score	0-1	147	94,8	50	34,0	97	66,0	11,0	8,2	13,6	NE	23,8	NE	157	94,6	85	54,1	72	45,9	8,9	7,7	10,4	13,9	11,5	16,2	<.0001	0,47	0,33	0,67		Convergence criterion (GCONV=1E-8) satisfied.	0,6228
	2	8	5,2	4	50,0	4	50,0	1,1	0,6	NE	NE	0,6	NE	7	4,2	4	57,1	3	42,9	7,2	1,8	19,4	8,1	1,8	19,4	0,9769	1,02	0,25	4,17		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing													2	1,2	1	50,0	1	50,0	8,7	NE	NE	8,7	NE	NE		NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Independence status (Katz ADL)	Independent (5-6)	64	41,3	20	31,3	44	68,8	10,7	6,5	17,5		NE	13,6		NE	67	40,4	35	52,2	32	47,8	8,5	5,7	10,2	11,5	9,7	15,7	0,0021	0,42	0,24	0,74		Convergence criterion (GCONV=1E-8) satisfied.	NE
	Very dependent (0-2)	3	1,9	1	33,3	2	66,7	2,4	2,4		NE	NE	2,4		NE	1	0,6			1	100,0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	88	56,8	33	37,5	55	62,5	11,0	7,7	14,3		NE	23,8		NE	98	59,0	55	56,1	43	43,9	8,8	7,5	10,8	14,9	11,5	16,9	0,0012	0,49	0,32	0,76		Convergence criterion (GCONV=1E-8) satisfied.	
Best response to prior therapy	CR/PR	126	81,3	49	38,9	77	61,1	10,2	7,5	11,0	28,3		13,6		NE	133	80,1	70	52,6	63	47,4	8,9	7,7	10,4	13,8	11,3	16,2	0,0086	0,61	0,42	0,89		Convergence criterion (GCONV=1E-8) satisfied.	0,0316
	SD	22	14,2	3	13,6	19	86,4		NE	2,6		NE		NE		NE	20	12,0	12	60,0	8	40,0	8,3	0,8	13,9	15,7	8,3	33,6	0,0005	0,14	0,04	0,49		Convergence criterion (GCONV=1E-8) satisfied.	
	PD	7	4,5	2	28,6	5	71,4	14,3	12,1		NE	NE	12,1		NE	8	4,8	4	50,0	4	50,0	7,6	6,2	16,6	16,6	6,2	24,2	0,2323	0,37	0,07	2,03		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing (UE)															5	3,0	4	80,0	1	20,0	7,5	1,0	24,3		9,4	1,0	24,3			NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Histologic grade (follicular)	1	54	34,8	18	33,3	36	66,7	12,1	6,9	26,8		NE	23,8		NE	51	30,7	32	62,7	19	37,3	7,5	5,4	10,1	11,5	8,5	16,2	0,0004	0,36	0,20	0,65		Convergence criterion (GCONV=1E-8) satisfied.	0,0824
	2	69	44,5	22	31,9	47	68,1	11,0	7,7	19,5		NE	17,5		NE	68	41,0	39	57,4	29	42,6	9,4	7,7	10,8	13,0	10,8	14,6	0,0020	0,44	0,26	0,75		Convergence criterion (GCONV=1E-8) satisfied.	
	3															5	3,0	2	40,0	3	60,0	16,9	16,9	19,4	18,1	16,9	19,4			NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	3a	24	15,5	10	41,7	14	58,3	6,8	0,6	22,5		NE	6,8		NE	35	21,1	16	45,7	19	54,3	9,3	5,6	16,2	16,6	9,7	29,3	0,3144	0,66	0,29	1,49		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown/Variants	8	5,2	4	50,0	4	50,0	8,2	2,8	14,3	14,3		2,8		NE	7	4,2	1	14,3	6	85,7	13,8	13,8		NE		NE	13,8		NE	0,3090	2,97	0,33	26,68		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	27,1	15	35,7	27	64,3	11,5	6,8	26,8	29,2		13,1		NE	34	20,5	19	55,9	15	44,1	7,6	6,4	14,9	16,9	11,4	33,6	0,1624	0,62	0,31	1,22		Convergence criterion (GCONV=1E-8) satisfied.	0,6009
	Intermediate (2)	47	30,3	17	36,2	30	63,8	10,7	6,5	19,5	23,8		13,6		NE	58	34,9	33	56,9	25	43,1	8,7	6,3	10,4	13,3	10,2	15,8	0,0095	0,46	0,25	0,84		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	60	38,7	20	33,3	40	66,7	8,2	6,3	12,5		NE	11,9		NE	67	40,4	36	53,7	31	46,3	8,3	7,6	10,6	11,7	10,2	16,2	0,0026	0,44	0,25	0,76		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	6	3,9	2	33,3	4	66,7	14,3	14,3		NE		22,5		14,3	NE	7	4,2	2	28,6	5	71,4	11,4	11,3		NE		NE	11,3		NE	0,8418	0,82	0,11	6,00		Convergence criterion (GCONV=1E-8) satisfied.	
Fc gamma receptor IIa	131HH	42	27,1	10	23,8	32	76,2	23,8	6,6		NE		NE		23,8	NE	36	21,7	19	52,8	17	47,2	7,6	6,4	11,7	16,4	7,7	17,7	0,0087	0,37	0,17	0,80		Convergence criterion (GCONV=1E-8) satisfied.	0,6309
	131HR	66	42,6	24	36,4	42	63,6	11,0	6,8	13,7		NE	13,1		NE	78	47,0	44	56,4	34	43,6	9,4	8,0	10,4	11,7	10,4	15,8	0,0007	0,42	0,25	0,70		Convergence criterion (GCONV=1E-8) satisfied.	
	131RR	34	21,9	13	38,2	21	61,8	7,7	2,8	29,2	29,2		11,0		NE	34	20,5	18	52,9	16	47,1	8,9	2,4	13,7	16,2	11,3	33,6	0,1827	0,62	0,30	1,26		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	13	8,4	7	53,8	6	46,2	8,2	2,1	10,5	10,5		6,1		NE	18	10,8	9	50,0	9	50,0	7,8	0,8	14,6	14,6	6,2	21,6	0,9115	0,95	0,35	2,56		Convergence criterion (GCONV=1E-8) satisfied.	
Fc gamma receptor IIIa	158VV	19	12,3	8	42,1	11	57,9	11,6	2,4	17,5	22,5		11,0		NE	30	18,1	18	60,0	12	40,0	7,7	2,8	13,0	13,8	8,0	16,4	0,2671	0,62	0,27	1,45		Convergence criterion (GCONV=1E-8) satisfied.	0,5502
	158VF	65	41,9	23	35,4	42	64,6	11,5	7,7	13,7	28,3		13,6		NE	65	39,2	33	50,8	32	49,2	9,4	6,4	10,8	11,7	10,8	16,6	0,0146	0,52	0,30	0,89		Convergence criterion (GCONV=1E-8) satisfied.	
	158FF	58	37,4	16	27,6	42	72,4	10,3	6,3		NE		NE		29,2	NE	53	31,9	30	56,6	23	43,4	8,8	7,2	11,0	15,8	10,4	16,7	0,0012	0,37	0,20	0,69		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	13	8,4	7	53,8	6	46,2	8,2	2,1	10,5	10,5		6,1		NE	18	10,8	9	50,0	9	50,0	7,8	0,8	14,6	14,6	6,2	21,6	0,9115	0,95	0,35	2,56		Convergence criterion (GCONV=1E-8) satisfied.	
Fc gamma receptor IIb/IIc	232II	104	67,1	34	32,7	70	67,3	11,6	7,5	17,5		NE	22,5		NE	107	64,5	56	52,3	51	47,7	8,7	6,5	10,4	14,2	11,0	16,6	0,0003	0,46	0,30	0,71		Convergence criterion (GCONV=1E-8) satisfied.	0,3630
	232IT	36	23,2	13	36,1	23	63,9	10,7	6,3	26,8	29,2		11,0		NE	37	22,3	22	59,5	15	40,5	10,1	7,5	11,7	13,7	10,6	19,4	0,0516	0,51	0,25	1,02		Convergence criterion (GCONV=1E-8) satisfied.	
	232TT	1	0,6			1	100,0		NE		NE		NE		NE	4	2,4	3	75,0	1	25,0	7,2	7,2	13,8	13,8	7,2	13,8	0,1521	<0.01	0,00		NE	Convergence criterion (GCONV=1E-8) satisfied.	


	Missing	14	9,0	7	50,0	7	50,0	8,2	2,1	11,0	11,0	8,0	NE	18	10,8	9	50,0	9	50,0	7,8	0,8	14,6	14,6	6,2	21,6	0,6613	0,80	0,30	2,16		Convergence criterion (GCONV=1E-8) satisfied.	
Absolute lymphocyte count	>= median	72	46,5	19	26,4	53	73,6	13,6	9,3	23,8	NE	23,8	NE	84	50,6	41	48,8	43	51,2	10,2	8,1	11,5	14,6	11,7	17,7	0,0007	0,39	0,23	0,69		Convergence criterion (GCONV=1E-8) satisfied.	0,4345
	< median	83	53,5	35	42,2	48	57,8	7,7	6,3	11,0	28,3	11,9	NE	79	47,6	48	60,8	31	39,2	7,7	6,3	9,3	11,5	10,6	16,2	0,0055	0,54	0,35	0,84		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing													3	1,8	1	33,3	2	66,7	6,4	6,4	NE	NE	6,4	NE		NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Time from initial NHL diagnosis to randomization	< 6 months	6	3,9			6	100,0	NE	NE	NE	NE	NE	NE	6	3,6	4	66,7	2	33,3	2,4	1,0	16,6	12,1	1,0	NE	0,0150	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,0277
	6-12 months	11	7,1	3	27,3	8	72,7	10,7	1,4	NE	NE	1,4	NE	18	10,8	10	55,6	8	44,4	6,4	0,8	13,7	13,9	6,2	33,6	0,2534	0,48	0,13	1,74		Convergence criterion (GCONV=1E-8) satisfied.	
	> 12 months	138	89,0	51	37,0	87	63,0	10,5	7,7	12,1	29,2	19,5	NE	142	85,5	76	53,5	66	46,5	9,3	7,8	10,4	13,8	11,4	16,4	0,0006	0,54	0,38	0,77		Convergence criterion (GCONV=1E-8) satisfied.	
Beta 2 microglobulin	>= 3.5 mg/L	28	18,1	12	42,9	16	57,1	6,8	1,4	13,6	17,5	9,3	NE	35	21,1	23	65,7	12	34,3	8,1	5,6	8,9	11,4	8,1	14,6	0,0394	0,48	0,23	0,98		Convergence criterion (GCONV=1E-8) satisfied.	0,8708
	< 3.5 mg/L	121	78,1	42	34,7	79	65,3	10,7	7,7	13,1	NE	23,8	NE	118	71,1	60	50,8	58	49,2	10,2	7,6	10,8	14,9	11,5	16,7	0,0016	0,53	0,36	0,79		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing	6	3,9			6	100,0	NE	NE	NE	NE	NE	NE	13	7,8	7	53,8	6	46,2	6,3	0,8	15,7	15,7	1,0	29,0	0,0161	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Prior therapies	<= 2	125	80,6	41	32,8	84	67,2	11,0	8,0	13,1	NE	20,5	NE	130	78,3	74	56,9	56	43,1	8,7	7,6	10,2	13,8	11,0	16,2	<.0001	0,43	0,29	0,63		Convergence criterion (GCONV=1E-8) satisfied.	0,1780
	> 2	30	19,4	13	43,3	17	56,7	7,5	2,0	23,8	28,3	9,3	NE	36	21,7	16	44,4	20	55,6	8,9	6,4	11,7	15,7	10,2	NE	0,5922	0,82	0,39	1,72		Convergence criterion (GCONV=1E-8) satisfied.	
Refractory Type	Rituximab + Chemotherapy	130	83,9	46	35,4	84	64,6	10,5	7,7	11,9	NE	17,5	NE	127	76,5	70	55,1	57	44,9	8,3	7,2	10,1	13,3	10,8	15,9	0,0003	0,51	0,35	0,74		Convergence criterion (GCONV=1E-8) satisfied.	0,6646
	Rituximab Monotherapy	25	16,1	8	32,0	17	68,0	19,5	0,9	NE	NE	19,5	NE	39	23,5	20	51,3	19	48,7	10,6	7,5	14,2	16,2	11,5	19,4	0,0098	0,34	0,15	0,80		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/t_eff_tte.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_eff_tte_sg_PFSRAD1_FOLY_IT_01SEP2014_01297.xls 04OCT2019
18:37

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: Progression-Free Survival (PFS) - IRC
STUDY: GO01297

Best response to prior therapy (N=316)



Patients at risk										
G-Benda, CR/PR	126	102	73	49	39	25	12	8	3	
G-Benda, SD	22	18	17	16	14	12	7	3	2	1
G-Benda, PD	7	6	5	3	2	1	1	1		
Benda, CR/PR	133	105	71	33	18	12	5	2	1	1
Benda, SD	20	16	11	7	2	2	2	1	1	
Benda, PD	8	5	3	3	1					


Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_km_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_km_sg_PFSRAD1_FOLY_IT_01SEP2014_01297.pdf
07OCT2019 15:55

Page 1 of 3

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: Progression-Free Survival (PFS) - IRC
STUDY: GO01297

Time from initial NHL diagnosis to randomization (N=321)




Patients at risk										
G-Benda, < 6 months	6	6	6	5	5	4	3	2		
G-Benda, 6-12 months	11	8	5	4	4	2	2	1	1	1
G-Benda, > 12 months	138	112	84	59	46	32	15	9	4	
Benda, < 6 months	6	4	3	2						
Benda, 6-12 months	18	13	7	4	3	2	2			
Benda, > 12 months	142	113	77	39	20	12	5	3	2	1


Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_km_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_km_sg_PFSRAD1_FOLY_IT_01SEP2014_01297.pdf
07OCT2019 15:55

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: Progression-Free Survival (PFS) - IRC
STUDY: GO01297

Geographic region (N=321)





Patients at risk										
G-Benda, Western Europe	72	56	42	25	19	11	7	2		
G-Benda, North America	65	56	44	36	30	23	11	9	4	1
G-Benda, Other	18	14	9	7	6	4	2	1	1	
Benda, Western Europe	78	63	41	20	13	8	2			
Benda, North America	73	54	36	20	9	5	4	3	2	1
Benda, Other	15	13	10	5	1	1	1			

Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_km_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_km_sg_PFSRAD1_FOLY_IT_01SEP2014_01297.pdf
07OCT2019 15:55

Page 3 of 3

4 (Anhang): Ergebnisse für EQ-5D-VAS - Verbesserung des Gesundheitszustands um MID zehn - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients, Patients with Baseline and post Baseline EQ-5D VAS result
ENDPOINT: EQ-5D VAS - Responder (MID=10), Improvement MODEL:
Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Efficacy)

			G-Benda (N=129)				Benda (N=130)				G-Benda vs. Benda														Benda vs. G-Benda				
			Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk				
Endpoint	Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
Cycle 5 Day 1	All	n/a	107	82,9	35	32,7	100	76,9	36	36,0	0,86		Convergence criterion (GCONV=1E-8) satisfied.	0,49	1,53	-0,033		Algorithm converged.	-0,162	0,097	0,91		Algorithm converged.	0,62	1,32	0,6184		1,10		Algorithm converged.	0,75	1,60
	Sex	Male	65	50,4	25	38,5	56	43,1	21	37,5	1,04		Convergence criterion (GCONV=1E-8) satisfied.	0,50	2,18	0,010		Algorithm converged.	-0,164	0,183	1,03		Algorithm converged.	0,65	1,62	0,9135	0,3529	0,98		Algorithm converged.	0,62	1,54
		Female	42	32,6	10	23,8	44	33,8	15	34,1	0,60		Convergence criterion (GCONV=1E-8) satisfied.	0,23	1,55	-0,103		Algorithm converged.	-0,293	0,087	0,70		Algorithm converged.	0,35	1,38	0,3004		1,43		Algorithm converged.	0,73	2,82
	Age	< 60 years	45	34,9	15	33,3	43	33,1	19	44,2	0,63		Convergence criterion (GCONV=1E-8) satisfied.	0,27	1,50	-0,109		Algorithm converged.	-0,311	0,094	0,75		Algorithm converged.	0,44	1,28	0,2996	0,3483	1,33		Algorithm converged.	0,78	2,26
		>= 60 years	62	48,1	20	32,3	57	43,8	17	29,8	1,12		Convergence criterion (GCONV=1E-8) satisfied.	0,51	2,44	0,024		Algorithm converged.	-0,142	0,191	1,08		Algorithm converged.	0,63	1,85	0,7748		0,92		Algorithm converged.	0,54	1,58
	Race/ethnicity	White	101	78,3	33	32,7	88	67,7	31	35,2	0,89		Convergence criterion (GCONV=1E-8) satisfied.	0,49	1,63	-0,026		Algorithm converged.	-0,161	0,110	0,93		Algorithm converged.	0,62	1,38	0,7111	0,4079	1,08		Algorithm converged.	0,72	1,61
		Other	2	1,6			5	3,8	1	20,0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE
		Missing/Unknown	4	3,1	2	50,0	7	5,4	4	57,1	0,75		Convergence criterion (GCONV=1E-8) satisfied.	0,06	8,83	-0,071		Algorithm converged.	-0,683	0,541	0,88		Algorithm converged.	0,27	2,82	0,8232		1,14		Algorithm converged.	0,35	3,69
	Geographic region	Western Europe	43	33,3	11	25,6	44	33,8	18	40,9	0,50		Convergence criterion (GCONV=1E-8) satisfied.	0,20	1,24	-0,153		Algorithm converged.	-0,349	0,042	0,63		Algorithm converged.	0,34	1,16	0,1386	0,2901	1,60		Algorithm converged.	0,86	2,98
		North America	53	41,1	19	35,8	47	36,2	14	29,8	1,32		Convergence criterion (GCONV=1E-8) satisfied.	0,57	3,05	0,061		Algorithm converged.	-0,123	0,244	1,20		Algorithm converged.	0,68	2,12	0,5225		0,83		Algorithm converged.	0,47	1,47
		Other	11	8,5	5	45,5	9	6,9	4	44,4	1,04		Convergence criterion (GCONV=1E-8) satisfied.	0,18	6,12	0,010		Algorithm converged.	-0,428	0,448	1,02		Algorithm converged.	0,39	2,71	0,9640		0,98		Algorithm converged.	0,37	2,59
	Body mass index	Underweight (< 18.5)					1	0,8																			0,0767					
		Normal weight (18.5 -< 25)	34	26,4	12	35,3	28	21,5	14	50,0	0,55		Convergence criterion (GCONV=1E-8) satisfied.	0,20	1,51	-0,147		Algorithm converged.	-0,392	0,098	0,71		Algorithm converged.	0,39	1,27	0,2447		1,42		Algorithm converged.	0,79	2,55
		Overweight (25 - < 30)	38	29,5	9	23,7	28	21,5	11	39,3	0,48		Convergence criterion (GCONV=1E-8) satisfied.	0,17	1,39	-0,156		Algorithm converged.	-0,382	0,070	0,60		Algorithm converged.	0,29	1,26	0,1762		1,66		Algorithm converged.	0,80	3,45
		Obese (>= 30)	34	26,4	14	41,2	38	29,2	9	23,7	2,26		Convergence criterion (GCONV=1E-8) satisfied.	0,82	6,21	0,175		Algorithm converged.	-0,039	0,389	1,74		Algorithm converged.	0,87	3,49	0,1204		0,58		Algorithm converged.	0,29	1,16
		Missing	1	0,8			5	3,8	2	40,0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE
	Baseline ECOG Performance Status score	0-1	104	80,6	32	30,8	95	73,1	34	35,8	0,80		Convergence criterion (GCONV=1E-8) satisfied.	0,44	1,44	-0,050		Algorithm converged.	-0,181	0,081	0,86		Algorithm converged.	0,58	1,28	0,4528		1,16		Algorithm converged.	0,78	1,73
		2	3	2,3	3	100,0	4	3,1	1	25,0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.						*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.		
		Missing					1	0,8	1	100,0																							
	Independence status (Katz ADL)	Independent (5-6)	42	32,6	12	28,6	39	30,0	14	35,9	0,71		Convergence criterion (GCONV=1E-8) satisfied.	0,28	1,82	-0,073		Algorithm converged.	-0,277	0,130	0,80		Algorithm converged.	0,42	1,50	0,4818	<.0001	1,26		Algorithm converged.	0,67	2,37
		Very dependent (0-2)	2	1,6	1	50,0																											
		Missing	63	48,8	22	34,9	61	46,9	22	36,1	0,95		Convergence criterion (GCONV=1E-8) satisfied.	0,46	1,99	-0,011		Algorithm converged.	-0,180	0,157	0,97		Algorithm converged.	0,60	1,56	0,8940		1,03		Algorithm converged.	0,64	1,66
	Best response to prior therapy	CR/PR	88	68,2	26	29,5	80	61,5	28	35,0	0,78		Convergence criterion (GCONV=1E-8) satisfied.	0,41	1,49	-0,055		Algorithm converged.	-0,196	0,087	0,84		Algorithm converged.	0,54	1,31	0,4501	0,4393	1,18		Algorithm converged.	0,76	1,84
		SD	15	11,6	8	53,3	14	10,8	7	50,0	1,14		Convergence criterion (GCONV=1E-8) satisfied.	0,27	4,91	0,033		Algorithm converged.	-0,330	0,397	1,07		Algorithm converged.	0,53	2,16	0,8578		0,94		Algorithm converged.	0,46	1,90
		PD	4	3,1	1	25,0	3	2,3				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
		Missing (UE)					3	2,3	1	33,3	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE	NE	NE		Algorithm converged.	NE	NE	NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Histologic grade (follicular)	1	43	33,3	21	48,8	29	22,3	8	27,6	2,51		Convergence criterion (GCONV=1E-8) satisfied.	0,91	6,88	0,213		Algorithm converged.	-0,008	0,433	1,77		Algorithm converged.	0,91	3,44	0,0920	0,0340	0,56		Algorithm converged.	0,29	1,10
		2	45	34,9	9	20,0	43	33,1	19	44,2	0,32		Convergence criterion (GCONV=1E-8) satisfied.	0,12	0,81	-0,242		Algorithm converged.	-0,431	-0,053	0,45		Algorithm converged.	0,23	0,89	0,0212		2,21		Algorithm converged.	1,13	4,33
		3	3	2,3	1	33,3	3	2,3	1	33,3	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE	NE	NE		Algorithm converged.	NE	NE	NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE

		3a	13	10,1		4	30,8	20	15,4	6	30,0	1,04		Convergence criterion (GCONV=1E-8) satisfied.	0,23	4,73	0,008		Algorithm converged.	-0,314	0,329	1,03		Algorithm converged.	0,36	2,95	0,9625		0,98		Algorithm converged.	0,34	2,80
		Missing/Unknown/Variants		6	4,7		1	16,7		5	83,8		2	40,0	0,30		Convergence criterion (GCONV=1E-8) satisfied.	0,02	4,91	-0,233		Algorithm converged.	-0,756	0,289	0,42		Algorithm converged.	0,05	3,36	0,4109		2,40		Algorithm converged.	0,30	19,34
	FLIPI	Low (0-1)	25	19,4		6	24,0	24	18,5	6	25,0	0,95		Convergence criterion (GCONV=1E-8) satisfied.	0,26	3,48	-0,010		Algorithm converged.	-0,251	0,231	0,96		Algorithm converged.	0,36	2,57	0,9351	0,9501	1,04		Algorithm converged.	0,39	2,78
		Intermediate (2)	33	25,6	11		33,3	34	26,2	14	41,2	0,71		Convergence criterion (GCONV=1E-8) satisfied.	0,26	1,93	-0,078		Algorithm converged.	-0,309	0,152	0,81		Algorithm converged.	0,43	1,52	0,5095		1,24		Algorithm converged.	0,66	2,31
		High (>=3)	43	33,3	14		32,6	37	28,5	15	40,5	0,71		Convergence criterion (GCONV=1E-8) satisfied.	0,28	1,77	-0,080		Algorithm converged.	-0,291	0,131	0,80		Algorithm converged.	0,45	1,44	0,4593		1,25		Algorithm converged.	0,70	2,23
		Missing/Unknown		6	4,7		4	66,7		5	83,8		1	20,0	0,00		Convergence criterion (GCONV=1E-8) satisfied.	0,50	127,90	0,467		Algorithm converged.	-0,048	0,982	3,33		Algorithm converged.	0,53	21,03	0,2002		0,30		Algorithm converged.	0,05	1,89
	Fc gamma receptor IIa	131HH	26	20,2		8	30,8	25	19,2	6	24,0	1,41		Convergence criterion (GCONV=1E-8) satisfied.	0,41	4,86	0,068		Algorithm converged.	-0,176	0,312	1,28		Algorithm converged.	0,52	3,17	0,5905	0,6107	0,78		Algorithm converged.	0,32	1,93
		131HR	46	35,7	20		43,5	52	40,0	21	40,4	1,14		Convergence criterion (GCONV=1E-8) satisfied.	0,51	2,54	0,031		Algorithm converged.	-0,165	0,227	1,08		Algorithm converged.	0,68	1,72	0,7565		0,93		Algorithm converged.	0,58	1,48
		131RR	25	19,4		6	24,0	17	13,1	6	35,3	0,58		Convergence criterion (GCONV=1E-8) satisfied.	0,15	2,24	-0,113		Algorithm converged.	-0,395	0,169	0,68		Algorithm converged.	0,26	1,76	0,4258		1,47		Algorithm converged.	0,57	2,80
		Missing	10	7,8		1	10,0		6	4,6	3	50,0	0,11		Convergence criterion (GCONV=1E-8) satisfied.	<0.01	1,52	-0,400		Algorithm converged.	-0,841	0,041	0,20		Algorithm converged.	0,03	1,51	0,1192		5,00		Algorithm converged.	0,66	37,85
	Fc gamma receptor IIIa	158VV	11	8,5		4	36,4	17	13,1	7	41,2	0,82		Convergence criterion (GCONV=1E-8) satisfied.	0,17	3,90	-0,048		Algorithm converged.	-0,416	0,320	0,88		Algorithm converged.	0,34	2,32	0,8010	0,9322	1,13		Algorithm converged.	0,43	2,98
		158VF	48	37,2	18		37,5	46	35,4	16	34,8	1,12		Convergence criterion (GCONV=1E-8) satisfied.	0,48	2,61	0,027		Algorithm converged.	-0,167	0,221	1,08		Algorithm converged.	0,63	1,85	0,7842		0,93		Algorithm converged.	0,54	1,59
		158FF	38	29,5	12		31,6	31	23,8	10	32,3	0,97		Convergence criterion (GCONV=1E-8) satisfied.	0,35	2,68	-0,007		Algorithm converged.	-0,228	0,214	0,98		Algorithm converged.	0,49	1,96	0,9520		1,02		Algorithm converged.	0,51	2,04
		Missing	10	7,8		1	10,0		6	4,6	3	50,0	0,11		Convergence criterion (GCONV=1E-8) satisfied.	<0.01	1,52	-0,400		Algorithm converged.	-0,841	0,041	0,20		Algorithm converged.	0,03	1,51	0,1192		5,00		Algorithm converged.	0,66	37,85
	Fc gamma receptor IIb/IIc	232II	67	51,9	24		35,8	64	49,2	19	29,7	1,32		Convergence criterion (GCONV=1E-8) satisfied.	0,64	2,75	0,061		Algorithm converged.	-0,099	0,222	1,21		Algorithm converged.	0,74	1,98	0,4570	1,0000	0,83		Algorithm converged.	0,51	1,36
		232IT	28	21,7		9	32,1	26	20,0	13	50,0	0,47		Convergence criterion (GCONV=1E-8) satisfied.	0,16	1,43	-0,179		Algorithm converged.	-0,437	0,080	0,64		Algorithm converged.	0,33	1,25	0,1904		1,56		Algorithm converged.	0,80	3,01
		232TT		1	0,8		1	100,0		4	3,1	1	25,0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	WARNING: Negative of Hessian not positive definite.						*	WARNING: Negative of Hessian not positive definite.		
		Missing	11	8,5		1	9,1		6	4,6	3	50,0	0,10		Convergence criterion (GCONV=1E-8) satisfied.	<0.01	1,35	-0,409		Algorithm converged.	-0,844	0,026	0,18		Algorithm converged.	0,02	1,39	0,1003		6,50		Algorithm converged.	0,72	42,00
	Absolute lymphocyte count	>= median	47	36,4	19		40,4	50	38,5	18	36,0	1,21		Convergence criterion (GCONV=1E-8) satisfied.	0,53	2,74	0,044		Algorithm converged.	-0,149	0,238	1,12		Algorithm converged.	0,68	1,86	0,6540	0,2795	0,89		Algorithm converged.	0,54	1,48
		< median	50	46,5	16		26,7	50	38,5	18	36,0	0,65		Convergence criterion (GCONV=1E-8) satisfied.	0,29	1,46	-0,093		Algorithm converged.	-0,267	0,081	0,74		Algorithm converged.	0,42	1,30	0,2928		1,35		Algorithm converged.	0,77	2,36
	Time from initial NHL diagnosis to randomization	< 6 months		4	3,1		3	75,0		4	3,1	2	50,0	3,00		Convergence criterion (GCONV=1E-8) satisfied.	0,15	59,89	0,250		Algorithm converged.	-0,398	0,898	1,50		Algorithm converged.	0,48	4,65	0,4825	0,6719	0,67		Algorithm converged.	0,22	2,07
		6-12 months		6	4,7		3	50,0	10	7,7	5	50,0	1,00		Convergence criterion (GCONV=1E-8) satisfied.	0,13	7,57	0,000		Algorithm converged.	-0,506	0,506	1,00		Algorithm converged.	0,36	2,75	1,0000		1,00		Algorithm converged.	0,36	2,75
		> 12 months	97	75,2	29		29,9	86	66,2	29	33,7	0,84		Convergence criterion (GCONV=1E-8) satisfied.	0,45	1,56	-0,038		Algorithm converged.	-0,173	0,097	0,89		Algorithm converged.	0,58	1,36	0,5789		1,13		Algorithm converged.	0,74	1,73
	Beta 2 microglobulin	>= 3.5 mg/L	17	13,2	10		58,8	21	16,2	10	47,6	1,57		Convergence criterion (GCONV=1E-8) satisfied.	0,43	5,71	0,112		Algorithm converged.	-0,205	0,429	1,24		Algorithm converged.	0,68	2,25	0,4897	0,3887	0,81		Algorithm converged.	0,44	1,47
		< 3.5 mg/L	85	65,9	24		28,2	75	57,7	24	32,0	0,84		Convergence criterion (GCONV=1E-8) satisfied.	0,42	1,65	-0,038		Algorithm converged.	-0,180	0,105	0,88		Algorithm converged.	0,55	1,42	0,6040		1,13		Algorithm converged.	0,71	1,82
		Missing		5	3,9		1	20,0		4	3,1	2	50,0	0,25		Convergence criterion (GCONV=1E-8) satisfied.	0,01	4,73	-0,300		Algorithm converged.	-0,903	0,303	0,40		Algorithm converged.	0,05	2,98	0,3712		2,50		Algorithm converged.	0,34	18,63
	Prior therapies	<= 2	91	70,5	26		28,6	79	60,8	28	35,4	0,73		Convergence criterion (GCONV=1E-8) satisfied.	0,38	1,39	-0,069		Algorithm converged.	-0,209	0,072	0,81		Algorithm converged.	0,52	1,25	0,3377	0,1498	1,24		Algorithm converged.	0,80	1,93
		> 2	16	12,4	9		56,3	21	16,2	8	38,1	2,09		Convergence criterion (GCONV=1E-8) satisfied.	0,56	7,85	0,182		Algorithm converged.	-0,138	0,501	1,48		Algorithm converged.	0,74	2,96	0,2722		0,68		Algorithm converged.	0,34	1,36
	Refractory Type	Rituximab + Chemotherapy	91	70,5	32		35,2	73	56,2	27	37,0	0,92		Convergence criterion (GCONV=1E-8) satisfied.	0,49	1,75	-0,018		Algorithm converged.	-0,166	0,130	0,95		Algorithm converged.	0,63	1,43	0,8089	0,3756	1,05		Algorithm converged.	0,70	1,58
		Rituximab Monotherapy	16	12,4	3		18,8	27	20,8	9	33,3	0,46		Convergence criterion (GCONV=1E-8) satisfied.	0,10	2,05	-0,146		Algorithm converged.	-0,407	0,115	0,56		Algorithm converged.	0,18	1,78	0,3272		1,78		Algorithm converged.	0,56	6,62
Follow Up Visit 1 Month 2	All	n/a	93	72,1	35		37,6	75	57,7	29	38,7	0,96		Convergence criterion (GCONV=1E-8) satisfied.	0,51	1,79	-0,010		Algorithm converged.	-0,158	0,137	0,97		Algorithm converged.	0,66	1,43	0,8910		1,03		Algorithm converged.	0,70	1,51
	Sex	Male	58	45,0	25		43,1	41	31,5	18	43,9	0,97		Convergence criterion (GCONV=1E-8) satisfied.	0,43	2,17	-0,008		Algorithm converged.	-0,206	0,190	0,98		Algorithm converged.	0,62	1,55	0,9370	0,8062	1,02		Algorithm converged.	0,65	1,61
		Female	35	27,1	10		28,6	34	26,2	11	32,4	0,84		Convergence criterion (GCONV=1E-8) satisfied.	0,30	2,33	-0,038		Algorithm converged.	-0,255	0,179	0,88		Algorithm converged.	0,43	1,80	0,7332		1,13		Algorithm converged.	0,55	2,31
	Age	< 60 years	39	30,2	13		33,3	32	24,6	13	40,6	0,73		Convergence criterion (GCONV=1E-8) satisfied.	0,28	1,93	-0,073		Algorithm converged.	-0,298	0,153	0,82		Algorithm converged.	0,45	1,51	0,5252	0,4743	1,22		Algorithm converged.	0,66	2,24
		>= 60 years	54	41,9	22		40,7	43	33,1	16	37,2	1,16		Convergence criterion (GCONV=1E-8) satisfied.	0,51	2,64	0,035		Algorithm converged.	-0,160	0,230	1,09		Algorithm converged.	0,66	1,81	0,7245		0,91		Algorithm converged.	0,55	1,51
	Race/ethnicity	White	88	68,2	33		37,5	68	52,3	25	36,8	1,03		Convergence criterion (GCONV=1E-8) satisfied.	0,54	1,99	0,007		Algorithm converged.	-0,146	0,160	1,02		Algorithm converged.	0,68	1,54	0,9250	0,8297	0,98		Algorithm converged.	0,65	1,48
		Other		21	16,6		1	50,0		5	83,8		2	40,0	1,50		Convergence criterion (GCONV=1E-8) satisfied.	0,06	40,63	0,100		Algorithm converged.	-0,715	0,915	1,25		Algorithm converged.	0,22	7,22	0,8030		0,80		Algorithm converged.	0,14	6,62
		Missing/Unknown		3	2,3		1	33,3		2	1,5	2	100,0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	WARNING: Negative of Hessian not positive definite.						*	WARNING: Negative of Hessian not positive definite.		
	Geographic region	Western Europe	95	27,1	14		40,0	30	23,1	14	46,7	0,76		Convergence criterion (GCONV=1E-8) satisfied.	0,28	2,04	-0,067		Algorithm converged.	-0,308	0,175	0,86		Algorithm converged.	0,49	1,50	0,5880	0,3737	1,17		Algorithm converged.	0,67	2,04
		North America	47	36,4	18		38,3	37	28,5	11	29,7	1,47		Convergence criterion (GCONV=1E-8) satisfied.	0,59	3,67	0,086		Algorithm converged.	-0,117	0,288	1,29		Algorithm converged.	0,70	2,38	0,4189		0,78		Algorithm converged.	0,42	1,43
		Other	11	8,5		3	27,3		8	6,2	4	50,0	0,38		Convergence criterion (GCONV=1E-8) satisfied.	0,06	2,55	-0,227		Algorithm converged.	-0,662	0,208	0,55		Algorithm converged.	0,17	1,79	0,3173		1,83		Algorithm converged.	0,56	6,01

	Body mass index	Underweight (< 18.5)					1	0,8																		0,6675								
		Normal weight (18.5 - < 25)	28	21,7	10	35,7	21	16,2	9	42,9	0,74		Convergence criterion (GCONV=1E-8) satisfied.	0,23	2,36	-0,071		Algorithm converged.	-0,348	0,205	0,83		Algorithm converged.	0,41	1,68	0,6100		1,20		Algorithm converged.	0,60	2,42
		Overweight (25 - < 30)	84	26,4	13	38,2	22	16,9	10	45,5	0,74		Convergence criterion (GCONV=1E-8) satisfied.	0,25	2,20	-0,072		Algorithm converged.	-0,337	0,192	0,84		Algorithm converged.	0,45	1,57	0,5882		1,19		Algorithm converged.	0,64	2,22
		Obese (>= 30)	30	23,3	12	40,0	28	21,5	8	28,6	1,67		Convergence criterion (GCONV=1E-8) satisfied.	0,56	5,00	0,114		Algorithm converged.	-0,128	0,357	1,40		Algorithm converged.	0,67	2,91	0,3673		0,71		Algorithm converged.	0,34	1,48
		Missing		1	0,8			3	2,3	2	66,7		Quasi-complete separation of data points detected.					ERROR: The mean parameter is either invalid or at a limit of its range for some observations.					WARNING: Negative of Hessian not positive definite.							WARNING: Negative of Hessian not positive definite.		
	Baseline ECOG Performance Status score	0-1	81	70,5	33	36,3	73	56,2	27	37,0	0,97		Convergence criterion (GCONV=1E-8) satisfied.	0,51	1,84	-0,007		Algorithm converged.	-0,156	0,141	0,98		Algorithm converged.	0,65	1,47	0,9239		1,02		Algorithm converged.	0,68	1,53
		2		2	1,6	2	100,0	1	0,8	1	100,0																								
		Missing					1	0,8	1	100,0																										
	Independence status (Katz ADL)	Independent (5-6)	35	27,1	11	31,4	32	24,6	13	40,6	0,67		Convergence criterion (GCONV=1E-8) satisfied.	0,25	1,83	-0,092		Algorithm converged.	-0,321	0,137	0,77		Algorithm converged.	0,41	1,47	0,4348		NE	1,29		Algorithm converged.	0,68	2,46
		Missing	58	45,0	24	41,4	43	33,1	16	37,2	1,19		Convergence criterion (GCONV=1E-8) satisfied.	0,53	2,68	0,042		Algorithm converged.	-0,150	0,234	1,11		Algorithm converged.	0,68	1,82	0,6738		0,90		Algorithm converged.	0,55	1,47
	Best response to prior therapy	CR/PR	75	58,1	24	32,0	61	46,9	24	39,3	0,73		Convergence criterion (GCONV=1E-8) satisfied.	0,36	1,47	-0,073		Algorithm converged.	-0,235	0,088	0,81		Algorithm converged.	0,52	1,28	0,3722		1,23		Algorithm converged.	0,78	1,94
		SD	15	11,6	8	53,3	10	7,7	5	50,0	1,14		Convergence criterion (GCONV=1E-8) satisfied.	0,23	5,67	0,033		Algorithm converged.	-0,366	0,433	1,07		Algorithm converged.	0,49	2,33	0,8712		0,94		Algorithm converged.	0,43	2,04
		PD		3	2,3	3	100,0	3	2,3				Complete separation of data points detected.					ERROR: The mean parameter is either invalid or at a limit of its range for some observations.					ERROR: The mean parameter is either invalid or at a limit of its range for some observations.							ERROR: The mean parameter is either invalid or at a limit of its range for some observations.		
		Missing (UE)					1	0,8																										
	Histologic grade (follicular)	1	38	29,5	21	55,3	20	15,4	10	50,0	1,24		Convergence criterion (GCONV=1E-8) satisfied.	0,42	3,66	0,053		Algorithm converged.	-0,218	0,323	1,11		Algorithm converged.	0,65	1,87	0,7078		0,90		Algorithm converged.	0,54	1,53
		2	42	32,6	11	26,2	35	26,9	14	40,0	0,53		Convergence criterion (GCONV=1E-8) satisfied.	0,20	1,40	-0,138		Algorithm converged.	-0,348	0,072	0,65		Algorithm converged.	0,34	1,25	0,2016		1,53		Algorithm converged.	0,80	2,93
		3					1	0,8	1	100,0																										
		3a		9	7,0	3	33,3	15	11,5	3	20,0	2,00	Convergence criterion (GCONV=1E-8) satisfied.	0,31	13,06	0,133		Algorithm converged.	-0,235	0,502	1,67		Algorithm converged.	0,42	6,56	0,4650		0,60		Algorithm converged.	0,15	2,36
		Missing/Unknown/Variants		4	3,1			4	3,1	1	25,0		Quasi-complete separation of data points detected.					ERROR: Error in computing the link function, its derivatives, or the variance function.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999,99		Algorithm converged.	0,00	NE
	FLIPI	Low (0-1)	25	19,4	9	36,0	19	14,6	5	26,3	1,57		Convergence criterion (GCONV=1E-8) satisfied.	0,43	5,82	0,097		Algorithm converged.	-0,176	0,370	1,37		Algorithm converged.	0,55	3,42	0,5026	0,3526	0,73		Algorithm converged.	0,29	1,83
		Intermediate (2)	30	23,3	13	43,3	27	20,8	11	40,7	1,11		Convergence criterion (GCONV=1E-8) satisfied.	0,39	3,19	0,026		Algorithm converged.	-0,231	0,282	1,06		Algorithm converged.	0,58	1,96	0,8433		0,94		Algorithm converged.	0,51	1,73
		High (>=3)	36	27,9	12	33,3	26	20,0	13	50,0	0,50		Convergence criterion (GCONV=1E-8) satisfied.	0,18	1,41	-0,167		Algorithm converged.	-0,413	0,080	0,67		Algorithm converged.	0,37	1,22	0,1860		1,50		Algorithm converged.	0,82	2,74
		Missing/Unknown		2	1,6	1	50,0	3	2,3				Quasi-complete separation of data points detected.					ERROR: Error in computing the link function, its derivatives, or the variance function.					WARNING: Negative of Hessian not positive definite.							WARNING: Negative of Hessian not positive definite.		
	Fc gamma receptor IIa	131HH	27	20,9	9	33,3	21	16,2	8	38,1	0,81		Convergence criterion (GCONV=1E-8) satisfied.	0,25	2,67	-0,048		Algorithm converged.	-0,321	0,226	0,88		Algorithm converged.	0,41	1,88	0,7315	0,5571	1,14		Algorithm converged.	0,53	2,45
		131HR	85	27,1	16	45,7	37	28,5	16	43,2	1,11		Convergence criterion (GCONV=1E-8) satisfied.	0,44	2,80	0,025		Algorithm converged.	-0,205	0,254	1,06		Algorithm converged.	0,63	1,77	0,8329		0,95		Algorithm converged.	0,56	1,59
		131RR	22	17,1	9	40,9	13	10,0	3	23,1	2,31		Convergence criterion (GCONV=1E-8) satisfied.	0,49	10,82	0,178		Algorithm converged.	-0,129	0,486	1,77		Algorithm converged.	0,58	6,39	0,3131		0,56		Algorithm converged.	0,19	1,72
		Missing		9	7,0	1	11,1	4	3,1	2	50,0	0,13	Convergence criterion (GCONV=1E-8) satisfied.	<0.01	2,18	-0,389		Algorithm converged.	-0,920	0,142	0,22		Algorithm converged.	0,03	1,80	0,1587		4,50		Algorithm converged.	0,56	36,44
	Fc gamma receptor IIIa	158VV	11	8,5	3	27,3	11	8,5	5	45,5	0,45		Convergence criterion (GCONV=1E-8) satisfied.	0,08	2,67	-0,182		Algorithm converged.	-0,577	0,213	0,60		Algorithm converged.	0,19	1,92	0,3889	0,4665	1,67		Algorithm converged.	0,52	6,33
		158VF	40	31,0	18	45,0	32	24,6	14	43,8	1,05		Convergence criterion (GCONV=1E-8) satisfied.	0,41	2,68	0,013		Algorithm converged.	-0,218	0,243	1,03		Algorithm converged.	0,61	1,73	0,9156		0,97		Algorithm converged.	0,58	1,64
		158FF	33	25,6	13	39,4	28	21,5	8	28,6	1,62		Convergence criterion (GCONV=1E-8) satisfied.	0,55	4,77	0,108		Algorithm converged.	-0,128	0,344	1,38		Algorithm converged.	0,67	2,84	0,3836		0,73		Algorithm converged.	0,35	1,49
		Missing		9	7,0	1	11,1	4	3,1	2	50,0	0,13	Convergence criterion (GCONV=1E-8) satisfied.	<0.01	2,18	-0,389		Algorithm converged.	-0,920	0,142	0,22		Algorithm converged.	0,03	1,80	0,1587		4,50		Algorithm converged.	0,56	36,44
	Fc gamma receptor IIb/IIc	232II	59	45,7	22	37,3	46	35,4	17	37,0	1,01		Convergence criterion (GCONV=1E-8) satisfied.	0,46	2,25	0,003		Algorithm converged.	-0,183	0,190	1,01		Algorithm converged.	0,61	1,67	0,9722		0,99		Algorithm converged.	0,60	1,64
		232IT	23	17,8	11	47,8	23	17,7	10	43,5	1,19		Convergence criterion (GCONV=1E-8) satisfied.	0,37	3,81	0,043		Algorithm converged.	-0,244	0,331	1,10		Algorithm converged.	0,58	2,07	0,7675		0,91		Algorithm converged.	0,48	1,71
		232TT		1	0,8	1	100,0	2	1,5				Complete separation of data points detected.					ERROR: Error in computing the link function, its derivatives, or the variance function.					WARNING: Negative of Hessian not positive definite.							WARNING: Negative of Hessian not positive definite.		
		Missing	10	7,8	1	10,0	4	3,1	2	50,0	0,11		Convergence criterion (GCONV=1E-8) satisfied.	<0.01	1,92	-0,400		Algorithm converged.	-0,924	0,124	0,20		Algorithm converged.	0,02	1,64	0,1334		5,00		Algorithm converged.	0,61	40,91
	Absolute lymphocyte count	>= median	44	34,1	20	45,5	35	26,9	13	37,1	1,41		Convergence criterion (GCONV=1E-8) satisfied.	0,57	3,49	0,083		Algorithm converged.	-0,134	0,301	1,22		Algorithm converged.	0,71	2,10	0,4627	0,2548	0,82		Algorithm converged.	0,48	1,40
		< median	49	38,0	15	30,6	38	29,2	15	39,5	0,68		Convergence criterion (GCONV=1E-8) satisfied.	0,28	1,65	-0,089		Algorithm converged.	-0,291	0,113	0,78		Algorithm converged.	0,44	1,38	0,3877		1,29		Algorithm converged.	0,72	2,30
		Missing					2	1,5	1	50,0	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE	NE	NE		Algorithm converged.	NE	NE	NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Time from initial NHL diagnosis to randomization	< 6 months		4	3,1	4	100,0	3	2,3	1	33,3		Quasi-complete separation of data points detected.					ERROR: The mean parameter is either invalid or at a limit of its range for some observations.					WARNING: The relative Hessian convergence criterion of 16560671630 is greater than the limit of 0.0001. The convergence is questionable.							WARNING: The relative Hessian convergence criterion of 16560671630 is greater than the limit of 0.0001. The convergence is questionable.		

		6-12 months		5	3,9		2	40,0		7	5,4		4	57,1	0,50		Convergence criterion (GCONV=1E-8) satisfied.	0,05	5,15	-8,171		Algorithm converged.	-0,736	0,393	0,70		Algorithm converged.	0,20	2,44	0,5762		1,43		Algorithm converged.	0,41	4,99
		> 12 months	84	65,1	29	34,5	65	50,0		24	36,9	0,90		Convergence criterion (GCONV=1E-8) satisfied.	0,46	1,77	-0,024		Algorithm converged.	-0,179	0,131	0,94		Algorithm converged.	0,61	1,44	0,7612		1,07		Algorithm converged.	0,69	1,65
	Beta 2 microglobulin	>= 3.5 mg/L	13	10,1		5	38,5	18	13,8		10	55,6	0,50		Convergence criterion (GCONV=1E-8) satisfied.	0,12	2,14	-0,171		Algorithm converged.	-0,521	0,179	0,69		Algorithm converged.	0,31	1,54	0,3690	0,3307	1,44		Algorithm converged.	0,65	3,22
		< 3.5 mg/L	76	58,9	27		35,5	55	42,3		18	32,7	1,13		Convergence criterion (GCONV=1E-8) satisfied.	0,54	2,36	0,028		Algorithm converged.	-0,136	0,192	1,09		Algorithm converged.	0,67	1,76	0,7402		0,92		Algorithm converged.	0,57	1,50
		Missing		4	3,1		3	75,0		2	1,5		1	50,0	3,00		Convergence criterion (GCONV=1E-8) satisfied.	0,08	107,45	0,250		Algorithm converged.	-0,563	1,063	1,50		Algorithm converged.	0,34	6,70	0,5955		0,67		Algorithm converged.	0,15	2,98
	Prior therapies	<= 2	77	59,7	26		33,8	56	43,1		21	37,5	0,85		Convergence criterion (GCONV=1E-8) satisfied.	0,41	1,74	-0,037		Algorithm converged.	-0,202	0,128	0,90		Algorithm converged.	0,57	1,43	0,6554	0,3469	1,11		Algorithm converged.	0,70	1,76
		> 2	16	12,4	9		56,3	19	14,6		8	42,1	1,77		Convergence criterion (GCONV=1E-8) satisfied.	0,46	6,78	0,141		Algorithm converged.	-0,188	0,471	1,34		Algorithm converged.	0,68	2,64	0,4050		0,75		Algorithm converged.	0,38	1,48
	Refractory Type	Rituximab + Chemotherapy	78	60,5	29		37,2	56	43,1		25	44,6	0,73		Convergence criterion (GCONV=1E-8) satisfied.	0,36	1,48	-0,075		Algorithm converged.	-0,243	0,094	0,83		Algorithm converged.	0,55	1,26	0,3821	0,1505	1,20		Algorithm converged.	0,80	1,81
		Rituximab Monotherapy	15	11,6	6		40,0	19	14,6		4	21,1	2,50		Convergence criterion (GCONV=1E-8) satisfied.	0,55	11,33	0,189		Algorithm converged.	-0,119	0,498	1,90		Algorithm converged.	0,65	5,53	0,2392		0,53		Algorithm converged.	0,18	1,53

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_base/qa/program/t_pro_rsp2.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_pro_rsp2_sg_IMPR_VASR_VASpop_FOLY_IT_01SEP2014_01297.xls 07AUG2020 16:10

5 (Anhang): Ergebnisse für EQ-5D-VAS - Verschlechterung des Gesundheitszustands um MID zehn - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients, Patients with Baseline and post Baseline EQ-5D VAS result

ENDPOINT: EQ-5D VAS - Responder(MID=10), Worsening

MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Efficacy)

			G-Benda (N=129)				Benda (N=130)				G-Benda vs. Benda																Benda vs. G-Benda			
			Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk								Relative Risk			
Endpoint	Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		95% Lower CL	95% Upper CL	Absolute Risk		95% Lower CL	95% Upper CL	Relative Risk		95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		95% Lower CL	95% Upper CL
											Convergence Reason				Convergence Reason				Convergence Reason						Convergence Reason			
Cycle 5 Day 1	All	n/a	107	82,9	16	15,0	100	76,9	25	25,0	0,53	Convergence criterion (GCONV=1E-8) satisfied.	0,26	1,06	-0,100	Algorithm converged.	-0,209	0,008	0,60	Algorithm converged.	0,34	1,05	0,0747		1,67	Algorithm converged.	0,95	2,94
	Sex	Male	65	50,4	7	10,8	56	43,1	13	23,2	0,40	Convergence criterion (GCONV=1E-8) satisfied.	0,15	1,09	-0,124	Algorithm converged.	-0,258	0,009	0,46	Algorithm converged.	0,20	1,08	0,0753	0,3603	2,16	Algorithm converged.	0,92	5,03
		Female	42	32,6	9	21,4	44	33,8	12	27,3	0,73	Convergence criterion (GCONV=1E-8) satisfied.	0,27	1,96	-0,058	Algorithm converged.	-0,239	0,122	0,79	Algorithm converged.	0,37	1,67	0,5306		1,27	Algorithm converged.	0,60	2,70
	Age	< 60 years	45	34,9	6	13,3	43	33,1	11	25,6	0,45	Convergence criterion (GCONV=1E-8) satisfied.	0,15	1,34	-0,122	Algorithm converged.	-0,286	0,041	0,52	Algorithm converged.	0,21	1,29	0,1571	0,6949	1,92	Algorithm converged.	0,78	4,73
		>= 60 years	62	48,1	10	16,1	57	43,8	14	24,6	0,59	Convergence criterion (GCONV=1E-8) satisfied.	0,24	1,46	-0,084	Algorithm converged.	-0,229	0,060	0,66	Algorithm converged.	0,32	1,36	0,2572		1,52	Algorithm converged.	0,74	3,15
	Race/ethnicity	White	101	78,3	15	14,9	88	67,7	22	25,0	0,52	Convergence criterion (GCONV=1E-8) satisfied.	0,25	1,09	-0,101	Algorithm converged.	-0,215	0,013	0,59	Algorithm converged.	0,33	1,07	0,0840	0,5020	1,68	Algorithm converged.	0,93	3,04
		Other	2	1,6			5	3,8	1	20,0	*	Quasi-complete separation of data points detected.			*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01	Algorithm converged.	0,00	NE	1,0000		>999.99	Algorithm converged.	0,00	NE
		Missing/Unknown	4	3,1	1	25,0	7	5,4	2	28,6	0,83	Convergence criterion (GCONV=1E-8) satisfied.	0,05	13,63	-0,036	Algorithm converged.	-0,576	0,505	0,88	Algorithm converged.	0,11	6,88	0,8990		1,14	Algorithm converged.	0,15	8,99
	Geographic region	Western Europe	43	33,3	9	20,9	44	33,8	8	18,2	1,19	Convergence criterion (GCONV=1E-8) satisfied.	0,41	3,44	0,027	Algorithm converged.	-0,139	0,194	1,15	Algorithm converged.	0,49	2,71	0,7468	0,1097	0,87	Algorithm converged.	0,37	2,04
		North America	53	41,1	6	11,3	47	36,2	13	27,7	0,33	Convergence criterion (GCONV=1E-8) satisfied.	0,12	0,97	-0,163	Algorithm converged.	-0,317	-0,010	0,41	Algorithm converged.	0,17	0,99	0,0476		2,44	Algorithm converged.	1,01	5,91
		Other	11	8,5	1	9,1	9	6,9	4	44,4	0,13	Convergence criterion (GCONV=1E-8) satisfied.	0,01	1,43	-0,354	Algorithm converged.	-0,720	0,013	0,20	Algorithm converged.	0,03	1,52	0,1211		4,89	Algorithm converged.	0,66	36,36
	Body mass index	Underweight (< 18.5)					1	0,8																0,1718				
		Normal weight (18.5 -< 25)	34	26,4	5	14,7	28	21,5	9	32,1	0,36	Convergence criterion (GCONV=1E-8) satisfied.	0,11	1,25	-0,174	Algorithm converged.	-0,384	0,036	0,46	Algorithm converged.	0,17	1,21	0,1149		2,19	Algorithm converged.	0,83	5,78
		Overweight (25 - < 30)	38	29,5	9	23,7	28	21,5	6	21,4	1,14	Convergence criterion (GCONV=1E-8) satisfied.	0,35	3,67	0,023	Algorithm converged.	-0,181	0,226	1,11	Algorithm converged.	0,44	2,75	0,8294		0,90	Algorithm converged.	0,36	2,25
		Obese (>= 30)	34	26,4	2	5,9	38	29,2	10	26,3	0,18	Convergence criterion (GCONV=1E-8) satisfied.	0,04	0,87	-0,204	Algorithm converged.	-0,365	-0,044	0,22	Algorithm converged.	0,05	0,95	0,0423		4,47	Algorithm converged.	1,05	18,99
		Missing	1	0,8			5	3,8																				
	Baseline ECOG Performance Status Score	0-1	104	80,6	16	15,4	95	73,1	25	26,3	0,51	Convergence criterion (GCONV=1E-8) satisfied.	0,25	1,03	-0,109	Algorithm converged.	-0,222	0,003	0,58	Algorithm converged.	0,33	1,03	0,0614		1,71	Algorithm converged.	0,97	3,00
		2	3	2,3			4	3,1																				
		Missing					1	0,8																				
	Independence status (Katz ADL)	Independent (5-6)	42	32,6	7	16,7	39	30,0	9	23,1	0,67	Convergence criterion (GCONV=1E-8) satisfied.	0,22	2,01	-0,064	Algorithm converged.	-0,238	0,110	0,72	Algorithm converged.	0,30	1,75	0,4718	<.0001	1,38	Algorithm converged.	0,57	3,36
		Very dependent (0-2)	2	1,6																								
		Missing	63	48,8	9	14,3	61	46,9	10	26,2	0,47	Convergence criterion (GCONV=1E-8) satisfied.	0,19	1,16	-0,119	Algorithm converged.	-0,260	0,021	0,54	Algorithm converged.	0,26	1,14	0,1061		1,84	Algorithm converged.	0,88	3,84
	Best response to prior therapy	CR/PR	88	68,2	14	15,9	80	61,5	20	25,0	0,57	Convergence criterion (GCONV=1E-8) satisfied.	0,26	1,22	-0,091	Algorithm converged.	-0,213	0,031	0,64	Algorithm converged.	0,35	1,17	0,1479	0,2394	1,57	Algorithm converged.	0,85	2,90
		SD	15	11,6	1	6,7	14	10,8	4	28,6	0,18	Convergence criterion (GCONV=1E-8) satisfied.	0,02	1,85	-0,219	Algorithm converged.	-0,487	0,049	0,23	Algorithm converged.	0,03	1,84	0,1676		4,29	Algorithm converged.	0,54	33,85
		PD	4	3,1	1	25,0	3	2,3			*	Quasi-complete separation of data points detected.			*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE	Algorithm converged.	NE	NE	NE		NE	Algorithm converged.	NE	NE
		Missing (UE)					3	2,3	1	33,3	NE	Convergence criterion (GCONV=1E-8) satisfied.	NE	NE	NE	Algorithm converged.	NE	NE	NE	Algorithm converged.	NE	NE	NE		NE	Algorithm converged.	NE	NE
	Histologic grade (follicular)	1	43	33,3	3	7,0	29	22,3	8	27,6	0,20	Convergence criterion (GCONV=1E-8) satisfied.	0,05	0,82	-0,206	Algorithm converged.	-0,386	-0,026	0,25	Algorithm converged.	0,07	0,87	0,0299	0,2792	3,95	Algorithm converged.	1,14	13,67
		2	45	34,9	10	22,2	43	33,1	11	25,6	0,83	Convergence criterion (GCONV=1E-8) satisfied.	0,31	2,22	-0,034	Algorithm converged.	-0,212	0,145	0,87	Algorithm converged.	0,41	1,83	0,7120		1,15	Algorithm converged.	0,55	2,43
		3					3	2,3																				
		3a	13	10,1	1	7,7	20	15,4	4	20,0	0,33	Convergence criterion (GCONV=1E-8) satisfied.	0,03	3,38	-0,123	Algorithm converged.	-0,350	0,104	0,38	Algorithm converged.	0,05	0,07	0,3673		2,60	Algorithm converged.	0,33	20,75
		Missing/Unknown/Variants	6	4,7	2	33,3	5	3,8	2	40,0	0,75	Convergence criterion (GCONV=1E-8) satisfied.	0,06	8,83	-0,067	Algorithm converged.	-0,638	0,505	0,83	Algorithm converged.	0,18	3,96	0,8188		1,20	Algorithm converged.	0,25	5,71
	FLIPI	Low (0-1)	25	19,4	4	16,0	24	18,5	7	29,2	0,46	Convergence criterion (GCONV=1E-8) satisfied.	0,12	1,85	-0,132	Algorithm converged.	-0,363	0,100	0,55	Algorithm converged.	0,18	1,64	0,2818	0,6685	1,82	Algorithm converged.	0,61	5,44

		Intermediate (2)	33	25,6	6	18,2	34	26,2	7	20,6	0,86		Convergence criterion (GCONV=1E-8) satisfied.	0,25	2,89	-0,024		Algorithm converged.	-0,213	0,165	0,88		Algorithm converged.	0,33	2,35	0,8036		1,13		Algorithm converged.	0,43	3,02
		High (>=3)	43	33,3	5	11,6	37	28,5	9	24,3	0,41		Convergence criterion (GCONV=1E-8) satisfied.	0,12	1,36	-0,127		Algorithm converged.	-0,295	0,041	0,48		Algorithm converged.	0,18	1,30	0,1484		2,09		Algorithm converged.	0,77	5,69
		Missing/Unknown		4,7	1	16,7	5	3,8	2	40,0	0,30		Convergence criterion (GCONV=1E-8) satisfied.	0,02	4,91	-0,233		Algorithm converged.	-0,756	0,289	0,42		Algorithm converged.	0,05	0,36	0,4109		2,40		Algorithm converged.	0,30	19,34
	Fc gamma receptor IIa	131HH	26	20,2	6	23,1	25	19,2	8	32,0	0,64		Convergence criterion (GCONV=1E-8) satisfied.	0,18	2,20	-0,089		Algorithm converged.	-0,333	0,155	0,72		Algorithm converged.	0,29	1,78	0,4790	0,3570	1,39		Algorithm converged.	0,56	3,43
		131HR	46	35,7	2	4,3	52	40,0	10	19,2	0,19		Convergence criterion (GCONV=1E-8) satisfied.	0,04	0,92	-0,149		Algorithm converged.	-0,271	-0,027	0,23		Algorithm converged.	0,05	0,98	0,0467		4,42		Algorithm converged.	1,02	19,15
		131RR	25	19,4	4	16,0	17	13,1	7	41,2	0,27		Convergence criterion (GCONV=1E-8) satisfied.	0,06	1,15	-0,252		Algorithm converged.	-0,526	0,023	0,39		Algorithm converged.	0,13	1,12	0,0813		2,57		Algorithm converged.	0,89	7,45
		Missing	10	7,8	4	40,0	6	4,6				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Fc gamma receptor IIIa	158VV	11	8,5			17	13,1	2	11,8		*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			<0.01		Algorithm converged.	0,00		NE	1,0000	0,3160	>999.99		Algorithm converged.	0,00		NE
		158VF	48	37,2	7	14,6	46	35,4	18	39,1	0,27		Convergence criterion (GCONV=1E-8) satisfied.	0,10	0,72	-0,245		Algorithm converged.	-0,418	-0,073	0,37		Algorithm converged.	0,17	0,81	0,0124		2,68		Algorithm converged.	1,24	6,82
		158FF	38	29,5	5	13,2	31	23,8	5	16,1	0,79		Convergence criterion (GCONV=1E-8) satisfied.	0,21	3,01	-0,030		Algorithm converged.	-0,198	0,139	0,82		Algorithm converged.	0,26	2,56	0,7275		1,23		Algorithm converged.	0,39	3,85
		Missing	10	7,8	4	40,0	6	4,6				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Fc gamma receptor IIb/IIc	232IT	67	51,9	8	11,9	64	49,2	20	31,3	0,30		Convergence criterion (GCONV=1E-8) satisfied.	0,12	0,74	-0,193		Algorithm converged.	-0,331	-0,056	0,38		Algorithm converged.	0,18	0,80	0,0114	0,6863	2,62		Algorithm converged.	1,24	5,51
		232IT	28	21,7	3	10,7	26	20,0	4	15,4	0,66		Convergence criterion (GCONV=1E-8) satisfied.	0,13	3,28	-0,047		Algorithm converged.	-0,227	0,133	0,70		Algorithm converged.	0,17	2,82	0,6121		1,44		Algorithm converged.	0,35	5,81
		232TT		10,8				42,1	1	25,0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01		Algorithm converged.	0,00		NE	1,0000		>999.99		Algorithm converged.	0,00		NE
		Missing	11	8,5	5	45,5	6	4,6				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.				*	WARNING: Negative of Hessian not positive definite.						*	WARNING: Negative of Hessian not positive definite.			
	Absolute lymphocyte count	>= median	47	36,4	6	12,8	50	38,5	17	34,0	0,28		Convergence criterion (GCONV=1E-8) satisfied.	0,10	0,80	-0,212		Algorithm converged.	-0,375	-0,050	0,38		Algorithm converged.	0,16	0,87	0,0225	0,0859	2,66		Algorithm converged.	1,15	6,18
		< median	60	46,5	10	16,7	50	38,5	8	16,0	1,05		Convergence criterion (GCONV=1E-8) satisfied.	0,38	2,90	0,007		Algorithm converged.	-0,132	0,145	1,04		Algorithm converged.	0,44	2,44	0,9251		0,96		Algorithm converged.	0,41	2,25
	Time from initial NHL diagnosis to randomization	< 6 months		4	3,1			4	3,1																										
		6-12 months		6	4,7	1	16,7	10	7,7	1	10,0	1,80		Convergence criterion (GCONV=1E-8) satisfied.	0,09	35,42	0,067		Algorithm converged.	-0,285	0,418	1,67		Algorithm converged.	0,13	22,00	0,6980		0,60		Algorithm converged.	0,05	7,92
		> 12 months	97	75,2	15	15,5	86	66,2	24	27,9	0,47		Convergence criterion (GCONV=1E-8) satisfied.	0,23	0,98	-0,124		Algorithm converged.	-0,243	-0,005	0,55		Algorithm converged.	0,31	0,99	0,0446		1,80		Algorithm converged.	1,01	3,21
	Beta 2 microglobulin	>= 3.5 mg/L	17	13,2	1	5,9	21	16,2	2	9,5	0,59		Convergence criterion (GCONV=1E-8) satisfied.	0,05	7,17	-0,036		Algorithm converged.	-0,205	0,132	0,62		Algorithm converged.	0,06	6,25	0,6832	0,9867	1,62		Algorithm converged.	0,16	16,37
		< 3.5 mg/L	85	65,9	15	17,6	75	57,7	21	28,0	0,55		Convergence criterion (GCONV=1E-8) satisfied.	0,26	1,17	-0,104		Algorithm converged.	-0,234	0,026	0,63		Algorithm converged.	0,35	1,13	0,1222		1,59		Algorithm converged.	0,88	2,85
		Missing		3,9				4	3,1	2	50,0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	WARNING: Negative of Hessian not positive definite.						*	WARNING: Negative of Hessian not positive definite.			
	Prior therapies	<= 2	91	70,5	12	13,2	79	60,8	21	26,6	0,42		Convergence criterion (GCONV=1E-8) satisfied.	0,19	0,92	-0,134		Algorithm converged.	-0,254	-0,014	0,50		Algorithm converged.	0,26	0,94	0,0324	0,1744	2,02		Algorithm converged.	1,06	3,83
		> 2	16	12,4	4	25,0	21	16,2	4	19,0	1,42		Convergence criterion (GCONV=1E-8) satisfied.	0,29	6,81	0,060		Algorithm converged.	-0,211	0,330	1,31		Algorithm converged.	0,39	4,46	0,6632		0,76		Algorithm converged.	0,22	2,59
	Refractory Type	Rituximab + Chemotherapy	91	70,5	12	13,2	73	56,2	19	26,0	0,43		Convergence criterion (GCONV=1E-8) satisfied.	0,19	0,96	-0,128		Algorithm converged.	-0,251	-0,006	0,51		Algorithm converged.	0,26	0,97	0,0415	0,2379	1,97		Algorithm converged.	1,03	3,80
		Rituximab Monotherapy	16	12,4	4	25,0	27	20,8	6	22,2	1,17		Convergence criterion (GCONV=1E-8) satisfied.	0,27	4,98	0,028		Algorithm converged.	-0,236	0,292	1,12		Algorithm converged.	0,37	3,39	0,8343		0,89		Algorithm converged.	0,29	2,68
Follow Up Visit 1 Month 2	All	n/a	93	72,1	18	19,4	75	57,7	12	16,0	1,26		Convergence criterion (GCONV=1E-8) satisfied.	0,56	2,81	0,034		Algorithm converged.	-0,082	0,149	1,21		Algorithm converged.	0,62	2,35	0,5743		0,83		Algorithm converged.	0,43	1,61
	Sex	Male	58	45,0	11	19,0	41	31,5	8	19,5	0,97		Convergence criterion (GCONV=1E-8) satisfied.	0,35	2,66	-0,005		Algorithm converged.	-0,163	0,152	0,97		Algorithm converged.	0,43	2,20	0,9457	0,4292	1,03		Algorithm converged.	0,45	2,33
		Female	35	27,1	7	20,0	34	26,2	4	11,8	1,87		Convergence criterion (GCONV=1E-8) satisfied.	0,49	7,10	0,082		Algorithm converged.	-0,089	0,253	1,70		Algorithm converged.	0,55	5,28	0,3592		0,59		Algorithm converged.	0,19	1,83
	Age	< 60 years	39	30,2	7	17,9	32	24,6	4	12,5	1,53		Convergence criterion (GCONV=1E-8) satisfied.	0,41	5,78	0,054		Algorithm converged.	-0,112	0,221	1,44		Algorithm converged.	0,46	4,47	0,5325	0,7028	0,70		Algorithm converged.	0,22	2,17
		>= 60 years	54	41,9	11	20,4	43	33,1	8	18,6	1,12		Convergence criterion (GCONV=1E-8) satisfied.	0,41	3,09	0,018		Algorithm converged.	-0,141	0,176	1,09		Algorithm converged.	0,48	2,48	0,8280		0,91		Algorithm converged.	0,40	2,07
	Race/ethnicity	White	88	68,2	17	19,3	68	52,3	11	16,2	1,24		Convergence criterion (GCONV=1E-8) satisfied.	0,54	2,86	0,031		Algorithm converged.	-0,089	0,152	1,19		Algorithm converged.	0,60	2,38	0,6138	0,3574	0,84		Algorithm converged.	0,42	1,67
		Other		2	1,6			5	3,8	1	20,0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01		Algorithm converged.	0,00		NE	1,0000		>999.99		Algorithm converged.	0,00		NE
		Missing/Unknown		3	2,3	1	33,3	2	1,5				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Geographic region	Western Europe	35	27,1	8	22,9	30	23,1	2	6,7	4,15		Convergence criterion (GCONV=1E-8) satisfied.	0,81	21,31	0,162		Algorithm converged.	-0,003	0,327	3,43		Algorithm converged.	0,79	14,92	0,1006	0,0780	0,29		Algorithm converged.	0,07	1,27

		North America	47	36,4	10	21,3	37	28,5	9	24,3	0,84		Convergence criterion (GCONV=1E-8) satisfied.	0,30	2,35	-0,030		Algorithm converged.	-0,212	0,151	0,87		Algorithm converged.	0,40	1,93	0,7401		1,14		Algorithm converged.	0,52	2,52
		Other	11	8,5			8	36,2	1	12,5		*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			<0.01		Algorithm converged.	0,00	NE	0,9999		>999.99		Algorithm converged.	0,00	NE
	Body mass index	Underweight (< 18.5)					1	0,8																		0,3392						
		Normal weight (18.5 - < 25)	28	21,7	6	21,4	21	16,2	2	9,5	2,59		Convergence criterion (GCONV=1E-8) satisfied.	0,47	14,38	0,119		Algorithm converged.	-0,078	0,316	2,25		Algorithm converged.	0,50	10,05	0,2883		0,44		Algorithm converged.	0,10	1,99
		Overweight (25 - < 30)	34	26,4	8	23,5	22	16,9	3	13,6	1,95		Convergence criterion (GCONV=1E-8) satisfied.	0,46	8,33	0,099		Algorithm converged.	-0,103	0,301	1,73		Algorithm converged.	0,51	5,81	0,3784		0,58		Algorithm converged.	0,17	1,95
		Obese (>= 30)	30	23,3	4	13,3	28	21,5	7	25,0	0,46		Convergence criterion (GCONV=1E-8) satisfied.	0,12	1,79	-0,117		Algorithm converged.	-0,318	0,085	0,53		Algorithm converged.	0,17	1,63	0,2693		1,88		Algorithm converged.	0,61	5,72
		Missing		1	0,8			3	2,3																									
	Baseline ECOG Performance Status score	0-1	91	70,5	18	19,8	73	56,2	12	16,4	1,25		Convergence criterion (GCONV=1E-8) satisfied.	0,56	2,81	0,033		Algorithm converged.	-0,085	0,151	1,20		Algorithm converged.	0,62	2,33	0,5839		0,83		Algorithm converged.	0,43	1,61
		2		2	1,6			1	0,8																									
		Missing						1	0,8																									
	Independence status (Katz ADL)	Independent (5-6)	35	27,1	10	28,6	32	24,6	7	21,9	1,43		Convergence criterion (GCONV=1E-8) satisfied.	0,47	4,35	0,067		Algorithm converged.	-0,140	0,274	1,31		Algorithm converged.	0,56	3,02	0,5325		NE	0,77		Algorithm converged.	0,33	1,77
		Missing	58	45,0	8	13,8	43	33,1	5	11,6	1,22		Convergence criterion (GCONV=1E-8) satisfied.	0,37	4,01	0,022		Algorithm converged.	-0,109	0,152	1,19		Algorithm converged.	0,42	3,37	0,7489		0,84		Algorithm converged.	0,30	2,40
	Best response to prior therapy	CR/PR	75	58,1	16	21,3	61	46,9	7	11,5	2,09		Convergence criterion (GCONV=1E-8) satisfied.	0,80	5,47	0,099		Algorithm converged.	-0,024	0,221	1,86		Algorithm converged.	0,82	4,23	0,1390		0,54		Algorithm converged.	0,24	1,22
		SD	15	11,6	2	13,3	10	7,7	2	20,0	0,62		Convergence criterion (GCONV=1E-8) satisfied.	0,07	5,28	-0,067		Algorithm converged.	-0,368	0,235	0,67		Algorithm converged.	0,11	3,99	0,6569		1,50		Algorithm converged.	0,25	8,98
		PD		3	2,3			3	2,3	3	100,0		*	Complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.						*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.		
		Missing (UE)						1	0,8																									
	Histologic grade (follicular)	1	38	29,5	5	13,2	20	15,4	3	15,0	0,86		Convergence criterion (GCONV=1E-8) satisfied.	0,18	4,03	-0,018		Algorithm converged.	-0,208	0,171	0,88		Algorithm converged.	0,23	3,30	0,8463	0,4481	1,14		Algorithm converged.	0,30	4,29
		2	42	32,6	11	26,2	35	26,9	4	11,4	2,75		Convergence criterion (GCONV=1E-8) satisfied.	0,79	9,58	0,148		Algorithm converged.	-0,022	0,317	2,29		Algorithm converged.	0,80	6,57	0,1226		0,44		Algorithm converged.	0,15	1,25
		3					1	0,8																									
		3a		9	7,0	1	11,1	15	11,5	4	26,7	0,34		Convergence criterion (GCONV=1E-8) satisfied.	0,03	3,69	-0,156		Algorithm converged.	-0,459	0,148	0,42		Algorithm converged.	0,05	3,17	0,3978		2,40		Algorithm converged.	0,32	18,26
		Missing/Unknown/Variants	4	3,1	1	25,0	4	3,1	1	25,0	1,00		Convergence criterion (GCONV=1E-8) satisfied.	0,04	24,55	0,000		Algorithm converged.	-0,600	0,600	1,00		Algorithm converged.	0,09	11,03	1,0000		1,00		Algorithm converged.	0,09	11,03
	FLIPI	Low (0-1)	25	19,4	5	20,0	19	14,6	4	21,1	0,94		Convergence criterion (GCONV=1E-8) satisfied.	0,21	4,10	-0,011		Algorithm converged.	-0,252	0,231	0,95		Algorithm converged.	0,29	3,07	0,9316	0,6147	1,05		Algorithm converged.	0,33	3,40
		Intermediate (2)	30	23,3	7	23,3	27	20,8	3	11,1	2,43		Convergence criterion (GCONV=1E-8) satisfied.	0,56	10,57	0,122		Algorithm converged.	-0,070	0,314	2,10		Algorithm converged.	0,60	7,32	0,2442		0,48		Algorithm converged.	0,14	1,66
		High (>=3)	36	27,9	6	16,7	26	20,0	4	15,4	1,10		Convergence criterion (GCONV=1E-8) satisfied.	0,28	4,37	0,013		Algorithm converged.	-0,172	0,197	1,08		Algorithm converged.	0,34	3,46	0,8924		0,92		Algorithm converged.	0,29	2,95
		Missing/Unknown		2	1,6			3	2,3	1	33,3		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE
	Fc gamma receptor IIa	131HH	27	20,9	6	22,2	21	16,2	3	14,3	1,71		Convergence criterion (GCONV=1E-8) satisfied.	0,37	7,86	0,079		Algorithm converged.	-0,137	0,296	1,56		Algorithm converged.	0,44	5,50	0,4930	0,4131	0,64		Algorithm converged.	0,18	2,27
		131HR	35	27,1	6	17,1	37	28,5	6	16,2	1,07		Convergence criterion (GCONV=1E-8) satisfied.	0,31	3,69	0,009		Algorithm converged.	-0,163	0,182	1,06		Algorithm converged.	0,38	2,97	0,9160		0,95		Algorithm converged.	0,34	2,66
		131RR	22	17,1	2	9,1	13	10,0	3	23,1	0,33		Convergence criterion (GCONV=1E-8) satisfied.	0,05	2,33	-0,140		Algorithm converged.	-0,398	0,119	0,39		Algorithm converged.	0,08	2,06	0,2692		2,54		Algorithm converged.	0,49	13,25
		Missing		9	7,0	4	44,4	4	3,1			*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	WARNING: Negative of Hessian not positive definite.						*	WARNING: Negative of Hessian not positive definite.		
	Fc gamma receptor IIIa	158VV	11	8,5			11	8,5	2	18,2		*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			<0.01		Algorithm converged.	0,00	NE	0,9999	0,1981	>999.99		Algorithm converged.	0,00	NE
		158VF	40	31,0	9	22,5	32	24,6	7	21,9	1,04		Convergence criterion (GCONV=1E-8) satisfied.	0,34	3,18	0,006		Algorithm converged.	-0,187	0,199	1,03		Algorithm converged.	0,43	2,46	0,9495		0,97		Algorithm converged.	0,41	2,32
		158FF	33	25,6	5	15,2	28	21,5	3	10,7	1,49		Convergence criterion (GCONV=1E-8) satisfied.	0,32	6,87	0,044		Algorithm converged.	-0,123	0,212	1,41		Algorithm converged.	0,37	5,40	0,6122		0,71		Algorithm converged.	0,19	2,70
		Missing		9	7,0	4	44,4	4	3,1			*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	WARNING: Negative of Hessian not positive definite.						*	WARNING: Negative of Hessian not positive definite.		
	Fc gamma receptor IIb/IIc	232II	59	45,7	10	16,9	46	35,4	11	23,9	0,65		Convergence criterion (GCONV=1E-8) satisfied.	0,25	1,70	-0,070		Algorithm converged.	-0,226	0,086	0,71		Algorithm converged.	0,33	1,52	0,3777		1,41		Algorithm converged.	0,66	3,03
		232IT	23	17,8	3	13,0	23	17,7	1	4,3	3,30		Convergence criterion (GCONV=1E-8) satisfied.	0,32	34,35	0,087		Algorithm converged.	-0,074	0,248	3,00		Algorithm converged.	0,34	26,76	0,3251		0,33		Algorithm converged.	0,04	2,97
		232TT		1	0,8			2	1,5																									
		Missing	10	7,8	5	50,0	4	3,1				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.				*	WARNING: Negative of Hessian not positive definite.						*	WARNING: Negative of Hessian not positive definite.		
	Absolute lymphocyte count	>= median	44	34,1	7	15,9	35	26,9	5	14,3	1,14		Convergence criterion (GCONV=1E-8) satisfied.	0,33	3,94	0,016		Algorithm converged.	-0,142	0,175	1,11		Algorithm converged.	0,39	3,21	0,8420	0,7305	0,90		Algorithm converged.	0,31	2,59
		< median	49	38,0	11	22,4	38	29,2	6	15,8	1,54		Convergence criterion (GCONV=1E-8) satisfied.	0,51	4,64	0,067		Algorithm converged.	-0,098	0,231	1,42		Algorithm converged.	0,58	3,50	0,4435		0,70		Algorithm converged.	0,29	1,73
		Missing						2	1,5	1	50,0	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE	NE	NE		Algorithm converged.	NE	NE	NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE

| | | |

6 (Anhang): Ergebnisse für FACT-G - Verbesserung der Gesundheitsbezogenen Lebensqualität um MID sechs - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients, Patients with Baseline and post Baseline FACT-G Total result
ENDPOINT: FACT-G Total - Responder (MID=6), Improvement
MODEL: Unstratified Analysis STUDY:
G001297
Dichotomous Analysis by Subgroups (Efficacy)

			G-Benda (N=130)				Benda (N=133)				G-Benda vs. Benda													Benda vs. G-Benda				
			Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk				
Endpoint	Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
Cycle 5 Day 1	All	n/a	110	84,6	24	21,8	103	77,4	23	22,3	0,97	Convergence criterion (GCONV=1E-8) satisfied.	0,51	1,86	-0,005	Algorithm converged.	-0,117	0,106	0,98	Algorithm converged.	0,59	1,62	0,9283		1,02	Algorithm converged.	0,62	1,70
	Sex	Male	65	50,0	16	24,6	55	41,4	11	20,0	1,31	Convergence criterion (GCONV=1E-8) satisfied.	0,55	3,11	0,046	Algorithm converged.	-0,103	0,195	1,23	Algorithm converged.	0,62	2,43	0,5486	0,2988	0,81	Algorithm converged.	0,41	1,60
		Female	45	34,6	8	17,8	48	36,1	12	25,0	0,65	Convergence criterion (GCONV=1E-8) satisfied.	0,24	1,77	-0,072	Algorithm converged.	-0,238	0,094	0,71	Algorithm converged.	0,32	1,58	0,4017		1,41	Algorithm converged.	0,63	3,12
	Age	< 60 years	45	34,6	7	15,6	44	33,1	14	31,8	0,39	Convergence criterion (GCONV=1E-8) satisfied.	0,14	1,10	-0,163	Algorithm converged.	-0,336	0,011	0,49	Algorithm converged.	0,22	1,10	0,0820	0,0185	2,05	Algorithm converged.	0,91	4,58
		>= 60 years	65	50,0	17	26,2	59	44,4	9	15,3	1,97	Convergence criterion (GCONV=1E-8) satisfied.	0,80	4,84	0,109	Algorithm converged.	-0,032	0,250	1,71	Algorithm converged.	0,83	3,55	0,1461		0,58	Algorithm converged.	0,28	1,21
	Race/ethnicity	White	101	77,7	21	20,8	92	69,2	20	21,7	0,94	Convergence criterion (GCONV=1E-8) satisfied.	0,47	1,88	-0,009	Algorithm converged.	-0,125	0,106	0,96	Algorithm converged.	0,56	1,65	0,8723	0,5323	1,05	Algorithm converged.	0,61	1,80
		Other	5	3,8	1	20,0	5	3,8	2	40,0	0,38	Convergence criterion (GCONV=1E-8) satisfied.	0,02	6,35	-0,200	Algorithm converged.	-0,754	0,354	0,50	Algorithm converged.	0,06	3,91	0,5087		2,00	Algorithm converged.	0,26	15,62
		Missing/Unknown	4	3,1	2	50,0	6	4,5	1	16,7	0,00	Convergence criterion (GCONV=1E-8) satisfied.	0,27	91,52	0,333	Algorithm converged.	-0,240	0,907	3,00	Algorithm converged.	0,39	23,07	0,2912		0,33	Algorithm converged.	0,04	2,56
	Geographic region	Western Europe	45	34,6	12	26,7	46	34,6	11	23,9	1,16	Convergence criterion (GCONV=1E-8) satisfied.	0,45	2,98	0,028	Algorithm converged.	-0,151	0,206	1,12	Algorithm converged.	0,55	2,26	0,7627	0,1402	0,90	Algorithm converged.	0,44	1,82
		North America	54	41,5	12	22,2	49	36,8	10	20,4	1,11	Convergence criterion (GCONV=1E-8) satisfied.	0,43	2,87	0,018	Algorithm converged.	-0,140	0,176	1,09	Algorithm converged.	0,52	2,29	0,8227		0,92	Algorithm converged.	0,44	1,93
		Other	11	8,5			8	6,0	2	25,0		* Quasi-complete separation of data points detected.				* ERROR: Error in computing the link function, its derivatives, or the variance function.					<0.01	Algorithm converged.	0,00	NE	0,9999		>999.99	Algorithm converged.	0,00	NE
	Body mass index	Underweight (< 18.5)					1	0,8																0,8440				
		Normal weight (18.5 - < 25)	36	27,7	9	25,0	30	22,6	8	26,7	0,92	Convergence criterion (GCONV=1E-8) satisfied.	0,30	2,77	-0,017	Algorithm converged.	-0,229	0,196	0,94	Algorithm converged.	0,41	2,13	0,8774		1,07	Algorithm converged.	0,47	2,42
		Overweight (25 - < 30)	38	29,2	8	21,1	29	21,8	5	17,2	1,28	Convergence criterion (GCONV=1E-8) satisfied.	0,37	4,42	0,038	Algorithm converged.	-0,151	0,227	1,22	Algorithm converged.	0,45	3,34	0,6976		0,82	Algorithm converged.	0,30	2,24
		Obese (>= 30)	35	26,9	7	20,0	38	28,6	7	18,4	1,11	Convergence criterion (GCONV=1E-8) satisfied.	0,35	3,55	0,016	Algorithm converged.	-0,165	0,197	1,09	Algorithm converged.	0,42	2,78	0,8641		0,92	Algorithm converged.	0,36	2,36
		Missing	1	0,8			5	3,8	3	60,0		* Quasi-complete separation of data points detected.				* ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				* WARNING: Negative of Hessian not positive definite.						* WARNING: Negative of Hessian not positive definite.		
	Baseline ECOG Performance Status score	0-1	108	83,1	22	20,4	98	73,7	21	21,4	0,94	Convergence criterion (GCONV=1E-8) satisfied.	0,48	1,84	-0,011	Algorithm converged.	-0,122	0,101	0,95	Algorithm converged.	0,56	1,62	0,8519		1,05	Algorithm converged.	0,62	1,79
		2	2	1,5	2	100,0	4	3,0	1	25,0		* Quasi-complete separation of data points detected.				* ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				* ERROR: The mean parameter is either invalid or at a limit of its range for some observations.						* ERROR: The mean parameter is either invalid or at a limit of its range for some observations.		
		Missing					1	0,8	1	100,0																		
	Independence status (Katz ADL)	Independent (5-6)	44	33,8	8	18,2	39	29,3	9	23,1	0,74	Convergence criterion (GCONV=1E-8) satisfied.	0,25	2,16	-0,049	Algorithm converged.	-0,224	0,126	0,79	Algorithm converged.	0,34	1,84	0,5822	<.0001	1,27	Algorithm converged.	0,54	2,97
		Very dependent (0-2)	2	1,5	1	50,0																						
		Missing	64	49,2	15	23,4	64	48,1	14	21,9	1,09	Convergence criterion (GCONV=1E-8) satisfied.	0,48	2,50	0,016	Algorithm converged.	-0,129	0,161	1,07	Algorithm converged.	0,56	2,03	0,8328		0,93	Algorithm converged.	0,49	1,77
	Best response to prior therapy	CR/PR	89	68,5	18	20,2	83	62,4	17	20,5	0,98	Convergence criterion (GCONV=1E-8) satisfied.	0,47	2,07	-0,003	Algorithm converged.	-0,123	0,118	0,99	Algorithm converged.	0,55	1,78	0,9666	0,9134	1,01	Algorithm converged.	0,56	1,83
		SD	16	12,3	5	31,3	14	10,5	5	35,7	0,82	Convergence criterion (GCONV=1E-8) satisfied.	0,18	3,74	-0,045	Algorithm converged.	-0,383	0,294	0,88	Algorithm converged.	0,32	2,40	0,7957		1,14	Algorithm converged.	0,42	3,14
		PD	5	3,8	1	20,0	3	2,3	1	33,3	0,50	Convergence criterion (GCONV=1E-8) satisfied.	0,02	12,90	-0,133	Algorithm converged.	-0,772	0,505	0,60	Algorithm converged.	0,06	6,44	0,6732		1,67	Algorithm converged.	0,16	17,89
		Missing (UE)					3	2,3																				
	Histologic grade (follicular)	1	42	32,3	10	23,8	29	21,8	8	27,6	0,82	Convergence criterion (GCONV=1E-8) satisfied.	0,28	2,42	-0,038	Algorithm converged.	-0,245	0,170	0,86	Algorithm converged.	0,39	1,92	0,7184	0,9382	1,16	Algorithm converged.	0,52	2,58
		2	49	37,7	10	20,4	47	35,3	9	19,1	1,08	Convergence criterion (GCONV=1E-8) satisfied.	0,40	2,96	0,013	Algorithm converged.	-0,147	0,172	1,07	Algorithm converged.	0,48	2,39	0,8770		0,94	Algorithm converged.	0,42	2,10
		3					2	1,5																				
		3a	13	10,0	2	15,4	20	15,0	5	25,0	0,55	Convergence criterion (GCONV=1E-8) satisfied.	0,09	3,35	-0,096	Algorithm converged.	-0,369	0,177	0,62	Algorithm converged.	0,14	2,71	0,5213		1,62	Algorithm converged.	0,37	7,17
		Missing/Unknown/Variants	6	4,6	2	33,3	5	3,8	1	20,0	2,00	Convergence criterion (GCONV=1E-8) satisfied.	0,13	31,98	0,133	Algorithm converged.	-0,382	0,648	1,67	Algorithm converged.	0,21	13,43	0,6313		0,60	Algorithm converged.	0,07	4,83

| | | |

	Body mass index	Underweight (< 18.5)					1	0,8																									
		Normal weight (18.5 - < 25)	29	22,3		7	24,1	22	16,5	8	36,4	0,56		Convergence criterion (GCONV=1E-8) satisfied.	0,17	1,88	-0,122		Algorithm converged.	-0,377	0,132	0,66		Algorithm converged.	0,28	1,55	0,3445		0,5423	1,51		Algorithm converged.	0,64	3,52
		Overweight (25 - < 30)	36	27,7	10	27,8	23	17,3	4	17,4	1,83			Convergence criterion (GCONV=1E-8) satisfied.	0,50	6,71	0,104		Algorithm converged.	-0,109	0,317	1,60		Algorithm converged.	0,57	4,50	0,3751			0,63		Algorithm converged.	0,22	1,76
		Obese (>= 30)	30	23,1	11	36,7	26	19,5	8	30,8	1,30			Convergence criterion (GCONV=1E-8) satisfied.	0,43	3,98	0,059		Algorithm converged.	-0,188	0,306	1,19		Algorithm converged.	0,57	2,51	0,6441			0,84		Algorithm converged.	0,40	1,77
		Missing		1	0,8			3	2,3	2	66,7		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	WARNING: Negative of Hessian not positive definite.				*			*	WARNING: Negative of Hessian not positive definite.		
	Baseline ECOG Performance Status score	0-1	95	73,1	27	28,4	73	54,9	20	27,4	1,05			Convergence criterion (GCONV=1E-8) satisfied.	0,53	2,08	0,010		Algorithm converged.	-0,126	0,147	1,04		Algorithm converged.	0,63	1,70	0,8836			0,96		Algorithm converged.	0,59	1,58
		2		1	0,8		1	100,0	1	0,8							1	100,0															
		Missing							1	0,8							1	100,0															
	Independence status (Katz ADL)	Independent (5-6)	36	27,7	7	19,4	31	23,3	8	25,8	0,69			Convergence criterion (GCONV=1E-8) satisfied.	0,22	2,20	-0,064		Algorithm converged.	-0,265	0,137	0,75		Algorithm converged.	0,31	1,84	0,5346		NE	1,33		Algorithm converged.	0,54	3,24
		Missing	60	46,2	21	35,0	44	33,1	14	31,8	1,15			Convergence criterion (GCONV=1E-8) satisfied.	0,50	2,64	0,032		Algorithm converged.	-0,151	0,215	1,10		Algorithm converged.	0,63	1,91	0,7356			0,91		Algorithm converged.	0,52	1,58
	Best response to prior therapy	CR/PR	76	58,5	21	27,6	61	45,9	18	29,5	0,91			Convergence criterion (GCONV=1E-8) satisfied.	0,43	1,92	-0,019		Algorithm converged.	-0,171	0,134	0,94		Algorithm converged.	0,55	1,59	0,8087	0,4229		1,07		Algorithm converged.	0,63	1,82
		SD	15	11,5	5	33,3	11	8,3	4	36,4	0,87			Convergence criterion (GCONV=1E-8) satisfied.	0,17	4,47	-0,030		Algorithm converged.	-0,401	0,341	0,92		Algorithm converged.	0,32	2,65	0,8722			1,09		Algorithm converged.	0,38	3,15
		PD		5	3,8		2	40,0	2	1,5			*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.				*	WARNING: Negative of Hessian not positive definite.				*			*	WARNING: Negative of Hessian not positive definite.		
		Missing (UE)							1	0,8																									
	Histologic grade (follicular)	1	39	30,0	15	38,5	19	14,3	5	26,3	1,75			Convergence criterion (GCONV=1E-8) satisfied.	0,52	5,85	0,121		Algorithm converged.	-0,129	0,371	1,46		Algorithm converged.	0,62	3,42	0,3819			0,68		Algorithm converged.	0,29	1,60
		2	44	33,8	10	22,7	35	26,3	12	34,3	0,56			Convergence criterion (GCONV=1E-8) satisfied.	0,21	1,52	-0,116		Algorithm converged.	-0,316	0,085	0,66		Algorithm converged.	0,33	1,35	0,2578			1,51		Algorithm converged.	0,74	3,08
		3					1	0,8																									
		3a		8	6,2		3	37,5	16	12,0	4	25,0	1,80		Convergence criterion (GCONV=1E-8) satisfied.	0,29	11,16	0,125		Algorithm converged.	-0,272	0,522	1,50		Algorithm converged.	0,44	5,15	0,5193			0,67		Algorithm converged.	0,19	2,29
		Missing/Unknown/Variants		5	3,8				4	8,0	1	25,0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0,01		Algorithm converged.	0,00		NE	1,0000		>999,99			Algorithm converged.	0,00		NE
	FLIPI	Low (0-1)	28	21,5	5	17,9	19	14,3	4	21,1	0,82			Convergence criterion (GCONV=1E-8) satisfied.	0,19	3,53	-0,032		Algorithm converged.	-0,264	0,200	0,85		Algorithm converged.	0,26	2,76	0,7843	0,6839		1,18		Algorithm converged.	0,36	3,83
		Intermediate (2)	29	22,3	8	27,6	27	20,3	10	37,0	0,65			Convergence criterion (GCONV=1E-8) satisfied.	0,21	2,00	-0,095		Algorithm converged.	-0,339	0,150	0,74		Algorithm converged.	0,35	1,61	0,4521			1,34		Algorithm converged.	0,62	2,89
		High (>=3)	36	27,7	13	36,1	26	19,5	8	30,8	1,27			Convergence criterion (GCONV=1E-8) satisfied.	0,43	3,73	0,053		Algorithm converged.	-0,183	0,290	1,17		Algorithm converged.	0,57	2,42	0,6639			0,85		Algorithm converged.	0,41	1,75
		Missing/Unknown		3	2,3		2	66,7	3	2,3			*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.				*	WARNING: Negative of Hessian not positive definite.				*			*	WARNING: Negative of Hessian not positive definite.		
	Fc gamma receptor IIa	131HH	26	20,0	5	19,2	21	15,8	6	28,6	0,60			Convergence criterion (GCONV=1E-8) satisfied.	0,15	2,32	-0,093		Algorithm converged.	-0,339	0,152	0,67		Algorithm converged.	0,24	1,90	0,4548	0,5067		1,49		Algorithm converged.	0,53	4,20
		131HR	38	29,2	14	36,8	36	27,1	10	27,8	1,52			Convergence criterion (GCONV=1E-8) satisfied.	0,57	4,05	0,091		Algorithm converged.	-0,121	0,303	1,33		Algorithm converged.	0,68	2,60	0,4097			0,75		Algorithm converged.	0,39	1,48
		131RR	23	17,7	7	30,4	14	10,5	5	35,7	0,79			Convergence criterion (GCONV=1E-8) satisfied.	0,19	3,22	-0,053		Algorithm converged.	-0,366	0,261	0,85		Algorithm converged.	0,33	2,17	0,7376			1,17		Algorithm converged.	0,46	2,99
		Missing		9	6,9		2	22,2	4	3,0	1	25,0	0,86		Convergence criterion (GCONV=1E-8) satisfied.	0,05	13,48	-0,028		Algorithm converged.	-0,532	0,476	0,89		Algorithm converged.	0,11	7,20	0,9121			1,12		Algorithm converged.	0,14	9,11
	Fc gamma receptor IIIa	158VV	11	8,5	3	27,3	11	8,3	3	27,3	1,00			Convergence criterion (GCONV=1E-8) satisfied.	0,15	6,53	0,000		Algorithm converged.	-0,372	0,372	1,00		Algorithm converged.	0,26	3,91	1,0000	0,8170		1,00		Algorithm converged.	0,26	3,91
		158VF	41	31,5	11	26,8	32	24,1	10	31,3	0,81			Convergence criterion (GCONV=1E-8) satisfied.	0,29	2,23	-0,044		Algorithm converged.	-0,254	0,166	0,86		Algorithm converged.	0,42	1,77	0,6784			1,16		Algorithm converged.	0,57	2,39
		158FF	35	26,9	12	34,3	28	21,1	8	28,6	1,30			Convergence criterion (GCONV=1E-8) satisfied.	0,44	3,83	0,057		Algorithm converged.	-0,172	0,287	1,20		Algorithm converged.	0,57	2,52	0,6310			0,83		Algorithm converged.	0,40	1,75
		Missing		9	6,9		2	22,2	4	3,0	1	25,0	0,86		Convergence criterion (GCONV=1E-8) satisfied.	0,05	13,48	-0,028		Algorithm converged.	-0,532	0,476	0,89		Algorithm converged.	0,11	7,20	0,9121			1,12		Algorithm converged.	0,14	9,11
	Fc gamma receptor IIb/IIc	232II	60	46,2	17	28,3	44	33,1	13	29,5	0,94			Convergence criterion (GCONV=1E-8) satisfied.	0,40	2,22	-0,012		Algorithm converged.	-0,189	0,164	0,96		Algorithm converged.	0,52	1,76	0,8926			1,04		Algorithm converged.	0,57	1,92
		232IT	25	19,2	8	32,0	25	18,8	7	28,0	1,21			Convergence criterion (GCONV=1E-8) satisfied.	0,36	4,07	0,040		Algorithm converged.	-0,214	0,294	1,14		Algorithm converged.	0,49	2,67	0,7580			0,88		Algorithm converged.	0,37	2,05
		232TT		1	0,8		1	100,0	2	1,5	1	50,0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	WARNING: Negative of Hessian not positive definite.				*			*	WARNING: Negative of Hessian not positive definite.		
		Missing	10	7,7	2	20,0	4	3,0	1	25,0	0,75			Convergence criterion (GCONV=1E-8) satisfied.	0,05	11,65	-0,050		Algorithm converged.	-0,541	0,441	0,80		Algorithm converged.	0,10	6,54	0,8352			1,25		Algorithm converged.	0,15	10,23
	Absolute lymphocyte count	>= median	46	35,4	13	28,3	37	27,8	9	24,3	1,23			Convergence criterion (GCONV=1E-8) satisfied.	0,46	3,29	0,039		Algorithm converged.	-0,150	0,229	1,16		Algorithm converged.	0,56	2,41	0,6877	0,4876		0,86		Algorithm converged.	0,41	1,79
		< median	50	38,5	15	30,0	36	27,1	13	36,1	0,76			Convergence criterion (GCONV=1E-8) satisfied.	0,31	1,88	-0,061		Algorithm converged.	-0,263	0,141	0,83		Algorithm converged.	0,45	1,52	0,5492			1,20		Algorithm converged.	0,66	2,21
		Missing					2	1,5																									
	Time from initial NHL diagnosis to randomization	< 6 months		4	3,1		2	50,0	4	3,0	1	25,0	3,00		Convergence criterion (GCONV=1E-8) satisfied.	0,15	59,89	0,250		Algorithm converged.	-0,398	0,898	2,00		Algorithm converged.	0,28	14,20	0,4882	0,7229		3,50		Algorithm converged.	0,07	3,55
		6-12 months		5	3,8		3	60,0	6	4,5	3	50,0	1,50		Convergence criterion (GCONV=1E-8) satisfied.	0,14	16,54	0,100		Algorithm converged.	-0,487	0,687	1,20		Algorithm converged.	0,41	3,51	0,7392			0,83		Algorithm converged.	0,28	2,44
		> 12 months	87	66,9	23	26,4	65	48,9	18	27,7	0,94			Convergence criterion (GCONV=1E-8) satisfied.	0,46	1,93	-0,013		Algorithm converged.	-0,155	0,130	0,95		Algorithm converged.	0,56	1,62	0,8629			1,05		Algorithm converged.	0,62	1,77
	Beta 2 microglobulin	>= 3.5 mg/L	13	10,0	6	46,2	17	12,8	7	41,2	1,22			Convergence criterion (GCONV=1E-8) satisfied.	0,29	5,26	0,050		Algorithm converged.	-0,308	0,408	1,12		Algorithm converged.	0,50	2,54	0,7843	0,9228		0,89		Algorithm converged.	0,39	2,02

		< 3.5 mg/L	79	60,8	22	27,8	55	41,4	13	23,6	1,25		Convergence criterion (GCONV=1E-8) satisfied.	0,56	2,76	0,042		Algorithm converged.	-0,107	0,192	1,18		Algorithm converged.	0,65	2,13	0,5878		0,85		Algorithm converged.	0,47	1,54
		Missing		43,1				37,3		268,7		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	WARNING: Negative of Hessian not positive definite.						*	WARNING: Negative of Hessian not positive definite.		
	Prior therapies	<= 2	78	60,0	22	28,2	55	41,4	18	32,7	0,81		Convergence criterion (GCONV=1E-8) satisfied.	0,38	1,71	-0,045		Algorithm converged.	-0,204	0,114	0,86		Algorithm converged.	0,51	1,45	0,5741	0,2784	1,16		Algorithm converged.	0,69	1,95
		> 2	18	13,8	6	33,3	20	15,0	4	20,0	2,00		Convergence criterion (GCONV=1E-8) satisfied.	0,46	8,70	0,133		Algorithm converged.	-0,146	0,413	1,67		Algorithm converged.	0,56	4,97	0,3598		0,60		Algorithm converged.	0,20	1,79
	Refractory Type	Rituximab + Chemotherapy	79	60,8	22	27,8	55	41,4	19	34,5	0,73		Convergence criterion (GCONV=1E-8) satisfied.	0,35	1,54	-0,067		Algorithm converged.	-0,227	0,093	0,81		Algorithm converged.	0,48	1,34	0,4059	0,0987	1,24		Algorithm converged.	0,75	2,06
		Rituximab Monotherapy	17	13,1	6	35,3	20	15,0	3	15,0	3,09		Convergence criterion (GCONV=1E-8) satisfied.	0,64	15,00	0,203		Algorithm converged.	-0,073	0,479	2,35		Algorithm converged.	0,69	8,02	0,1713		0,43		Algorithm converged.	0,12	1,45

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_base/qa/program/t_pro_rsp2.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_pro_rsp2_sg_IMPR_FACTGTR_FACTGpop_FOLY_IT_01SEP2014_01297.xls 07AUG2020 15:58

7 (Anhang): Ergebnisse für FACT-G - Verschlechterung der Gesundheitsbezogenen Lebensqualität um MID sechs - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients, Patients with Baseline and post Baseline FACT-G Total result
ENDPOINT: FACT-G Total - Responder (MID=6), Worsening
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Efficacy)

			G-Benda (N=130)				Benda (N=133)				G-Benda vs. Benda														Benda vs. G-Benda			
			Patients		Patients with Event		Patients		Patients with Event		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk			
Endpoint	Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
Cycle 5 Day 1	All	n/a	110	84.6	35	31.8	103	77.4	37	35.9	0.83	Convergence criterion (GCONV=1E-8) satisfied.	0.47	1.47	-0.041	Algorithm converged.	-0.168	0.086	0.89	Algorithm converged.	0.61	1.29	0.5271		1.13	Algorithm converged.	0.78	1.64
	Sex	Male	65	50.0	23	35.4	55	41.4	18	32.7	1.13	Convergence criterion (GCONV=1E-8) satisfied.	0.53	2.40	0.027	Algorithm converged.	-0.143	0.197	1.08	Algorithm converged.	0.65	1.79	0.7603	0.2286	0.92	Algorithm converged.	0.56	1.53
		Female	45	34.6	12	26.7	48	36.1	19	39.6	0.56	Convergence criterion (GCONV=1E-8) satisfied.	0.23	1.34	-0.129	Algorithm converged.	-0.318	0.060	0.67	Algorithm converged.	0.37	1.22	0.1950		1.48	Algorithm converged.	0.82	2.70
	Age	< 60 years	45	34.6	17	37.8	44	33.1	18	40.9	0.88	Convergence criterion (GCONV=1E-8) satisfied.	0.37	2.05	-0.031	Algorithm converged.	-0.234	0.172	0.92	Algorithm converged.	0.55	1.55	0.7625	0.8517	1.08	Algorithm converged.	0.65	1.81
		>= 60 years	65	50.0	18	27.7	59	44.4	19	32.2	0.81	Convergence criterion (GCONV=1E-8) satisfied.	0.37	1.74	-0.045	Algorithm converged.	-0.207	0.116	0.86	Algorithm converged.	0.50	1.48	0.5837		1.16	Algorithm converged.	0.68	2.00
	Race/ethnicity	White	101	77.7	34	33.7	92	69.2	34	37.0	0.87	Convergence criterion (GCONV=1E-8) satisfied.	0.48	1.56	-0.033	Algorithm converged.	-0.168	0.102	0.91	Algorithm converged.	0.62	1.34	0.6323	0.2462	1.10	Algorithm converged.	0.75	1.61
		Other	5	3.8	1	20.0	5	3.8	3	60.0	0.17	Convergence criterion (GCONV=1E-8) satisfied.	<0.01	2.82	-0.400	Algorithm converged.	-0.954	0.154	0.33	Algorithm converged.	0.05	2.21	0.2555		3.00	Algorithm converged.	0.45	19.93
		Missing/Unknown	4	3.1			6	4.5																				
	Geographic region	Western Europe	45	34.6	12	26.7	46	34.6	17	37.0	0.62	Convergence criterion (GCONV=1E-8) satisfied.	0.25	1.51	-0.103	Algorithm converged.	-0.293	0.087	0.72	Algorithm converged.	0.39	1.33	0.2977	0.6839	1.39	Algorithm converged.	0.75	2.56
		North America	54	41.5	20	37.0	49	36.8	18	36.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.45	2.26	0.003	Algorithm converged.	-0.184	0.190	1.01	Algorithm converged.	0.61	1.67	0.9747		0.99	Algorithm converged.	0.60	1.64
		Other	11	8.5	3	27.3	8	6.0	2	25.0	1.12	Convergence criterion (GCONV=1E-8) satisfied.	0.14	8.99	0.023	Algorithm converged.	-0.376	0.422	1.09	Algorithm converged.	0.23	5.09	0.9118		0.92	Algorithm converged.	0.20	4.28
	Body mass index	Underweight (< 18.5)					1	0.8																0.0339				
		Normal weight (18.5 -< 25)	36	27.7	8	22.2	30	22.6	11	36.7	0.49	Convergence criterion (GCONV=1E-8) satisfied.	0.17	1.45	-0.144	Algorithm converged.	-0.364	0.075	0.61	Algorithm converged.	0.28	1.31	0.2031		1.65	Algorithm converged.	0.76	3.57
		Overweight (25 - < 30)	38	29.2	13	34.2	29	21.8	5	17.2	2.50	Convergence criterion (GCONV=1E-8) satisfied.	0.77	8.07	0.170	Algorithm converged.	-0.034	0.374	1.98	Algorithm converged.	0.80	4.94	0.1405		0.50	Algorithm converged.	0.20	1.25
		Obese (>= 30)	35	26.9	14	40.0	38	28.6	20	52.6	0.60	Convergence criterion (GCONV=1E-8) satisfied.	0.24	1.52	-0.126	Algorithm converged.	-0.353	0.101	0.76	Algorithm converged.	0.46	1.26	0.2874		1.32	Algorithm converged.	0.79	2.18
		Missing	1	0.8			5	3.8	1	20.0	*	Quasi-complete separation of data points detected.			*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01	Algorithm converged.	0.00	NE	1.0000		>999.99	Algorithm converged.	0.00	NE
	Baseline ECOG Performance Status score	0-1	108	83.1	35	32.4	98	73.7	37	37.8	0.79	Convergence criterion (GCONV=1E-8) satisfied.	0.45	1.40	-0.053	Algorithm converged.	-0.184	0.077	0.86	Algorithm converged.	0.59	1.25	0.4217		1.17	Algorithm converged.	0.80	1.69
		2	2	1.5			4	3.0																				
		Missing					1	0.8																				
	Independence status (Katz ADL)	Independent (5-6)	44	33.8	12	27.3	39	29.3	14	35.9	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.26	1.70	-0.086	Algorithm converged.	-0.286	0.114	0.76	Algorithm converged.	0.40	1.44	0.3996	<.0001	1.32	Algorithm converged.	0.69	2.49
		Very dependent (0-2)	2	1.5																								
		Missing	64	49.2	23	35.9	64	48.1	23	35.9	1.00	Convergence criterion (GCONV=1E-8) satisfied.	0.49	2.06	0.000	Algorithm converged.	-0.166	0.166	1.00	Algorithm converged.	0.63	1.59	1.0000		1.00	Algorithm converged.	0.63	1.59
	Best response to prior therapy	CR/PR	89	68.5	28	31.5	83	62.4	30	36.1	0.81	Convergence criterion (GCONV=1E-8) satisfied.	0.43	1.53	-0.047	Algorithm converged.	-0.188	0.095	0.87	Algorithm converged.	0.57	1.32	0.5165		1.15	Algorithm converged.	0.76	1.75
		SD	16	12.3	7	43.8	14	10.5	5	35.7	1.40	Convergence criterion (GCONV=1E-8) satisfied.	0.32	6.11	0.080	Algorithm converged.	-0.269	0.430	1.23	Algorithm converged.	0.50	3.00	0.6571		0.82	Algorithm converged.	0.33	2.00
		PD	5	3.8			3	2.3																				
		Missing (UE)					3	2.3	2	66.7	NE	Convergence criterion (GCONV=1E-8) satisfied.	NE	NE	NE	Algorithm converged.	NE	NE	NE	Algorithm converged.	NE	NE	NE		NE	Algorithm converged.	NE	NE
	Histologic grade (follicular)	1	42	32.3	10	23.8	29	21.8	9	31.0	0.69	Convergence criterion (GCONV=1E-8) satisfied.	0.24	2.00	-0.072	Algorithm converged.	-0.284	0.140	0.77	Algorithm converged.	0.36	1.65	0.4978	0.5415	1.30	Algorithm converged.	0.61	2.80
		2	49	37.7	21	42.9	47	35.3	17	36.2	1.32	Convergence criterion (GCONV=1E-8) satisfied.	0.58	3.01	0.067	Algorithm converged.	-0.128	0.262	1.18	Algorithm converged.	0.72	1.95	0.5050		0.84	Algorithm converged.	0.51	1.39
		3					2	1.5																				
		3a	13	10.0	3	23.1	20	15.0	9	45.0	0.37	Convergence criterion (GCONV=1E-8) satisfied.	0.08	1.75	-0.219	Algorithm converged.	-0.535	0.097	0.51	Algorithm converged.	0.17	1.55	0.2360		1.95	Algorithm converged.	0.65	5.88
		Missing/Unknown/Variants	6	4.6	1	16.7	5	3.8	2	40.0	0.30	Convergence criterion (GCONV=1E-8) satisfied.	0.02	4.91	-0.233	Algorithm converged.	-0.756	0.289	0.42	Algorithm converged.	0.05	3.36	0.4109		2.40	Algorithm converged.	0.30	19.34
	FLIPI	Low (0-1)	30	23.1	12	40.0	24	18.0	10	41.7	0.93	Convergence criterion (GCONV=1E-8) satisfied.	0.31	2.78	-0.017	Algorithm converged.	-0.281	0.247	0.96	Algorithm converged.	0.50	1.83	0.9013	0.9381	1.04	Algorithm converged.	0.55	1.99
		Intermediate (2)	32	24.6	11	34.4	35	26.3	14	40.0	0.79	Convergence criterion (GCONV=1E-8) satisfied.	0.29	2.12	-0.056	Algorithm converged.	-0.287	0.175	0.86	Algorithm converged.	0.46	1.61	0.6360		1.16	Algorithm converged.	0.62	2.18
		High (>=3)	42	32.3	12	28.6	39	29.3	11	28.2	1.02	Convergence criterion (GCONV=1E-8) satisfied.	0.39	2.68	0.004	Algorithm converged.	-0.193	0.200	1.01	Algorithm converged.	0.51	2.02	0.9709		0.99	Algorithm converged.	0.49	1.97
		Missing/Unknown	6	4.6			5	3.8	2	40.0	*	Quasi-complete separation of data points detected.			*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			*	WARNING: Negative of Hessian not positive definite.						*	WARNING: Negative of Hessian not positive definite.		
	Fc gamma receptor IIa	131HH	26	20.0	10	38.5	25	18.8	12	48.0	0.68	Convergence criterion (GCONV=1E-8) satisfied.	0.22	2.06	-0.095	Algorithm converged.	-0.366	0.175	0.80	Algorithm converged.	0.42	1.51	0.4939	0.6677	1.25	Algorithm converged.	0.66	2.35
		131HR	48	36.9	12	25.0	54	40.6	13	24.1	1.05	Convergence criterion (GCONV=1E-8) satisfied.	0.43	2.59	0.009	Algorithm converged.	-0.158	0.177	1.04	Algorithm converged.	0.53	2.05	0.9136		0.96	Algorithm converged.	0.49	1.90
		131RR	25	19.2	10	40.0	17	12.8	10	58.8	0.47	Convergence criterion (GCONV=1E-8) satisfied.	0.13	1.64	-0.188	Algorithm converged.	-0.491	0.114	0.68	Algorithm converged.	0.36	1.27	0.2253		1.47	Algorithm converged.	0.79	2.74

		Missing	11	8.5	3	27.3	7	5.3	2	28.6	0.94	Convergence criterion (GCONV=1E-8) satisfied.	0.11	7.73	-0.013	Algorithm converged.	-0.439	0.413	0.95	Algorithm converged.	0.21	4.35	0.9521		1.05		Algorithm converged.	0.23	4.78
	Fc gamma receptor IIIa	158VV	12	9.2	5	41.7	18	13.5	5	27.8	1.86	Convergence criterion (GCONV=1E-8) satisfied.	0.40	8.69	0.139	Algorithm converged.	-0.208	0.486	1.50	Algorithm converged.	0.55	4.08	0.4275	0.5350	0.67		Algorithm converged.	0.24	1.81
		158VF	48	36.9	14	29.2	45	33.8	16	35.6	0.75	Convergence criterion (GCONV=1E-8) satisfied.	0.31	1.78	-0.064	Algorithm converged.	-0.254	0.126	0.82	Algorithm converged.	0.45	1.48	0.5111		1.22		Algorithm converged.	0.68	2.20
		158FF	39	30.0	13	33.3	33	24.8	14	42.4	0.68	Convergence criterion (GCONV=1E-8) satisfied.	0.26	1.77	-0.091	Algorithm converged.	-0.315	0.133	0.79	Algorithm converged.	0.43	1.43	0.4276		1.27		Algorithm converged.	0.70	2.31
		Missing	11	8.5	3	27.3	7	5.3	2	28.6	0.94	Convergence criterion (GCONV=1E-8) satisfied.	0.11	7.73	-0.013	Algorithm converged.	-0.439	0.413	0.95	Algorithm converged.	0.21	4.35	0.9521		1.05		Algorithm converged.	0.23	4.78
	Fc gamma receptor IIb/IIc	232II	66	50.8	24	36.4	65	48.9	24	36.9	0.98	Convergence criterion (GCONV=1E-8) satisfied.	0.48	1.99	-0.006	Algorithm converged.	-0.171	0.159	0.98	Algorithm converged.	0.63	1.55	0.9470	0.4402	1.02		Algorithm converged.	0.65	1.59
		232IT	31	23.8	7	22.6	27	20.3	9	33.3	0.58	Convergence criterion (GCONV=1E-8) satisfied.	0.18	1.86	-0.108	Algorithm converged.	-0.338	0.123	0.68	Algorithm converged.	0.29	1.57	0.3648		1.48		Algorithm converged.	0.64	3.43
		232TT	1	0.8			4	3.0	2	50.0		* Quasi-complete separation of data points detected.				* ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				* WARNING: Negative of Hessian not positive definite.						* WARNING: Negative of Hessian not positive definite.		
		Missing	12	9.2	4	33.3	7	5.3	2	28.6	1.25	Convergence criterion (GCONV=1E-8) satisfied.	0.16	9.54	0.048	Algorithm converged.	-0.380	0.476	1.17	Algorithm converged.	0.28	4.82	0.8313		0.86		Algorithm converged.	0.21	3.54
	Absolute lymphocyte count	>= median	51	39.2	18	35.3	53	39.8	22	41.5	0.77	Convergence criterion (GCONV=1E-8) satisfied.	0.35	1.70	-0.062	Algorithm converged.	-0.249	0.124	0.85	Algorithm converged.	0.52	1.39	0.5166	0.7536	1.18		Algorithm converged.	0.72	1.92
		< median	59	45.4	17	28.8	50	37.6	15	30.0	0.94	Convergence criterion (GCONV=1E-8) satisfied.	0.41	2.16	-0.012	Algorithm converged.	-0.184	0.160	0.96	Algorithm converged.	0.54	1.72	0.8921		1.04		Algorithm converged.	0.58	1.87
	Time from initial NHL diagnosis to randomization	< 6 months	4	3.1	1	25.0	4	3.0	1	25.0	1.00	Convergence criterion (GCONV=1E-8) satisfied.	0.04	24.55	0.000	Algorithm converged.	-0.600	0.600	1.00	Algorithm converged.	0.09	11.03	1.0000	0.3390	1.00		Algorithm converged.	0.09	11.03
		6-12 months	6	4.6	3	50.0	10	7.5	2	20.0	4.00	Convergence criterion (GCONV=1E-8) satisfied.	0.43	37.11	0.300	Algorithm converged.	-0.171	0.771	2.50	Algorithm converged.	0.57	10.93	0.2235		0.40		Algorithm converged.	0.09	1.75
		> 12 months	100	76.9	31	31.0	89	66.9	34	38.2	0.73	Convergence criterion (GCONV=1E-8) satisfied.	0.40	1.33	-0.072	Algorithm converged.	-0.208	0.064	0.81	Algorithm converged.	0.55	1.20	0.2988		1.23		Algorithm converged.	0.83	1.83
	Beta 2 microglobulin	>= 3.5 mg/L	16	12.3	2	12.5	22	16.5	7	31.8	0.31	Convergence criterion (GCONV=1E-8) satisfied.	0.05	1.73	-0.193	Algorithm converged.	-0.446	0.060	0.39	Algorithm converged.	0.09	1.65	0.2014	0.1834	2.55		Algorithm converged.	0.61	10.67
		< 3.5 mg/L	89	68.5	32	36.0	77	57.9	28	36.4	0.98	Convergence criterion (GCONV=1E-8) satisfied.	0.52	1.85	-0.004	Algorithm converged.	-0.151	0.142	0.99	Algorithm converged.	0.66	1.48	0.9564		1.01		Algorithm converged.	0.67	1.52
		Missing	5	3.8	1	20.0	4	3.0	2	50.0	0.25	Convergence criterion (GCONV=1E-8) satisfied.	0.01	4.73	-0.300	Algorithm converged.	-0.903	0.303	0.40	Algorithm converged.	0.05	2.98	0.3712		2.50		Algorithm converged.	0.34	18.63
	Prior therapies	<= 2	91	70.0	30	33.0	81	60.9	30	37.0	0.84	Convergence criterion (GCONV=1E-8) satisfied.	0.45	1.57	-0.041	Algorithm converged.	-0.183	0.102	0.89	Algorithm converged.	0.59	1.34	0.5760	0.8909	1.12		Algorithm converged.	0.75	1.69
		> 2	19	14.6	5	26.3	22	16.5	7	31.8	0.77	Convergence criterion (GCONV=1E-8) satisfied.	0.20	2.98	-0.055	Algorithm converged.	-0.333	0.223	0.83	Algorithm converged.	0.31	2.18	0.7011		1.21		Algorithm converged.	0.46	3.19
	Refractory Type	Rituximab + Chemotherapy	93	71.5	30	32.3	76	57.1	24	31.6	1.03	Convergence criterion (GCONV=1E-8) satisfied.	0.54	1.98	0.007	Algorithm converged.	-0.134	0.148	1.02	Algorithm converged.	0.66	1.59	0.9250	0.2642	0.98		Algorithm converged.	0.63	1.52
		Rituximab Monotherapy	17	13.1	5	29.4	27	20.3	13	48.1	0.45	Convergence criterion (GCONV=1E-8) satisfied.	0.12	1.63	-0.187	Algorithm converged.	-0.474	0.100	0.61	Algorithm converged.	0.27	1.41	0.2467		1.64		Algorithm converged.	0.71	3.77
Follow Up Visit 1 Month 2	All	n/a	96	73.8	27	28.1	75	56.4	23	30.7	0.88	Convergence criterion (GCONV=1E-8) satisfied.	0.46	1.72	-0.025	Algorithm converged.	-0.163	0.112	0.92	Algorithm converged.	0.57	1.46	0.7165		1.09		Algorithm converged.	0.68	1.74
	Sex	Male	58	44.6	15	25.9	40	30.1	14	35.0	0.65	Convergence criterion (GCONV=1E-8) satisfied.	0.27	1.56	-0.091	Algorithm converged.	-0.277	0.094	0.74	Algorithm converged.	0.40	1.36	0.3284	0.2934	1.35		Algorithm converged.	0.74	2.48
		Female	38	29.2	12	31.6	35	26.3	9	25.7	1.33	Convergence criterion (GCONV=1E-8) satisfied.	0.48	3.70	0.059	Algorithm converged.	-0.148	0.266	1.23	Algorithm converged.	0.59	2.55	0.5824		0.81		Algorithm converged.	0.39	1.69
	Age	< 60 years	39	30.0	10	25.6	32	24.1	10	31.3	0.76	Convergence criterion (GCONV=1E-8) satisfied.	0.27	2.14	-0.056	Algorithm converged.	-0.267	0.155	0.82	Algorithm converged.	0.39	1.72	0.6010	0.7055	1.22		Algorithm converged.	0.58	2.56
		>= 60 years	57	43.8	17	29.8	43	32.3	13	30.2	0.98	Convergence criterion (GCONV=1E-8) satisfied.	0.41	2.33	-0.004	Algorithm converged.	-0.186	0.177	0.99	Algorithm converged.	0.54	1.80	0.9648		1.01		Algorithm converged.	0.55	1.85
	Race/ethnicity	White	89	68.5	27	30.3	68	51.1	22	32.4	0.91	Convergence criterion (GCONV=1E-8) satisfied.	0.46	1.80	-0.020	Algorithm converged.	-0.167	0.126	0.94	Algorithm converged.	0.59	1.49	0.7867	0.2735	1.07		Algorithm converged.	0.67	1.70
		Other	4	3.1			5	3.8	1	20.0		* Quasi-complete separation of data points detected.				* ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01	Algorithm converged.	0.00	NE	1.0000		>999.99		Algorithm converged.	0.00	NE
		Missing/Unknown	3	2.3			2	1.5																					
	Geographic region	Western Europe	37	28.5	11	29.7	32	24.1	10	31.3	0.93	Convergence criterion (GCONV=1E-8) satisfied.	0.33	2.60	-0.015	Algorithm converged.	-0.233	0.203	0.95	Algorithm converged.	0.47	1.94	0.8911	0.0509	1.05		Algorithm converged.	0.51	2.15
		North America	48	36.9	11	22.9	38	28.6	13	34.2	0.57	Convergence criterion (GCONV=1E-8) satisfied.	0.22	1.48	-0.113	Algorithm converged.	-0.305	0.079	0.67	Algorithm converged.	0.34	1.32	0.2488		1.49		Algorithm converged.	0.76	2.95
		Other	11	8.5	5	45.5	5	3.8				* Quasi-complete separation of data points detected.				* ERROR: Error in computing the link function, its derivatives, or the variance function.				* WARNING: Negative of Hessian not positive definite.						* WARNING: Negative of Hessian not positive definite.		
	Body mass index	Underweight (< 18.5)					1	0.8																0.7295					
		Normal weight (18.5 -< 25)	29	22.3	9	31.0	22	16.5	6	27.3	1.20	Convergence criterion (GCONV=1E-8) satisfied.	0.35	4.08	0.038	Algorithm converged.	-0.213	0.289	1.14	Algorithm converged.	0.48	2.72	0.7714		0.88		Algorithm converged.	0.37	2.10
		Overweight (25 - < 30)	36	27.7	11	30.6	23	17.3	7	30.4	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.32	3.13	0.001	Algorithm converged.	-0.240	0.242	1.00	Algorithm converged.	0.46	2.21	0.9922		1.00		Algorithm converged.	0.45	2.19
		Obese (>= 30)	30	23.1	7	23.3	26	19.5	10	38.5	0.49	Convergence criterion (GCONV=1E-8) satisfied.	0.15	1.55	-0.151	Algorithm converged.	-0.392	0.089	0.61	Algorithm converged.	0.27	1.36	0.2269		1.65		Algorithm converged.	0.73	3.71
		Missing	1	0.8			3	2.3																					
	Baseline ECOG Performance Status score	0-1	95	73.1	27	28.4	73	54.9	23	31.5	0.86	Convergence criterion (GCONV=1E-8) satisfied.	0.44	1.68	-0.031	Algorithm converged.	-0.171	0.109	0.90	Algorithm converged.	0.57	1.44	0.6640		1.11		Algorithm converged.	0.70	1.76
		2	1	0.8			1	0.8																					
		Missing					1	0.8																					
	Independence status (Katz ADL)	Independent (5-6)	36	27.7	12	33.3	31	23.3	9	29.0	1.22	Convergence criterion (GCONV=1E-8) satisfied.	0.43	3.46	0.043	Algorithm converged.	-0.179	0.265	1.15	Algorithm converged.	0.56	2.36	0.7063	NE	0.87		Algorithm converged.	0.42	1.79

		Missing	60	46.2	15	25.0	44	33.1	14	31.8	0.71		Convergence criterion (GCONV=1E-8) satisfied.	0.30	1.69	-0.068		Algorithm converged.	-0.244	0.108	0.79		Algorithm converged.	0.42	1.45	0.4427		1.27		Algorithm converged.	0.69	2.36
	Best response to prior therapy	CR/PR	76	58.5	24	31.6	61	45.9	18	29.5	1.10		Convergence criterion (GCONV=1E-8) satisfied.	0.53	2.29	0.021		Algorithm converged.	-0.134	0.176	1.07		Algorithm converged.	0.64	1.78	0.7943	0.1491	0.93		Algorithm converged.	0.56	1.56
		SD	15	11.5	3	20.0	11	8.3	4	36.4	0.44		Convergence criterion (GCONV=1E-8) satisfied.	0.08	2.55	-0.164		Algorithm converged.	-0.513	0.185	0.55		Algorithm converged.	0.15	1.98	0.3595		1.82		Algorithm converged.	0.51	6.53
		PD	5	3.8			2	1.5	1	50.0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01		Algorithm converged.	0.00	NE	1.0000		>999.99		Algorithm converged.	0.00	NE
		Missing (UE)					1	0.8																								
	Histologic grade (follicular)	1	39	30.0	10	25.6	19	14.3	7	36.8	0.59		Convergence criterion (GCONV=1E-8) satisfied.	0.18	1.92	-0.112		Algorithm converged.	-0.369	0.145	0.70		Algorithm converged.	0.31	1.54	0.3716	0.8414	1.44		Algorithm converged.	0.65	3.18
		2	44	33.8	13	29.5	35	26.3	9	25.7	1.21		Convergence criterion (GCONV=1E-8) satisfied.	0.45	3.28	0.038		Algorithm converged.	-0.160	0.236	1.15		Algorithm converged.	0.56	2.37	0.7072		0.87		Algorithm converged.	0.42	1.80
		3					1	0.8																								
		3a	8	6.2	2	25.0	16	12.0	6	37.5	0.56		Convergence criterion (GCONV=1E-8) satisfied.	0.08	3.69	-0.125		Algorithm converged.	-0.507	0.257	0.67		Algorithm converged.	0.17	2.59	0.5580		1.50		Algorithm converged.	0.39	5.83
		Missing/Unknown/Variants	5	3.8	2	40.0	4	3.0	1	25.0	2.00		Convergence criterion (GCONV=1E-8) satisfied.	0.11	35.80	0.150		Algorithm converged.	-0.454	0.754	1.60		Algorithm converged.	0.21	11.92	0.6465		0.63		Algorithm converged.	0.08	4.66
	FLIPI	Low (0-1)	28	21.5	7	25.0	19	14.3	5	26.3	0.93		Convergence criterion (GCONV=1E-8) satisfied.	0.25	3.54	-0.013		Algorithm converged.	-0.268	0.242	0.95		Algorithm converged.	0.35	2.55	0.9190	0.9981	1.05		Algorithm converged.	0.39	2.83
		Intermediate (2)	29	22.3	8	27.6	27	20.3	8	29.6	0.90		Convergence criterion (GCONV=1E-8) satisfied.	0.28	2.89	-0.020		Algorithm converged.	-0.257	0.216	0.93		Algorithm converged.	0.41	2.13	0.8657		1.07		Algorithm converged.	0.47	2.46
		High (>=3)	36	27.7	12	33.3	26	19.5	9	34.6	0.94		Convergence criterion (GCONV=1E-8) satisfied.	0.33	2.74	-0.013		Algorithm converged.	-0.252	0.226	0.96		Algorithm converged.	0.48	1.94	0.9161		1.04		Algorithm converged.	0.51	2.09
		Missing/Unknown	3	2.3			3	2.3	1	33.3		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01		Algorithm converged.	0.00	NE	1.0000		>999.99		Algorithm converged.	0.00	NE
	Fc gamma receptor IIa	131HH	26	20.0	6	23.1	21	15.8	7	33.3	0.60		Convergence criterion (GCONV=1E-8) satisfied.	0.17	2.17	-0.103		Algorithm converged.	-0.361	0.156	0.69		Algorithm converged.	0.27	1.75	0.4366	0.2020	1.44		Algorithm converged.	0.57	3.65
		131HR	38	29.2	12	31.6	36	27.1	8	22.2	1.62		Convergence criterion (GCONV=1E-8) satisfied.	0.57	4.58	0.094		Algorithm converged.	-0.107	0.294	1.42		Algorithm converged.	0.66	3.07	0.3709		0.70		Algorithm converged.	0.33	1.52
		131RR	23	17.7	6	26.1	14	10.5	7	50.0	0.35		Convergence criterion (GCONV=1E-8) satisfied.	0.09	1.43	-0.239		Algorithm converged.	-0.557	0.078	0.52		Algorithm converged.	0.22	1.24	0.1403		1.92		Algorithm converged.	0.81	4.55
		Missing	9	6.9	3	33.3	4	3.0	1	25.0	1.50		Convergence criterion (GCONV=1E-8) satisfied.	0.11	21.31	0.083		Algorithm converged.	-0.441	0.608	1.33		Algorithm converged.	0.19	9.21	0.7705		0.75		Algorithm converged.	0.11	5.18
	Fc gamma receptor IIIa	158VV	11	8.5	3	27.3	11	8.3	3	27.3	1.00		Convergence criterion (GCONV=1E-8) satisfied.	0.15	6.53	0.000		Algorithm converged.	-0.372	0.372	1.00		Algorithm converged.	0.26	3.91	1.0000	0.9416	1.00		Algorithm converged.	0.26	3.91
		158VF	41	31.5	12	29.3	32	24.1	10	31.3	0.91		Convergence criterion (GCONV=1E-8) satisfied.	0.33	2.49	-0.020		Algorithm converged.	-0.232	0.193	0.94		Algorithm converged.	0.46	1.89	0.8545		1.07		Algorithm converged.	0.53	2.15
		158FF	35	26.9	9	25.7	28	21.1	9	32.1	0.73		Convergence criterion (GCONV=1E-8) satisfied.	0.24	2.19	-0.064		Algorithm converged.	-0.290	0.161	0.80		Algorithm converged.	0.37	1.74	0.5745		1.25		Algorithm converged.	0.57	2.72
		Missing	9	6.9	3	33.3	4	3.0	1	25.0	1.50		Convergence criterion (GCONV=1E-8) satisfied.	0.11	21.31	0.083		Algorithm converged.	-0.441	0.608	1.33		Algorithm converged.	0.19	9.21	0.7705		0.75		Algorithm converged.	0.11	5.18
	Fc gamma receptor IIb/IIc	232II	60	46.2	18	30.0	44	33.1	17	38.6	0.68		Convergence criterion (GCONV=1E-8) satisfied.	0.30	1.55	-0.086		Algorithm converged.	-0.271	0.098	0.78		Algorithm converged.	0.45	1.33	0.3555		1.29		Algorithm converged.	0.75	2.20
		232IT	25	19.2	6	24.0	25	18.8	5	20.0	1.26		Convergence criterion (GCONV=1E-8) satisfied.	0.33	4.84	0.040		Algorithm converged.	-0.189	0.269	1.20		Algorithm converged.	0.42	3.43	0.7335		0.83		Algorithm converged.	0.29	2.38
		232TT	1	0.8			2	1.5																								
		Missing	10	7.7	3	30.0	4	3.0	1	25.0	1.29		Convergence criterion (GCONV=1E-8) satisfied.	0.09	17.95	0.050		Algorithm converged.	-0.461	0.561	1.20		Algorithm converged.	0.17	8.38	0.8541		0.83		Algorithm converged.	0.12	5.82
	Absolute lymphocyte count	>= median	46	35.4	14	30.4	37	27.8	14	37.8	0.72		Convergence criterion (GCONV=1E-8) satisfied.	0.29	1.79	-0.074		Algorithm converged.	-0.279	0.131	0.80		Algorithm converged.	0.44	1.47	0.4778	0.5941	1.24		Algorithm converged.	0.68	2.27
		< median	50	38.5	13	26.0	36	27.1	9	25.0	1.05		Convergence criterion (GCONV=1E-8) satisfied.	0.39	2.82	0.010		Algorithm converged.	-0.177	0.197	1.04		Algorithm converged.	0.50	2.17	0.9166		0.96		Algorithm converged.	0.46	2.00
		Missing					2	1.5																								
	Time from initial NHL diagnosis to randomization	< 6 months	4	3.1	1	25.0	4	3.0	2	50.0	0.33		Convergence criterion (GCONV=1E-8) satisfied.	0.02	6.65	-0.250		Algorithm converged.	-0.898	0.398	0.50		Algorithm converged.	0.07	3.55	0.4882	0.4333	2.00		Algorithm converged.	0.28	14.20
		6-12 months	5	3.8			6	4.5	1	16.7		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01		Algorithm converged.	0.00	NE	1.0000		>999.99		Algorithm converged.	0.00	NE
		> 12 months	87	66.9	26	29.9	65	48.9	20	30.8	0.96		Convergence criterion (GCONV=1E-8) satisfied.	0.48	1.93	-0.009		Algorithm converged.	-0.157	0.139	0.97		Algorithm converged.	0.60	1.58	0.9065		1.03		Algorithm converged.	0.63	1.67
	Beta 2 microglobulin	>= 3.5 mg/L	13	10.0	4	30.8	17	12.8	4	23.5	1.44		Convergence criterion (GCONV=1E-8) satisfied.	0.28	7.34	0.072		Algorithm converged.	-0.249	0.394	1.31		Algorithm converged.	0.40	4.27	0.6567	0.5166	0.76		Algorithm converged.	0.23	2.50
		< 3.5 mg/L	79	60.8	22	27.8	55	41.4	18	32.7	0.79		Convergence criterion (GCONV=1E-8) satisfied.	0.38	1.68	-0.049		Algorithm converged.	-0.207	0.110	0.85		Algorithm converged.	0.51	1.43	0.5422		1.18		Algorithm converged.	0.70	1.98
		Missing	4	3.1	1	25.0	3	2.3	1	33.3	0.67		Convergence criterion (GCONV=1E-8) satisfied.	0.02	18.06	-0.083		Algorithm converged.	-0.765	0.598	0.75		Algorithm converged.	0.07	7.73	0.8090		1.33		Algorithm converged.	0.13	13.74
	Prior therapies	<= 2	78	60.0	22	28.2	55	41.4	16	29.1	0.96		Convergence criterion (GCONV=1E-8) satisfied.	0.45	2.05	-0.009		Algorithm converged.	-0.165	0.147	0.97		Algorithm converged.	0.56	1.67	0.9112	0.7194	1.03		Algorithm converged.	0.60	1.78
		> 2	18	13.8	5	27.8	20	15.0	7	35.0	0.71		Convergence criterion (GCONV=1E-8) satisfied.	0.18	2.84	-0.072		Algorithm converged.	-0.366	0.222	0.79		Algorithm converged.	0.31	2.06	0.6352		1.26		Algorithm converged.	0.48	3.27
	Refractory Type	Rituximab + Chemotherapy	79	60.8	24	30.4	55	41.4	15	27.3	1.16		Convergence criterion (GCONV=1E-8) satisfied.	0.54	2.50	0.031		Algorithm converged.	-0.124	0.186	1.11		Algorithm converged.	0.65	1.92	0.6983	0.1301	0.90		Algorithm converged.	0.52	1.55
		Rituximab Monotherapy	17	13.1	3	17.6	20	15.0	8	40.0	0.32		Convergence criterion (GCONV=1E-8) satisfied.	0.07	1.49	-0.224		Algorithm converged.	-0.504	0.057	0.44		Algorithm converged.	0.14	1.41	0.1663		2.27		Algorithm converged.	0.71	7.22

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_base/qa/program/t_pro_rsp2.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_pro_rsp2_sg_WR_FACTGTR_FACTGpop_FOLY_IT_01SEP2014_01297.xls

8 (Anhang): Ergebnisse für FACT-LymS - Verbesserung der Gesundheitsbezogenen Lebensqualität um MID fünf - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients, Patients with Baseline and post Baseline FACT-LYM Subscale result

ENDPOINT: FACT-LYM Subscale - Responder (MID=5), Improvement
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Efficacy)

			G-Benda (N=135)				Benda (N=135)				G-Benda vs. Benda																Benda vs. G-Benda			
			Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk								Relative Risk			
Endpoint	Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
Cycle 5 Day 1	All	n/a	114	84,4	28	24,6	105	77,8	30	28,6	0,81		Convergence criterion (GCONV=1E-8) satisfied.	0,45	1,48	-0,040		Algorithm converged.	-0,157	0,077	0,86		Algorithm converged.	0,55	1,34	0,5020		1,16		Algorithm converged.	0,75	1,81
	Sex	Male	66	48,9	20	30,3	55	40,7	14	25,5	1,27		Convergence criterion (GCONV=1E-8) satisfied.	0,57	2,84	0,048		Algorithm converged.	-0,111	0,208	1,19		Algorithm converged.	0,67	2,13	0,5569	0,0795	0,84		Algorithm converged.	0,47	1,50
		Female	48	35,6	8	16,7	50	37,0	16	32,0	0,43		Convergence criterion (GCONV=1E-8) satisfied.	0,16	1,11	-0,153		Algorithm converged.	-0,320	0,013	0,52		Algorithm converged.	0,25	1,10	0,0885		1,92		Algorithm converged.	0,91	4,07
	Age	< 60 years	47	34,8	11	23,4	44	32,6	18	40,9	0,44		Convergence criterion (GCONV=1E-8) satisfied.	0,18	1,09	-0,175		Algorithm converged.	-0,364	0,014	0,57		Algorithm converged.	0,31	1,07	0,0811	0,0731	1,75		Algorithm converged.	0,93	3,27
		>= 60 years	67	49,6	17	25,4	61	45,2	12	19,7	1,39		Convergence criterion (GCONV=1E-8) satisfied.	0,60	3,21	0,057		Algorithm converged.	-0,087	0,201	1,29		Algorithm converged.	0,67	2,48	0,4446		0,78		Algorithm converged.	0,40	1,49
	Race/ethnicity	White	105	77,8	27	25,7	94	69,6	26	27,7	0,91		Convergence criterion (GCONV=1E-8) satisfied.	0,48	1,70	-0,019		Algorithm converged.	-0,143	0,104	0,93		Algorithm converged.	0,59	1,47	0,7566	0,2363	1,08		Algorithm converged.	0,68	1,71
		Other	5	3,7			5	3,7	1	20,0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE
		Missing/Unknown	4	3,0	1	25,0	6	4,4	3	50,0	0,33		Convergence criterion (GCONV=1E-8) satisfied.	0,02	5,33	-0,250		Algorithm converged.	-0,833	0,333	0,50		Algorithm converged.	0,08	3,27	0,4691		2,00		Algorithm converged.	0,31	13,06
	Geographic region	Western Europe	46	34,1	12	26,1	47	34,8	11	23,4	1,16		Convergence criterion (GCONV=1E-8) satisfied.	0,45	2,97	0,027		Algorithm converged.	-0,149	0,202	1,11		Algorithm converged.	0,55	2,27	0,7645	0,3697	0,90		Algorithm converged.	0,44	1,82
		North America	57	42,2	15	26,3	49	36,3	16	32,7	0,74		Convergence criterion (GCONV=1E-8) satisfied.	0,32	1,70	-0,063		Algorithm converged.	-0,237	0,111	0,81		Algorithm converged.	0,45	1,46	0,4750		1,24		Algorithm converged.	0,69	2,24
		Other	11	8,1	1	9,1	9	6,7	3	33,3	0,20		Convergence criterion (GCONV=1E-8) satisfied.	0,02	2,39	-0,242		Algorithm converged.	-0,594	0,109	0,27		Algorithm converged.	0,03	2,19	0,2219		3,67		Algorithm converged.	0,46	29,49
	Body mass index	Underweight (< 18.5)					1	0,7																			0,4900					
		Normal weight (18.5 - < 25)	37	27,4	9	24,3	30	22,2	12	40,0	0,48		Convergence criterion (GCONV=1E-8) satisfied.	0,17	1,37	-0,157		Algorithm converged.	-0,380	0,066	0,61		Algorithm converged.	0,30	1,25	0,1743		1,64		Algorithm converged.	0,80	3,37
		Overweight (25 - < 30)	40	29,6	10	25,0	30	22,2	7	23,3	1,10		Convergence criterion (GCONV=1E-8) satisfied.	0,36	3,32	0,017		Algorithm converged.	-0,186	0,219	1,07		Algorithm converged.	0,46	2,49	0,8724		0,93		Algorithm converged.	0,40	2,17
		Obese (>= 30)	35	25,9	9	25,7	39	28,9	9	23,1	1,15		Convergence criterion (GCONV=1E-8) satisfied.	0,40	3,34	0,026		Algorithm converged.	-0,170	0,222	1,11		Algorithm converged.	0,50	2,49	0,7918		0,90		Algorithm converged.	0,40	2,00
		Missing	2	1,5			5	3,7	2	40,0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	WARNING: Negative of Hessian not positive definite.						*	WARNING: Negative of Hessian not positive definite.		
	Baseline ECOG Performance Status score	0-1	111	82,2	25	22,5	100	74,1	29	29,0	0,71		Convergence criterion (GCONV=1E-8) satisfied.	0,38	1,32	-0,065		Algorithm converged.	-0,183	0,053	0,78		Algorithm converged.	0,49	1,23	0,2832		1,29		Algorithm converged.	0,81	2,04
		2	3	2,2	3	100,0	4	3,0				*	Complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 251958.43009 is greater than the limit of 0.0001. The convergence is questionable.				*	WARNING: The relative Hessian convergence criterion of 171796142563 is greater than the limit of 0.0001. The convergence is questionable.						*	WARNING: The relative Hessian convergence criterion of 171796142563 is greater than the limit of 0.0001. The convergence is questionable.		
		Missing					1	0,7	1	100,0																						
	Independence status (Katz ADL)	Independent (5-6)	45	33,3	8	17,8	41	30,4	12	29,3	0,52		Convergence criterion (GCONV=1E-8) satisfied.	0,19	1,45	-0,115		Algorithm converged.	-0,293	0,064	0,61		Algorithm converged.	0,28	1,34	0,2151	<.0001	1,65		Algorithm converged.	0,75	3,62
		Very dependent (0-2)		2	1,5																											
		Missing	57	49,6	20	29,9	64	47,4	18	28,1	1,09		Convergence criterion (GCONV=1E-8) satisfied.	0,51	2,31	0,017		Algorithm converged.	-0,138	0,173	1,06		Algorithm converged.	0,62	1,82	0,8279		0,94		Algorithm converged.	0,55	1,61
	Best response to prior therapy	CR/PR	93	68,9	22	23,7	85	63,0	24	28,2	0,79		Convergence criterion (GCONV=1E-8) satisfied.	0,40	1,54	-0,046		Algorithm converged.	-0,175	0,083	0,84		Algorithm converged.	0,51	1,38	0,4863	0,8684	1,19		Algorithm converged.	0,73	1,96
		SD	16	11,9	5	31,3	14	10,4	4	28,6	1,14		Convergence criterion (GCONV=1E-8) satisfied.	0,24	5,46	0,027		Algorithm converged.	-0,301	0,355	1,09		Algorithm converged.	0,36	3,29	0,8734		0,91		Algorithm converged.	0,30	2,75
		PD	5	3,7	1	20,0	3	2,2	1	33,3	0,50		Convergence criterion (GCONV=1E-8) satisfied.	0,02	12,90	-0,133		Algorithm converged.	-0,772	0,505	0,60		Algorithm converged.	0,06	6,44	0,6732		1,67		Algorithm converged.	0,16	17,89
		Missing (UE)					3	2,2	1	33,3	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE	NE	NE		Algorithm converged.	NE	NE	NE		Algorithm converged.	NE	NE	NE			NE		Algorithm converged.	NE	NE
	Histologic grade (follicular)	1	44	32,6	16	36,4	30	22,2	7	23,3	1,88		Convergence criterion (GCONV=1E-8) satisfied.	0,66	5,34	0,130		Algorithm converged.	-0,077	0,338	1,56		Algorithm converged.	0,73	3,32	0,2508	0,1585	0,64		Algorithm converged.	0,30	1,37
		2	61	37,8	6	11,8	48	35,6	13	27,1	0,36		Convergence criterion (GCONV=1E-8) satisfied.	0,12	1,04	-0,153		Algorithm converged.	-0,307	0,001	0,43		Algorithm converged.	0,18	1,05	0,0643		2,30		Algorithm converged.	0,95	5,57
		3					2	1,5																								
		3a	14	10,4	4	28,6	20	14,8	7	35,0	0,74		Convergence criterion (GCONV=1E-8) satisfied.	0,17	3,26	-0,064		Algorithm converged.	-0,380	0,251	0,82		Algorithm converged.	0,29	2,27	0,6969		1,22		Algorithm converged.	0,44	3,40

| | | |

| | | |

		< 3.5 mg/L	82	60,7	25	30,5	54	48,0	15	27,8	1,14		Convergence criterion (GCONV=1E-8) satisfied.	0,53	2,44	0,027		Algorithm converged.	-0,128	0,183	1,10		Algorithm converged.	0,64	1,88	0,7355		0,91		Algorithm converged.	0,53	1,56
		Missing		43,0				37,2	1	33,3		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999,99		Algorithm converged.	0,00	NE
	Prior therapies	<= 2	82	60,7	24	29,3	56	41,5	19	33,9	0,81		Convergence criterion (GCONV=1E-8) satisfied.	0,39	1,67	-0,047		Algorithm converged.	-0,205	0,112	0,86		Algorithm converged.	0,52	1,42	0,5599	0,8864	1,16		Algorithm converged.	0,71	1,91
		> 2	17	12,6	5	29,4	19	14,1	7	36,8	0,71		Convergence criterion (GCONV=1E-8) satisfied.	0,18	2,89	-0,074		Algorithm converged.	-0,381	0,232	0,80		Algorithm converged.	0,31	2,05	0,6396		1,25		Algorithm converged.	0,49	3,22
	Refractory Type	Rituximab + Chemotherapy	81	60,0	21	25,9	56	41,5	21	37,5	0,58		Convergence criterion (GCONV=1E-8) satisfied.	0,28	1,22	-0,116		Algorithm converged.	-0,274	0,043	0,69		Algorithm converged.	0,42	1,14	0,1478	0,0854	1,45		Algorithm converged.	0,88	2,38
		Rituximab Monotherapy	18	13,3	8	44,4	19	14,1	5	26,3	2,24		Convergence criterion (GCONV=1E-8) satisfied.	0,56	8,91	0,181		Algorithm converged.	-0,122	0,484	1,69		Algorithm converged.	0,68	4,21	0,2604		0,59		Algorithm converged.	0,24	1,47

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_base/qa/program/t_pro_rsp2.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_pro_rsp2_sg_IMPR_FACTLSR_FACTLpop_FOLY_IT_01SEP2014_01297.xls 07AUG2020 16:04

9 (Anhang): Ergebnisse für FACT-LymS - Verschlechterung der Gesundheitsbezogenen Lebensqualität um MID fünf - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients, Patients with Baseline and post Baseline FACT-LYM Subscale result
ENDPOINT: FACT-LYM Subscale - Responder (MID=5), Worsening
MODEL: Unstratified Analysis
STUDY: G001297
Dichotomous Analysis by Subgroups (Efficacy)

			G-Benda (N=135)				Benda (N=135)				G-Benda vs. Benda															Benda vs. G-Benda			
			Patients		Patients with Event		Patients		Patients with Event		Odds Ratio				Absolute Risk Difference				Relative Risk							Relative Risk			
Endpoint	Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
Cycle 5 Day 1	All	n/a	114	84.4	15	13.2	105	77.8	15	14.3	0.91		Convergence criterion (GCONV=1E-8) satisfied.	0.42	1.96	-0.011		Algorithm converged.	-0.103	0.080	0.92		Algorithm converged.	0.47	1.79	0.8084		1.09		Algorithm converged.	0.56	2.11
	Sex	Male	66	48.9	8	12.1	55	40.7	5	9.1	1.38		Convergence criterion (GCONV=1E-8) satisfied.	0.42	4.49	0.030		Algorithm converged.	-0.079	0.140	1.33		Algorithm converged.	0.46	3.84	0.5943	0.3849	0.75		Algorithm converged.	0.26	2.16
		Female	48	35.6	7	14.6	50	37.0	10	20.0	0.68		Convergence criterion (GCONV=1E-8) satisfied.	0.24	1.97	-0.054		Algorithm converged.	-0.203	0.095	0.73		Algorithm converged.	0.30	1.76	0.4822		1.37		Algorithm converged.	0.57	3.31
	Age	< 60 years	47	34.8	7	14.9	44	32.6	5	11.4	1.36		Convergence criterion (GCONV=1E-8) satisfied.	0.40	4.67	0.035		Algorithm converged.	-0.103	0.174	1.31		Algorithm converged.	0.45	3.83	0.6207	0.3992	0.76		Algorithm converged.	0.26	2.23
		>= 60 years	67	49.6	8	11.9	61	45.2	10	16.4	0.69		Convergence criterion (GCONV=1E-8) satisfied.	0.25	1.88	-0.045		Algorithm converged.	-0.166	0.077	0.73		Algorithm converged.	0.31	1.73	0.4714		1.37		Algorithm converged.	0.58	3.25
	Race/ethnicity	White	105	77.8	13	12.4	94	69.6	14	14.9	0.81		Convergence criterion (GCONV=1E-8) satisfied.	0.36	1.82	-0.025		Algorithm converged.	-0.121	0.071	0.83		Algorithm converged.	0.41	1.68	0.6058	0.4062	1.20		Algorithm converged.	0.60	2.43
		Other	5	3.7	2	40.0	5	3.7	1	20.0	2.67		Convergence criterion (GCONV=1E-8) satisfied.	0.16	45.14	0.200		Algorithm converged.	-0.354	0.754	2.00		Algorithm converged.	0.26	15.62	0.5087		0.50		Algorithm converged.	0.06	3.91
		Missing/Unknown	4	3.0			6	4.4																								
	Geographic region	Western Europe	46	34.1	7	15.2	47	34.8	9	19.1	0.76		Convergence criterion (GCONV=1E-8) satisfied.	0.26	2.24	-0.039		Algorithm converged.	-0.192	0.114	0.79		Algorithm converged.	0.32	1.96	0.6168	0.5059	1.26		Algorithm converged.	0.51	3.10
		North America	57	42.2	7	12.3	49	36.3	4	8.2	1.57		Convergence criterion (GCONV=1E-8) satisfied.	0.43	5.74	0.041		Algorithm converged.	-0.073	0.156	1.50		Algorithm converged.	0.47	4.84	0.4930		0.66		Algorithm converged.	0.21	2.14
		Other	11	8.1	1	9.1	9	6.7	2	22.2	0.35		Convergence criterion (GCONV=1E-8) satisfied.	0.03	4.65	-0.131		Algorithm converged.	-0.452	0.189	0.41		Algorithm converged.	0.04	3.82	0.4327		2.44		Algorithm converged.	0.26	22.80
	Body mass index	Underweight (< 18.5)					1	0.7																			0.8125					
		Normal weight (18.5 -< 25)	37	27.4	4	10.8	30	22.2	3	10.0	1.09		Convergence criterion (GCONV=1E-8) satisfied.	0.22	5.30	0.008		Algorithm converged.	-0.139	0.155	1.08		Algorithm converged.	0.26	4.46	0.9142		0.93		Algorithm converged.	0.22	3.82
		Overweight (25 - < 30)	40	29.6	5	12.5	30	22.2	5	16.7	0.71		Convergence criterion (GCONV=1E-8) satisfied.	0.19	2.73	-0.042		Algorithm converged.	-0.210	0.127	0.75		Algorithm converged.	0.24	2.36	0.6226		1.33		Algorithm converged.	0.42	4.19
		Obese (>= 30)	35	25.9	6	17.1	39	28.9	6	15.4	1.14		Convergence criterion (GCONV=1E-8) satisfied.	0.33	3.92	0.018		Algorithm converged.	-0.151	0.186	1.11		Algorithm converged.	0.40	3.14	0.8377		0.90		Algorithm converged.	0.32	2.53
		Missing	2	1.5			5	3.7	1	20.0		*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			<0.01		Algorithm converged.	0.00	NE	1.0000		>999.99		Algorithm converged.	0.00	NE
	Baseline ECOG Performance Status score	0-1	111	82.2	15	13.5	100	74.1	14	14.0	0.96		Convergence criterion (GCONV=1E-8) satisfied.	0.44	2.10	-0.005		Algorithm converged.	-0.098	0.088	0.97		Algorithm converged.	0.49	1.90	0.9184	0.2773	1.04		Algorithm converged.	0.53	2.04
		2	3	2.2			4	3.0	1	25.0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01		Algorithm converged.	0.00	NE	1.0000		>999.99		Algorithm converged.	0.00	NE
		Missing					1	0.7																								
	Independence status (Katz ADL)	Independent (5-6)	45	33.3	7	15.6	41	30.4	8	19.5	0.76		Convergence criterion (GCONV=1E-8) satisfied.	0.25	2.32	-0.040		Algorithm converged.	-0.201	0.121	0.80		Algorithm converged.	0.32	2.00	0.6300	<.0001	1.25		Algorithm converged.	0.50	3.15
		Very dependent (0-2)	2	1.5																												
		Missing	67	49.6	8	11.9	64	47.4	7	10.9	1.10		Convergence criterion (GCONV=1E-8) satisfied.	0.38	3.24	0.010		Algorithm converged.	-0.099	0.119	1.09		Algorithm converged.	0.42	2.84	0.8571		0.92		Algorithm converged.	0.35	2.38
	Best response to prior therapy	CR/PR	93	68.9	14	15.1	85	63.0	15	17.6	0.83		Convergence criterion (GCONV=1E-8) satisfied.	0.37	1.83	-0.026		Algorithm converged.	-0.135	0.083	0.85		Algorithm converged.	0.44	1.66	0.6401		1.17		Algorithm converged.	0.60	2.28
		SD	16	11.9	1	6.3	14	10.4				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
		PD	5	3.7			3	2.2																								
		Missing (UE)					3	2.2																								
	Histologic grade (follicular)	1	44	32.6	2	4.5	30	22.2	3	10.0	0.43		Convergence criterion (GCONV=1E-8) satisfied.	0.07	2.73	-0.055		Algorithm converged.	-0.178	0.069	0.45		Algorithm converged.	0.08	2.56	0.3712		2.20		Algorithm converged.	0.39	12.38
		2	51	37.8	10	19.6	48	35.6	8	16.7	1.22		Convergence criterion (GCONV=1E-8) satisfied.	0.44	3.40	0.029		Algorithm converged.	-0.122	0.181	1.18		Algorithm converged.	0.51	2.73	0.7052		0.85		Algorithm converged.	0.37	1.97
		3					2	1.5	2	100.0																						
		3a	14	10.4	3	21.4	20	14.8	2	10.0	2.45		Convergence criterion (GCONV=1E-8) satisfied.	0.35	17.08	0.114		Algorithm converged.	-0.138	0.366	2.14		Algorithm converged.	0.41	11.20	0.3664		0.47		Algorithm converged.	0.09	2.44
		Missing/Unknown/Variants	5	3.7			5	3.7																								
	FLIPI	Low (0-1)	30	22.2	3	10.0	24	17.8	4	16.7	0.56		Convergence criterion (GCONV=1E-8) satisfied.	0.11	2.76	-0.067		Algorithm converged.	-0.250	0.117	0.60		Algorithm converged.	0.15	2.43	0.4737	0.3433	1.67		Algorithm converged.	0.41	6.74
		Intermediate (2)	34	25.2	3	8.8	36	26.7	5	13.9	0.60		Convergence criterion (GCONV=1E-8) satisfied.	0.13	2.73	-0.051		Algorithm converged.	-0.198	0.097	0.64		Algorithm converged.	0.16	2.46	0.5109		1.57		Algorithm converged.	0.41	6.09
		High (>=3)	44	32.6	8	18.2	40	29.6	4	10.0	2.00		Convergence criterion (GCONV=1E-8) satisfied.	0.55	7.24	0.082		Algorithm converged.	-0.065	0.229	1.82		Algorithm converged.	0.59	5.58	0.2960		0.55		Algorithm converged.	0.18	1.69
		Missing/Unknown	6	4.4	1	16.7	5	3.7	2	40.0	0.30		Convergence criterion (GCONV=1E-8) satisfied.	0.02	4.91	-0.233		Algorithm converged.	-0.756	0.289	0.42		Algorithm converged.	0.05	3.36	0.4109		2.40		Algorithm converged.	0.30	19.34
	Fc gamma receptor IIa	131HH	27	20.0	3	11.1	25	18.5	5	20.0	0.50		Convergence criterion (GCONV=1E-8) satisfied.	0.11	2.35	-0.089		Algorithm converged.	-0.285	0.108	0.56		Algorithm converged.	0.15	2.09	0.3842	0.0026	1.80		Algorithm converged.	0.48	6.76

		131HR	50	37.0	9	18.0	55	40.7	3	5.5	3.80		Convergence criterion (GCONV=1E-8) satisfied.	0.97	14.96	0.125		Algorithm converged.	0.003	0.248	3.30		Algorithm converged.	0.95	11.51	0.0610		0.30		Algorithm converged.	0.09	1.06
		131RR	26	19.3	1	3.8	18	13.3	6	33.3	0.08		Convergence criterion (GCONV=1E-8) satisfied.	<0.01	0.74	-0.295		Algorithm converged.	-0.525	-0.065	0.12		Algorithm converged.	0.02	0.88	0.0371		8.67		Algorithm converged.	1.14	65.98
		Missing	11	8.1	2	18.2	7	5.2	1	14.3	1.33		Convergence criterion (GCONV=1E-8) satisfied.	0.10	18.19	0.039		Algorithm converged.	-0.306	0.384	1.27		Algorithm converged.	0.14	11.55	0.8303		0.79		Algorithm converged.	0.09	7.13
	Fc gamma receptor IIIa	158VV	12	8.9	1	8.3	18	13.3	2	11.1	0.73		Convergence criterion (GCONV=1E-8) satisfied.	0.06	9.04	-0.028		Algorithm converged.	-0.241	0.186	0.75		Algorithm converged.	0.08	7.38	0.8052	0.9760	1.33		Algorithm converged.	0.14	13.12
		158VF	49	36.3	6	12.2	47	34.8	7	14.9	0.80		Convergence criterion (GCONV=1E-8) satisfied.	0.25	2.58	-0.026		Algorithm converged.	-0.164	0.111	0.82		Algorithm converged.	0.30	2.27	0.7051		1.22		Algorithm converged.	0.44	3.35
		158FF	42	31.1	6	14.3	33	24.4	5	15.2	0.93		Convergence criterion (GCONV=1E-8) satisfied.	0.26	3.38	-0.009		Algorithm converged.	-0.170	0.153	0.94		Algorithm converged.	0.32	2.82	0.9162		1.06		Algorithm converged.	0.35	3.17
		Missing	11	8.1	2	18.2	7	5.2	1	14.3	1.33		Convergence criterion (GCONV=1E-8) satisfied.	0.10	18.19	0.039		Algorithm converged.	-0.306	0.384	1.27		Algorithm converged.	0.14	11.55	0.8303		0.79		Algorithm converged.	0.09	7.13
	Fc gamma receptor IIb/IIc	232II	70	51.9	10	14.3	67	49.6	12	17.9	0.76		Convergence criterion (GCONV=1E-8) satisfied.	0.31	1.91	-0.036		Algorithm converged.	-0.159	0.087	0.80		Algorithm converged.	0.37	1.72	0.5646		1.25		Algorithm converged.	0.58	2.71
		232IT	31	23.0	3	9.7	27	20.0	2	7.4	1.34		Convergence criterion (GCONV=1E-8) satisfied.	0.21	8.68	0.023		Algorithm converged.	-0.121	0.166	1.31		Algorithm converged.	0.24	7.25	0.7597		0.77		Algorithm converged.	0.14	4.25
		232TT	1	0.7			4	3.0																								
		Missing	12	8.9	2	16.7	7	5.2	1	14.3	1.20		Convergence criterion (GCONV=1E-8) satisfied.	0.09	16.24	0.024		Algorithm converged.	-0.310	0.358	1.17		Algorithm converged.	0.13	10.66	0.8914		0.86		Algorithm converged.	0.09	7.83
	Absolute lymphocyte count	>= median	52	38.5	9	17.3	55	40.7	12	21.8	0.75		Convergence criterion (GCONV=1E-8) satisfied.	0.29	1.96	-0.045		Algorithm converged.	-0.195	0.105	0.79		Algorithm converged.	0.36	1.72	0.5589	0.3573	1.26		Algorithm converged.	0.58	2.74
		< median	62	45.9	6	9.7	50	37.0	3	6.0	1.68		Convergence criterion (GCONV=1E-8) satisfied.	0.40	7.08	0.037		Algorithm converged.	-0.062	0.136	1.61		Algorithm converged.	0.42	6.13	0.4828		0.62		Algorithm converged.	0.16	2.36
	Time from initial NHL diagnosis to randomization	< 6 months	4	3.0	1	25.0	4	3.0				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.	NE	NE	NE	0.0322	NE		Algorithm converged.	NE	NE
		6-12 months	6	4.4	2	33.3	10	7.4				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
		> 12 months	104	77.0	12	11.5	91	67.4	15	16.5	0.66		Convergence criterion (GCONV=1E-8) satisfied.	0.29	1.50	-0.049		Algorithm converged.	-0.147	0.048	0.70		Algorithm converged.	0.35	1.42	0.3214		1.43		Algorithm converged.	0.71	2.89
	Beta 2 microglobulin	>= 3.5 mg/L	16	11.9			23	17.0	3	13.0		*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			<0.01		Algorithm converged.	0.00	NE	0.9999	0.0806	>999.99		Algorithm converged.	0.00	NE
		< 3.5 mg/L	94	69.6	14	14.9	78	57.8	12	15.4	0.96		Convergence criterion (GCONV=1E-8) satisfied.	0.42	2.22	-0.005		Algorithm converged.	-0.113	0.103	0.97		Algorithm converged.	0.48	1.97	0.9287		1.03		Algorithm converged.	0.51	2.10
		Missing	4	3.0	1	25.0	4	3.0				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Prior therapies	<= 2	96	71.1	15	15.6	82	60.7	14	17.1	0.90		Convergence criterion (GCONV=1E-8) satisfied.	0.41	1.99	-0.014		Algorithm converged.	-0.124	0.095	0.92		Algorithm converged.	0.47	1.78	0.7942	0.2993	1.09		Algorithm converged.	0.56	2.13
		> 2	18	13.3			23	17.0	1	4.3		*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			<0.01		Algorithm converged.	0.00	NE	1.0000		>999.99		Algorithm converged.	0.00	NE
	Refractory Type	Rituximab + Chemotherapy	95	70.4	13	13.7	77	57.0	13	16.9	0.78		Convergence criterion (GCONV=1E-8) satisfied.	0.34	1.80	-0.032		Algorithm converged.	-0.141	0.077	0.81		Algorithm converged.	0.40	1.64	0.5606	0.5606	1.23		Algorithm converged.	0.61	2.50
		Rituximab Monotherapy	19	14.1	2	10.5	28	20.7	2	7.1	1.53		Convergence criterion (GCONV=1E-8) satisfied.	0.20	11.92	0.034		Algorithm converged.	-0.134	0.202	1.47		Algorithm converged.	0.23	9.57	0.6847		0.68		Algorithm converged.	0.10	4.41
Follow Up Visit 1 Month 2	All	n/a	99	73.3	10	10.1	75	55.6	7	9.3	1.09		Convergence criterion (GCONV=1E-8) satisfied.	0.40	3.02	0.008		Algorithm converged.	-0.081	0.096	1.08		Algorithm converged.	0.43	2.71	0.8660		0.92		Algorithm converged.	0.37	2.31
	Sex	Male	58	43.0	6	10.3	40	29.6	5	12.5	0.81		Convergence criterion (GCONV=1E-8) satisfied.	0.23	2.85	-0.022		Algorithm converged.	-0.151	0.107	0.83		Algorithm converged.	0.27	2.53	0.7397	0.4668	1.21		Algorithm converged.	0.40	3.69
		Female	41	30.4	4	9.8	35	25.9	2	5.7	1.78		Convergence criterion (GCONV=1E-8) satisfied.	0.31	10.38	0.040		Algorithm converged.	-0.079	0.159	1.71		Algorithm converged.	0.33	8.77	0.5217		0.59		Algorithm converged.	0.11	3.01
	Age	< 60 years	41	30.4	3	7.3	32	23.7	1	3.1	2.45		Convergence criterion (GCONV=1E-8) satisfied.	0.24	24.71	0.042		Algorithm converged.	-0.058	0.142	2.34		Algorithm converged.	0.26	21.46	0.4517	0.4000	0.43		Algorithm converged.	0.05	3.91
		>= 60 years	58	43.0	7	12.1	43	31.9	6	14.0	0.85		Convergence criterion (GCONV=1E-8) satisfied.	0.26	2.73	-0.019		Algorithm converged.	-0.152	0.114	0.86		Algorithm converged.	0.31	2.39	0.7797		1.16		Algorithm converged.	0.42	3.20
	Race/ethnicity	White	92	68.1	9	9.8	68	50.4	7	10.3	0.94		Convergence criterion (GCONV=1E-8) satisfied.	0.33	2.68	-0.005		Algorithm converged.	-0.099	0.089	0.95		Algorithm converged.	0.37	2.42	0.9151	0.1851	1.05		Algorithm converged.	0.41	2.68
		Other	4	3.0	1	25.0	5	3.7				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
		Missing/Unknown	3	2.2			2	1.5																								
	Geographic region	Western Europe	38	28.1	5	13.2	31	23.0	3	9.7	1.41		Convergence criterion (GCONV=1E-8) satisfied.	0.31	6.45	0.035		Algorithm converged.	-0.115	0.184	1.36		Algorithm converged.	0.35	5.25	0.6557	0.8260	0.74		Algorithm converged.	0.19	2.84
		North America	50	37.0	4	8.0	38	28.1	3	7.9	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.21	4.83	0.001		Algorithm converged.	-0.113	0.115	1.01		Algorithm converged.	0.24	4.26	0.9856		0.99		Algorithm converged.	0.23	4.15
		Other	11	8.1	1	9.1	6	4.4	1	16.7	0.50		Convergence criterion (GCONV=1E-8) satisfied.	0.03	9.77	-0.076		Algorithm converged.	-0.419	0.267	0.55		Algorithm converged.	0.04	7.25	0.6461		1.83		Algorithm converged.	0.14	24.37
	Body mass index	Underweight (< 18.5)					1	0.7																			0.5324				
		Normal weight (18.5 -< 25)	30	22.2	4	13.3	21	15.6	1	4.8	3.08		Convergence criterion (GCONV=1E-8) satisfied.	0.32	29.70	0.086		Algorithm converged.	-0.066	0.238	2.80		Algorithm converged.	0.34	23.31	0.3410		0.36		Algorithm converged.	0.04	2.97
		Overweight (25 - < 30)	37	27.4	4	10.8	23	17.0	2	8.7	1.27		Convergence criterion (GCONV=1E-8) satisfied.	0.21	7.57	0.021		Algorithm converged.	-0.131	0.174	1.24		Algorithm converged.	0.25	6.25	0.7917		0.80		Algorithm converged.	0.16	4.05

		Obese (>= 30)	30	22.2	2	6.7	27	20.0	4	14.8	0.41		Convergence criterion (GCONV=1E-8) satisfied.	0.07	2.45	-0.081		Algorithm converged.	-0.242	0.080	0.45		Algorithm converged.	0.09	2.26	0.3327		2.22		Algorithm converged.	0.44	11.18
		Missing	2	1.5			3	2.2																								
	Baseline ECOG Performance Status score	0-1	97	71.9	10	10.3	73	54.1	7	9.6	1.08		Convergence criterion (GCONV=1E-8) satisfied.	0.39	3.00	0.007		Algorithm converged.	-0.083	0.098	1.08		Algorithm converged.	0.43	2.69	0.8770	1.0000	0.93		Algorithm converged.	0.37	2.33
		2	2	1.5			1	0.7																								
		Missing					1	0.7																								
	Independence status (Katz ADL)	Independent (5-6)	37	27.4	5	13.5	31	23.0	2	6.5	2.27		Convergence criterion (GCONV=1E-8) satisfied.	0.41	12.59	0.071		Algorithm converged.	-0.069	0.211	2.09		Algorithm converged.	0.44	10.06	0.3557	NE	0.48		Algorithm converged.	0.10	2.29
		Missing	62	45.9	5	8.1	44	32.6	5	11.4	0.68		Convergence criterion (GCONV=1E-8) satisfied.	0.19	2.52	-0.033		Algorithm converged.	-0.149	0.083	0.71		Algorithm converged.	0.22	2.30	0.5682		1.41		Algorithm converged.	0.43	4.58
	Best response to prior therapy	CR/PR	79	58.5	9	11.4	61	45.2	6	9.8	1.18		Convergence criterion (GCONV=1E-8) satisfied.	0.40	3.51	0.016		Algorithm converged.	-0.087	0.118	1.16		Algorithm converged.	0.44	3.08	0.7684		0.86		Algorithm converged.	0.32	2.29
		SD	15	11.1	1	6.7	11	8.1				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 2.9864164671 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
		PD	5	3.7			2	1.5	1	50.0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01		Algorithm converged.	0.00	NE	1.0000		>999.99		Algorithm converged.	0.00	NE
		Missing (UE)					1	0.7																								
	Histologic grade (follicular)	1	40	29.6			20	14.8	2	10.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 6.1295861294 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0.00	NE	0.9999		>999.99		Algorithm converged.	0.00	NE
		2	46	34.1	8	17.4	34	25.2	2	5.9	3.37		Convergence criterion (GCONV=1E-8) satisfied.	0.67	17.00	0.115		Algorithm converged.	-0.020	0.250	2.96		Algorithm converged.	0.67	13.05	0.1524		0.34		Algorithm converged.	0.08	1.49
		3					1	0.7																								
		3a	8	5.9	1	12.5	16	11.9	2	12.5	1.00		Convergence criterion (GCONV=1E-8) satisfied.	0.08	13.02	0.000		Algorithm converged.	-0.281	0.281	1.00		Algorithm converged.	0.11	9.44	1.0000		1.00		Algorithm converged.	0.11	9.44
		Missing/Unknown/Variants	5	3.7	1	20.0	4	3.0	1	25.0	0.75		Convergence criterion (GCONV=1E-8) satisfied.	0.03	17.51	-0.050		Algorithm converged.	-0.600	0.500	0.80		Algorithm converged.	0.07	9.18	0.8578		1.25		Algorithm converged.	0.11	14.34
	FLIPI	Low (0-1)	29	21.5	2	6.9	18	13.3	2	11.1	0.59		Convergence criterion (GCONV=1E-8) satisfied.	0.08	4.63	-0.042		Algorithm converged.	-0.214	0.130	0.62		Algorithm converged.	0.10	4.03	0.6171	0.5604	1.61		Algorithm converged.	0.25	10.45
		Intermediate (2)	31	23.0	1	3.2	27	20.0	2	7.4	0.42		Convergence criterion (GCONV=1E-8) satisfied.	0.04	4.87	-0.042		Algorithm converged.	-0.159	0.075	0.44		Algorithm converged.	0.04	4.54	0.4871		2.30		Algorithm converged.	0.22	23.94
		High (>=3)	36	26.7	6	16.7	27	20.0	3	11.1	1.60		Convergence criterion (GCONV=1E-8) satisfied.	0.36	7.07	0.056		Algorithm converged.	-0.114	0.225	1.50		Algorithm converged.	0.41	5.47	0.5388		0.67		Algorithm converged.	0.18	2.43
		Missing/Unknown	3	2.2	1	33.3	3	2.2				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Fc gamma receptor IIa	131HH	28	20.7	2	7.1	20	14.8	3	15.0	0.44		Convergence criterion (GCONV=1E-8) satisfied.	0.07	2.89	-0.079		Algorithm converged.	-0.262	0.105	0.48		Algorithm converged.	0.09	2.59	0.3908	0.3522	2.10		Algorithm converged.	0.39	11.43
		131HR	40	29.6	5	12.5	37	27.4	2	5.4	2.50		Convergence criterion (GCONV=1E-8) satisfied.	0.45	13.76	0.071		Algorithm converged.	-0.055	0.197	2.31		Algorithm converged.	0.48	11.20	0.2977		0.43		Algorithm converged.	0.09	2.09
		131RR	23	17.0	1	4.3	14	10.4	1	7.1	0.59		Convergence criterion (GCONV=1E-8) satisfied.	0.03	10.27	-0.028		Algorithm converged.	-0.187	0.131	0.61		Algorithm converged.	0.04	8.98	0.7177		1.64		Algorithm converged.	0.11	24.23
		Missing	8	5.9	2	25.0	4	3.0	1	25.0	1.00		Convergence criterion (GCONV=1E-8) satisfied.	0.06	15.99	0.000		Algorithm converged.	-0.520	0.520	1.00		Algorithm converged.	0.13	8.00	1.0000		1.00		Algorithm converged.	0.13	8.00
	Fc gamma receptor IIIa	158VV	11	8.1	1	9.1	11	8.1	1	9.1	1.00		Convergence criterion (GCONV=1E-8) satisfied.	0.05	18.30	0.000		Algorithm converged.	-0.240	0.240	1.00		Algorithm converged.	0.07	14.05	1.0000	0.4049	1.00		Algorithm converged.	0.07	14.05
		158VF	42	31.1	3	7.1	32	23.7	4	12.5	0.54		Convergence criterion (GCONV=1E-8) satisfied.	0.11	2.60	-0.054		Algorithm converged.	-0.192	0.085	0.57		Algorithm converged.	0.14	2.37	0.4413		1.75		Algorithm converged.	0.42	7.27
		158FF	38	28.1	4	10.5	28	20.7	1	3.6	3.18		Convergence criterion (GCONV=1E-8) satisfied.	0.34	30.09	0.070		Algorithm converged.	-0.050	0.189	2.95		Algorithm converged.	0.35	24.96	0.3213		0.34		Algorithm converged.	0.04	2.87
		Missing	8	5.9	2	25.0	4	3.0	1	25.0	1.00		Convergence criterion (GCONV=1E-8) satisfied.	0.06	15.99	0.000		Algorithm converged.	-0.520	0.520	1.00		Algorithm converged.	0.13	8.00	1.0000		1.00		Algorithm converged.	0.13	8.00
	Fc gamma receptor IIb/IIc	232II	63	46.7	6	9.5	44	32.6	4	9.1	1.05		Convergence criterion (GCONV=1E-8) satisfied.	0.28	3.97	0.004		Algorithm converged.	-0.107	0.116	1.05		Algorithm converged.	0.31	3.50	0.9397	0.9972	0.95		Algorithm converged.	0.29	3.19
		232IT	26	19.3	2	7.7	25	18.5	2	8.0	0.96		Convergence criterion (GCONV=1E-8) satisfied.	0.12	7.38	-0.003		Algorithm converged.	-0.151	0.145	0.96		Algorithm converged.	0.15	6.31	0.9674		1.04		Algorithm converged.	0.16	6.83
		232TT	1	0.7			2	1.5																								
		Missing	9	6.7	2	22.2	4	3.0	1	25.0	0.86		Convergence criterion (GCONV=1E-8) satisfied.	0.05	13.48	-0.028		Algorithm converged.	-0.532	0.476	0.89		Algorithm converged.	0.11	7.20	0.9121		1.12		Algorithm converged.	0.14	9.11
	Absolute lymphocyte count	>= median	47	34.8	6	12.8	36	26.7	3	8.3	1.61		Convergence criterion (GCONV=1E-8) satisfied.	0.37	6.93	0.044		Algorithm converged.	-0.087	0.176	1.53		Algorithm converged.	0.41	5.71	0.5253	0.4161	0.65		Algorithm converged.	0.18	2.43
		< median	52	38.5	4	7.7	37	27.4	4	10.8	0.69		Convergence criterion (GCONV=1E-8) satisfied.	0.16	2.95	-0.031		Algorithm converged.	-0.155	0.092	0.71		Algorithm converged.	0.19	2.66	0.6134		1.41		Algorithm converged.	0.38	5.26
		Missing					2	1.5																								
	Time from initial NHL diagnosis to randomization	< 6 months	4	3.0	1	25.0	4	3.0	1	25.0	1.00		Convergence criterion (GCONV=1E-8) satisfied.	0.04	24.55	0.000		Algorithm converged.	-0.600	0.600	1.00		Algorithm converged.	0.09	11.03	1.0000	0.4364	1.00		Algorithm converged.	0.09	11.03
		6-12 months	5	3.7	1	20.0	6	4.4				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE

		> 12 months	90	66.7	8	8.9	65	48.1	6	9.2	0.96		Convergence criterion (GCONV=1E-8) satisfied.	0.32	2.91	-0.003		Algorithm converged.	-0.095	0.088	0.96		Algorithm converged.	0.35	2.64	0.9416		1.04		Algorithm converged.	0.38	2.85
	Beta 2 microglobulin	>= 3.5 mg/L	13	9.6	1	7.7	18	13.3	1	5.6	1.42		Convergence criterion (GCONV=1E-8) satisfied.	0.08	24.95	0.021		Algorithm converged.	-0.158	0.201	1.38		Algorithm converged.	0.10	20.16	0.8118	0.7558	0.72		Algorithm converged.	0.05	10.52
		< 3.5 mg/L	82	60.7	8	9.8	54	40.0	6	11.1	0.86		Convergence criterion (GCONV=1E-8) satisfied.	0.28	2.65	-0.014		Algorithm converged.	-0.119	0.092	0.88		Algorithm converged.	0.32	2.39	0.7990		1.14		Algorithm converged.	0.42	3.10
		Missing	4	3.0	1	25.0	3	2.2				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Prior therapies	<= 2	82	60.7	8	9.8	56	41.5	4	7.1	1.41		Convergence criterion (GCONV=1E-8) satisfied.	0.40	4.91	0.026		Algorithm converged.	-0.067	0.119	1.37		Algorithm converged.	0.43	4.32	0.5955	0.5524	0.73		Algorithm converged.	0.23	2.31
		> 2	17	12.6	2	11.8	19	14.1	3	15.8	0.71		Convergence criterion (GCONV=1E-8) satisfied.	0.10	4.86	-0.040		Algorithm converged.	-0.265	0.184	0.75		Algorithm converged.	0.14	3.94	0.7291		1.34		Algorithm converged.	0.25	7.10
	Refractory Type	Rituximab + Chemotherapy	81	60.0	7	8.6	56	41.5	4	7.1	1.23		Convergence criterion (GCONV=1E-8) satisfied.	0.34	4.42	0.015		Algorithm converged.	-0.076	0.106	1.21		Algorithm converged.	0.37	3.94	0.7517	0.8868	0.83		Algorithm converged.	0.25	2.69
		Rituximab Monotherapy	18	13.3	3	16.7	19	14.1	3	15.8	1.07		Convergence criterion (GCONV=1E-8) satisfied.	0.19	6.13	0.009		Algorithm converged.	-0.229	0.247	1.06		Algorithm converged.	0.24	4.57	0.9423		0.95		Algorithm converged.	0.22	4.10

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_base/qa/program/t_pro_rsp2.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_pro_rsp2_sg_WR_FACTLSR_FACTLpop_FOLY_IT_01SEP2014_01297.xls
11JAN2021 16:02

Anhang 4-G2: Weitere Analysen zu Gesundheitszustand (EQ-5D-VAS) und Gesundheitsbezogener Lebensqualität (FACT-Lym): MMRM-Analysen und Mittelwerte pro Visite

10 (Anhang): Ergebnisse für EQ-5D-VAS MMRM - Hauptanalysen aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients, Patients with Baseline and post Baseline EQ-5D VAS result
ENDPOINT: EQ-5D VAS
MODEL: Stratified Analysis by Refractory Type, Prior Therapies STUDY:
GO01297
Analysis of MMRM for all Visits and Follow-Up Visits

		G-Benda (N=129)					Benda (N=130)					Difference between Treatments (G-Benda - Benda)					
		N			Statistics		N			Statistics							
Name	Level	Total	with baseline value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baseline value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population/ Method[4]	
All	n/a	129	129	129	1,6	4,6	130	130	130	5,9	4,3	4,3	5,3	-6,2	14,8	Intent-to-Treat Patients, Follicular Lymphoma Patients, Patients with Baseline and post Baseline EQ-5D VAS result	adjusted

[1] Patients with a value at baseline and at least one post-baseline value
[2] LSMeans of change from baseline from MMRM (including all available records from all visits) [3]
Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition, for the total population, adjusted for randomization stratification factors. Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/t_mmrm_allfu.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_mmrm_allfu_str_VAS_VASpop_FOLY_IT_01SEP2014_01297.xls 08MAY2020 9:57

11 (Anhang): Ergebnisse für FACT-G MMRM - Hauptanalysen aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients, Patients with Baseline and post Baseline FACT-G Total result
ENDPOINT: FACT-G Total
MODEL: Stratified Analysis by Refractory Type, Prior Therapies STUDY:
GO01297
Analysis of MMRM for all Visits and Follow-Up Visits

		G-Benda (N=130)					Benda (N=133)					Difference between Treatments (G-Benda - Benda)					
		N			Statistics		N			Statistics							
Name	Level	Total	with baseline value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baseline value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population/ Method[4]	
All	n/a	130	130	130	15,9	0,8	133	133	133	14,6	0,8	-1,3	0,9	-3,2	0,6	Intent-to-Treat Patients, Follicular Lymphoma Patients, Patients with Baseline and post Baseline FACT-G Total result	adjusted

[1] Patients with a value at baseline and at least one post-baseline value
[2] LSMeans of change from baseline from MMRM (including all available records from all visits) [3]
Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition, for the total population, adjusted for randomization stratification factors. Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/t_mmrm_allfu.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_mmrm_allfu_str_FACTGT_FACTGpop_FOLY_IT_01SEP2014_01297.xls 08MAY2020 9:53

12 (Anhang): Ergebnisse für FACT-LymS MMRM - Hauptanalysen aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients, Patients with Baseline and post Baseline FACT-LYM Subscale result
ENDPOINT: FACT-LYM Subscale
MODEL: Stratified Analysis by Refractory Type, Prior Therapies STUDY:
GO01297
Analysis of MMRM for all Visits and Follow-Up Visits

		G-Benda (N=135)					Benda (N=135)					Difference between Treatments (G-Benda - Benda)					
		N			Statistics		N			Statistics							
Name	Level	Total	with baseline value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baseline value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population/ Method[4]	
All	n/a	135	135	135	10,0	0,4	135	135	135	10,7	0,4	0,7	0,5	-0,3	1,6	Intent-to-Treat Patients, Follicular Lymphoma Patients, Patients with Baseline and post Baseline FACT-LYM Subscale result	adjusted

[1] Patients with a value at baseline and at least one post-baseline value
[2] LSMeans of change from baseline from MMRM (including all available records from all visits) [3]
Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition, for the total population, adjusted for randomization stratification factors. Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/t_mmrm_allfu.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_mmrm_allfu_str_FACTLS_FACTLpop_FOLY_IT_01SEP2014_01297.xls 08MAY2020 9:54

13 (Anhang): Ergebnisse für EQ-5D-VAS Mittelwerte pro Visite aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients

ENDPOINT: EQ-5D VAS
MODEL: Unadjusted Analysis STUDY: GO01297
Compliance/Mean

		G-Benda (N=155)						Benda (N=166)					
		Patients				Statistics		Patients				Statistics	
Name	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
Baseline	n/a	155	100,0	142	91,6	68,44	20,80	166	100,0	146	88,0	69,45	20,36
Cycle 3 Day 1	n/a	150	96,8	123	82,0	72,41	17,16	156	94,0	125	80,1	70,40	20,50
Cycle 5 Day 1	n/a	142	91,6	113	79,6	75,61	14,58	150	90,4	111	74,0	69,57	21,25
Study Treatment Completion/Early Withdrawal	n/a	147	94,8	114	77,6	74,65	18,85	150	90,4	118	78,7	79,24	64,88
Follow Up Visit 1 Month 2	n/a	129	83,2	99	76,7	77,09	16,52	135	81,3	82	60,7	79,20	15,48

[1] in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values Clinical cut-off:
01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/t_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_pro_mean_VAS_FOLY_IT_01SEP2014_01297.xls 29OCT2019 13:21

14 (Anhang): Ergebnisse für FACT-G Mittelwerte pro Visite aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
MODEL: Unadjusted Analysis STUDY: GO01297
Compliance/Mean

		G-Benda (N=155)						Benda (N=166)					
		Patients				Statistics		Patients				Statistics	
Name	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
Baseline	n/a	155	100,0	141	91,0	81,42	16,45	166	100,0	147	88,6	80,09	16,19
Cycle 3 Day 1	n/a	150	96,8	125	83,3	82,71	15,84	156	94,0	128	82,1	79,65	15,00
Cycle 5 Day 1	n/a	142	91,6	118	83,1	82,05	16,57	150	90,4	115	76,7	78,57	16,04
Study Treatment Completion/Early Withdrawal	n/a	147	94,8	114	77,6	80,98	18,45	150	90,4	117	78,0	79,82	15,19
Follow Up Visit 1 Month 2	n/a	129	83,2	103	79,8	84,44	16,06	135	81,3	82	60,7	81,88	13,94

[1] in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values Clinical cut-off:
01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/t_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_pro_mean_FACTGT_FOLY_IT_01SEP2014_01297.xls 29OCT2019 13:11

15 (Anhang): Ergebnisse für FACT-LymS Mittelwerte pro Visite aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
MODEL: Unadjusted Analysis STUDY: GO01297
Compliance/Mean


		G-Benda (N=155)						Benda (N=166)					
		Patients				Statistics		Patients				Statistics	
Name	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
Baseline	n/a	155	100,0	147	94,8	45,84	9,13	166	100,0	150	90,4	44,63	9,55
Cycle 3 Day 1	n/a	150	96,8	126	84,0	47,34	9,14	156	94,0	126	80,8	45,65	8,90
Cycle 5 Day 1	n/a	142	91,6	117	82,4	47,33	9,39	150	90,4	115	76,7	46,24	9,02
Study Treatment Completion/Early Withdrawal	n/a	147	94,8	115	78,2	46,09	10,11	150	90,4	118	78,7	47,91	8,90
Follow Up Visit 1 Month 2	n/a	129	83,2	103	79,8	48,96	8,24	135	81,3	83	61,5	48,27	7,94

[1] in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values Clinical cut-off:
01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/t_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_pro_mean_FACTLS_FOLY_IT_01SEP2014_01297.xls 29OCT2019 13:12

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Laboratory Test: Prorated FACT-G TOTAL




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:29

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Laboratory Test: Your own health state today



C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

16 (Anhang): Ergebnisse für EQ-5D-VAS Mittelwerte pro Visite - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients ENDPOINT: EQ-5D
VAS
MODEL: Unadjusted Analysis STUDY: GO01297
Compliance/Mean

		G-Benda (N=155)						Benda (N=166)					
		Patients				Statistics		Patients				Statistics	
Name	Level	in study[1]	%	with valu	%	Mean[2]	SD(Mean)	in study[1]	%	with valu	%	Mean[2]	SD(Mean)
All													
Baseline	n/a	155	100	142	91,6	68,44	20,8	166	100	146	88	69,45	20,36
Cycle 3 Day 1	n/a	150	96,8	123	82	72,41	17,16	156	94	125	80,1	70,4	20,5
Cycle 5 Day 1	n/a	142	91,6	113	79,6	75,61	14,58	150	90,4	111	74	69,57	21,25
Study Treatment Completion/Early Withdrawal	n/a	147	94,8	114	77,6	74,65	18,85	150	90,4	118	78,7	79,24	64,88
Follow Up Visit 1 Month 2	n/a	129	83,2	99	76,7	77,09	16,52	135	81,3	82	60,7	79,2	15,48
Sex													
Baseline	Female	70	100	61	87,1	69,23	19,49	71	100	66	93	70,61	19,84
Cycle 3 Day 1	Female	67	95,7	53	79,1	71,91	15,46	69	97,2	56	81,2	72,7	21,26
Cycle 5 Day 1	Female	62	88,6	46	74,2	73,78	14,09	68	95,8	46	67,6	69,96	21,43
Study Treatment Completion/Early Withdrawal	Female	67	95,7	51	76,1	71,98	20,01	68	95,8	50	73,5	73,8	17,42
Follow Up Visit 1 Month 2	Female	55	78,6	40	72,7	76,98	16,98	61	85,9	34	55,7	78,47	16,24
Baseline	Male	85	100	81	95,3	67,84	21,84	95	100	80	84,2	68,49	20,85
Cycle 3 Day 1	Male	83	97,6	70	84,3	72,79	18,45	87	91,6	69	79,3	68,54	19,83
Cycle 5 Day 1	Male	80	94,1	67	83,8	76,87	14,88	82	86,3	65	79,3	69,29	21,28
Study Treatment Completion/Early Withdrawal	Male	80	94,1	63	78,8	76,81	17,72	82	86,3	68	82,9	83,24	84,21
Follow Up Visit 1 Month 2	Male	74	87,1	59	79,7	77,17	16,35	74	77,9	48	64,9	79,71	15,08
Age													
Baseline	< 60 years	59	100	56	94,9	71,04	19,46	61	100	56	91,8	65,55	22,32
Cycle 3 Day 1	< 60 years	58	98,3	50	86,2	72,4	18,44	59	96,7	47	79,7	68,13	20,17
Cycle 5 Day 1	< 60 years	56	94,9	45	80,4	77,13	15,66	58	95,1	45	77,6	69,4	21,05
Study Treatment Completion/Early Withdrawal	< 60 years	53	89,8	45	84,9	74,89	18,06	57	93,4	42	73,7	74,36	16,95
Follow Up Visit 1 Month 2	< 60 years	49	83,1	39	79,6	78,97	16,56	54	88,5	33	61,1	78,97	15,75
Baseline	>= 60 years	96	100	86	89,6	66,74	21,58	105	100	90	85,7	71,87	18,75
Cycle 3 Day 1	>= 60 years	92	95,8	73	79,3	72,41	16,36	97	92,4	78	80,4	71,77	20,71
Cycle 5 Day 1	>= 60 years	86	89,6	68	79,1	74,6	13,84	92	87,6	66	71,7	69,68	21,55
Study Treatment Completion/Early Withdrawal	>= 60 years	94	97,9	69	73,4	74,49	19,48	93	88,6	76	81,7	81,93	79,93
Follow Up Visit 1 Month 2	>= 60 years	80	83,3	60	75	75,87	16,52	81	77,1	49	60,5	79,35	15,46
Race/ethnicity													
Baseline	Missing/Unknown	9	100	7	77,8	66,57	22,89	15	100	13	86,7	66,15	18,5

Cycle 3 Day 1	Missing/Unknown	9	100	5	55,6	79	14,32	14	93,3	10	71,4	64,4	13,81
Cycle 5 Day 1	Missing/Unknown	8	88,9	4	50	82,5	17,08	14	93,3	7	50	64	22,91
Study Treatment Completion/Early Withdrawal	Missing/Unknown	9	100	4	44,4	91	10,03	14	93,3	12	85,7	65,83	16,1
Follow Up Visit 1 Month 2	Missing/Unknown	8	88,9	3	37,5	83,33	20,21	12	80	2	16,7	82	2,83
Baseline	Other	7	100	5	71,4	77,6	17,85	8	100	8	100	69,25	24,73
Cycle 3 Day 1	Other	7	100	4	57,1	68,75	8,54	8	100	7	87,5	68,14	20,05
Cycle 5 Day 1	Other	5	71,4	4	80	72	10,3	7	87,5	5	71,4	76	17,76
Study Treatment Completion/Early Withdrawal	Other	5	71,4	4	80	72,5	22,17	7	87,5	6	85,7	74,5	25,75
Follow Up Visit 1 Month 2	Other	4	57,1	3	75	83,33	11,55	6	75	5	83,3	83,2	14,81
Baseline	White	139	100	130	93,5	68,18	20,86	143	100	125	87,4	69,8	20,39
Cycle 3 Day 1	White	134	96,4	114	85,1	72,25	17,5	134	93,7	108	80,6	71,1	21,08
Cycle 5 Day 1	White	129	92,8	105	81,4	75,49	14,67	129	90,2	99	76,7	69,64	21,39
Study Treatment Completion/Early Withdrawal	White	133	95,7	106	79,7	74,11	18,84	129	90,2	100	77,5	81,13	69,9
Follow Up Visit 1 Month 2	White	117	84,2	93	79,5	76,69	16,62	117	81,8	75	64,1	78,85	15,78
Geographic region													
Baseline	North America	65	100	63	96,9	71,14	21,49	73	100	68	93,2	72	20,36
Cycle 3 Day 1	North America	64	98,5	58	90,6	72,86	18,34	68	93,2	55	80,9	71,84	20,18
Cycle 5 Day 1	North America	63	96,9	55	87,3	78,95	13,18	65	89	50	76,9	73,22	21,62
Study Treatment Completion/Early Withdrawal	North America	62	95,4	57	91,9	75,23	20,64	65	89	53	81,5	77,43	16,44
Follow Up Visit 1 Month 2	North America	57	87,7	49	86	77,94	15,32	57	78,1	39	68,4	79,77	16,28
Baseline	Other	18	100	17	94,4	66,71	17,49	15	100	14	93,3	63,57	21,88
Cycle 3 Day 1	Other	17	94,4	15	88,2	76	18,15	14	93,3	13	92,9	73,77	20,97
Cycle 5 Day 1	Other	15	83,3	11	73,3	80,73	13,48	13	86,7	9	69,2	69,11	19,09
Study Treatment Completion/Early Withdrawal	Other	18	100	14	77,8	80,64	15,83	13	86,7	11	84,6	73	19,84
Follow Up Visit 1 Month 2	Other	14	77,8	12	85,7	83,5	11,35	13	86,7	8	61,5	80	15,81
Baseline	Western Europe	72	100	62	86,1	66,16	20,9	78	100	64	82,1	68,02	19,93
Cycle 3 Day 1	Western Europe	69	95,8	50	72,5	70,8	15,53	74	94,9	57	77	68,25	20,84
Cycle 5 Day 1	Western Europe	64	88,9	47	73,4	70,51	15,1	72	92,3	52	72,2	66,13	21,04
Study Treatment Completion/Early Withdrawal	Western Europe	67	93,1	43	64,2	71,93	17,04	72	92,3	54	75	82,28	94,51
Follow Up Visit 1 Month 2	Western Europe	58	80,6	38	65,5	73,97	18,87	65	83,3	35	53,8	78,37	14,9
Body mass index													
Baseline	Missing	2	100	1	50	60	NE	7	100	6	85,7	63,5	31,52
Cycle 3 Day 1	Missing	2	100	1	50	70	NE	6	85,7	5	83,3	64,2	33,36
Cycle 5 Day 1	Missing	2	100	1	50	67	NE	6	85,7	5	83,3	65,2	34,46
Study Treatment Completion/Early Withdrawal	Missing	2	100	1	50	70	NE	6	85,7	3	50	94	5,57
Follow Up Visit 1 Month 2	Missing	2	100	1	50	65	NE	6	85,7	3	50	93,67	7,51
Baseline	Normal weight (18.5 -< 25)	54	100	47	87	64,68	24,36	50	100	44	88	69,43	18,28
Cycle 3 Day 1	Normal weight (18.5 -< 25)	53	98,1	40	75,5	71,13	17,87	47	94	41	87,2	72	19,77
Cycle 5 Day 1	Normal weight (18.5 -< 25)	49	90,7	38	77,6	75,21	14,62	44	88	33	75	67,15	20,82
Study Treatment Completion/Early Withdrawal	Normal weight (18.5 -< 25)	51	94,4	38	74,5	74,82	17,58	45	90	38	84,4	71,87	12,78
Follow Up Visit 1 Month 2	Normal weight (18.5 -< 25)	41	75,9	31	75,6	76,45	17,3	42	84	24	57,1	79,79	10,48

Baseline	Overweight (25 - < 30)	53	100	51	96,2	69,1	19,75	56	100	48	85,7	68,81	22,45
Cycle 3 Day 1	Overweight (25 - < 30)	50	94,3	40	80	72,88	15,92	53	94,6	35	66	68,34	21,5
Cycle 5 Day 1	Overweight (25 - < 30)	49	92,5	39	79,6	73,72	11,95	51	91,1	32	62,7	73,56	18,83
Study Treatment Completion/Early Withdrawal	Overweight (25 - < 30)	51	96,2	35	68,6	75,74	17,29	51	91,1	36	70,6	91,94	114,83
Follow Up Visit 1 Month 2	Overweight (25 - < 30)	47	88,7	35	74,5	75,91	16,54	44	78,6	25	56,8	82,92	13,39
Baseline	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	59	NE
Cycle 3 Day 1	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	40	NE
Cycle 5 Day 1	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	50	NE
Study Treatment Completion/Early Withdrawal	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	45	NE
Follow Up Visit 1 Month 2	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	50	NE
Baseline	Obese (>= 30)	46	100	43	93,5	71,95	17,55	52	100	47	90,4	71,09	18,99
Cycle 3 Day 1	Obese (>= 30)	45	97,8	42	93,3	73,24	18,14	49	94,2	43	87,8	71,98	18,8
Cycle 5 Day 1	Obese (>= 30)	42	91,3	35	83,3	78,4	17,13	48	92,3	40	83,3	69,4	21,99
Study Treatment Completion/Early Withdrawal	Obese (>= 30)	43	93,5	40	93	73,65	21,75	47	90,4	40	85,1	74,55	19,14
Follow Up Visit 1 Month 2	Obese (>= 30)	39	84,8	32	82,1	79,38	16,16	42	80,8	29	69	75	19,02
Baseline ECOG Performance Status score													
Baseline	Missing	0	NE	0	NE	NE	NE	2	100	1	50	60	NE
Cycle 3 Day 1	Missing	0	NE	0	NE	NE	NE	1	50	1	100	80	NE
Cycle 5 Day 1	Missing	0	NE	0	NE	NE	NE	1	50	1	100	80	NE
Study Treatment Completion/Early Withdrawal	Missing	0	NE			NE	NE	1	50			NE	NE
Follow Up Visit 1 Month 2	Missing	0	NE	0	NE	NE	NE	1	50	1	100	80	NE
Baseline	0-1	147	100	135	91,8	70,19	19,55	157	100	138	87,9	70,5	20,21
Cycle 3 Day 1	0-1	144	98	120	83,3	72,93	16,65	149	94,9	119	79,9	70,74	20,4
Cycle 5 Day 1	0-1	137	93,2	109	79,6	75,96	14,67	143	91,1	106	74,1	69,7	21,57
Study Treatment Completion/Early Withdrawal	0-1	139	94,6	109	78,4	75,31	18,85	142	90,4	113	79,6	79,65	66,11
Follow Up Visit 1 Month 2	0-1	125	85	96	76,8	77,82	15,09	130	82,8	80	61,5	79,18	15,68
Baseline	2	8	100	7	87,5	34,71	15,46	7	100	7	100	50	14,43
Cycle 3 Day 1	2	6	75	3	50	51,67	28,43	6	85,7	5	83,3	60,4	24,64
Cycle 5 Day 1	2	5	62,5	4	80	66	7,79	6	85,7	4	66,7	63,5	13,63
Study Treatment Completion/Early Withdrawal	2	8	100	5	62,5	60,2	13,05	7	100	5	71,4	70	25,5
Follow Up Visit 1 Month 2	2	4	50	3	75	53,67	41,36	4	57,1	1	25	80	NE
Independence status (Katz ADL)													
Baseline	Missing	88	100	83	94,3	69,27	20,7	98	100	81	82,7	67,58	21,93
Cycle 3 Day 1	Missing	86	97,7	71	82,6	73,11	17,37	92	93,9	72	78,3	68,46	21,3
Cycle 5 Day 1	Missing	83	94,3	66	79,5	75,77	15,38	92	93,9	70	76,1	66,13	21,66
Study Treatment Completion/Early Withdrawal	Missing	86	97,7	70	81,4	74,71	18,91	95	96,9	74	77,9	82,26	80,8
Follow Up Visit 1 Month 2	Missing	77	87,5	60	77,9	78,85	16,2	87	88,8	49	56,3	78,65	15,98
Baseline	Very dependent (0-2)	3	100	3	100	52,67	21,94	1	100	1	100	70	NE
Cycle 3 Day 1	Very dependent (0-2)	3	100	3	100	53,33	25,17	0	NE	0	NE	NE	NE
Cycle 5 Day 1	Very dependent (0-2)	3	100	2	66,7	72,5	3,54	0	NE	0	NE	NE	NE
Study Treatment Completion/Early Withdrawal	Very dependent (0-2)	1	33,3			NE	NE	0	NE			NE	NE

Baseline	Independent (5-6)	64	100	56	87,5	68,05	20,93	67	100	64	95,5	71,8	18,24
Cycle 3 Day 1	Independent (5-6)	61	95,3	49	80,3	72,55	16,09	64	95,5	53	82,8	73,04	19,26
Cycle 5 Day 1	Independent (5-6)	56	87,5	45	80,4	75,51	13,81	58	86,6	41	70,7	75,44	19,4
Study Treatment Completion/Early Withdrawal	Independent (5-6)	60	93,8	44	73,3	74,55	18,96	55	82,1	44	80	74,16	18,14
Follow Up Visit 1 Month 2	Independent (5-6)	52	81,3	39	75	74,38	16,86	48	71,6	33	68,8	80	14,92
Best response to prior therapy													
Baseline	Missing (UE)	0	NE	0	NE	NE	NE	5	100	4	80	71,25	15,48
Cycle 3 Day 1	Missing (UE)	0	NE	0	NE	NE	NE	5	100	4	80	80	18,26
Cycle 5 Day 1	Missing (UE)	0	NE	0	NE	NE	NE	5	100	4	80	66,25	28,69
Study Treatment Completion/Early Withdrawal	Missing (UE)	0	NE	0	NE	NE	NE	5	100	4	80	79,25	11,79
Follow Up Visit 1 Month 2	Missing (UE)	0	NE	0	NE	NE	NE	4	80	2	50	80	0
Baseline	CR/PR	126	100	116	92,1	68,9	20,24	133	100	117	88	68,96	21,08
Cycle 3 Day 1	CR/PR	121	96	100	82,6	72,42	17,55	123	92,5	100	81,3	69,36	19,99
Cycle 5 Day 1	CR/PR	114	90,5	92	80,7	75,86	14,7	119	89,5	88	73,9	69,08	20,35
Study Treatment Completion/Early Withdrawal	CR/PR	119	94,4	90	75,6	74,48	19,71	119	89,5	95	79,8	73,01	18,31
Follow Up Visit 1 Month 2	CR/PR	104	82,5	79	76	76,52	15,55	108	81,2	66	61,1	78,8	16,31
Baseline	PD	7	100	5	71,4	58	10,37	8	100	7	87,5	72,29	17,09
Cycle 3 Day 1	PD	7	100	4	57,1	67,5	6,45	8	100	7	87,5	70,43	24,73
Cycle 5 Day 1	PD	7	100	6	85,7	67,33	4,55	6	75	4	66,7	64	31,75
Study Treatment Completion/Early Withdrawal	PD	6	85,7	4	66,7	72,25	12,66	6	75	3	50	60	43,59
Follow Up Visit 1 Month 2	PD	6	85,7	5	83,3	64,6	33,54	5	62,5	4	80	76,25	17,97
Baseline	SD	22	100	21	95,5	68,38	25,42	20	100	18	90	71,11	18,67
Cycle 3 Day 1	SD	22	100	19	86,4	73,37	17,03	20	100	14	70	75,07	23,42
Cycle 5 Day 1	SD	21	95,5	15	71,4	77,4	16	20	100	15	75	74,8	23,22
Study Treatment Completion/Early Withdrawal	SD	22	100	20	90,9	75,9	16,26	20	100	16	80	119,81	168,45
Follow Up Visit 1 Month 2	SD	19	86,4	15	78,9	84,27	11,38	18	90	10	55,6	82,8	10,41
Histologic grade (follicular)													
Baseline	1	54	100	53	98,1	67,3	24,06	51	100	44	86,3	67,86	19,83
Cycle 3 Day 1	1	53	98,1	44	83	74,95	18,01	49	96,1	39	79,6	70,69	19,73
Cycle 5 Day 1	1	51	94,4	43	84,3	79,28	12,22	48	94,1	34	70,8	67,79	24,12
Study Treatment Completion/Early Withdrawal	1	52	96,3	43	82,7	78,93	17,89	49	96,1	39	79,6	74,13	18,95
Follow Up Visit 1 Month 2	1	47	87	38	80,9	81,95	11,59	41	80,4	24	58,5	82,38	12,65
Baseline	2	69	100	60	87	69,23	19,37	68	100	60	88,2	69,82	19,85
Cycle 3 Day 1	2	65	94,2	55	84,6	72,02	17,26	64	94,1	53	82,8	72,15	18,26
Cycle 5 Day 1	2	62	89,9	50	80,6	73,66	15,34	63	92,6	47	74,6	71,57	19,6
Study Treatment Completion/Early Withdrawal	2	63	91,3	47	74,6	72,62	19,95	63	92,6	49	77,8	89,37	97,96
Follow Up Visit 1 Month 2	2	56	81,2	47	83,9	75,4	16,18	61	89,7	37	60,7	81,3	14,11
Baseline	3	0	NE	0	NE	NE	NE	5	100	5	100	53	29,21
Cycle 3 Day 1	3	0	NE	0	NE	NE	NE	5	100	4	80	57,25	21,84
Cycle 5 Day 1	3	0	NE	0	NE	NE	NE	3	60	3	100	61,67	14,57
Study Treatment Completion/Early Withdrawal	3	0	NE	0	NE	NE	NE	3	60	1	33,3	60	NE
Follow Up Visit 1 Month 2	3	0	NE	0	NE	NE	NE	2	40	1	50	80	NE

Baseline	3a	24	100	21	87,5	66,52	18,36	35	100	30	85,7	73,2	16,94
Cycle 3 Day 1	3a	24	100	17	70,8	65,06	13,95	32	91,4	25	78,1	69,48	26,42
Cycle 5 Day 1	3a	22	91,7	14	63,6	72	16,11	31	88,6	22	71	67,73	23,02
Study Treatment Completion/Early Withdrawal	3a	24	100	19	79,2	73,53	15,69	31	88,6	26	83,9	68,27	18,49
Follow Up Visit 1 Month 2	3a	21	87,5	10	47,6	69,7	26,03	27	77,1	16	59,3	70,88	20,11
Baseline	Missing/Unknown/Variants	8	100	8	100	75	14,7	7	100	7	100	71,86	32,31
Cycle 3 Day 1	Missing/Unknown/Variants	8	100	7	87,5	77,29	15,33	6	85,7	4	66,7	63,25	15,56
Cycle 5 Day 1	Missing/Unknown/Variants	7	87,5	6	85,7	74	18,23	5	71,4	5	100	75,6	11,26
Study Treatment Completion/Early Withdrawal	Missing/Unknown/Variants	8	100	5	62,5	61,2	22,6	4	57,1	3	75	81,67	7,64
Follow Up Visit 1 Month 2	Missing/Unknown/Variants	5	62,5	4	80	69,25	24,65	4	57,1	4	100	73,75	17,02
FLIPI													
Baseline	Missing/Unknown	6	100	6	100	64,33	20,22	7	100	7	100	78,29	31,84
Cycle 3 Day 1	Missing/Unknown	6	100	6	100	70,17	13,27	7	100	5	71,4	76,8	11,54
Cycle 5 Day 1	Missing/Unknown	6	100	6	100	75,5	10,29	6	85,7	5	83,3	81,8	7,76
Study Treatment Completion/Early Withdrawal	Missing/Unknown	5	83,3	5	100	80,6	10,21	5	71,4	4	80	71,75	22,34
Follow Up Visit 1 Month 2	Missing/Unknown	4	66,7	2	50	85	7,07	4	57,1	3	75	87,33	11,24
Baseline	High (>=3)	60	100	55	91,7	66,42	21,53	67	100	57	85,1	65,16	20,37
Cycle 3 Day 1	High (>=3)	59	98,3	47	79,7	70,64	17,22	60	89,6	48	80	67,48	24,39
Cycle 5 Day 1	High (>=3)	56	93,3	44	78,6	73,82	16,44	57	85,1	42	73,7	65,69	21,96
Study Treatment Completion/Early Withdrawal	High (>=3)	59	98,3	46	78	71,57	21,74	59	88,1	47	79,7	72,83	16,64
Follow Up Visit 1 Month 2	High (>=3)	51	85	38	74,5	73,13	19,8	52	77,6	29	55,8	75,41	17,91
Baseline	Intermediate (2)	47	100	44	93,6	70,61	21,82	58	100	51	87,9	71,86	17,25
Cycle 3 Day 1	Intermediate (2)	45	95,7	35	77,8	76,31	18,44	55	94,8	43	78,2	75,26	13,71
Cycle 5 Day 1	Intermediate (2)	42	89,4	34	81	77,88	14,44	53	91,4	38	71,7	76,34	15,26
Study Treatment Completion/Early Withdrawal	Intermediate (2)	42	89,4	30	71,4	77,67	18,81	52	89,7	42	80,8	75,12	18
Follow Up Visit 1 Month 2	Intermediate (2)	38	80,9	31	81,6	81,06	16,14	47	81	30	63,8	82,9	12,69
Baseline	Low (0-1)	42	100	37	88,1	69,51	18,94	34	100	31	91,2	71,35	21,52
Cycle 3 Day 1	Low (0-1)	40	95,2	35	87,5	71,26	16,35	34	100	29	85,3	66,93	22,18
Cycle 5 Day 1	Low (0-1)	38	90,5	29	76,3	75,69	12,61	34	100	26	76,5	63,58	26,06
Study Treatment Completion/Early Withdrawal	Low (0-1)	41	97,6	33	80,5	75,3	15,1	34	100	25	73,5	99,4	137,23
Follow Up Visit 1 Month 2	Low (0-1)	36	85,7	28	77,8	77,5	10,83	32	94,1	20	62,5	77,9	15,31
Fc gamma receptor IIa													
Baseline	Missing	13	100	13	100	77,46	14,33	18	100	12	66,7	69,33	24,08
Cycle 3 Day 1	Missing	13	100	11	84,6	71,27	14,89	15	83,3	10	66,7	77,3	8,39
Cycle 5 Day 1	Missing	13	100	10	76,9	71,3	12,88	14	77,8	8	57,1	71,63	11,06
Study Treatment Completion/Early Withdrawal	Missing	12	92,3	8	66,7	74,5	9,13	16	88,9	6	37,5	66	28,32
Follow Up Visit 1 Month 2	Missing	11	84,6	9	81,8	75,44	15,71	12	66,7	5	41,7	79,8	6,42
Baseline	131HH	42	100	40	95,2	68,75	22,22	36	100	32	88,9	68,75	22,27
Cycle 3 Day 1	131HH	39	92,9	32	82,1	74	18,17	34	94,4	29	85,3	62,48	27,5
Cycle 5 Day 1	131HH	37	88,1	27	73	76,96	14,53	33	91,7	28	84,8	59,11	27,76
Study Treatment Completion/Early Withdrawal	131HH	40	95,2	29	72,5	76,66	23,02	33	91,7	31	93,9	70,39	18,7

Follow Up Visit 1 Month 2	131HH	35	83,3	29	82,9	76,97	20,29	32	88,9	22	68,8	75,91	15,22
Baseline	131HR	66	100	56	84,8	65,27	22,32	78	100	71	91	69,97	19,49
Cycle 3 Day 1	131HR	65	98,5	54	83,1	69,93	18,26	75	96,2	61	81,3	72,48	17,4
Cycle 5 Day 1	131HR	62	93,9	51	82,3	75,08	15,56	72	92,3	56	77,8	75,23	17,32
Study Treatment Completion/Early Withdrawal	131HR	61	92,4	49	80,3	74,29	16,98	68	87,2	57	83,8	76,51	17,46
Follow Up Visit 1 Month 2	131HR	54	81,8	39	72,2	76,18	16,32	63	80,8	41	65,1	82,37	14,13
Baseline	131RR	34	100	33	97,1	69,88	17,86	34	100	31	91,2	69	19,73
Cycle 3 Day 1	131RR	33	97,1	26	78,8	76,08	14,19	32	94,1	25	78,1	71,76	19,95
Cycle 5 Day 1	131RR	30	88,2	25	83,3	76,96	13,59	31	91,2	19	61,3	67,42	19,06
Study Treatment Completion/Early Withdrawal	131RR	34	100	28	82,4	73,25	19,93	33	97,1	24	72,7	100,46	139,29
Follow Up Visit 1 Month 2	131RR	29	85,3	22	75,9	79,55	11,84	28	82,4	14	50	74,86	20,54
Fc gamma receptor IIIa													
Baseline	Missing	13	100	13	100	77,46	14,33	18	100	12	66,7	69,33	24,08
Cycle 3 Day 1	Missing	13	100	11	84,6	71,27	14,89	15	83,3	10	66,7	77,3	8,39
Cycle 5 Day 1	Missing	13	100	10	76,9	71,3	12,88	14	77,8	8	57,1	71,63	11,06
Study Treatment Completion/Early Withdrawal	Missing	12	92,3	8	66,7	74,5	9,13	16	88,9	6	37,5	66	28,32
Follow Up Visit 1 Month 2	Missing	11	84,6	9	81,8	75,44	15,71	12	66,7	5	41,7	79,8	6,42
Baseline	158FF	58	100	54	93,1	66,96	21,1	53	100	44	83	70,02	19,15
Cycle 3 Day 1	158FF	56	96,6	46	82,1	70,85	14,18	51	96,2	41	80,4	74,02	17,2
Cycle 5 Day 1	158FF	52	89,7	41	78,8	74,27	13,98	49	92,5	36	73,5	73,83	17,16
Study Treatment Completion/Early Withdrawal	158FF	56	96,6	41	73,2	72,83	20,68	48	90,6	41	85,4	77,17	15,97
Follow Up Visit 1 Month 2	158FF	47	81	36	76,6	74,94	16,24	46	86,8	32	69,6	80,75	14,64
Baseline	158VF	65	100	58	89,2	66,55	21,92	65	100	62	95,4	73,69	17,53
Cycle 3 Day 1	158VF	63	96,9	54	85,7	73,56	19,9	62	95,4	52	83,9	70,98	19,01
Cycle 5 Day 1	158VF	60	92,3	51	85	76,59	15,51	59	90,8	48	81,4	68,6	21,26
Study Treatment Completion/Early Withdrawal	158VF	61	93,8	52	85,2	74,23	19,07	59	90,8	49	83,1	73,29	17,91
Follow Up Visit 1 Month 2	158VF	54	83,1	43	79,6	78,3	16,58	52	80	33	63,5	80,64	14,88
Baseline	158VV	19	100	17	89,5	72,65	19,21	30	100	28	93,3	59,18	23,66
Cycle 3 Day 1	158VV	18	94,7	12	66,7	74,25	17,71	28	93,3	22	78,6	59,14	28,79
Cycle 5 Day 1	158VV	17	89,5	11	64,7	80	13,96	28	93,3	19	67,9	63,05	29,55
Study Treatment Completion/Early Withdrawal	158VV	18	94,7	13	72,2	82,15	15,92	27	90	22	81,5	99,95	146,46
Follow Up Visit 1 Month 2	158VV	17	89,5	11	64,7	80,73	19	25	83,3	12	48	70,83	20,31
Fc gamma receptor IIb/IIc													
Baseline	Missing	14	100	14	100	77,64	13,78	18	100	12	66,7	69,33	24,08
Cycle 3 Day 1	Missing	14	100	12	85,7	70,33	14,57	15	83,3	10	66,7	77,3	8,39
Cycle 5 Day 1	Missing	14	100	11	78,6	70,27	12,68	14	77,8	8	57,1	71,63	11,06
Study Treatment Completion/Early Withdrawal	Missing	13	92,9	9	69,2	71,78	11,82	16	88,9	6	37,5	66	28,32
Follow Up Visit 1 Month 2	Missing	12	85,7	10	83,3	74,4	15,17	12	66,7	5	41,7	79,8	6,42
Baseline	232II	104	100	93	89,4	67,2	21,15	107	100	96	89,7	68,88	20,62
Cycle 3 Day 1	232II	99	95,2	79	79,8	71,53	18,59	100	93,5	82	82	70,21	21,96
Cycle 5 Day 1	232II	92	88,5	71	77,2	75,32	14,74	95	88,8	71	74,7	68,9	21,91

Study Treatment Completion/Early Withdrawal	232II	98	94,2	76	77,6	73,59	18,91	95	88,8	76	80	84	78,85
Follow Up Visit 1 Month 2	232II	85	81,7	63	74,1	75,87	17,02	85	79,4	50	58,8	77,72	15,25
Baseline	232IT	36	100	34	94,4	67,97	22,05	37	100	34	91,9	70,59	19,13
Cycle 3 Day 1	232IT	36	100	31	86,1	74,55	13,7	37	100	29	78,4	70,34	19,27
Cycle 5 Day 1	232IT	35	97,2	30	85,7	77,43	14,35	37	100	28	75,7	69,82	23,09
Study Treatment Completion/Early Withdrawal	232IT	35	97,2	28	80	77,54	20,34	36	97,3	33	91,7	71,82	21,7
Follow Up Visit 1 Month 2	232IT	31	86,1	25	80,6	80,32	15,5	35	94,6	25	71,4	81,96	17,5
Baseline	232TT	1	100	1	100	70	NE	4	100	4	100	73,75	18,87
Cycle 3 Day 1	232TT	1	100	1	100	100	NE	4	100	4	100	57,5	17,08
Cycle 5 Day 1	232TT	1	100	1	100	100	NE	4	100	4	100	75,5	14,06
Study Treatment Completion/Early Withdrawal	232TT	1	100	1	100	100	NE	3	75	3	100	66,67	32,15
Follow Up Visit 1 Month 2	232TT	1	100	1	100	100	NE	3	75	2	66,7	80	14,14
Absolute lymphocyte count													
Baseline	Missing	0	NE	0	NE	NE	NE	3	100	2	66,7	59,5	13,44
Cycle 3 Day 1	Missing	0	NE	0	NE	NE	NE	2	66,7	2	100	65	7,07
Cycle 5 Day 1	Missing	0	NE			NE	NE	2	66,7			NE	NE
Study Treatment Completion/Early Withdrawal	Missing	0	NE	0	NE	NE	NE	2	66,7	2	100	70	14,14
Follow Up Visit 1 Month 2	Missing	0	NE	0	NE	NE	NE	2	66,7	2	100	46	19,8
Baseline	< median	83	100	78	94	69,59	21,05	79	100	69	87,3	69,1	17,65
Cycle 3 Day 1	< median	79	95,2	67	84,8	75,19	15,87	77	97,5	65	84,4	69,26	19,32
Cycle 5 Day 1	< median	75	90,4	61	81,3	76,7	14,25	76	96,2	57	75	69,56	20,7
Study Treatment Completion/Early Withdrawal	< median	80	96,4	61	76,3	74,93	21	75	94,9	63	84	81,49	87,93
Follow Up Visit 1 Month 2	< median	68	81,9	51	75	79,43	14,78	67	84,8	43	64,2	78,09	16,42
Baseline	>= median	72	100	64	88,9	67,03	20,57	84	100	75	89,3	70,03	22,81
Cycle 3 Day 1	>= median	71	98,6	56	78,9	69,07	18,17	77	91,7	58	75,3	71,86	22,13
Cycle 5 Day 1	>= median	67	93,1	52	77,6	74,33	14,99	72	85,7	54	75	69,57	22,01
Study Treatment Completion/Early Withdrawal	>= median	67	93,1	53	79,1	74,32	16,21	73	86,9	53	72,6	76,91	15,25
Follow Up Visit 1 Month 2	>= median	61	84,7	48	78,7	74,6	18,02	66	78,6	37	56,1	82,27	11,9
Time from initial NHL diagnosis to randomization													
Baseline	6-12 months	11	100	11	100	65,18	21,94	18	100	16	88,9	61,31	20,11
Cycle 3 Day 1	6-12 months	11	100	8	72,7	67,5	20,7	18	100	15	83,3	65,07	20,58
Cycle 5 Day 1	6-12 months	8	72,7	6	75	78,33	11,69	17	94,4	11	64,7	59,64	23,23
Study Treatment Completion/Early Withdrawal	6-12 months	11	100	9	81,8	76,11	11,93	17	94,4	10	58,8	135,2	216,43
Follow Up Visit 1 Month 2	6-12 months	7	63,6	5	71,4	79	7,42	17	94,4	7	41,2	78,29	11,06
Baseline	< 6 months	6	100	4	66,7	37,5	32,11	6	100	6	100	62,83	21,54
Cycle 3 Day 1	< 6 months	6	100	4	66,7	71	19,43	6	100	3	50	86	10,39
Cycle 5 Day 1	< 6 months	6	100	5	83,3	67,8	19,34	6	100	4	66,7	82	5,42
Study Treatment Completion/Early Withdrawal	< 6 months	6	100	5	83,3	68	17,89	6	100	4	66,7	85	5,77
Follow Up Visit 1 Month 2	< 6 months	6	100	5	83,3	65,2	35,11	4	66,7	3	75	75	21,79
Baseline	> 12 months	138	100	127	92	69,69	19,71	142	100	124	87,3	70,81	20,19
Cycle 3 Day 1	> 12 months	133	96,4	111	83,5	72,81	16,95	132	93	107	81,1	70,71	20,56

Cycle 5 Day 1	> 12 months	128	92,8	102	79,7	75,83	14,51	127	89,4	96	75,6	70,19	21,14
Study Treatment Completion/Early Withdrawal	> 12 months	130	94,2	100	76,9	74,85	19,46	127	89,4	104	81,9	73,63	18,73
Follow Up Visit 1 Month 2	> 12 months	116	84,1	89	76,7	77,65	15,39	114	80,3	72	63,2	79,46	15,78
Beta 2 microglobulin													
Baseline	Missing	6	100	5	83,3	62	17,89	13	100	8	61,5	67,88	12,98
Cycle 3 Day 1	Missing	6	100	5	83,3	68,4	21,51	10	76,9	6	60	73,83	15,98
Cycle 5 Day 1	Missing	6	100	6	100	69,83	12,09	10	76,9	6	60	58	28,57
Study Treatment Completion/Early Withdrawal	Missing	5	83,3	3	60	71,67	12,58	12	92,3	8	66,7	81,5	9,62
Follow Up Visit 1 Month 2	Missing	5	83,3	5	100	61,2	32,82	10	76,9	4	40	73,5	5,07
Baseline	< 3.5 mg/L	121	100	112	92,6	70,89	20,13	118	100	106	89,8	71,42	20,65
Cycle 3 Day 1	< 3.5 mg/L	118	97,5	99	83,9	74,17	16,09	113	95,8	91	80,5	69,96	21,15
Cycle 5 Day 1	< 3.5 mg/L	112	92,6	90	80,4	76,76	14,24	108	91,5	82	75,9	69,28	20,89
Study Treatment Completion/Early Withdrawal	< 3.5 mg/L	116	95,9	95	81,9	76	18,14	107	90,7	85	79,4	80,24	76
Follow Up Visit 1 Month 2	< 3.5 mg/L	105	86,8	81	77,1	78,98	14,53	97	82,2	59	60,8	78,71	17,09
Baseline	>= 3.5 mg/L	28	100	25	89,3	58,72	21,9	35	100	32	91,4	63,28	20,06
Cycle 3 Day 1	>= 3.5 mg/L	26	92,9	19	73,1	64,26	19,8	33	94,3	28	84,8	71,11	19,7
Cycle 5 Day 1	>= 3.5 mg/L	24	85,7	17	70,8	71,59	16,67	32	91,4	23	71,9	73,61	20,3
Study Treatment Completion/Early Withdrawal	>= 3.5 mg/L	26	92,9	16	61,5	67,19	22,8	31	88,6	25	80,6	75,12	16,03
Follow Up Visit 1 Month 2	>= 3.5 mg/L	19	67,9	13	68,4	71,46	17,28	28	80	19	67,9	81,89	10,83

Prior therapies													
Baseline	<= 2	125	100	115	92	68,77	21,11	130	100	112	86,2	70,21	20,77
Cycle 3 Day 1	<= 2	123	98,4	100	81,3	72,62	16,63	123	94,6	97	78,9	71,52	20,53
Cycle 5 Day 1	<= 2	117	93,6	94	80,3	75,68	14,89	117	90	88	75,2	69,42	22,14
Study Treatment Completion/Early Withdrawal	<= 2	118	94,4	90	76,3	74,29	19,68	116	89,2	90	77,6	80,82	73,58
Follow Up Visit 1 Month 2	<= 2	105	84	81	77,1	76,4	17,61	103	79,2	62	60,2	80,42	14,24
Baseline	> 2	30	100	27	90	67,04	19,77	36	100	34	94,4	66,94	19
Cycle 3 Day 1	> 2	27	90	23	85,2	71,48	19,69	33	91,7	28	84,8	66,54	20,31
Cycle 5 Day 1	> 2	25	83,3	19	76	75,26	13,28	33	91,7	23	69,7	70,13	17,85
Study Treatment Completion/Early Withdrawal	> 2	29	96,7	24	82,8	76	15,61	34	94,4	28	82,4	74,14	19,01
Follow Up Visit 1 Month 2	> 2	24	80	18	75	80,22	10,08	32	88,9	20	62,5	75,4	18,72
Refractory Type													
Baseline	Rituximab + Chemotherapy	130	100	120	92,3	67,3	20,66	127	100	113	89	69,04	19,78
Cycle 3 Day 1	Rituximab + Chemotherapy	127	97,7	103	81,1	71,28	17,52	119	93,7	94	79	71,97	18,99
Cycle 5 Day 1	Rituximab + Chemotherapy	120	92,3	94	78,3	75,1	14,99	113	89	79	69,9	69,44	20,86
Study Treatment Completion/Early Withdrawal	Rituximab + Chemotherapy	122	93,8	93	76,2	73,67	19,18	115	90,6	88	76,5	81,5	74,2
Follow Up Visit 1 Month 2	Rituximab + Chemotherapy	106	81,5	82	77,4	76,01	17,41	103	81,1	60	58,3	80,62	13,46
Baseline	Rituximab Monotherapy	25	100	22	88	74,64	20,93	39	100	33	84,6	70,85	22,47
Cycle 3 Day 1	Rituximab Monotherapy	23	92	20	87	78,2	14,18	37	94,9	31	83,8	65,65	24,27
Cycle 5 Day 1	Rituximab Monotherapy	22	88	19	86,4	78,16	12,38	37	94,9	32	86,5	69,88	22,52
Study Treatment Completion/Early Withdrawal	Rituximab Monotherapy	25	100	21	84	79	17,08	35	89,7	30	85,7	72,6	20,15
Follow Up Visit 1 Month 2	Rituximab Monotherapy	23	92	17	73,9	82,29	10,17	32	82,1	22	68,8	75,32	19,86

[1] in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values Clinical cut-off:
01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/t_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.xls 29OCT2019
13:21

17 (Anhang): Ergebnisse für FACT-G Mittelwerte pro Visite - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients ENDPOINT: FACT-G Total
MODEL: Unadjusted Analysis STUDY: GO01297
Compliance/Mean

		G-Benda (N=155)						Benda (N=166)					
		Patients				Statistics		Patients				Statistics	
Name	Level	instudy[1]	%	withvalu	%	Mean[2]	SD(Mean)	instudy[1]	%	withvalu	%	Mean[2]	SD(Mean)
All													
Baseline	n/a	155	100	141	91	81,42	16,45	166	100	147	88,6	80,09	16,19
Cycle 3 Day 1	n/a	150	96,8	125	83,3	82,71	15,84	156	94	128	82,1	79,65	15
Cycle 5 Day 1	n/a	142	91,6	118	83,1	82,05	16,57	150	90,4	115	76,7	78,57	16,04
Study Treatment Completion/Early Withdrawal	n/a	147	94,8	114	77,6	80,98	18,45	150	90,4	117	78	79,82	15,19
Follow Up Visit 1 Month 2	n/a	129	83,2	103	79,8	84,44	16,06	135	81,3	82	60,7	81,88	13,94
Sex													
Baseline	Female	70	100	62	88,6	80,39	16,23	71	100	66	93	78,08	16,88
Cycle 3 Day 1	Female	67	95,7	55	82,1	81,1	14,13	69	97,2	58	84,1	77,64	15,25
Cycle 5 Day 1	Female	62	88,6	50	80,6	80,61	15,64	68	95,8	50	73,5	75,65	16,02
Study Treatment Completion/Early Withdrawal	Female	67	95,7	52	77,6	78,02	19,17	68	95,8	50	73,5	76,14	15,83
Follow Up Visit 1 Month 2	Female	55	78,6	43	78,2	84,74	13,28	61	85,9	35	57,4	82,39	15,12
Baseline	Male	85	100	79	92,9	82,23	16,68	95	100	81	85,3	81,73	15,52
Cycle 3 Day 1	Male	83	97,6	70	84,3	83,98	17,06	87	91,6	70	80,5	81,31	14,7
Cycle 5 Day 1	Male	80	94,1	68	85	83,11	17,26	82	86,3	65	79,3	80,81	15,8
Study Treatment Completion/Early Withdrawal	Male	80	94,1	62	77,5	83,46	17,58	82	86,3	67	81,7	82,56	14,19
Follow Up Visit 1 Month 2	Male	74	87,1	60	81,1	84,22	17,89	74	77,9	47	63,5	81,5	13,15
Age													
Baseline	< 60 years	59	100	55	93,2	80,23	18,09	61	100	58	95,1	78,01	16,41
Cycle 3 Day 1	< 60 years	58	98,3	49	84,5	80,72	17,77	59	96,7	47	79,7	77,43	14,9
Cycle 5 Day 1	< 60 years	56	94,9	47	83,9	77,64	18,48	58	95,1	46	79,3	78,1	15,2
Study Treatment Completion/Early Withdrawal	< 60 years	53	89,8	47	88,7	79,2	19,5	57	93,4	44	77,2	79,75	16,39
Follow Up Visit 1 Month 2	< 60 years	49	83,1	41	83,7	82,84	19,45	54	88,5	33	61,1	80,82	14,99
Baseline	>= 60 years	96	100	86	89,6	82,19	15,37	105	100	89	84,8	81,45	15,99
Cycle 3 Day 1	>= 60 years	92	95,8	76	82,6	84	14,44	97	92,4	81	83,5	80,93	15,01
Cycle 5 Day 1	>= 60 years	86	89,6	71	82,6	84,98	14,59	92	87,6	69	75	78,88	16,67
Study Treatment Completion/Early Withdrawal	>= 60 years	94	97,9	67	71,3	82,23	17,71	93	88,6	73	78,5	79,86	14,53
Follow Up Visit 1 Month 2	>= 60 years	80	83,3	62	77,5	85,5	13,42	81	77,1	49	60,5	82,59	13,31
Race/ethnicity													
Baseline	Missing/Unknown	9	100	7	77,8	87,51	10,01	15	100	13	86,7	78,31	14,75
Cycle 3 Day 1	Missing/Unknown	9	100	5	55,6	96,12	8,21	14	93,3	9	64,3	79,16	10,87
Cycle 5 Day 1	Missing/Unknown	8	88,9	4	50	97,26	9,97	14	93,3	7	50	80,79	10,18
Study Treatment Completion/Early Withdrawal	Missing/Unknown	9	100	4	44,4	100,55	6,59	14	93,3	11	78,6	73,22	12,51

Follow Up Visit 1 Month 2	Missing/Unknown	8	88,9	3	37,5	93,41	10,9	12	80	2	16,7	92,94	0,73
Baseline	Other	7	100	7	100	81,91	14,65	8	100	8	100	72,04	24,74
Cycle 3 Day 1	Other	7	100	5	71,4	77,14	21,12	8	100	7	87,5	73,63	22,22
Cycle 5 Day 1	Other	5	71,4	5	100	82,1	18,26	7	87,5	5	71,4	74,28	22,78
Study Treatment Completion/Early Withdrawal	Other	5	71,4	4	80	85,91	22,19	7	87,5	5	71,4	78,9	20,89
Follow Up Visit 1 Month 2	Other	4	57,1	4	100	91,99	11,28	6	75	5	83,3	86,57	16,46
Baseline	White	139	100	127	91,4	81,06	16,84	143	100	126	88,1	80,79	15,69
Cycle 3 Day 1	White	134	96,4	115	85,8	82,37	15,67	134	93,7	112	83,6	80,06	14,83
Cycle 5 Day 1	White	129	92,8	109	84,5	81,49	16,54	129	90,2	103	79,8	78,63	16,12
Study Treatment Completion/Early Withdrawal	White	133	95,7	106	79,7	80,06	18,29	129	90,2	101	78,3	80,58	15,13
Follow Up Visit 1 Month 2	White	117	84,2	96	82,1	83,84	16,28	117	81,8	75	64,1	81,27	13,89
Geographic region													
Baseline	North America	65	100	62	95,4	82,38	17,4	73	100	70	95,9	83,06	17,24
Cycle 3 Day 1	North America	64	98,5	58	90,6	83,42	16,93	68	93,2	57	83,8	82,96	15,81
Cycle 5 Day 1	North America	63	96,9	57	90,5	83,09	16,6	65	89	51	78,5	81,5	16,61
Study Treatment Completion/Early Withdrawal	North America	62	95,4	58	93,5	80,81	19,46	65	89	53	81,5	81,46	17,42
Follow Up Visit 1 Month 2	North America	57	87,7	50	87,7	85,88	16,15	57	78,1	39	68,4	82,5	14,77
Baseline	Other	18	100	17	94,4	79,33	16,8	15	100	12	80	68,69	12,27
Cycle 3 Day 1	Other	17	94,4	14	82,4	84,03	16,07	14	93,3	13	92,9	69,97	13,5
Cycle 5 Day 1	Other	15	83,3	11	73,3	82,27	17,79	13	86,7	10	76,9	66,38	15,84
Study Treatment Completion/Early Withdrawal	Other	18	100	14	77,8	84,4	15,15	13	86,7	11	84,6	73,07	8,62
Follow Up Visit 1 Month 2	Other	14	77,8	12	85,7	87,43	14,46	13	86,7	6	46,2	77,35	8,35
Baseline	Western Europe	72	100	62	86,1	81,03	15,56	78	100	65	83,3	79	14,71
Cycle 3 Day 1	Western Europe	69	95,8	53	76,8	81,6	14,76	74	94,9	58	78,4	78,56	13,57
Cycle 5 Day 1	Western Europe	64	88,9	50	78,1	80,82	16,53	72	92,3	54	75	78,05	14,62
Study Treatment Completion/Early Withdrawal	Western Europe	67	93,1	42	62,7	80,08	18,26	72	92,3	53	73,6	79,58	13,58
Follow Up Visit 1 Month 2	Western Europe	58	80,6	41	70,7	81,8	16,36	65	83,3	37	56,9	81,96	13,92
Body mass index													
Baseline	Missing	2	100	1	50	81	NE	7	100	6	85,7	80,67	16,1
Cycle 3 Day 1	Missing	2	100	2	100	80	1,41	6	85,7	4	66,7	82,14	13,53
Cycle 5 Day 1	Missing	2	100	2	100	73,48	9,17	6	85,7	5	83,3	80,15	5,59
Study Treatment Completion/Early Withdrawal	Missing	2	100	2	100	78,4	13,95	6	85,7	3	50	90,09	12,1
Follow Up Visit 1 Month 2	Missing	2	100	2	100	78,4	9,55	6	85,7	3	50	92,12	13,09
Baseline	Normal weight (18.5 -< 25)	54	100	48	88,9	82,25	14,97	50	100	45	90	79,63	16,26
Cycle 3 Day 1	Normal weight (18.5 -< 25)	53	98,1	41	77,4	84,54	12,37	47	94	43	91,5	81,45	12,19
Cycle 5 Day 1	Normal weight (18.5 -< 25)	49	90,7	39	79,6	85,93	13,18	44	88	34	77,3	80,73	12,54
Study Treatment Completion/Early Withdrawal	Normal weight (18.5 -< 25)	51	94,4	36	70,6	83,06	15,96	45	90	37	82,2	79,97	13,53
Follow Up Visit 1 Month 2	Normal weight (18.5 -< 25)	41	75,9	31	75,6	86,46	10,43	42	84	25	59,5	84,34	11,22
Baseline	Overweight (25 - < 30)	53	100	48	90,6	80,78	16,82	56	100	49	87,5	80,92	16,19
Cycle 3 Day 1	Overweight (25 - < 30)	50	94,3	42	84	82,87	14,27	53	94,6	37	69,8	79,95	16,79
Cycle 5 Day 1	Overweight (25 - < 30)	49	92,5	41	83,7	82,38	16,47	51	91,1	33	64,7	81,16	17,88
Study Treatment Completion/Early Withdrawal	Overweight (25 - < 30)	51	96,2	37	72,5	81,42	15,45	51	91,1	38	74,5	80,21	17,66
Follow Up Visit 1 Month 2	Overweight (25 - < 30)	47	88,7	38	80,9	83,29	14,49	44	78,6	25	56,8	80,09	16,72

Baseline	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	54	NE
Cycle 3 Day 1	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	51	NE
Cycle 5 Day 1	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	52,96	NE
Study Treatment Completion/Early Withdrawal	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	49,85	NE
Follow Up Visit 1 Month 2	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	52,96	NE
Baseline	Obese (>= 30)	46	100	44	95,7	81,22	18,04	52	100	46	88,5	80,15	16,36
Cycle 3 Day 1	Obese (>= 30)	45	97,8	40	88,9	80,81	20,49	49	94,2	43	87,8	78,02	15,85
Cycle 5 Day 1	Obese (>= 30)	42	91,3	36	85,7	77,96	19,45	48	92,3	42	87,5	75,21	17,29
Study Treatment Completion/Early Withdrawal	Obese (>= 30)	43	93,5	39	90,7	78,78	23,15	47	90,4	38	80,9	79,26	13,85
Follow Up Visit 1 Month 2	Obese (>= 30)	39	84,8	32	82,1	84,21	21,94	42	80,8	28	66,7	81,22	12,6
Baseline ECOG Performance Status score													
Baseline	Missing	0	NE	0	NE	NE	NE	2	100	1	50	53	NE
Cycle 3 Day 1	Missing	0	NE	0	NE	NE	NE	1	50	1	100	95	NE
Cycle 5 Day 1	Missing	0	NE	0	NE	NE	NE	1	50	1	100	78	NE
Study Treatment Completion/Early Withdrawal	Missing	0	NE			NE	NE	1	50			NE	NE
Follow Up Visit 1 Month 2	Missing	0	NE	0	NE	NE	NE	1	50	1	100	99	NE
Baseline	0-1	147	100	135	91,8	82,63	15,6	157	100	139	88,5	80,86	15,64
Cycle 3 Day 1	0-1	144	98	122	84,7	82,83	15,9	149	94,9	122	81,9	79,69	14,82
Cycle 5 Day 1	0-1	137	93,2	114	83,2	82,29	16,65	143	91,1	110	76,9	78,53	15,9
Study Treatment Completion/Early Withdrawal	0-1	139	94,6	109	78,4	81,59	18,4	142	90,4	113	79,6	80,19	15,03
Follow Up Visit 1 Month 2	0-1	125	85	101	80,8	84,33	16,19	130	82,8	80	61,5	81,64	13,98
Baseline	2	8	100	6	75	54,18	11,09	7	100	7	100	68,81	21,74
Cycle 3 Day 1	2	6	75	3	50	78	15,1	6	85,7	5	83,3	75,38	20,63
Cycle 5 Day 1	2	5	62,5	4	80	75,29	14,32	6	85,7	4	66,7	79,8	24,17
Study Treatment Completion/Early Withdrawal	2	8	100	5	62,5	67,62	15,48	7	100	4	57,1	69,42	18,2
Follow Up Visit 1 Month 2	2	4	50	2	50	90	5,66	4	57,1	1	25	84,12	NE
Independence status (Katz ADL)													
Baseline	Missing	88	100	80	90,9	81,72	16,27	98	100	83	84,7	81,17	16,46
Cycle 3 Day 1	Missing	86	97,7	75	87,2	82,57	16,01	92	93,9	73	79,3	81,03	15,42
Cycle 5 Day 1	Missing	83	94,3	70	84,3	81,16	16,4	92	93,9	72	78,3	78,85	15,27
Study Treatment Completion/Early Withdrawal	Missing	86	97,7	70	81,4	80,59	19,23	95	96,9	74	77,9	81,25	14,8
Follow Up Visit 1 Month 2	Missing	77	87,5	64	83,1	84,61	16,38	87	88,8	50	57,5	81,56	14,55
Baseline	Very dependent (0-2)	3	100	3	100	68,46	23,25	1	100	1	100	51,92	NE
Cycle 3 Day 1	Very dependent (0-2)	3	100	3	100	68,46	16,29	0	NE	0	NE	NE	NE
Cycle 5 Day 1	Very dependent (0-2)	3	100	2	66,7	73,71	26,46	0	NE	0	NE	NE	NE
Study Treatment Completion/Early Withdrawal	Very dependent (0-2)	1	33,3			NE	NE	0	NE			NE	NE
Baseline	Independent (5-6)	64	100	58	90,6	81,69	16,43	67	100	63	94	79,12	15,62
Cycle 3 Day 1	Independent (5-6)	61	95,3	47	77	83,85	15,43	64	95,5	55	85,9	77,8	14,36
Cycle 5 Day 1	Independent (5-6)	56	87,5	46	82,1	83,78	16,69	58	86,6	43	74,1	78,09	17,43
Study Treatment Completion/Early Withdrawal	Independent (5-6)	60	93,8	44	73,3	81,6	17,32	55	82,1	43	78,2	77,35	15,7
Follow Up Visit 1 Month 2	Independent (5-6)	52	81,3	39	75	84,16	15,71	48	71,6	32	66,7	82,38	13,16
Best response to prior therapy													

Baseline	Missing (UE)	0	NE	0	NE	NE	NE	5	100	4	80	78,98	5,9
Cycle 3 Day 1	Missing (UE)	0	NE	0	NE	NE	NE	5	100	4	80	74,14	12,83
Cycle 5 Day 1	Missing (UE)	0	NE	0	NE	NE	NE	5	100	4	80	68,82	10,56
Study Treatment Completion/Early Withdrawal	Missing (UE)	0	NE	0	NE	NE	NE	5	100	4	80	72,25	11,58
Follow Up Visit 1 Month 2	Missing (UE)	0	NE	0	NE	NE	NE	4	80	2	50	76,29	9,49
Baseline	CR/PR	126	100	114	90,5	81,44	16,49	133	100	118	88,7	79,37	16,24
Cycle 3 Day 1	CR/PR	121	96	103	85,1	82,13	16,64	123	92,5	102	82,9	78,22	14,78
Cycle 5 Day 1	CR/PR	114	90,5	96	84,2	82,23	17,05	119	89,5	92	77,3	77,41	15,79
Study Treatment Completion/Early Withdrawal	CR/PR	119	94,4	89	74,8	80,58	19,41	119	89,5	95	79,8	79,69	15,29
Follow Up Visit 1 Month 2	CR/PR	104	82,5	83	79,8	83,75	16,6	108	81,2	66	61,1	81,81	14,5
Baseline	PD	7	100	6	85,7	71,83	18,81	8	100	7	87,5	75,25	17,16
Cycle 3 Day 1	PD	7	100	4	57,1	83,6	14,94	8	100	7	87,5	86,36	10,97
Cycle 5 Day 1	PD	7	100	6	85,7	75,29	19,56	6	75	4	66,7	87,27	5,72
Study Treatment Completion/Early Withdrawal	PD	6	85,7	5	83,3	78,25	16,45	6	75	3	50	91,17	5,35
Follow Up Visit 1 Month 2	PD	6	85,7	5	83,3	82,23	15,13	5	62,5	3	60	86,28	9,1
Baseline	SD	22	100	21	95,5	84,05	15,32	20	100	18	90	86,94	16,19
Cycle 3 Day 1	SD	22	100	18	81,8	85,85	10,83	20	100	15	75	87,71	16,25
Cycle 5 Day 1	SD	21	95,5	16	76,2	83,54	12,35	20	100	15	75	85,94	18,1
Study Treatment Completion/Early Withdrawal	SD	22	100	20	90,9	83,45	14,6	20	100	15	75	80,38	16,23
Follow Up Visit 1 Month 2	SD	19	86,4	15	78,9	88,95	13,16	18	90	11	61,1	82,11	13,06
Histologic grade (follicular)													
Baseline	1	54	100	51	94,4	85,48	15,04	51	100	43	84,3	82,15	16,45
Cycle 3 Day 1	1	53	98,1	46	86,8	86,52	15,13	49	96,1	40	81,6	82,55	13,74
Cycle 5 Day 1	1	51	94,4	44	86,3	87,43	14,47	48	94,1	35	72,9	82,22	15,51
Study Treatment Completion/Early Withdrawal	1	52	96,3	44	84,6	85,64	16,41	49	96,1	40	81,6	80,4	17,21
Follow Up Visit 1 Month 2	1	47	87	40	85,1	89,14	12,97	41	80,4	24	58,5	83,48	15,47
Baseline	2	69	100	62	89,9	78,17	18,08	68	100	61	89,7	80,39	15,15
Cycle 3 Day 1	2	65	94,2	54	83,1	80,45	16,46	64	94,1	55	85,9	79,16	12,9
Cycle 5 Day 1	2	62	89,9	53	85,5	78,66	16,85	63	92,6	51	81	76,93	15,35
Study Treatment Completion/Early Withdrawal	2	63	91,3	46	73	79,26	20,44	63	92,6	47	74,6	81,92	13,76
Follow Up Visit 1 Month 2	2	56	81,2	49	87,5	82,05	16,71	61	89,7	36	59	83,37	11,71
Baseline	3	0	NE	0	NE	NE	NE	5	100	5	100	68,08	11,54
Cycle 3 Day 1	3	0	NE	0	NE	NE	NE	5	100	4	80	74,16	7,61
Cycle 5 Day 1	3	0	NE	0	NE	NE	NE	3	60	2	66,7	79,28	9,78
Study Treatment Completion/Early Withdrawal	3	0	NE	0	NE	NE	NE	3	60	1	33,3	59,4	NE
Follow Up Visit 1 Month 2	3	0	NE	0	NE	NE	NE	2	40	1	50	54	NE
Baseline	3a	24	100	20	83,3	82,6	14,13	35	100	31	88,6	79,86	18,81
Cycle 3 Day 1	3a	24	100	18	75	81,05	16,19	32	91,4	24	75	80,47	20,05
Cycle 5 Day 1	3a	22	91,7	15	68,2	78,72	17,3	31	88,6	22	71	78,52	19,06
Study Treatment Completion/Early Withdrawal	3a	24	100	19	79,2	78,28	16,67	31	88,6	26	83,9	77,08	14,29
Follow Up Visit 1 Month 2	3a	21	87,5	9	42,9	84,03	18,66	27	77,1	17	63	80,77	15,16
Baseline	Missing/Unknown/Variants	8	100	8	100	77,81	13,21	7	100	7	100	74,48	11,95
Cycle 3 Day 1	Missing/Unknown/Variants	8	100	7	87,5	79,47	12,49	6	85,7	5	83,3	62,16	14,23

Cycle 5 Day 1	Missing/Unknown/Variants	7	87,5	6	85,7	80,96	20,53	5	71,4	5	100	69,62	12,45
Study Treatment Completion/Early Withdrawal	Missing/Unknown/Variants	8	100	5	62,5	66,04	13,38	4	57,1	3	75	69,8	11,21
Follow Up Visit 1 Month 2	Missing/Unknown/Variants	5	62,5	5	100	70,98	19,15	4	57,1	4	100	70,61	10,41
FLIPI													
Baseline	Missing/Unknown	6	100	6	100	67,85	16,31	7	100	7	100	85,82	14,5
Cycle 3 Day 1	Missing/Unknown	6	100	6	100	75,9	16,5	7	100	6	85,7	80,35	9,56
Cycle 5 Day 1	Missing/Unknown	6	100	6	100	81,27	18,96	6	85,7	5	83,3	74,51	13,04
Study Treatment Completion/Early Withdrawal	Missing/Unknown	5	83,3	5	100	87,64	14,61	5	71,4	4	80	72,29	18,44
Follow Up Visit 1 Month 2	Missing/Unknown	4	66,7	3	75	81	15,39	4	57,1	3	75	80,1	14,83
Baseline	High (>=3)	60	100	53	88,3	80,22	17,61	67	100	58	86,6	79,15	16,86
Cycle 3 Day 1	High (>=3)	59	98,3	49	83,1	83,08	16,55	60	89,6	47	78,3	77,16	16,3
Cycle 5 Day 1	High (>=3)	56	93,3	45	80,4	82,68	18,61	57	85,1	45	78,9	77,28	17,88
Study Treatment Completion/Early Withdrawal	High (>=3)	59	98,3	46	78	78	21,25	59	88,1	46	78	80,03	14,15
Follow Up Visit 1 Month 2	High (>=3)	51	85	38	74,5	84,66	18,45	52	77,6	29	55,8	79,84	13,43
Baseline	Intermediate (2)	47	100	42	89,4	81,93	16,6	58	100	51	87,9	78,71	15,77
Cycle 3 Day 1	Intermediate (2)	45	95,7	33	73,3	82,95	15,66	55	94,8	45	81,8	81,13	13,67
Cycle 5 Day 1	Intermediate (2)	42	89,4	35	83,3	81,52	15,65	53	91,4	39	73,6	79,6	13,68
Study Treatment Completion/Early Withdrawal	Intermediate (2)	42	89,4	31	73,8	82,88	17,71	52	89,7	41	78,8	80,37	15,39
Follow Up Visit 1 Month 2	Intermediate (2)	38	80,9	32	84,2	84,27	14,72	47	81	29	61,7	83,23	13,77
Baseline	Low (0-1)	42	100	40	95,2	84,5	13,94	34	100	31	91,2	82,83	16,09
Cycle 3 Day 1	Low (0-1)	40	95,2	37	92,5	83,13	15,34	34	100	30	88,2	81,17	15,79
Cycle 5 Day 1	Low (0-1)	38	90,5	32	84,2	81,91	14,74	34	100	26	76,5	80,02	16,99
Study Treatment Completion/Early Withdrawal	Low (0-1)	41	97,6	32	78	82,39	15,08	34	100	26	76,5	79,73	16,73
Follow Up Visit 1 Month 2	Low (0-1)	36	85,7	30	83,3	84,68	14,93	32	94,1	21	65,6	83,09	15,4
Fc gamma receptor IIa													
Baseline	Missing	13	100	13	100	85,58	12,1	18	100	13	72,2	75,35	16
Cycle 3 Day 1	Missing	13	100	12	92,3	80,95	13,42	15	83,3	10	66,7	83,38	9,59
Cycle 5 Day 1	Missing	13	100	11	84,6	83,84	16,56	14	77,8	8	57,1	81,08	12,09
Study Treatment Completion/Early Withdrawal	Missing	12	92,3	8	66,7	82,81	16,08	16	88,9	6	37,5	81,03	5,64
Follow Up Visit 1 Month 2	Missing	11	84,6	9	81,8	83,91	14,49	12	66,7	4	33,3	70,52	17,75
Baseline	131HH	42	100	37	88,1	85,07	14,06	36	100	32	88,9	77,42	16,4
Cycle 3 Day 1	131HH	39	92,9	31	79,5	83,94	17,02	34	94,4	29	85,3	76,06	16,71
Cycle 5 Day 1	131HH	37	88,1	29	78,4	83,11	16,66	33	91,7	28	84,8	71,52	14,95
Study Treatment Completion/Early Withdrawal	131HH	40	95,2	31	77,5	84,15	20,85	33	91,7	30	90,9	77,03	16,15
Follow Up Visit 1 Month 2	131HH	35	83,3	29	82,9	86,87	16,05	32	88,9	23	71,9	80,56	14,1
Baseline	131HR	66	100	59	89,4	79,44	17,78	78	100	71	91	81,51	15,91
Cycle 3 Day 1	131HR	65	98,5	56	86,2	80,86	16,96	75	96,2	63	84	81,23	14,83
Cycle 5 Day 1	131HR	62	93,9	52	83,9	81,45	17,84	72	92,3	59	81,9	83,29	14,75
Study Treatment Completion/Early Withdrawal	131HR	61	92,4	48	78,7	80,36	18,32	68	87,2	56	82,4	81,91	15,98
Follow Up Visit 1 Month 2	131HR	54	81,8	42	77,8	83,01	18,32	63	80,8	40	63,5	84,65	14,02
Baseline	131RR	34	100	32	94,1	79,16	17,57	34	100	31	91,2	81,6	16,74
Cycle 3 Day 1	131RR	33	97,1	26	78,8	86,06	12,75	32	94,1	26	81,3	78,38	14,96
Cycle 5 Day 1	131RR	30	88,2	26	86,7	81,33	14,54	31	91,2	20	64,5	73,48	18,3

Study Treatment Completion/Early Withdrawal	131RR	34	100	27	79,4	77,9	16,66	33	97,1	25	75,8	78,18	13,59
Follow Up Visit 1 Month 2	131RR	29	85,3	23	79,3	84,19	12,39	28	82,4	15	53,6	79,56	11,41
Fc gamma receptor IIIa													
Baseline	Missing	13	100	13	100	85,58	12,1	18	100	13	72,2	75,35	16
Cycle 3 Day 1	Missing	13	100	12	92,3	80,95	13,42	15	83,3	10	66,7	83,38	9,59
Cycle 5 Day 1	Missing	13	100	11	84,6	83,84	16,56	14	77,8	8	57,1	81,08	12,09
Study Treatment Completion/Early Withdrawal	Missing	12	92,3	8	66,7	82,81	16,08	16	88,9	6	37,5	81,03	5,64
Follow Up Visit 1 Month 2	Missing	11	84,6	9	81,8	83,91	14,49	12	66,7	4	33,3	70,52	17,75
Baseline	158FF	58	100	53	91,4	80,69	15,5	53	100	46	86,8	81,35	18,91
Cycle 3 Day 1	158FF	56	96,6	49	87,5	82,18	12,73	51	96,2	42	82,4	80,11	15,36
Cycle 5 Day 1	158FF	52	89,7	44	84,6	82,18	13,61	49	92,5	38	77,6	77,83	17,12
Study Treatment Completion/Early Withdrawal	158FF	56	96,6	40	71,4	78,59	18,17	48	90,6	43	89,6	80,02	16,45
Follow Up Visit 1 Month 2	158FF	47	81	38	80,9	83,69	13,1	46	86,8	33	71,7	82,73	12,59
Baseline	158VF	65	100	59	90,8	79,62	17,49	65	100	61	93,8	80,53	15,27
Cycle 3 Day 1	158VF	63	96,9	52	82,5	82,77	18,29	62	95,4	55	88,7	79,4	13,95
Cycle 5 Day 1	158VF	60	92,3	51	85	80,43	18,25	59	90,8	49	83,1	79,63	15,3
Study Treatment Completion/Early Withdrawal	158VF	61	93,8	52	85,2	80,53	19,09	59	90,8	48	81,4	81,03	14,27
Follow Up Visit 1 Month 2	158VF	54	83,1	45	83,3	84,51	18,06	52	80	33	63,5	84,5	14,5
Baseline	158VV	19	100	16	84,2	87,09	18,17	30	100	27	90	79,24	13,49
Cycle 3 Day 1	158VV	18	94,7	12	66,7	86,41	19,26	28	93,3	21	75	77,59	19,17
Cycle 5 Day 1	158VV	17	89,5	12	70,6	86,82	19,82	28	93,3	20	71,4	76,37	17,76
Study Treatment Completion/Early Withdrawal	158VV	18	94,7	14	77,8	88,46	17,81	27	90	20	74,1	76,13	16,69
Follow Up Visit 1 Month 2	158VV	17	89,5	11	64,7	87,16	19,5	25	83,3	12	48	76,11	12,94
Fc gamma receptor IIb/IIc													
Baseline	Missing	14	100	14	100	85,26	11,69	18	100	13	72,2	75,35	16
Cycle 3 Day 1	Missing	14	100	13	92,9	80,56	12,92	15	83,3	10	66,7	83,38	9,59
Cycle 5 Day 1	Missing	14	100	12	85,7	82,22	16,76	14	77,8	8	57,1	81,08	12,09
Study Treatment Completion/Early Withdrawal	Missing	13	92,9	9	69,2	81,69	15,41	16	88,9	6	37,5	81,03	5,64
Follow Up Visit 1 Month 2	Missing	12	85,7	10	83,3	84,13	13,68	12	66,7	4	33,3	70,52	17,75
Baseline	232II	104	100	91	87,5	79,13	16,97	107	100	95	88,8	80,54	15,39
Cycle 3 Day 1	232II	99	95,2	81	81,8	81,14	16,37	100	93,5	85	85	80,09	14,61
Cycle 5 Day 1	232II	92	88,5	73	79,3	79,21	16,71	95	88,8	74	77,9	78,81	16,19
Study Treatment Completion/Early Withdrawal	232II	98	94,2	77	78,6	78,65	18,69	95	88,8	74	77,9	79,24	14,85
Follow Up Visit 1 Month 2	232II	85	81,7	66	77,6	82,46	16,92	85	79,4	49	57,6	82,1	13,55
Baseline	232IT	36	100	35	97,2	85,56	16,11	37	100	35	94,6	82,16	17,26
Cycle 3 Day 1	232IT	36	100	30	83,3	87,13	14,73	37	100	29	78,4	79,7	15,77
Cycle 5 Day 1	232IT	35	97,2	32	91,4	87,8	14,82	37	100	29	78,4	78,8	16,11
Study Treatment Completion/Early Withdrawal	232IT	35	97,2	27	77,1	86,54	17,78	36	97,3	34	94,4	81,67	16,76
Follow Up Visit 1 Month 2	232IT	31	86,1	26	83,9	88,73	13,86	35	94,6	27	77,1	83,31	13,97
Baseline	232TT	1	100	1	100	91	NE	4	100	4	100	66,83	23,49
Cycle 3 Day 1	232TT	1	100	1	100	106	NE	4	100	4	100	60,43	20,27
Cycle 5 Day 1	232TT	1	100	1	100	104	NE	4	100	4	100	67,49	21,17
Study Treatment Completion/Early Withdrawal	232TT	1	100	1	100	104	NE	3	75	3	100	70,84	20,25

Follow Up Visit 1 Month 2	232TT	1	100	1	100	106	NE	3	75	2	66,7	79,98	18,41
Absolute lymphocyte count													
Baseline	Missing	0	NE	0	NE	NE	NE	3	100	2	66,7	68	4,24
Cycle 3 Day 1	Missing	0	NE	0	NE	NE	NE	2	66,7	2	100	67	4,24
Cycle 5 Day 1	Missing	0	NE			NE	NE	2	66,7			NE	NE
Study Treatment Completion/Early Withdrawal	Missing	0	NE	0	NE	NE	NE	2	66,7	2	100	70	5,66
Follow Up Visit 1 Month 2	Missing	0	NE	0	NE	NE	NE	2	66,7	2	100	69	4,24
Baseline	< median	83	100	76	91,6	81,81	16,73	79	100	69	87,3	79,85	16,77
Cycle 3 Day 1	< median	79	95,2	69	87,3	85,18	14,28	77	97,5	64	83,1	80,34	16,17
Cycle 5 Day 1	< median	75	90,4	64	85,3	85,4	15,05	76	96,2	57	75	78,64	16,99
Study Treatment Completion/Early Withdrawal	< median	80	96,4	61	76,3	81,48	18,9	75	94,9	61	81,3	78,13	15,45
Follow Up Visit 1 Month 2	< median	68	81,9	55	80,9	86,59	12,76	67	84,8	41	61,2	81,64	15,29
Baseline	>= median	72	100	65	90,3	80,97	16,24	84	100	76	90,5	80,63	15,85
Cycle 3 Day 1	>= median	71	98,6	56	78,9	79,68	17,23	77	91,7	62	80,5	79,34	13,88
Cycle 5 Day 1	>= median	67	93,1	54	80,6	78,08	17,53	72	85,7	58	80,6	78,49	15,19
Study Treatment Completion/Early Withdrawal	>= median	67	93,1	53	79,1	80,4	18,07	73	86,9	54	74	82,09	14,89
Follow Up Visit 1 Month 2	>= median	61	84,7	48	78,7	81,97	18,99	66	78,6	39	59,1	82,79	12,58
Time from initial NHL diagnosis to randomization													
Baseline	6-12 months	11	100	11	100	75,81	16,61	18	100	16	88,9	75,93	11,51
Cycle 3 Day 1	6-12 months	11	100	7	63,6	81,28	10,46	18	100	14	77,8	76,28	11,68
Cycle 5 Day 1	6-12 months	8	72,7	6	75	76,77	9,09	17	94,4	11	64,7	75,28	11,42
Study Treatment Completion/Early Withdrawal	6-12 months	11	100	9	81,8	77,33	13,93	17	94,4	9	52,9	78,31	9,52
Follow Up Visit 1 Month 2	6-12 months	7	63,6	5	71,4	86,32	14,1	17	94,4	6	35,3	79,74	9,26
Baseline	< 6 months	6	100	4	66,7	80,58	14,6	6	100	6	100	80,2	20,85
Cycle 3 Day 1	< 6 months	6	100	4	66,7	92,09	11,53	6	100	3	50	79,22	30,14
Cycle 5 Day 1	< 6 months	6	100	5	83,3	83,22	21,4	6	100	4	66,7	80,41	23,9
Study Treatment Completion/Early Withdrawal	< 6 months	6	100	5	83,3	82,52	15,09	6	100	4	66,7	84,75	12,5
Follow Up Visit 1 Month 2	< 6 months	6	100	4	66,7	90,9	14,76	4	66,7	4	100	81,15	11,84
Baseline	> 12 months	138	100	126	91,3	81,94	16,52	142	100	125	88	80,62	16,51
Cycle 3 Day 1	> 12 months	133	96,4	114	85,7	82,47	16,21	132	93	111	84,1	80,08	15,02
Cycle 5 Day 1	> 12 months	128	92,8	107	83,6	82,3	16,74	127	89,4	100	78,7	78,86	16,26
Study Treatment Completion/Early Withdrawal	> 12 months	130	94,2	100	76,9	81,23	19,03	127	89,4	104	81,9	79,76	15,72
Follow Up Visit 1 Month 2	> 12 months	116	84,1	94	81	84,06	16,28	114	80,3	72	63,2	82,1	14,47
Beta 2 microglobulin													
Baseline	Missing	6	100	5	83,3	78,59	19,4	13	100	9	69,2	85,19	16,27
Cycle 3 Day 1	Missing	6	100	5	83,3	81,92	18,72	10	76,9	4	40	87,12	4,52
Cycle 5 Day 1	Missing	6	100	6	100	72,1	21,44	10	76,9	6	60	84,53	4,72
Study Treatment Completion/Early Withdrawal	Missing	5	83,3	3	60	77,41	11,81	12	92,3	8	66,7	86	11,59
Follow Up Visit 1 Month 2	Missing	5	83,3	4	80	85,16	12,52	10	76,9	5	50	77,86	10,78
Baseline	< 3.5 mg/L	121	100	111	91,7	83,38	15,15	118	100	106	89,8	81,2	16,15
Cycle 3 Day 1	< 3.5 mg/L	118	97,5	100	84,7	84,13	15,16	113	95,8	96	85	79,54	15,48
Cycle 5 Day 1	< 3.5 mg/L	112	92,6	95	84,8	82,99	15,67	108	91,5	85	78,7	78,07	16,7
Study Treatment Completion/Early Withdrawal	< 3.5 mg/L	116	95,9	95	81,9	82,12	17,37	107	90,7	84	78,5	79,82	14,98

Follow Up Visit 1 Month 2	< 3.5 mg/L	105	86,8	85	81	85,41	14,9	97	82,2	59	60,8	82,51	14,09
Baseline	>= 3.5 mg/L	28	100	25	89,3	73,27	19,38	35	100	32	91,4	74,99	15,62
Cycle 3 Day 1	>= 3.5 mg/L	26	92,9	20	76,9	75,83	17,51	33	94,3	28	84,8	78,95	14,31
Cycle 5 Day 1	>= 3.5 mg/L	24	85,7	17	70,8	80,34	19,4	32	91,4	24	75	78,83	15,53
Study Treatment Completion/Early Withdrawal	>= 3.5 mg/L	26	92,9	16	61,5	74,88	24,55	31	88,6	25	80,6	77,83	16,81
Follow Up Visit 1 Month 2	>= 3.5 mg/L	19	67,9	14	73,7	78,3	22,47	28	80	18	64,3	80,95	14,66
Prior therapies													
Baseline	<= 2	125	100	112	89,6	81,2	16,65	130	100	113	86,9	79,66	15,96
Cycle 3 Day 1	<= 2	123	98,4	101	82,1	82,41	16,04	123	94,6	99	80,5	79,82	15,29
Cycle 5 Day 1	<= 2	117	93,6	98	83,8	81,32	17,08	117	90	91	77,8	79,25	16,35
Study Treatment Completion/Early Withdrawal	<= 2	118	94,4	92	78	80,47	18,85	116	89,2	90	77,6	79,96	15,15
Follow Up Visit 1 Month 2	<= 2	105	84	84	80	84,25	16,49	103	79,2	61	59,2	84,13	13,05
Baseline	> 2	30	100	29	96,7	82,27	15,92	36	100	34	94,4	81,53	17,12
Cycle 3 Day 1	> 2	27	90	24	88,9	83,97	15,26	33	91,7	29	87,9	79,06	14,22
Cycle 5 Day 1	> 2	25	83,3	20	80	85,65	13,61	33	91,7	24	72,7	75,99	14,81
Study Treatment Completion/Early Withdrawal	> 2	29	96,7	22	75,9	83,1	16,86	34	94,4	27	79,4	79,34	15,59
Follow Up Visit 1 Month 2	> 2	24	80	19	79,2	85,25	14,36	32	88,9	21	65,6	75,33	14,7
Refractory Type													
Baseline	Rituximab + Chemotherapy	130	100	119	91,5	81	16,38	127	100	112	88,2	78,3	15,9
Cycle 3 Day 1	Rituximab + Chemotherapy	127	97,7	104	81,9	81,28	15,85	119	93,7	95	79,8	79,16	14,23
Cycle 5 Day 1	Rituximab + Chemotherapy	120	92,3	98	81,7	81,29	17,03	113	89	84	74,3	78,38	15,83
Study Treatment Completion/Early Withdrawal	Rituximab + Chemotherapy	122	93,8	92	75,4	79,95	18,73	115	90,6	88	76,5	79,35	14,92
Follow Up Visit 1 Month 2	Rituximab + Chemotherapy	106	81,5	84	79,2	83,54	16,57	103	81,1	59	57,3	82,54	13,83
Baseline	Rituximab Monotherapy	25	100	22	88	83,7	17,01	39	100	35	89,7	85,84	15,99
Cycle 3 Day 1	Rituximab Monotherapy	23	92	21	91,3	89,8	14,09	37	94,9	33	89,2	81,04	17,19
Cycle 5 Day 1	Rituximab Monotherapy	22	88	20	90,9	85,79	13,87	37	94,9	31	83,8	79,08	16,84
Study Treatment Completion/Early Withdrawal	Rituximab Monotherapy	25	100	22	88	85,29	16,92	35	89,7	29	82,9	81,24	16,16
Follow Up Visit 1 Month 2	Rituximab Monotherapy	23	92	19	82,6	88,41	13,18	32	82,1	23	71,9	80,18	14,41

[1] in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values Clinical cut-off:
01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/t_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.xls 29OCT2019 13:21

18 (Anhang): Ergebnisse für FACT-LymS Mittelwerte pro Visite - Subgruppenanalysen aus RCT mit dem zu bewertenden Arzneimittel

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients ENDPOINT: FACT-LYM
Subscale
MODEL: Unadjusted Analysis STUDY: GO01297
Compliance/Mean

		G-Benda (N=155)						Benda (N					
		Patients				Statistics		Patients				Statistics	
Name	Level	in study[1]	%	with valu	%	Mean[2]	SD(Mean)	in study[1]	%	with valu	%	Mean[2]	SD(Mean)
All													
Baseline	n/a	155	100	147	94,8	45,84	9,13	166	100	150	90,4	44,63	9,55
Cycle 3 Day 1	n/a	150	96,8	126	84	47,34	9,14	156	94	126	80,8	45,65	8,9
Cycle 5 Day 1	n/a	142	91,6	117	82,4	47,33	9,39	150	90,4	115	76,7	46,24	9,02
Study Treatment Completion/Early Withdrawal	n/a	147	94,8	115	78,2	46,09	10,11	150	90,4	118	78,7	47,91	8,9
Follow Up Visit 1 Month 2	n/a	129	83,2	103	79,8	48,96	8,24	135	81,3	83	61,5	48,27	7,94
Sex													
Baseline	Female	70	100	66	94,3	45,39	8,52	71	100	69	97,2	41,68	10,4
Cycle 3 Day 1	Female	67	95,7	55	82,1	46,71	8,41	69	97,2	56	81,2	43,56	9,29
Cycle 5 Day 1	Female	62	88,6	49	79	46,24	8,97	68	95,8	50	73,5	43,29	9,37
Study Treatment Completion/Early Withdrawal	Female	67	95,7	52	77,6	44,42	10,55	68	95,8	51	75	45,14	9,92
Follow Up Visit 1 Month 2	Female	55	78,6	43	78,2	48,54	8,05	61	85,9	35	57,4	46,36	8,73
Baseline	Male	85	100	81	95,3	46,2	9,64	95	100	81	85,3	47,14	8
Cycle 3 Day 1	Male	83	97,6	71	85,5	47,84	9,69	87	91,6	70	80,5	47,33	8,26
Cycle 5 Day 1	Male	80	94,1	68	85	48,12	9,67	82	86,3	65	79,3	48,51	8,1
Study Treatment Completion/Early Withdrawal	Male	80	94,1	63	78,8	47,47	9,6	82	86,3	67	81,7	50,02	7,45
Follow Up Visit 1 Month 2	Male	74	87,1	60	81,1	49,26	8,42	74	77,9	48	64,9	49,67	7,07
Age													
Baseline	< 60 years	59	100	57	96,6	44,22	10,89	61	100	58	95,1	42,55	10,38
Cycle 3 Day 1	< 60 years	58	98,3	49	84,5	46,06	10,78	59	96,7	46	78	43,8	9,92
Cycle 5 Day 1	< 60 years	56	94,9	47	83,9	45,28	10,46	58	95,1	46	79,3	45,94	9,94
Study Treatment Completion/Early Withdrawal	< 60 years	53	89,8	47	88,7	45,38	10,41	57	93,4	44	77,2	46,92	10,33
Follow Up Visit 1 Month 2	< 60 years	49	83,1	41	83,7	48,45	9,04	54	88,5	34	63	48,47	7,91
Baseline	>= 60 years	96	100	90	93,8	46,86	7,72	105	100	92	87,6	45,94	8,79
Cycle 3 Day 1	>= 60 years	92	95,8	77	83,7	48,16	7,89	97	92,4	80	82,5	46,72	8,13
Cycle 5 Day 1	>= 60 years	86	89,6	70	81,4	48,71	8,4	92	87,6	69	75	46,44	8,41
Study Treatment Completion/Early Withdrawal	>= 60 years	94	97,9	68	72,3	46,58	9,94	93	88,6	74	79,6	48,5	7,96
Follow Up Visit 1 Month 2	>= 60 years	80	83,3	62	77,5	49,29	7,72	81	77,1	49	60,5	48,13	8,03
Race/ethnicity													
Baseline	Missing/Unknown	9	100	7	77,8	49,52	5,36	15	100	13	86,7	46,89	7,49

Cycle 3 Day 1	Missing/Unknown	9	100	5	55,6	55,2	2,49	14	93,3	9	64,3	50,06	7,39
Cycle 5 Day 1	Missing/Unknown	8	88,9	4	50	54,25	2,87	14	93,3	7	50	49,35	6,23
Study Treatment Completion/Early Withdrawal	Missing/Unknown	9	100	4	44,4	55,75	4,19	14	93,3	11	78,6	47,73	7,62
Follow Up Visit 1 Month 2	Missing/Unknown	8	88,9	3	37,5	53,86	2,02	12	80	2	16,7	55,5	2,12
Baseline	Other	7	100	7	100	48,14	8,47	8	100	8	100	41,75	13,45
Cycle 3 Day 1	Other	7	100	5	71,4	41,6	11,15	8	100	7	87,5	40,29	12,78
Cycle 5 Day 1	Other	5	71,4	5	100	45,2	10,28	7	87,5	5	71,4	40,2	16,18
Study Treatment Completion/Early Withdrawal	Other	5	71,4	4	80	45,5	13,48	7	87,5	6	85,7	45,33	16,05
Follow Up Visit 1 Month 2	Other	4	57,1	4	100	52	4,55	6	75	5	83,3	48,6	9,56
Baseline	White	139	100	133	95,7	45,52	9,31	143	100	129	90,2	44,58	9,48
Cycle 3 Day 1	White	134	96,4	116	86,6	47,25	9,06	134	93,7	110	82,1	45,64	8,63
Cycle 5 Day 1	White	129	92,8	108	83,7	47,18	9,46	129	90,2	103	79,8	46,32	8,71
Study Treatment Completion/Early Withdrawal	White	133	95,7	107	80,5	45,75	10,03	129	90,2	101	78,3	48,08	8,58
Follow Up Visit 1 Month 2	White	117	84,2	96	82,1	48,68	8,42	117	81,8	76	65	48,06	7,9
Geographic region													
Baseline	North America	65	100	65	100	45,26	9,47	73	100	70	95,9	44,29	10,56
Cycle 3 Day 1	North America	64	98,5	58	90,6	46,99	9,01	68	93,2	57	83,8	45,41	9,39
Cycle 5 Day 1	North America	63	96,9	57	90,5	47,21	9,71	65	89	51	78,5	46,28	9,9
Study Treatment Completion/Early Withdrawal	North America	62	95,4	59	95,2	46,28	10,28	65	89	54	83,1	47,88	9,97
Follow Up Visit 1 Month 2	North America	57	87,7	50	87,7	49,22	8,46	57	78,1	40	70,2	47,39	8,58
Baseline	Other	18	100	17	94,4	45,18	10,23	15	100	13	86,7	42,45	6,83
Cycle 3 Day 1	Other	17	94,4	14	82,4	47,07	8,35	14	93,3	13	92,9	43,69	7,42
Cycle 5 Day 1	Other	15	83,3	11	73,3	47,09	9,04	13	86,7	10	76,9	42,37	8,79
Study Treatment Completion/Early Withdrawal	Other	18	100	14	77,8	48,64	6,96	13	86,7	11	84,6	43,8	6,9
Follow Up Visit 1 Month 2	Other	14	77,8	12	85,7	50,25	6,43	13	86,7	7	53,8	45,29	8,38
Baseline	Western Europe	72	100	65	90,3	46,58	8,56	78	100	67	85,9	45,41	8,89
Cycle 3 Day 1	Western Europe	69	95,8	54	78,3	47,8	9,6	74	94,9	56	75,7	46,35	8,76
Cycle 5 Day 1	Western Europe	64	88,9	49	76,6	47,54	9,28	72	92,3	54	75	46,92	8,12
Study Treatment Completion/Early Withdrawal	Western Europe	67	93,1	42	62,7	44,97	10,76	72	92,3	53	73,6	48,79	7,98
Follow Up Visit 1 Month 2	Western Europe	58	80,6	41	70,7	48,26	8,54	65	83,3	36	55,4	49,83	6,96
Body mass index													
Baseline	Missing	2	100	2	100	44,5	0,71	7	100	6	85,7	47,17	7,41
Cycle 3 Day 1	Missing	2	100	2	100	51	5,66	6	85,7	4	66,7	48,75	5,85
Cycle 5 Day 1	Missing	2	100	2	100	46,57	0,81	6	85,7	5	83,3	50,2	5,02
Study Treatment Completion/Early Withdrawal	Missing	2	100	2	100	44,5	0,71	6	85,7	3	50	53,33	3,51
Follow Up Visit 1 Month 2	Missing	2	100	2	100	44	1,41	6	85,7	3	50	53,33	4,51
Baseline	Normal weight (18.5 -< 25)	54	100	49	90,7	46,9	7,57	50	100	45	90	43,27	9,8
Cycle 3 Day 1	Normal weight (18.5 -< 25)	53	98,1	41	77,4	48,31	7,42	47	94	44	93,6	45,66	8,06
Cycle 5 Day 1	Normal weight (18.5 -< 25)	49	90,7	39	79,6	48,56	7,61	44	88	34	77,3	46,75	7,79
Study Treatment Completion/Early Withdrawal	Normal weight (18.5 -< 25)	51	94,4	37	72,5	47,67	8,23	45	90	37	82,2	47,09	8,25
Follow Up Visit 1 Month 2	Normal weight (18.5 -< 25)	41	75,9	32	78	49,96	6,93	42	84	24	57,1	47,89	7,78

Baseline	Overweight (25 - < 30)	53	100	52	98,1	46,45	8,22	56	100	51	91,1	46,78	9,43
Cycle 3 Day 1	Overweight (25 - < 30)	50	94,3	43	86	48,2	7,21	53	94,6	36	67,9	46,63	8,36
Cycle 5 Day 1	Overweight (25 - < 30)	49	92,5	40	81,6	48,45	8,69	51	91,1	33	64,7	47,9	9,6
Study Treatment Completion/Early Withdrawal	Overweight (25 - < 30)	51	96,2	36	70,6	46,49	9,25	51	91,1	38	74,5	49,41	8,57
Follow Up Visit 1 Month 2	Overweight (25 - < 30)	47	88,7	37	78,7	48,78	7,45	44	78,6	26	59,1	50,3	7,29
Baseline	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	50	NE
Cycle 3 Day 1	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	53	NE
Cycle 5 Day 1	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	50	NE
Study Treatment Completion/Early Withdrawal	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	50	NE
Follow Up Visit 1 Month 2	Underweight (< 18.5)	0	NE	0	NE	NE	NE	1	100	1	100	52	NE
Baseline	Obese (>= 30)	46	100	44	95,7	43,98	11,56	52	100	47	90,4	43,16	9,49
Cycle 3 Day 1	Obese (>= 30)	45	97,8	40	88,9	45,25	12,14	49	94,2	41	83,7	44,31	10,44
Cycle 5 Day 1	Obese (>= 30)	42	91,3	36	85,7	44,8	11,64	48	92,3	42	87,5	43,95	9,63
Study Treatment Completion/Early Withdrawal	Obese (>= 30)	43	93,5	40	93	44,35	12,4	47	90,4	39	83	46,75	10,03
Follow Up Visit 1 Month 2	Obese (>= 30)	39	84,8	32	82,1	48,47	10,39	42	80,8	29	69	46,1	8,58
Baseline ECOG Performance Status score													
Baseline	Missing	0	NE	0	NE	NE	NE	2	100	1	50	25	NE
Cycle 3 Day 1	Missing	0	NE	0	NE	NE	NE	1	50	1	100	50	NE
Cycle 5 Day 1	Missing	0	NE	0	NE	NE	NE	1	50	1	100	43	NE
Study Treatment Completion/Early Withdrawal	Missing	0	NE			NE	NE	1	50			NE	NE
Follow Up Visit 1 Month 2	Missing	0	NE	0	NE	NE	NE	1	50	1	100	56	NE
Baseline	0-1	147	100	140	95,2	46,37	8,95	157	100	142	90,4	44,94	9,3
Cycle 3 Day 1	0-1	144	98	123	85,4	47,52	9,06	149	94,9	120	80,5	45,87	8,75
Cycle 5 Day 1	0-1	137	93,2	113	82,5	47,51	9,43	143	91,1	110	76,9	46,57	8,57
Study Treatment Completion/Early Withdrawal	0-1	139	94,6	110	79,1	46,38	10,22	142	90,4	114	80,3	48,33	8,51
Follow Up Visit 1 Month 2	0-1	125	85	100	80	49,16	8,11	130	82,8	81	62,3	48,2	7,98
Baseline	2	8	100	7	87,5	35,23	5,99	7	100	7	100	41,14	12,2
Cycle 3 Day 1	2	6	75	3	50	40,33	11,5	6	85,7	5	83,3	39,6	12,1
Cycle 5 Day 1	2	5	62,5	4	80	42,25	7,14	6	85,7	4	66,7	38	17,91
Study Treatment Completion/Early Withdrawal	2	8	100	5	62,5	39,8	3,7	7	100	4	57,1	35,95	13,03
Follow Up Visit 1 Month 2	2	4	50	3	75	42,33	11,59	4	57,1	1	25	46	NE
Independence status (Katz ADL)													
Baseline	Missing	88	100	85	96,6	45,31	9,72	98	100	84	85,7	44,62	9,78
Cycle 3 Day 1	Missing	86	97,7	75	87,2	46,5	9,79	92	93,9	71	77,2	46,16	8,35
Cycle 5 Day 1	Missing	83	94,3	69	83,1	47,05	9,21	92	93,9	72	78,3	46,47	8,59
Study Treatment Completion/Early Withdrawal	Missing	86	97,7	71	82,6	45,77	10,8	95	96,9	74	77,9	47,87	9,02
Follow Up Visit 1 Month 2	Missing	77	87,5	64	83,1	48,62	9,08	87	88,8	51	58,6	47,92	8,09
Baseline	Very dependent (0-2)	3	100	3	100	43	10,44	1	100	1	100	45	NE
Cycle 3 Day 1	Very dependent (0-2)	3	100	3	100	44	11,79	0	NE	0	NE	NE	NE
Cycle 5 Day 1	Very dependent (0-2)	3	100	2	66,7	48,5	13,44	0	NE	0	NE	NE	NE
Study Treatment Completion/Early Withdrawal	Very dependent (0-2)	1	33,3			NE	NE	0	NE			NE	NE

Baseline	Independent (5-6)	64	100	59	92,2	46,73	8,23	67	100	65	97	44,64	9,39
Cycle 3 Day 1	Independent (5-6)	61	95,3	48	78,7	48,88	7,81	64	95,5	55	85,9	45	9,6
Cycle 5 Day 1	Independent (5-6)	56	87,5	46	82,1	47,71	9,74	58	86,6	43	74,1	45,86	9,78
Study Treatment Completion/Early Withdrawal	Independent (5-6)	60	93,8	44	73,3	46,61	8,99	55	82,1	44	80	47,97	8,81
Follow Up Visit 1 Month 2	Independent (5-6)	52	81,3	39	75	49,51	6,7	48	71,6	32	66,7	48,83	7,77
Best response to prior therapy													
Baseline	Missing (UE)	0	NE	0	NE	NE	NE	5	100	4	80	40	2,45
Cycle 3 Day 1	Missing (UE)	0	NE	0	NE	NE	NE	5	100	4	80	39,5	7,42
Cycle 5 Day 1	Missing (UE)	0	NE	0	NE	NE	NE	5	100	4	80	38	6,48
Study Treatment Completion/Early Withdrawal	Missing (UE)	0	NE	0	NE	NE	NE	5	100	4	80	41,75	4,72
Follow Up Visit 1 Month 2	Missing (UE)	0	NE	0	NE	NE	NE	4	80	2	50	40,5	0,71
Baseline	CR/PR	126	100	120	95,2	45,99	9,2	133	100	121	91	44,14	10,01
Cycle 3 Day 1	CR/PR	121	96	104	86	47,31	9,38	123	92,5	100	81,3	44,8	9,15
Cycle 5 Day 1	CR/PR	114	90,5	95	83,3	47,35	9,64	119	89,5	92	77,3	45,53	9,36
Study Treatment Completion/Early Withdrawal	CR/PR	119	94,4	90	75,6	45,8	10,64	119	89,5	95	79,8	47,4	9,46
Follow Up Visit 1 Month 2	CR/PR	104	82,5	82	78,8	48,6	8,31	108	81,2	67	62	47,8	8,45
Baseline	PD	7	100	6	85,7	40,93	10,92	8	100	7	87,5	44,43	6,29
Cycle 3 Day 1	PD	7	100	4	57,1	45,75	9,74	8	100	7	87,5	51,86	4,3
Cycle 5 Day 1	PD	7	100	6	85,7	44,83	10,61	6	75	4	66,7	53	2,94
Study Treatment Completion/Early Withdrawal	PD	6	85,7	5	83,3	44,6	9,26	6	75	3	50	53,33	6,03
Follow Up Visit 1 Month 2	PD	6	85,7	6	100	44,83	10,46	5	62,5	3	60	52,33	5,13
Baseline	SD	22	100	21	95,5	46,36	8,26	20	100	18	90	49	7,05
Cycle 3 Day 1	SD	22	100	18	81,8	47,88	7,93	20	100	15	75	50,07	6,27
Cycle 5 Day 1	SD	21	95,5	16	76,2	48,16	7,67	20	100	15	75	51	4,61
Study Treatment Completion/Early Withdrawal	SD	22	100	20	90,9	47,78	7,79	20	100	16	80	51,44	4,23
Follow Up Visit 1 Month 2	SD	19	86,4	15	78,9	52,53	5,83	18	90	11	61,1	51,45	3,21
Histologic grade (follicular)													
Baseline	1	54	100	54	100	47,22	8,23	51	100	45	88,2	45,93	9,02
Cycle 3 Day 1	1	53	98,1	47	88,7	49,71	8,41	49	96,1	38	77,6	47,16	9,08
Cycle 5 Day 1	1	51	94,4	44	86,3	50,34	8,47	48	94,1	35	72,9	47,2	8,44
Study Treatment Completion/Early Withdrawal	1	52	96,3	44	84,6	48,95	9,03	49	96,1	40	81,6	49,09	8,59
Follow Up Visit 1 Month 2	1	47	87	40	85,1	51,8	6,78	41	80,4	25	61	49,8	7,14
Baseline	2	69	100	64	92,8	45,51	9,53	68	100	62	91,2	44,54	9,6
Cycle 3 Day 1	2	65	94,2	54	83,1	46,54	8,47	64	94,1	54	84,4	45,87	7,64
Cycle 5 Day 1	2	62	89,9	53	85,5	46,07	8,71	63	92,6	51	81	46,04	8,42
Study Treatment Completion/Early Withdrawal	2	63	91,3	48	76,2	45,64	9,6	63	92,6	48	76,2	48,73	8,29
Follow Up Visit 1 Month 2	2	56	81,2	49	87,5	48,03	7,63	61	89,7	36	59	48,51	8,46
Baseline	3	0	NE	0	NE	NE	NE	5	100	5	100	43,37	8,71
Cycle 3 Day 1	3	0	NE	0	NE	NE	NE	5	100	4	80	44,25	8,06
Cycle 5 Day 1	3	0	NE	0	NE	NE	NE	3	60	2	66,7	38	4,24
Study Treatment Completion/Early Withdrawal	3	0	NE	0	NE	NE	NE	3	60	1	33,3	40	NE
Follow Up Visit 1 Month 2	3	0	NE	0	NE	NE	NE	2	40	1	50	52,5	NE

Baseline	3a	24	100	21	87,5	43,28	10,51	35	100	31	88,6	43,1	10,25
Cycle 3 Day 1	3a	24	100	18	75	43,84	11,52	32	91,4	25	78,1	44,45	10,61
Cycle 5 Day 1	3a	22	91,7	15	68,2	42,53	11,58	31	88,6	22	71	45,73	11,64
Study Treatment Completion/Early Withdrawal	3a	24	100	18	75	43	11,82	31	88,6	26	83,9	45,64	10,34
Follow Up Visit 1 Month 2	3a	21	87,5	9	42,9	42,89	13,43	27	77,1	17	63	46,79	7,91
Baseline	Missing/Unknown/Variants	8	100	8	100	45,82	7,61	7	100	7	100	44,71	11,19
Cycle 3 Day 1	Missing/Unknown/Variants	8	100	7	87,5	46,71	10	6	85,7	5	83,3	39	11,34
Cycle 5 Day 1	Missing/Unknown/Variants	7	87,5	5	71,4	48,6	11,01	5	71,4	5	100	47	8,15
Study Treatment Completion/Early Withdrawal	Missing/Unknown/Variants	8	100	5	62,5	36,4	10,31	4	57,1	3	75	41,33	6,51
Follow Up Visit 1 Month 2	Missing/Unknown/Variants	5	62,5	5	100	46,17	6,32	4	57,1	4	100	41,75	7,09
FLIPI													
Baseline	Missing/Unknown	6	100	6	100	43,26	10,35	7	100	7	100	53,71	4,5
Cycle 3 Day 1	Missing/Unknown	6	100	6	100	42,83	11,69	7	100	5	71,4	51,2	3,63
Cycle 5 Day 1	Missing/Unknown	6	100	6	100	46	7,9	6	85,7	5	83,3	49,6	6,47
Study Treatment Completion/Early Withdrawal	Missing/Unknown	5	83,3	5	100	45,8	12,7	5	71,4	3	60	42	9,54
Follow Up Visit 1 Month 2	Missing/Unknown	4	66,7	3	75	41	11,14	4	57,1	3	75	51,67	3,21
Baseline	High (>=3)	60	100	56	93,3	45,91	10,15	67	100	59	88,1	45,09	9,04
Cycle 3 Day 1	High (>=3)	59	98,3	49	83,1	47,21	10,1	60	89,6	48	80	45,7	8
Cycle 5 Day 1	High (>=3)	56	93,3	45	80,4	47,51	10,84	57	85,1	45	78,9	46,3	9,36
Study Treatment Completion/Early Withdrawal	High (>=3)	59	98,3	45	76,3	45,18	11,39	59	88,1	47	79,7	47,94	7,74
Follow Up Visit 1 Month 2	High (>=3)	51	85	38	74,5	48,55	9,52	52	77,6	30	57,7	47,2	7,93
Baseline	Intermediate (2)	47	100	44	93,6	45,81	8,88	58	100	52	89,7	43,59	9,42
Cycle 3 Day 1	Intermediate (2)	45	95,7	34	75,6	48,59	8,67	55	94,8	44	80	45,27	9,05
Cycle 5 Day 1	Intermediate (2)	42	89,4	35	83,3	47,67	9,07	53	91,4	39	73,6	46,77	7,64
Study Treatment Completion/Early Withdrawal	Intermediate (2)	42	89,4	31	73,8	47,66	9,25	52	89,7	42	80,8	48,12	9,41
Follow Up Visit 1 Month 2	Intermediate (2)	38	80,9	32	84,2	50,36	7,52	47	81	30	63,8	49,33	7,56
Baseline	Low (0-1)	42	100	41	97,6	46,15	7,98	34	100	32	94,1	43,5	10,64
Cycle 3 Day 1	Low (0-1)	40	95,2	37	92,5	47,11	7,81	34	100	29	85,3	45,21	10,61
Cycle 5 Day 1	Low (0-1)	38	90,5	31	81,6	46,96	8,02	34	100	26	76,5	44,7	10,76
Study Treatment Completion/Early Withdrawal	Low (0-1)	41	97,6	34	82,9	45,91	8,9	34	100	26	76,5	48,2	10,2
Follow Up Visit 1 Month 2	Low (0-1)	36	85,7	30	83,3	48,76	6,72	32	94,1	20	62,5	47,78	9,04
Fc gamma receptor IIa													
Baseline	Missing	13	100	13	100	46,8	7,89	18	100	13	72,2	41,91	10,76
Cycle 3 Day 1	Missing	13	100	12	92,3	47,5	10,54	15	83,3	9	60	48,33	8,08
Cycle 5 Day 1	Missing	13	100	11	84,6	47,45	9,17	14	77,8	8	57,1	46,33	10,35
Study Treatment Completion/Early Withdrawal	Missing	12	92,3	7	58,3	45,57	10,58	16	88,9	6	37,5	47,33	11,4
Follow Up Visit 1 Month 2	Missing	11	84,6	8	72,7	47,63	9,12	12	66,7	5	41,7	45,3	11,33
Baseline	131HH	42	100	40	95,2	47,2	8,77	36	100	32	88,9	43,05	9,66
Cycle 3 Day 1	131HH	39	92,9	31	79,5	48,33	9,66	34	94,4	29	85,3	44,08	8,8
Cycle 5 Day 1	131HH	37	88,1	28	75,7	48,22	10,18	33	91,7	28	84,8	42,77	9,04
Study Treatment Completion/Early Withdrawal	131HH	40	95,2	31	77,5	46,57	11,98	33	91,7	31	93,9	45,68	9,66

Follow Up Visit 1 Month 2	131HH	35	83,3	30	85,7	49,4	9,39	32	88,9	22	68,8	46,43	8,01
Baseline	131HR	66	100	61	92,4	44,57	10,28	78	100	73	93,6	45,89	8,83
Cycle 3 Day 1	131HR	65	98,5	57	87,7	45,95	9,39	75	96,2	63	84	46,84	8,62
Cycle 5 Day 1	131HR	62	93,9	52	83,9	46,42	9,95	72	92,3	59	81,9	48,83	7,01
Study Treatment Completion/Early Withdrawal	131HR	61	92,4	49	80,3	46,27	9,74	68	87,2	57	83,8	50,15	7,5
Follow Up Visit 1 Month 2	131HR	54	81,8	42	77,8	48,52	8,53	63	80,8	41	65,1	50,45	7,42
Baseline	131RR	34	100	33	97,1	46,14	7,71	34	100	32	94,1	44,44	10,46
Cycle 3 Day 1	131RR	33	97,1	26	78,8	49,16	7,06	32	94,1	25	78,1	43,54	9,73
Cycle 5 Day 1	131RR	30	88,2	26	86,7	48,15	7,65	31	91,2	20	64,5	43,41	11,63
Study Treatment Completion/Early Withdrawal	131RR	34	100	28	82,4	45,39	8,8	33	97,1	24	72,7	45,6	9,58
Follow Up Visit 1 Month 2	131RR	29	85,3	23	79,3	49,64	5,87	28	82,4	15	53,6	46	7,13
Fc gamma receptor IIIa													
Baseline	Missing	13	100	13	100	46,8	7,89	18	100	13	72,2	41,91	10,76
Cycle 3 Day 1	Missing	13	100	12	92,3	47,5	10,54	15	83,3	9	60	48,33	8,08
Cycle 5 Day 1	Missing	13	100	11	84,6	47,45	9,17	14	77,8	8	57,1	46,33	10,35
Study Treatment Completion/Early Withdrawal	Missing	12	92,3	7	58,3	45,57	10,58	16	88,9	6	37,5	47,33	11,4
Follow Up Visit 1 Month 2	Missing	11	84,6	8	72,7	47,63	9,12	12	66,7	5	41,7	45,3	11,33
Baseline	158FF	58	100	57	98,3	46,07	6,84	53	100	46	86,8	45,04	10,76
Cycle 3 Day 1	158FF	56	96,6	49	87,5	47,27	8,1	51	96,2	42	82,4	45,96	8,44
Cycle 5 Day 1	158FF	52	89,7	43	82,7	47,18	8,6	49	92,5	38	77,6	45,88	10,48
Study Treatment Completion/Early Withdrawal	158FF	56	96,6	42	75	44,64	9,61	48	90,6	42	87,5	47,64	9,7
Follow Up Visit 1 Month 2	158FF	47	81	39	83	48,12	7,83	46	86,8	33	71,7	48,19	7,14
Baseline	158VF	65	100	60	92,3	44,56	11,08	65	100	63	96,9	44,82	8,98
Cycle 3 Day 1	158VF	63	96,9	53	84,1	46,84	9,94	62	95,4	55	88,7	45,25	8,18
Cycle 5 Day 1	158VF	60	92,3	51	85	46,6	10,05	59	90,8	49	83,1	46,23	7,93
Study Treatment Completion/Early Withdrawal	158VF	61	93,8	52	85,2	46,09	10,63	59	90,8	49	83,1	48,32	8,26
Follow Up Visit 1 Month 2	158VF	54	83,1	45	83,3	48,93	8,54	52	80	33	63,5	49,89	7,91
Baseline	158VV	19	100	17	89,5	48,82	9,04	30	100	28	93,3	44,79	8,31
Cycle 3 Day 1	158VV	18	94,7	12	66,7	49,76	8,7	28	93,3	20	71,4	44,91	12,05
Cycle 5 Day 1	158VV	17	89,5	12	70,6	50,9	9,76	28	93,3	20	71,4	46,9	8,66
Study Treatment Completion/Early Withdrawal	158VV	18	94,7	14	77,8	50,69	8,95	27	90	21	77,8	47,67	8,62
Follow Up Visit 1 Month 2	158VV	17	89,5	11	64,7	52,99	7,62	25	83,3	12	48	45,25	8,41
Fc gamma receptor IIb/IIc													
Baseline	Missing	14	100	14	100	46,45	7,69	18	100	13	72,2	41,91	10,76
Cycle 3 Day 1	Missing	14	100	13	92,9	47,08	10,21	15	83,3	9	60	48,33	8,08
Cycle 5 Day 1	Missing	14	100	12	85,7	46,83	9	14	77,8	8	57,1	46,33	10,35
Study Treatment Completion/Early Withdrawal	Missing	13	92,9	8	61,5	45,13	9,88	16	88,9	6	37,5	47,33	11,4
Follow Up Visit 1 Month 2	Missing	12	85,7	9	75	47,67	8,53	12	66,7	5	41,7	45,3	11,33
Baseline	232II	104	100	96	92,3	44,87	9,61	107	100	98	91,6	44,79	9,01
Cycle 3 Day 1	232II	99	95,2	81	81,8	46,36	9,44	100	93,5	84	84	45,34	8,85
Cycle 5 Day 1	232II	92	88,5	73	79,3	46,12	9,18	95	88,8	74	77,9	45,98	8,63

Study Treatment Completion/Early Withdrawal	232II	98	94,2	78	79,6	45,08	10,05	95	88,8	75	78,9	47,67	8,04
Follow Up Visit 1 Month 2	232II	85	81,7	67	78,8	48,11	8,4	85	79,4	49	57,6	47,9	7,82
Baseline	232IT	36	100	36	100	47,97	8,14	37	100	35	94,6	46,51	9,4
Cycle 3 Day 1	232IT	36	100	31	86,1	49,61	7,41	37	100	29	78,4	47,4	7,76
Cycle 5 Day 1	232IT	35	97,2	31	88,6	50	9,67	37	100	29	78,4	48,05	7,87
Study Treatment Completion/Early Withdrawal	232IT	35	97,2	28	80	48,77	10,11	36	97,3	34	94,4	49,67	8,97
Follow Up Visit 1 Month 2	232IT	31	86,1	26	83,9	51,35	7,58	35	94,6	27	77,1	49,81	7,13
Baseline	232TT	1	100	1	100	53	NE	4	100	4	100	33	13,44
Cycle 3 Day 1	232TT	1	100	1	100	60	NE	4	100	4	100	33,5	12,12
Cycle 5 Day 1	232TT	1	100	1	100	59	NE	4	100	4	100	37,75	17,84
Study Treatment Completion/Early Withdrawal	232TT	1	100	1	100	58	NE	3	75	3	100	35	17
Follow Up Visit 1 Month 2	232TT	1	100	1	100	55	NE	3	75	2	66,7	44	15,56
Absolute lymphocyte count													
Baseline	Missing	0	NE	0	NE	NE	NE	3	100	2	66,7	34,5	6,36
Cycle 3 Day 1	Missing	0	NE	0	NE	NE	NE	2	66,7	2	100	29	8,49
Cycle 5 Day 1	Missing	0	NE			NE	NE	2	66,7			NE	NE
Study Treatment Completion/Early Withdrawal	Missing	0	NE	0	NE	NE	NE	2	66,7	2	100	39,5	12,02
Follow Up Visit 1 Month 2	Missing	0	NE	0	NE	NE	NE	2	66,7	2	100	38,5	12,02
Baseline	< median	83	100	80	96,4	47,19	7,51	79	100	70	88,6	43,99	9,69
Cycle 3 Day 1	< median	79	95,2	70	88,6	49,02	7,52	77	97,5	64	83,1	46,38	8,73
Cycle 5 Day 1	< median	75	90,4	63	84	49,02	8,11	76	96,2	57	75	46,5	9,16
Study Treatment Completion/Early Withdrawal	< median	80	96,4	61	76,3	46,57	9,83	75	94,9	62	82,7	47,86	9,35
Follow Up Visit 1 Month 2	< median	68	81,9	54	79,4	50,23	7,11	67	84,8	43	64,2	48,5	8,57
Baseline	>= median	72	100	67	93,1	44,22	10,59	84	100	78	92,9	45,46	9,38
Cycle 3 Day 1	>= median	71	98,6	56	78,9	45,25	10,53	77	91,7	60	77,9	45,44	8,67
Cycle 5 Day 1	>= median	67	93,1	54	80,6	45,36	10,42	72	85,7	58	80,6	45,98	8,95
Study Treatment Completion/Early Withdrawal	>= median	67	93,1	54	80,6	45,55	10,49	73	86,9	54	74	48,28	8,3
Follow Up Visit 1 Month 2	>= median	61	84,7	49	80,3	47,55	9,19	66	78,6	38	57,6	48,52	6,86
Time from initial NHL diagnosis to randomization													
Baseline	6-12 months	11	100	11	100	43,27	8,33	18	100	16	88,9	41,25	7,77
Cycle 3 Day 1	6-12 months	11	100	8	72,7	47,5	9,55	18	100	13	72,2	42,08	9
Cycle 5 Day 1	6-12 months	8	72,7	6	75	45	7,64	17	94,4	11	64,7	43,73	8,46
Study Treatment Completion/Early Withdrawal	6-12 months	11	100	9	81,8	43,88	8,82	17	94,4	10	58,8	45,4	7,75
Follow Up Visit 1 Month 2	6-12 months	7	63,6	5	71,4	52,4	6,58	17	94,4	6	35,3	44,83	6,34
Baseline	< 6 months	6	100	4	66,7	47,39	6,64	6	100	6	100	49,17	3,37
Cycle 3 Day 1	< 6 months	6	100	4	66,7	51,25	7,8	6	100	3	50	51	1
Cycle 5 Day 1	< 6 months	6	100	5	83,3	47,4	9,21	6	100	4	66,7	53,25	4,43
Study Treatment Completion/Early Withdrawal	< 6 months	6	100	5	83,3	46,6	8,02	6	100	4	66,7	53	4,97
Follow Up Visit 1 Month 2	< 6 months	6	100	5	83,3	47	11,25	4	66,7	4	100	50	1,41
Baseline	> 12 months	138	100	132	95,7	46	9,27	142	100	128	90,1	44,84	9,84
Cycle 3 Day 1	> 12 months	133	96,4	114	85,7	47,2	9,19	132	93	110	83,3	45,93	8,92

Cycle 5 Day 1	> 12 months	128	92,8	106	82,8	47,46	9,54	127	89,4	100	78,7	46,23	9,12
Study Treatment Completion/Early Withdrawal	> 12 months	130	94,2	101	77,7	46,26	10,36	127	89,4	104	81,9	47,95	9,08
Follow Up Visit 1 Month 2	> 12 months	116	84,1	93	80,2	48,88	8,19	114	80,3	73	64	48,46	8,23
Beta 2 microglobulin													
Baseline	Missing	6	100	5	83,3	45,4	7,02	13	100	9	69,2	46,22	11,55
Cycle 3 Day 1	Missing	6	100	5	83,3	44,66	5,91	10	76,9	5	50	50,4	7,3
Cycle 5 Day 1	Missing	6	100	5	83,3	41,2	9,18	10	76,9	6	60	49,5	6,95
Study Treatment Completion/Early Withdrawal	Missing	5	83,3	3	60	39,33	10,07	12	92,3	8	66,7	51,38	8,43
Follow Up Visit 1 Month 2	Missing	5	83,3	5	100	42,4	10,81	10	76,9	5	50	46,2	7,56
Baseline	< 3.5 mg/L	121	100	117	96,7	46,37	8,82	118	100	108	91,5	45,3	9,34
Cycle 3 Day 1	< 3.5 mg/L	118	97,5	101	85,6	47,88	9,05	113	95,8	93	82,3	45,66	9,29
Cycle 5 Day 1	< 3.5 mg/L	112	92,6	95	84,8	47,65	9,28	108	91,5	85	78,7	45,87	9,44
Study Treatment Completion/Early Withdrawal	< 3.5 mg/L	116	95,9	96	82,8	46,58	9,66	107	90,7	85	79,4	47,78	9,26
Follow Up Visit 1 Month 2	< 3.5 mg/L	105	86,8	84	80	49,51	8,02	97	82,2	59	60,8	48,4	8,41
Baseline	>= 3.5 mg/L	28	100	25	89,3	43,44	10,78	35	100	33	94,3	42	9,47
Cycle 3 Day 1	>= 3.5 mg/L	26	92,9	20	76,9	45,31	10,16	33	94,3	28	84,8	44,77	7,71
Cycle 5 Day 1	>= 3.5 mg/L	24	85,7	17	70,8	47,35	9,97	32	91,4	24	75	46,74	7,96
Study Treatment Completion/Early Withdrawal	>= 3.5 mg/L	26	92,9	16	61,5	44,44	12,61	31	88,6	25	80,6	47,24	7,8
Follow Up Visit 1 Month 2	>= 3.5 mg/L	19	67,9	14	73,7	48	8,13	28	80	19	67,9	48,42	6,72


Prior therapies													
Baseline	<= 2	125	100	119	95,2	45,76	9,43	130	100	115	88,5	44,58	9,55
Cycle 3 Day 1	<= 2	123	98,4	102	82,9	47,55	9,22	123	94,6	97	78,9	45,81	9,07
Cycle 5 Day 1	<= 2	117	93,6	97	82,9	47,08	9,75	117	90	91	77,8	46,17	9,39
Study Treatment Completion/Early Withdrawal	<= 2	118	94,4	91	77,1	45,74	10,59	116	89,2	91	78,4	48,19	9,04
Follow Up Visit 1 Month 2	<= 2	105	84	84	80	48,93	8,42	103	79,2	63	61,2	49,35	7,39
Baseline	> 2	30	100	28	93,3	46,16	7,9	36	100	35	97,2	44,78	9,67
Cycle 3 Day 1	> 2	27	90	24	88,9	46,47	8,9	33	91,7	29	87,9	45,14	8,44
Cycle 5 Day 1	> 2	25	83,3	20	80	48,55	7,51	33	91,7	24	72,7	46,49	7,6
Study Treatment Completion/Early Withdrawal	> 2	29	96,7	24	82,8	47,42	8,08	34	94,4	27	79,4	46,97	8,53
Follow Up Visit 1 Month 2	> 2	24	80	19	79,2	49,05	7,6	32	88,9	20	62,5	44,85	8,79
Refractory Type													
Baseline	Rituximab + Chemotherapy	130	100	123	94,6	45,62	9,06	127	100	114	89,8	43,95	9,66
Cycle 3 Day 1	Rituximab + Chemotherapy	127	97,7	105	82,7	47,1	9,31	119	93,7	94	79	45,72	8,38
Cycle 5 Day 1	Rituximab + Chemotherapy	120	92,3	97	80,8	47,17	9,75	113	89	84	74,3	45,84	9,21
Study Treatment Completion/Early Withdrawal	Rituximab + Chemotherapy	122	93,8	93	76,2	45,66	10,5	115	90,6	89	77,4	47,91	9,11
Follow Up Visit 1 Month 2	Rituximab + Chemotherapy	106	81,5	84	79,2	48,79	8,47	103	81,1	61	59,2	48,33	7,66
Baseline	Rituximab Monotherapy	25	100	24	96	46,92	9,6	39	100	36	92,3	46,77	8,98
Cycle 3 Day 1	Rituximab Monotherapy	23	92	21	91,3	48,59	8,29	37	94,9	32	86,5	45,45	10,41
Cycle 5 Day 1	Rituximab Monotherapy	22	88	20	90,9	48,14	7,58	37	94,9	31	83,8	47,32	8,51
Study Treatment Completion/Early Withdrawal	Rituximab Monotherapy	25	100	22	88	47,94	8,22	35	89,7	29	82,9	47,9	8,41
Follow Up Visit 1 Month 2	Rituximab Monotherapy	23	92	19	82,6	49,68	7,27	32	82,1	22	68,8	48,11	8,86

[1] in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit [2] mean: descriptive statistics - absolute values
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/t_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/t_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.xls 29OCT2019 13:20

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit


Refractory Type (N=321) Laboratory Test: Prorated FACT-G TOTAL



C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Age (N=321) Laboratory Test: Prorated FACT-G TOTAL




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Beta 2 microglobulin (N=302) Laboratory Test: Prorated FACT-G TOTAL




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit


Best response to prior therapy (N=316) Laboratory Test: Prorated FACT-G TOTAL



C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Time from initial NHL diagnosis to randomization (N=321) Laboratory Test: Prorated FACT-G TOTAL




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

ECOG BL (N=319) Laboratory Test: Prorated FACT-G TOTAL




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Fc gamma receptor IIa (N=290) Laboratory Test: Prorated FACT-G TOTAL




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Fc gamma receptor IIIa (N=290) Laboratory Test: Prorated FACT-G TOTAL




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Fc gamma receptor IIb/IIc (N=289) Laboratory Test: Prorated FACT-G TOTAL




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

FLIPI (N=308) Laboratory Test: Prorated FACT-G TOTAL




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

flip2grade (N=321) Laboratory Test: Prorated FACT-G TOTAL



Treatment with Subgroup


- G-Benda, 1 (N=54)
- G-Benda, 2 (N=69)
- G-Benda, 3a (N=24)
- G-Benda, Missing/Unknown/Variants (N=8)
- Benda, 1 (N=51)
- Benda, 2 (N=68)
- Benda, 3 (N=5)
- Benda, 3a (N=35)
- Benda, Missing/Unknown/Variants (N=7)

C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Absolute lymphocyte count (N=318) Laboratory Test: Prorated FACT-G TOTAL




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Prior therapies (N=321) Laboratory Test: Prorated FACT-G TOTAL




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Race/ethnicity (N=297) Laboratory Test: Prorated FACT-G TOTAL




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Geographic region (N=321) Laboratory Test: Prorated FACT-G TOTAL




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-G Total
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Sex (N=321) Laboratory Test: Prorated FACT-G TOTAL




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTGT_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Refractory Type (N=321) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Independence status (Katz ADL) (N=135) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Age (N=321) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Beta 2 microglobulin (N=302) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Best response to prior therapy (N=316) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Body mass index (N=312) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Time from initial NHL diagnosis to randomization (N=321) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

ECOG BL (N=319) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Fc gamma receptor IIa (N=290) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Fc gamma receptor IIIa (N=290) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Fc gamma receptor IIb/IIc (N=289) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

FLIPI (N=308) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

flip2grade (N=321) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




Treatment with Subgroup

- G-Benda, 1 (N=54)
- G-Benda, 2 (N=69)
- G-Benda, 3a (N=24)
- G-Benda, Missing/Unknown/Variants (N=8)
- Benda, 1 (N=51)
- Benda, 2 (N=68)
- Benda, 3 (N=5)
- Benda, 3a (N=35)
- Benda, Missing/Unknown/Variants (N=7)

C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Prior therapies (N=321) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Race/ethnicity (N=297) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Geographic region (N=321) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: FACT-LYM Subscale
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Sex (N=321) Laboratory Test: ADDITIONAL CONCERNS PRORATED SUBSCALE SCORE




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_FACTLS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:30

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Refractory Type (N=321) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Independence status (Katz ADL) (N=135) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Age (N=321) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Beta 2 microglobulin (N=302) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Best response to prior therapy (N=316) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Body mass index (N=312) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Time from initial NHL diagnosis to randomization (N=321) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

ECOG BL (N=319) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Fc gamma receptor IIa (N=290) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Fc gamma receptor IIIa (N=290) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Fc gamma receptor IIb/IIc (N=289) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

FLIPI (N=308) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

flip2grade (N=321) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Absolute lymphocyte count (N=318) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Prior therapies (N=321) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Race/ethnicity (N=297) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Geographic region (N=321) Laboratory Test: Your own health state today




C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

POPULATION: Intent-to-Treat Patients, Follicular Lymphoma Patients
ENDPOINT: EQ-5D VAS
STUDY: GO01297
Cutoff Date: 01SEP2014
Line Plot of Mean by Visit

Sex (N=321) Laboratory Test: Your own health state today



C3D1 = Cycle 3 Day 1, C5D1 = Cycle 5 Day 1,
STCEW = Study Treatment Completion/Early Withdrawal, FUV1M2 = Follow Up Visit 1 Month 2
Clinical cut-off: 01SEP2014

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/program/g_pro_mean.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRPrimary/qa/output/g_pro_mean_sg_VAS_FOLY_IT_01SEP2014_01297.pdf
29OCT2019 13:32

Anhang 4-G3: Generelle Verträglichkeit (Induktionsphase)

19 (Anhang): Ergebnisse für Patienten mit UE aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda															Benda vs. G-Benda				
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio					Absolute Risk Difference				Relative Risk						Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	162	98,8	168	100,0	165	98,2	1,47		Convergence criterion (GCONV=1E-8) satisfied.	0,24	8,93	0,006		Algorithm converged.	-0,020	0,032	1,01		Algorithm converged.	0,98	1,03	0,6713		0,99		Algorithm converged.	0,97	1,02
Sex	Male	91	55,5	89	97,8	95	56,5	93	97,9	0,96		Convergence criterion (GCONV=1E-8) satisfied.	0,13	6,94	-0,001		Algorithm converged.	-0,043	0,041	1,00		Algorithm converged.	0,96	1,04	0,9653	1,0000	1,00		Algorithm converged.	0,96	1,04
	Female	73	44,5	73	100,0	73	43,5	72	98,6		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	WARNING: Negative of Hessian not positive definite.						*	WARNING: Negative of Hessian not positive definite.		
Age	< 60 years	62	37,8	62	100,0	63	37,5	62	98,4		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.						*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.		
	>= 60 years	102	62,2	100	98,0	105	62,5	103	98,1	0,97		Convergence criterion (GCONV=1E-8) satisfied.	0,13	7,03	-0,001		Algorithm converged.	-0,038	0,037	1,00		Algorithm converged.	0,96	1,04	0,9767		1,00		Algorithm converged.	0,96	1,04
Geographic region	Western Europe	78	47,6	77	98,7	77	45,8	75	97,4	2,05		Convergence criterion (GCONV=1E-8) satisfied.	0,18	23,12	0,013		Algorithm converged.	-0,030	0,057	1,01		Algorithm converged.	0,97	1,06	0,5536		0,99		Algorithm converged.	0,94	1,03
	North America	67	40,9	67	100,0	73	43,5	72	98,6		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.						*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.		
	Other	19	11,6	18	94,7	18	10,7	18	100,0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*	WARNING: Negative of Hessian not positive definite.						*	WARNING: Negative of Hessian not positive definite.		
FLIPI	Low (0-1)	42	25,6	42	100,0	35	20,8	35	100,0																						
	Intermediate (2)	51	31,1	50	98,0	58	34,5	57	98,3	0,88		Convergence criterion (GCONV=1E-8) satisfied.	0,05	14,39	-0,002		Algorithm converged.	-0,053	0,048	1,00		Algorithm converged.	0,95	1,05	0,9271		1,00		Algorithm converged.	0,95	1,06
	High (>=3)	64	39,0	63	98,4	68	40,5	66	97,1	1,91		Convergence criterion (GCONV=1E-8) satisfied.	0,17	21,58	0,014		Algorithm converged.	-0,037	0,064	1,01		Algorithm converged.	0,96	1,07	0,5923		0,99		Algorithm converged.	0,94	1,04
	Missing/Unknown	7	4,3	7	100,0	7	4,2	7	100,0																						

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AAE_FOLY_SE_30NOV2018_01297.xls 07OCT2019 10:55

20 (Anhang): Ergebnisse für Patienten mit SUE aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any SAEs, Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda														Benda vs. G-Benda			
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk			
	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	44	26,8	168	100,0	38	22,6	1,25	Convergence criterion (GCONV=1E-8) satisfied.	0,76	2,07	0,042	Algorithm converged.	-0,051	0,135	1,19	Algorithm converged.	0,81	1,73	0,3748		0,84	Algorithm converged.	0,58	1,23
Sex	Male	91	55,5	21	23,1	95	56,5	19	20,0	1,20	Convergence criterion (GCONV=1E-8) satisfied.	0,60	2,42	0,031	Algorithm converged.	-0,087	0,149	1,15	Algorithm converged.	0,67	2,00	0,6101	0,9006	0,87	Algorithm converged.	0,50	1,50
	Female	73	44,5	23	31,5	73	43,5	19	26,0	1,31	Convergence criterion (GCONV=1E-8) satisfied.	0,64	2,68	0,055	Algorithm converged.	-0,092	0,201	1,21	Algorithm converged.	0,72	2,02	0,4661		0,83	Algorithm converged.	0,49	1,38
Age	< 60 years	62	37,8	11	17,7	63	37,5	9	14,3	1,29	Convergence criterion (GCONV=1E-8) satisfied.	0,50	3,38	0,035	Algorithm converged.	-0,094	0,163	1,24	Algorithm converged.	0,55	2,79	0,5993	0,8997	0,81	Algorithm converged.	0,36	1,81
	>= 60 years	102	62,2	33	32,4	105	62,5	29	27,6	1,25	Convergence criterion (GCONV=1E-8) satisfied.	0,69	2,27	0,047	Algorithm converged.	-0,077	0,172	1,17	Algorithm converged.	0,77	1,78	0,4581		0,85	Algorithm converged.	0,56	1,30
Geographic region	Western Europe	78	47,6	27	34,6	77	45,8	18	23,4	1,74	Convergence criterion (GCONV=1E-8) satisfied.	0,86	3,51	0,112	Algorithm converged.	-0,029	0,254	1,48	Algorithm converged.	0,89	2,46	0,1288	0,4129	0,68	Algorithm converged.	0,41	1,12
	North America	67	40,9	14	20,9	73	43,5	16	21,9	0,94	Convergence criterion (GCONV=1E-8) satisfied.	0,42	2,11	-0,010	Algorithm converged.	-0,146	0,126	0,95	Algorithm converged.	0,50	1,80	0,8830		1,05	Algorithm converged.	0,56	1,98
	Other	19	11,6	3	15,8	18	10,7	4	22,2	0,66	Convergence criterion (GCONV=1E-8) satisfied.	0,12	3,45	-0,064	Algorithm converged.	-0,317	0,188	0,71	Algorithm converged.	0,18	2,74	0,6200		1,41	Algorithm converged.	0,36	5,43
FLIPI	Low (0-1)	42	25,6	8	19,0	35	20,8	9	25,7	0,68	Convergence criterion (GCONV=1E-8) satisfied.	0,23	2,00	-0,067	Algorithm converged.	-0,254	0,121	0,74	Algorithm converged.	0,32	1,72	0,4838	0,4133	1,35	Algorithm converged.	0,58	3,13
	Intermediate (2)	51	31,1	16	31,4	58	34,5	12	20,7	1,75	Convergence criterion (GCONV=1E-8) satisfied.	0,74	4,17	0,107	Algorithm converged.	-0,058	0,271	1,52	Algorithm converged.	0,79	2,90	0,2073		0,66	Algorithm converged.	0,35	1,26
	High (>=3)	64	39,0	16	25,0	68	40,5	15	22,1	1,18	Convergence criterion (GCONV=1E-8) satisfied.	0,53	2,64	0,029	Algorithm converged.	-0,115	0,174	1,13	Algorithm converged.	0,61	2,10	0,6905		0,88	Algorithm converged.	0,48	1,63
	Missing/Unknown	7	4,3	4	57,1	7	4,2	2	28,6	3,33	Convergence criterion (GCONV=1E-8) satisfied.	0,36	30,70	0,286	Algorithm converged.	-0,211	0,782	2,00	Algorithm converged.	0,53	7,60	0,3090		0,50	Algorithm converged.	0,13	1,90

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_ASAE_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:41

21 (Anhang): Ergebnisse für Patienten mit Behandlungsabbruch wegen UE aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs leading to treatment discontinuation, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda															Benda vs. G-Benda				
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio				Absolute Risk Difference				Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	20	12,2	168	100,0	30	17,9	0,64	Convergence criterion (GCONV=1E-8) satisfied.	0,35	1,18	-0,057	Algorithm converged.	-0,133	0,020	0,68	Algorithm converged.	0,40	1,15	0,1532		1,46	Algorithm converged.	0,87	2,47
Sex	Male	91	55,5	8	8,8	95	56,5	14	14,7	0,56	Convergence criterion (GCONV=1E-8) satisfied.	0,22	1,40	-0,059	Algorithm converged.	-0,151	0,033	0,60	Algorithm converged.	0,26	1,35	0,2168	0,6717	1,68	Algorithm converged.	0,74	3,80
	Female	73	44,5	12	16,4	73	43,5	16	21,9	0,70	Convergence criterion (GCONV=1E-8) satisfied.	0,31	1,61	-0,055	Algorithm converged.	-0,182	0,073	0,75	Algorithm converged.	0,38	1,47	0,4032		1,33	Algorithm converged.	0,68	2,62
Age	< 60 years	62	37,8	7	11,3	63	37,5	9	14,3	0,76	Convergence criterion (GCONV=1E-8) satisfied.	0,27	2,20	-0,030	Algorithm converged.	-0,147	0,087	0,79	Algorithm converged.	0,31	1,99	0,6175	0,7072	1,27	Algorithm converged.	0,50	3,19
	>= 60 years	102	62,2	13	12,7	105	62,5	21	20,0	0,58	Convergence criterion (GCONV=1E-8) satisfied.	0,28	1,24	-0,073	Algorithm converged.	-0,173	0,028	0,64	Algorithm converged.	0,34	1,20	0,1648		1,57	Algorithm converged.	0,83	2,96
Geographic region	Western Europe	78	47,6	10	12,8	77	45,8	13	16,9	0,72	Convergence criterion (GCONV=1E-8) satisfied.	0,30	1,77	-0,041	Algorithm converged.	-0,152	0,071	0,76	Algorithm converged.	0,35	1,63	0,4789	0,9352	1,32	Algorithm converged.	0,61	2,82
	North America	67	40,9	8	11,9	73	43,5	14	19,2	0,57	Convergence criterion (GCONV=1E-8) satisfied.	0,22	1,46	-0,072	Algorithm converged.	-0,191	0,047	0,62	Algorithm converged.	0,28	1,39	0,2474		1,61	Algorithm converged.	0,72	3,58
	Other	19	11,6	2	10,5	18	10,7	3	16,7	0,59	Convergence criterion (GCONV=1E-8) satisfied.	0,09	4,01	-0,061	Algorithm converged.	-0,282	0,159	0,63	Algorithm converged.	0,12	3,35	0,5894		1,58	Algorithm converged.	0,30	0,40
FLIPI	Low (0-1)	42	25,6	4	9,5	35	20,8	3	8,6	1,12	Convergence criterion (GCONV=1E-8) satisfied.	0,23	5,39	0,010	Algorithm converged.	-0,119	0,138	1,11	Algorithm converged.	0,27	4,63	0,8850	0,7302	0,90	Algorithm converged.	0,22	3,75
	Intermediate (2)	51	31,1	8	15,7	58	34,5	14	24,1	0,58	Convergence criterion (GCONV=1E-8) satisfied.	0,22	1,53	-0,085	Algorithm converged.	-0,233	0,064	0,65	Algorithm converged.	0,30	1,42	0,2806		1,54	Algorithm converged.	0,70	3,37
	High (>=3)	64	39,0	7	10,9	68	40,5	13	19,1	0,52	Convergence criterion (GCONV=1E-8) satisfied.	0,19	1,40	-0,082	Algorithm converged.	-0,203	0,039	0,57	Algorithm converged.	0,24	1,34	0,1995		1,75	Algorithm converged.	0,74	4,10
	Missing/Unknown	7	4,3	1	14,3	7	4,2				* Quasi-complete separation of data points detected.				* ERROR: Error in computing the link function, its derivatives, or the variance function.			NE	Algorithm converged.	NE	NE	NE		NE	Algorithm converged.	NE	NE

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AELDIS_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:14

22 (Anhang): Ergebnisse für Patienten mit nicht schweren UE (Grad 1 - 2) aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) – Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade 1-2, Induction Phase Only
MODEL: Unstratified Analysis STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda															Benda vs. G-Benda				
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio					Absolute Risk Difference				Relative Risk						Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	77	47,0	168	100,0	78	46,4	1,02		Convergence criterion (GCONV=1E-8) satisfied.	0,66	1,57	0,005		Algorithm converged.	-0,102	0,113	1,01		Algorithm converged.	0,80	1,27	0,9240		0,99		Algorithm converged.	0,79	1,24
Sex	Male	91	55,5	48	52,7	95	56,5	49	51,6	1,05		Convergence criterion (GCONV=1E-8) satisfied.	0,59	1,86	0,012		Algorithm converged.	-0,132	0,155	1,02		Algorithm converged.	0,78	1,35	0,8733	0,9279	0,98		Algorithm converged.	0,74	1,29
	Female	73	44,5	29	39,7	73	43,5	29	39,7	1,00		Convergence criterion (GCONV=1E-8) satisfied.	0,52	1,94	0,000		Algorithm converged.	-0,159	0,159	1,00		Algorithm converged.	0,67	1,49	1,0000		1,00		Algorithm converged.	0,67	1,49
Age	< 60 years	62	37,8	33	53,2	63	37,5	37	58,7	0,80		Convergence criterion (GCONV=1E-8) satisfied.	0,39	1,62	-0,055		Algorithm converged.	-0,229	0,119	0,91		Algorithm converged.	0,66	1,24	0,5363	0,3894	1,10		Algorithm converged.	0,81	1,51
	>= 60 years	102	62,2	44	43,1	105	62,5	41	39,0	1,18		Convergence criterion (GCONV=1E-8) satisfied.	0,68	2,06	0,041		Algorithm converged.	-0,093	0,175	1,10		Algorithm converged.	0,80	1,53	0,5502		0,91		Algorithm converged.	0,65	1,25
Geographic region	Western Europe	78	47,6	33	42,3	77	45,8	40	51,9	0,68		Convergence criterion (GCONV=1E-8) satisfied.	0,36	1,28	-0,096		Algorithm converged.	-0,253	0,060	0,81		Algorithm converged.	0,58	1,14	0,2320	0,1056	1,23		Algorithm converged.	0,88	1,72
	North America	67	40,9	39	58,2	73	43,5	32	43,8	1,78		Convergence criterion (GCONV=1E-8) satisfied.	0,91	3,49	0,144		Algorithm converged.	-0,020	0,308	1,33		Algorithm converged.	0,96	1,85	0,0916		0,75		Algorithm converged.	0,54	1,05
	Other	19	11,6	5	26,3	18	10,7	6	33,3	0,71		Convergence criterion (GCONV=1E-8) satisfied.	0,17	2,94	-0,070		Algorithm converged.	-0,365	0,224	0,79		Algorithm converged.	0,29	2,14	0,6420		1,27		Algorithm converged.	0,47	3,43
FLIPI	Low (0-1)	42	25,6	26	61,9	35	20,8	20	57,1	1,22		Convergence criterion (GCONV=1E-8) satisfied.	0,49	3,04	0,048		Algorithm converged.	-0,172	0,268	1,08		Algorithm converged.	0,75	1,57	0,6735	0,7764	0,92		Algorithm converged.	0,64	1,34
	Intermediate (2)	51	31,1	22	43,1	58	34,5	25	43,1	1,00		Convergence criterion (GCONV=1E-8) satisfied.	0,47	2,14	0,000		Algorithm converged.	-0,186	0,187	1,00		Algorithm converged.	0,65	1,54	0,9972		1,00		Algorithm converged.	0,65	1,54
	High (>=3)	64	39,0	26	40,6	68	40,5	31	45,6	0,82		Convergence criterion (GCONV=1E-8) satisfied.	0,41	1,63	-0,050		Algorithm converged.	-0,218	0,119	0,89		Algorithm converged.	0,60	1,32	0,5663		1,12		Algorithm converged.	0,76	1,66
	Missing/Unknown	7	4,3	3	42,9	7	4,2	2	28,6	1,87		Convergence criterion (GCONV=1E-8) satisfied.	0,20	17,27	0,143		Algorithm converged.	-0,354	0,639	1,50		Algorithm converged.	0,35	6,40	0,5837		0,67		Algorithm converged.	0,16	2,84

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEG12_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:01

23 (Anhang): Ergebnisse für Patienten mit schweren UE (Grad ≥ 3) aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda														Benda vs. G-Benda			
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk			
	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	85	51,8	168	100,0	87	51,8	1,00	Convergence criterion (GCONV=1E-8) satisfied.	0,65	1,54	0,000	Algorithm converged.	-0,107	0,108	1,00	Algorithm converged.	0,81	1,23	0,9937		1,00	Algorithm converged.	0,81	1,23
Sex	Male	91	55,5	41	45,1	95	56,5	44	46,3	0,95	Convergence criterion (GCONV=1E-8) satisfied.	0,53	1,69	-0,013	Algorithm converged.	-0,156	0,131	0,97	Algorithm converged.	0,71	1,33	0,8630	0,8098	1,03	Algorithm converged.	0,75	1,41
	Female	73	44,5	44	60,3	73	43,5	43	58,9	1,06	Convergence criterion (GCONV=1E-8) satisfied.	0,55	2,05	0,014	Algorithm converged.	-0,145	0,173	1,02	Algorithm converged.	0,78	1,34	0,8661		0,98	Algorithm converged.	0,75	1,28
Age	< 60 years	62	37,8	29	46,8	63	37,5	25	39,7	1,34	Convergence criterion (GCONV=1E-8) satisfied.	0,66	2,72	0,071	Algorithm converged.	-0,102	0,244	1,18	Algorithm converged.	0,79	1,77	0,4250	0,3195	0,85	Algorithm converged.	0,57	1,27
	>= 60 years	102	62,2	56	54,9	105	62,5	62	59,0	0,84	Convergence criterion (GCONV=1E-8) satisfied.	0,49	1,46	-0,041	Algorithm converged.	-0,176	0,093	0,93	Algorithm converged.	0,73	1,18	0,5477		1,08	Algorithm converged.	0,85	1,36
Geographic region	Western Europe	78	47,6	44	56,4	77	45,8	35	45,5	1,55	Convergence criterion (GCONV=1E-8) satisfied.	0,82	2,93	0,110	Algorithm converged.	-0,047	0,266	1,24	Algorithm converged.	0,91	1,70	0,1762	0,1195	0,81	Algorithm converged.	0,59	1,10
	North America	67	40,9	28	41,8	73	43,5	40	54,8	0,59	Convergence criterion (GCONV=1E-8) satisfied.	0,30	1,16	-0,130	Algorithm converged.	-0,294	0,034	0,76	Algorithm converged.	0,54	1,08	0,1305		1,31	Algorithm converged.	0,92	1,86
	Other	19	11,6	13	68,4	18	10,7	12	66,7	1,08	Convergence criterion (GCONV=1E-8) satisfied.	0,27	4,29	0,018	Algorithm converged.	-0,284	0,319	1,03	Algorithm converged.	0,66	1,61	0,9094		0,97	Algorithm converged.	0,62	1,52
FLIPI	Low (0-1)	42	25,6	16	38,1	35	20,8	15	42,9	0,82	Convergence criterion (GCONV=1E-8) satisfied.	0,33	2,05	-0,048	Algorithm converged.	-0,268	0,172	0,89	Algorithm converged.	0,52	1,53	0,6708	0,7348	1,12	Algorithm converged.	0,65	1,94
	Intermediate (2)	51	31,1	28	54,9	58	34,5	32	55,2	0,99	Convergence criterion (GCONV=1E-8) satisfied.	0,46	2,11	-0,003	Algorithm converged.	-0,190	0,184	1,00	Algorithm converged.	0,71	1,40	0,9774		1,00	Algorithm converged.	0,72	1,41
	High (>=3)	64	39,0	37	57,8	68	40,5	35	51,5	1,29	Convergence criterion (GCONV=1E-8) satisfied.	0,65	2,57	0,063	Algorithm converged.	-0,106	0,233	1,12	Algorithm converged.	0,82	1,53	0,4648		0,89	Algorithm converged.	0,65	1,22
	Missing/Unknown	7	4,3	4	57,1	7	4,2	5	71,4	0,53	Convergence criterion (GCONV=1E-8) satisfied.	0,06	4,91	-0,143	Algorithm converged.	-0,639	0,354	0,80	Algorithm converged.	0,36	1,77	0,5820		1,25	Algorithm converged.	0,56	2,77

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEG345_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:09

24 (Anhang): Ergebnisse für Patienten mit UE Grad 1 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) – Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade 1, Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda														Benda vs. G-Benda			
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk			
	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	20	12,2	168	100,0	15	8,9	1,42	Convergence criterion (GCONV=1E-8) satisfied.	0,70	2,87	0,033	Algorithm converged.	-0,033	0,099	1,37	Algorithm converged.	0,72	2,57	0,3351		0,73	Algorithm converged.	0,39	1,38
Sex	Male	91	55,5	13	14,3	95	56,5	9	9,5	1,59	Convergence criterion (GCONV=1E-8) satisfied.	0,65	3,93	0,048	Algorithm converged.	-0,045	0,141	1,51	Algorithm converged.	0,68	3,36	0,3141	0,7019	0,66	Algorithm converged.	0,30	1,48
	Female	73	44,5	7	9,6	73	43,5	6	8,2	1,18	Convergence criterion (GCONV=1E-8) satisfied.	0,38	3,71	0,014	Algorithm converged.	-0,079	0,106	1,17	Algorithm converged.	0,41	3,30	0,7716		0,86	Algorithm converged.	0,30	2,43
Age	< 60 years	62	37,8	6	9,7	63	37,5	7	11,1	0,86	Convergence criterion (GCONV=1E-8) satisfied.	0,27	2,71	-0,014	Algorithm converged.	-0,121	0,093	0,87	Algorithm converged.	0,31	2,45	0,7931	0,2782	1,15	Algorithm converged.	0,41	3,22
	>= 60 years	102	62,2	14	13,7	105	62,5	8	7,6	1,93	Convergence criterion (GCONV=1E-8) satisfied.	0,77	4,82	0,061	Algorithm converged.	-0,023	0,145	1,80	Algorithm converged.	0,79	4,11	0,1619		0,56	Algorithm converged.	0,24	1,27
Geographic region	Western Europe	78	47,6	11	14,1	77	45,8	9	11,7	1,24	Convergence criterion (GCONV=1E-8) satisfied.	0,48	3,19	0,024	Algorithm converged.	-0,081	0,130	1,21	Algorithm converged.	0,53	2,75	0,6547	0,3946	0,83	Algorithm converged.	0,36	1,89
	North America	67	40,9	7	10,4	73	43,5	3	4,1	2,72	Convergence criterion (GCONV=1E-8) satisfied.	0,67	10,99	0,063	Algorithm converged.	-0,023	0,150	2,54	Algorithm converged.	0,69	9,43	0,1631		0,39	Algorithm converged.	0,11	1,46
	Other	19	11,6	2	10,5	18	10,7	3	16,7	0,59	Convergence criterion (GCONV=1E-8) satisfied.	0,09	4,01	-0,061	Algorithm converged.	-0,282	0,159	0,63	Algorithm converged.	0,12	3,35	0,5894		1,58	Algorithm converged.	0,30	8,40
FLIPI	Low (0-1)	42	25,6	9	21,4	35	20,8	5	14,3	1,64	Convergence criterion (GCONV=1E-8) satisfied.	0,49	5,43	0,071	Algorithm converged.	-0,098	0,241	1,50	Algorithm converged.	0,55	4,06	0,4254	0,9449	0,67	Algorithm converged.	0,25	1,81
	Intermediate (2)	51	31,1	3	5,9	58	34,5	3	5,2	1,15	Convergence criterion (GCONV=1E-8) satisfied.	0,22	5,95	0,007	Algorithm converged.	-0,079	0,093	1,14	Algorithm converged.	0,24	5,39	0,8713		0,88	Algorithm converged.	0,19	4,17
	High (>=3)	64	39,0	7	10,9	68	40,5	6	8,8	1,27	Convergence criterion (GCONV=1E-8) satisfied.	0,40	4,00	0,021	Algorithm converged.	-0,081	0,123	1,24	Algorithm converged.	0,44	3,49	0,6844		0,81	Algorithm converged.	0,29	2,27
	Missing/Unknown	7	4,3	1	14,3	7	4,2	1	14,3	1,00	Convergence criterion (GCONV=1E-8) satisfied.	0,05	19,96	0,000	Algorithm converged.	-0,367	0,367	1,00	Algorithm converged.	0,08	13,02	1,0000		1,00	Algorithm converged.	0,08	13,02

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEG1_FOLY_SE_30NOV2018_01297.xls 07OCT2019 10:58

25 (Anhang): Ergebnisse für Patienten mit UE Grad 2 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) – Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade 2, Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda															Benda vs. G-Benda				
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio					Absolute Risk Difference				Relative Risk						Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	57	34,8	168	100,0	63	37,5	0,89	Convergence criterion (GCONV=1E-8) satisfied.	0,57	1,39	-0,027	Algorithm converged.	-0,131	0,076	0,93	Algorithm converged.	0,70	1,23	0,6032		1,08	Algorithm converged.	0,81	1,44
Sex	Male	91	55,5	35	38,5	95	56,5	40	42,1	0,86	Convergence criterion (GCONV=1E-8) satisfied.	0,48	1,55	-0,036	Algorithm converged.	-0,177	0,104	0,91	Algorithm converged.	0,64	1,30	0,6132	0,8803	1,09	Algorithm converged.	0,77	1,55
	Female	73	44,5	22	30,1	73	43,5	23	31,5	0,94	Convergence criterion (GCONV=1E-8) satisfied.	0,46	1,89	-0,014	Algorithm converged.	-0,163	0,136	0,96	Algorithm converged.	0,59	1,56	0,8578		1,05	Algorithm converged.	0,64	1,70
Age	< 60 years	62	37,8	27	43,5	63	37,5	30	47,6	0,85	Convergence criterion (GCONV=1E-8) satisfied.	0,42	1,72	-0,041	Algorithm converged.	-0,215	0,134	0,91	Algorithm converged.	0,62	1,34	0,6482	0,9361	1,09	Algorithm converged.	0,74	1,61
	>= 60 years	102	62,2	30	29,4	105	62,5	33	31,4	0,91	Convergence criterion (GCONV=1E-8) satisfied.	0,50	1,64	-0,020	Algorithm converged.	-0,145	0,105	0,94	Algorithm converged.	0,62	1,41	0,7527		1,07	Algorithm converged.	0,71	1,61
Geographic region	Western Europe	78	47,6	22	28,2	77	45,8	31	40,3	0,58	Convergence criterion (GCONV=1E-8) satisfied.	0,30	1,14	-0,121	Algorithm converged.	-0,269	0,028	0,70	Algorithm converged.	0,45	1,09	0,1183	0,1890	1,43	Algorithm converged.	0,91	2,23
	North America	67	40,9	32	47,8	73	43,5	29	39,7	1,39	Convergence criterion (GCONV=1E-8) satisfied.	0,71	2,71	0,080	Algorithm converged.	-0,084	0,244	1,20	Algorithm converged.	0,82	1,75	0,3390		0,83	Algorithm converged.	0,57	1,21
	Other	19	11,6	3	15,8	18	10,7	3	16,7	0,94	Convergence criterion (GCONV=1E-8) satisfied.	0,16	5,39	-0,009	Algorithm converged.	-0,247	0,229	0,95	Algorithm converged.	0,22	4,10	0,9423		1,06	Algorithm converged.	0,24	4,57
FLIPI	Low (0-1)	42	25,6	17	40,5	35	20,8	15	42,9	0,91	Convergence criterion (GCONV=1E-8) satisfied.	0,37	2,25	-0,024	Algorithm converged.	-0,245	0,197	0,94	Algorithm converged.	0,56	1,60	0,8326	0,8419	1,06	Algorithm converged.	0,62	1,80
	Intermediate (2)	51	31,1	19	37,3	58	34,5	22	37,9	0,97	Convergence criterion (GCONV=1E-8) satisfied.	0,45	2,11	-0,007	Algorithm converged.	-0,189	0,175	0,98	Algorithm converged.	0,60	1,60	0,9421		1,02	Algorithm converged.	0,63	1,65
	High (>=3)	64	39,0	19	29,7	68	40,5	25	36,8	0,73	Convergence criterion (GCONV=1E-8) satisfied.	0,35	1,50	-0,071	Algorithm converged.	-0,231	0,089	0,81	Algorithm converged.	0,50	1,32	0,3917		1,24	Algorithm converged.	0,76	2,02
	Missing/Unknown	7	4,3	2	28,6	7	4,2	1	14,3	2,40	Convergence criterion (GCONV=1E-8) satisfied.	0,16	34,93	0,143	Algorithm converged.	-0,280	0,566	2,00	Algorithm converged.	0,23	17,34	0,5293		0,50	Algorithm converged.	0,06	4,33

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEG2_FOLY_SE_30NOV2018_01297.xls 07OCT2019
11:03

26 (Anhang): Ergebnisse für Patienten mit UE Grad 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade 3, Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda														Benda vs. G-Benda				
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio					Absolute Risk Difference				Relative Risk						Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	43	26,2	168	100,0	52	31,0	0,79	Convergence criterion (GCONV=1E-8) satisfied.	0,49	1,28	-0,047	Algorithm converged.	-0,144	0,050	0,85	Algorithm converged.	0,60	1,19	0,3415		1,18	Algorithm converged.	0,84	1,66
Sex	Male	91	55,5	22	24,2	95	56,5	28	29,5	0,76	Convergence criterion (GCONV=1E-8) satisfied.	0,40	1,46	-0,053	Algorithm converged.	-0,180	0,074	0,82	Algorithm converged.	0,51	1,32	0,4172	0,8529	1,22	Algorithm converged.	0,76	1,97
	Female	73	44,5	21	28,8	73	43,5	24	32,9	0,82	Convergence criterion (GCONV=1E-8) satisfied.	0,41	1,67	-0,041	Algorithm converged.	-0,191	0,109	0,88	Algorithm converged.	0,54	1,42	0,5914		1,14	Algorithm converged.	0,70	1,86
Age	< 60 years	62	37,8	15	24,2	63	37,5	16	25,4	0,94	Convergence criterion (GCONV=1E-8) satisfied.	0,42	2,11	-0,012	Algorithm converged.	-0,163	0,139	0,95	Algorithm converged.	0,52	1,75	0,8763	0,6441	1,05	Algorithm converged.	0,57	1,93
	>= 60 years	102	62,2	28	27,5	105	62,5	36	34,3	0,73	Convergence criterion (GCONV=1E-8) satisfied.	0,40	1,31	-0,068	Algorithm converged.	-0,194	0,057	0,80	Algorithm converged.	0,53	1,21	0,2901		1,25	Algorithm converged.	0,83	1,89
Geographic region	Western Europe	78	47,6	18	23,1	77	45,8	23	29,9	0,70	Convergence criterion (GCONV=1E-8) satisfied.	0,34	1,44	-0,068	Algorithm converged.	-0,206	0,071	0,77	Algorithm converged.	0,45	1,31	0,3403	0,3323	1,29	Algorithm converged.	0,76	2,20
	North America	67	40,9	20	29,9	73	43,5	20	27,4	1,13	Convergence criterion (GCONV=1E-8) satisfied.	0,54	2,35	0,025	Algorithm converged.	-0,125	0,174	1,09	Algorithm converged.	0,65	1,84	0,7482		0,92	Algorithm converged.	0,54	1,55
	Other	19	11,6	5	26,3	18	10,7	9	50,0	0,36	Convergence criterion (GCONV=1E-8) satisfied.	0,09	1,42	-0,237	Algorithm converged.	-0,541	0,067	0,53	Algorithm converged.	0,22	1,27	0,1542		1,90	Algorithm converged.	0,79	4,59
FLIPI	Low (0-1)	42	25,6	10	23,8	35	20,8	9	25,7	0,90	Convergence criterion (GCONV=1E-8) satisfied.	0,32	2,55	-0,019	Algorithm converged.	-0,213	0,175	0,93	Algorithm converged.	0,42	2,02	0,8468	0,9355	1,08	Algorithm converged.	0,49	2,36
	Intermediate (2)	51	31,1	12	23,5	58	34,5	17	29,3	0,74	Convergence criterion (GCONV=1E-8) satisfied.	0,31	1,75	-0,058	Algorithm converged.	-0,223	0,107	0,80	Algorithm converged.	0,42	1,52	0,4984		1,25	Algorithm converged.	0,66	2,35
	High (>=3)	64	39,0	20	31,3	68	40,5	23	33,8	0,89	Convergence criterion (GCONV=1E-8) satisfied.	0,43	1,84	-0,026	Algorithm converged.	-0,186	0,134	0,92	Algorithm converged.	0,56	1,51	0,7528		1,08	Algorithm converged.	0,66	1,77
	Missing/Unknown	7	4,3	1	14,3	7	4,2	3	42,9	0,22	Convergence criterion (GCONV=1E-8) satisfied.	0,02	2,97	-0,286	Algorithm converged.	-0,735	0,163	0,33	Algorithm converged.	0,04	2,48	0,2831		3,00	Algorithm converged.	0,40	22,30

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEG3_FOLY_SE_30NOV2018_01297.xls 07OCT2019
11:05

27 (Anhang): Ergebnisse für Patienten mit UE Grad 4 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade 4, Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda															Benda vs. G-Benda				
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio					Absolute Risk Difference				Relative Risk						Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL		Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	40	24,4	168	100,0	32	19,0	1,37	Convergence criterion (GCONV=1E-8) satisfied.	0,81	2,32		0,053	Algorithm converged.	-0,035	0,142	1,28	Algorithm converged.	0,85	1,93	0,2396		0,78	Algorithm converged.	0,52	1,18
Sex	Male	91	55,5	18	19,8	95	56,5	15	15,8	1,32	Convergence criterion (GCONV=1E-8) satisfied.	0,62	2,80		0,040	Algorithm converged.	-0,070	0,150	1,25	Algorithm converged.	0,67	2,33	0,4777	0,9385	0,80	Algorithm converged.	0,43	1,49
	Female	73	44,5	22	30,1	73	43,5	17	23,3	1,42	Convergence criterion (GCONV=1E-8) satisfied.	0,68	2,97		0,068	Algorithm converged.	-0,075	0,212	1,29	Algorithm converged.	0,75	2,23	0,3524		0,77	Algorithm converged.	0,45	1,33
Age	< 60 years	62	37,8	13	21,0	63	37,5	9	14,3	1,59	Convergence criterion (GCONV=1E-8) satisfied.	0,63	4,05		0,067	Algorithm converged.	-0,066	0,200	1,47	Algorithm converged.	0,68	3,18	0,3313	0,6755	0,68	Algorithm converged.	0,31	1,48
	>= 60 years	102	62,2	27	26,5	105	62,5	23	21,9	1,28	Convergence criterion (GCONV=1E-8) satisfied.	0,68	2,43		0,046	Algorithm converged.	-0,071	0,162	1,21	Algorithm converged.	0,74	1,96	0,4440		0,83	Algorithm converged.	0,51	1,34
Geographic region	Western Europe	78	47,6	25	32,1	77	45,8	11	14,3	2,83	Convergence criterion (GCONV=1E-8) satisfied.	1,28	6,27		0,178	Algorithm converged.	0,048	0,307	2,24	Algorithm converged.	1,19	4,24	0,0127	0,0013	0,45	Algorithm converged.	0,24	0,84
	North America	67	40,9	7	10,4	73	43,5	18	24,7	0,36	Convergence criterion (GCONV=1E-8) satisfied.	0,14	0,92		-0,142	Algorithm converged.	-0,265	-0,019	0,42	Algorithm converged.	0,19	0,95	0,0372		2,36	Algorithm converged.	1,05	5,29
	Other	19	11,6	8	42,1	18	10,7	3	16,7	3,64	Convergence criterion (GCONV=1E-8) satisfied.	0,78	16,93		0,254	Algorithm converged.	-0,027	0,535	2,53	Algorithm converged.	0,79	8,06	0,1173		0,40	Algorithm converged.	0,12	1,26
FLIPI	Low (0-1)	42	25,6	6	14,3	35	20,8	5	14,3	1,00	Convergence criterion (GCONV=1E-8) satisfied.	0,28	3,60		0,000	Algorithm converged.	-0,157	0,157	1,00	Algorithm converged.	0,33	3,00	1,0000	0,8690	1,00	Algorithm converged.	0,33	3,00
	Intermediate (2)	51	31,1	15	29,4	58	34,5	13	22,4	1,44	Convergence criterion (GCONV=1E-8) satisfied.	0,61	3,42		0,070	Algorithm converged.	-0,095	0,235	1,31	Algorithm converged.	0,69	2,49	0,4056		0,76	Algorithm converged.	0,40	1,45
	High (>=3)	64	39,0	16	25,0	68	40,5	12	17,6	1,56	Convergence criterion (GCONV=1E-8) satisfied.	0,67	3,61		0,074	Algorithm converged.	-0,066	0,213	1,42	Algorithm converged.	0,73	2,76	0,3054		0,71	Algorithm converged.	0,36	1,37
	Missing/Unknown	7	4,3	3	42,9	7	4,2	2	28,6	1,87	Convergence criterion (GCONV=1E-8) satisfied.	0,20	17,27		0,143	Algorithm converged.	-0,354	0,639	1,50	Algorithm converged.	0,35	6,40	0,5837		0,67	Algorithm converged.	0,16	2,84

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEG4_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:10

28 (Anhang): Ergebnisse für Patienten mit UE Grad 5 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade 5 (AEs leading to death), Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda													Benda vs. G-Benda			
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio					Absolute Risk Difference				Relative Risk						Relative Risk			
	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL		Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	2	1,2	168	100,0	3	1,8	0,68	Convergence criterion (GCONV=1E-8) satisfied.	0,11	4,12		-0,006	Algorithm converged.	-0,032	0,020	0,68	Algorithm converged.	0,12	4,03	0,6739		1,46	Algorithm converged.	0,25	8,65
Sex	Male	91	55,5	1	1,1	95	56,5	1	1,1	1,04	Convergence criterion (GCONV=1E-8) satisfied.	0,06	16,95		0,000	Algorithm converged.	-0,029	0,030	1,04	Algorithm converged.	0,07	16,44	0,9756	0,6906	0,96	Algorithm converged.	0,06	15,09
	Female	73	44,5	1	1,4	73	43,5	2	2,7	0,49	Convergence criterion (GCONV=1E-8) satisfied.	0,04	5,56		-0,014	Algorithm converged.	-0,060	0,032	0,50	Algorithm converged.	0,05	5,39	0,5679		2,00	Algorithm converged.	0,19	21,58
Age	< 60 years	62	37,8	1	1,6	63	37,5				* Quasi-complete separation of data points detected.					* WARNING: The relative Hessian convergence criterion of 11.462723585 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	0,1350	NE	Algorithm converged.	NE	NE
	>= 60 years	102	62,2	1	1,0	105	62,5	3	2,9	0,34	Convergence criterion (GCONV=1E-8) satisfied.	0,03	3,29		-0,019	Algorithm converged.	-0,056	0,018	0,34	Algorithm converged.	0,04	3,24	0,3508		2,91	Algorithm converged.	0,31	27,56
Geographic region	Western Europe	78	47,6	1	1,3	77	45,8	1	1,3	0,99	Convergence criterion (GCONV=1E-8) satisfied.	0,06	16,07		0,000	Algorithm converged.	-0,036	0,035	0,99	Algorithm converged.	0,06	15,50	0,9927	0,9496	1,01	Algorithm converged.	0,06	15,91
	North America	67	40,9	1	1,5	73	43,5	2	2,7	0,54	Convergence criterion (GCONV=1E-8) satisfied.	0,05	6,07		-0,012	Algorithm converged.	-0,060	0,035	0,54	Algorithm converged.	0,05	5,87	0,6166		1,84	Algorithm converged.	0,17	19,78
	Other	19	11,6			18	10,7																					
FLIPI	Low (0-1)	42	25,6			35	20,8	1	2,9		* Quasi-complete separation of data points detected.					* WARNING: The relative Hessian convergence criterion of 8.9603595923 is greater than the limit of 0.0001. The convergence is questionable.			<0.01	Algorithm converged.	0,00	NE	0,9999	0,2103	>999.99	Algorithm converged.	0,00	NE
	Intermediate (2)	51	31,1	1	2,0	58	34,5	2	3,4	0,56	Convergence criterion (GCONV=1E-8) satisfied.	0,05	6,36		-0,015	Algorithm converged.	-0,075	0,046	0,57	Algorithm converged.	0,05	6,09	0,6407		1,76	Algorithm converged.	0,16	18,83
	High (>=3)	64	39,0	1	1,6	68	40,5				* Quasi-complete separation of data points detected.					* ERROR: Error in computing the link function, its derivatives, or the variance function.			NE	Algorithm converged.	NE	NE	NE		NE	Algorithm converged.	NE	NE
	Missing/Unknown	7	4,3			7	4,2																					

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEG5_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:13

Anhang 4-G3: Generelle Verträglichkeit (gesamte Studiendauer)

29 (Anhang): Ergebnisse für Patienten mit UE aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	163	99,4	1	0,6	166	100,0	164	98,8	2	1,2	0,6883	1,05	0,82	1,35		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	90	98,9	1	1,1	94	56,6	92	97,9	2	2,1	0,5094	1,12	0,80	1,56		Convergence criterion (GCONV=1E-8) satisfied.	0,6700
	Female	73	44,5	73	100,0			72	43,4	72	100,0			0,9865	1,00	0,68	1,46		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	62	100,0			62	37,3	61	98,4	1	1,6	0,6076	1,12	0,73	1,71		Convergence criterion (GCONV=1E-8) satisfied.	0,7164
	>= 60 years	102	62,2	101	99,0	1	1,0	104	62,7	103	99,0	1	1,0	0,8448	1,03	0,76	1,40		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	78	100,0			77	46,4	76	98,7	1	1,3	0,2963	1,21	0,84	1,75		Convergence criterion (GCONV=1E-8) satisfied.	0,5527
	North America	67	40,9	67	100,0			72	43,4	71	98,6	1	1,4	0,4676	1,16	0,78	1,73		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	18	94,7	1	5,3	17	10,2	17	100,0			0,3235	0,70	0,35	1,42		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	42	100,0			35	21,1	35	100,0			0,3634	1,29	0,75	2,21		Convergence criterion (GCONV=1E-8) satisfied.	0,4135
	Intermediate (2)	51	31,1	50	98,0	1	2,0	57	34,3	56	98,2	1	1,8	0,4015	1,20	0,78	1,86		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	64	100,0			67	40,4	66	98,5	1	1,5	0,4603	0,86	0,58	1,28		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	7	100,0			7	4,2	7	100,0			0,4600	0,62	0,18	2,21		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect

* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.xls 04OCT2019
18:52

30 (Anhang): Ergebnisse für Patienten mit SUE aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any SAEs, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	69	42,1	95	57,9	166	100,0	60	36,1	106	63,9	0,0071	0,59	0,41	0,87		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	41	45,1	50	54,9	94	56,6	32	34,0	62	66,0	0,0472	0,60	0,36	1,00		Convergence criterion (GCONV=1E-8) satisfied.	0,3105
	Female	73	44,5	28	38,4	45	61,6	72	43,4	28	38,9	44	61,1	0,0936	0,61	0,34	1,09		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	20	32,3	42	67,7	62	37,3	13	21,0	49	79,0	0,3534	0,69	0,31	1,52		Convergence criterion (GCONV=1E-8) satisfied.	0,6697
	>= 60 years	102	62,2	49	48,0	53	52,0	104	62,7	47	45,2	57	54,8	0,0165	0,59	0,38	0,91		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	40	51,3	38	48,7	77	46,4	28	36,4	49	63,6	0,3786	0,79	0,46	1,34		Convergence criterion (GCONV=1E-8) satisfied.	0,2636
	North America	67	40,9	24	35,8	43	64,2	72	43,4	24	33,3	48	66,7	0,0212	0,48	0,26	0,90		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	5	26,3	14	73,7	17	10,2	8	47,1	9	52,9	0,0349	0,29	0,09	0,96		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	15	35,7	27	64,3	35	21,1	12	34,3	23	65,7	0,0231	0,33	0,12	0,89		Convergence criterion (GCONV=1E-8) satisfied.	0,5366
	Intermediate (2)	51	31,1	20	39,2	31	60,8	57	34,3	15	26,3	42	73,7	0,7878	1,10	0,54	2,26		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	27	42,2	37	57,8	67	40,4	30	44,8	37	55,2	0,0034	0,44	0,25	0,77		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	7	100,0			7	4,2	3	42,9	4	57,1	0,0237	5,14	1,06	24,85		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_ASAE_FOLY_SE_30NOV2018_01297.xls 04OCT2019 19:24

31 (Anhang): Ergebnisse für Patienten mit Behandlungsabbruch wegen UE aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs leading to treatment discontinuation, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	31	18,9	133	81,1	166	100,0	30	18,1	136	81,9	0,1848	0,69	0,40	1,19		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	14	15,4	77	84,6	94	56,6	14	14,9	80	85,1	0,2565	0,63	0,28	1,41		Convergence criterion (GCONV=1E-8) satisfied.	0,8383
	Female	73	44,5	17	23,3	56	76,7	72	43,4	16	22,2	56	77,8	0,4446	0,75	0,36	1,56		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	8	12,9	54	87,1	62	37,3	9	14,5	53	85,5	0,5267	0,73	0,27	1,96		Convergence criterion (GCONV=1E-8) satisfied.	0,6454
	>= 60 years	102	62,2	23	22,5	79	77,5	104	62,7	21	20,2	83	79,8	0,2728	0,70	0,37	1,33		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	17	21,8	61	78,2	77	46,4	13	16,9	64	83,1	0,7011	0,86	0,39	1,88		Convergence criterion (GCONV=1E-8) satisfied.	0,6025
	North America	67	40,9	12	17,9	55	82,1	72	43,4	14	19,4	58	80,6	0,2044	0,59	0,26	1,35		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	2	10,5	17	89,5	17	10,2	3	17,6	14	82,4	0,5752	0,60	0,10	3,67		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	6	14,3	36	85,7	35	21,1	3	8,6	32	91,4	0,8177	1,19	0,27	5,33		Convergence criterion (GCONV=1E-8) satisfied.	0,5468
	Intermediate (2)	51	31,1	9	17,6	42	82,4	57	34,3	14	24,6	43	75,4	0,2705	0,62	0,26	1,46		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	15	23,4	49	76,6	67	40,4	13	19,4	54	80,6	0,2436	0,61	0,27	1,40		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	1	14,3	6	85,7	7	4,2			7	100,0	0,3173	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AELDIS_FOLY_SE_30NOV2018_01297.xls 04OCT2019

19:05

32 (Anhang): Ergebnisse für Patienten mit nicht schweren UE (Grad 1 - 2) aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade 1-2, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	161	98,2	3	1,8	166	100,0	162	97,6	4	2,4	0,9629	0,99	0,78	1,27		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	89	97,8	2	2,2	94	56,6	91	96,8	3	3,2	0,9893	1,00	0,72	1,40		Convergence criterion (GCONV=1E-8) satisfied.	0,9254
	Female	73	44,5	72	98,6	1	1,4	72	43,4	71	98,6	1	1,4	0,9427	0,99	0,68	1,43		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	62	100,0			62	37,3	61	98,4	1	1,6	0,6562	1,10	0,72	1,68		Convergence criterion (GCONV=1E-8) satisfied.	0,7085
	>= 60 years	102	62,2	99	97,1	3	2,9	104	62,7	101	97,1	3	2,9	0,8262	0,97	0,71	1,32		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	77	98,7	1	1,3	77	46,4	76	98,7	1	1,3	0,6578	1,08	0,76	1,55		Convergence criterion (GCONV=1E-8) satisfied.	0,7004
	North America	67	40,9	66	98,5	1	1,5	72	43,4	70	97,2	2	2,8	0,6926	1,08	0,73	1,62		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	18	94,7	1	5,3	17	10,2	16	94,1	1	5,9	0,4074	0,74	0,36	1,51		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	41	97,6	1	2,4	35	21,1	35	100,0			0,5254	1,19	0,69	2,05		Convergence criterion (GCONV=1E-8) satisfied.	0,3113
	Intermediate (2)	51	31,1	50	98,0	1	2,0	57	34,3	55	96,5	2	3,5	0,3545	1,23	0,80	1,89		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	63	98,4	1	1,6	67	40,4	65	97,0	2	3,0	0,3115	0,82	0,55	1,21		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	7	100,0			7	4,2	7	100,0			0,2628	0,48	0,13	1,76		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEG12_FOLY_SE_30NOV2018_01297.xls 04OCT2019
18:54

33 (Anhang): Ergebnisse für Patienten mit schweren UE (Grad ≥ 3) aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	117	71,3	47	28,7	166	100,0	107	64,5	59	35,5	0,0889	0,79	0,60	1,04		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	64	70,3	27	29,7	94	56,6	58	61,7	36	38,3	0,1354	0,75	0,52	1,09		Convergence criterion (GCONV=1E-8) satisfied.	0,8177
	Female	73	44,5	53	72,6	20	27,4	72	43,4	49	68,1	23	31,9	0,3609	0,82	0,54	1,25		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	41	66,1	21	33,9	62	37,3	29	46,8	33	53,2	0,9330	1,02	0,61	1,70		Convergence criterion (GCONV=1E-8) satisfied.	0,2276
	>= 60 years	102	62,2	76	74,5	26	25,5	104	62,7	78	75,0	26	25,0	0,0340	0,70	0,50	0,97		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	58	74,4	20	25,6	77	46,4	48	62,3	29	37,7	0,8612	0,96	0,65	1,44		Convergence criterion (GCONV=1E-8) satisfied.	0,2667
	North America	67	40,9	45	67,2	22	32,8	72	43,4	46	63,9	26	36,1	0,0120	0,57	0,37	0,89		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	14	73,7	5	26,3	17	10,2	13	76,5	4	23,5	0,9521	1,02	0,47	2,22		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	28	66,7	14	33,3	35	21,1	19	54,3	16	45,7	0,2821	0,71	0,38	1,33		Convergence criterion (GCONV=1E-8) satisfied.	0,9312
	Intermediate (2)	51	31,1	32	62,7	19	37,3	57	34,3	35	61,4	22	38,6	0,6637	0,90	0,54	1,48		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	50	78,1	14	21,9	67	40,4	47	70,1	20	29,9	0,2212	0,77	0,51	1,17		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	7	100,0			7	4,2	6	85,7	1	14,3	0,4094	1,62	0,51	5,18		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas

Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.xls 04OCT2019

19:01

34 (Anhang): Ergebnisse für Patienten mit UE Grad 1 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) – Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade 1, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	147	89,6	17	10,4	166	100,0	156	94,0	10	6,0	0,9646	0,99	0,78	1,27		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	84	92,3	7	7,7	94	56,6	89	94,7	5	5,3	0,9779	1,00	0,72	1,38		Convergence criterion (GCONV=1E-8) satisfied.	0,8042
	Female	73	44,5	63	86,3	10	13,7	72	43,4	67	93,1	5	6,9	0,9905	1,00	0,69	1,46		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	55	88,7	7	11,3	62	37,3	60	96,8	2	3,2	0,7024	0,92	0,61	1,40		Convergence criterion (GCONV=1E-8) satisfied.	0,5457
	>= 60 years	102	62,2	92	90,2	10	9,8	104	62,7	96	92,3	8	7,7	0,8224	1,04	0,76	1,41		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	70	89,7	8	10,3	77	46,4	74	96,1	3	3,9	0,9386	1,01	0,71	1,45		Convergence criterion (GCONV=1E-8) satisfied.	0,2757
	North America	67	40,9	65	97,0	2	3,0	72	43,4	68	94,4	4	5,6	0,2080	1,28	0,87	1,87		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	12	63,2	7	36,8	17	10,2	14	82,4	3	17,6	0,1579	0,56	0,25	1,26		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	39	92,9	3	7,1	35	21,1	34	97,1	1	2,9	0,0792	1,59	0,94	2,68		Convergence criterion (GCONV=1E-8) satisfied.	0,2500
	Intermediate (2)	51	31,1	43	84,3	8	15,7	57	34,3	53	93,0	4	7,0	0,6818	0,91	0,59	1,42		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	59	92,2	5	7,8	67	40,4	62	92,5	5	7,5	0,4496	0,86	0,59	1,27		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	6	85,7	1	14,3	7	4,2	7	100,0			0,5987	0,71	0,20	2,51		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas

Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEG1_FOLY_SE_30NOV2018_01297.xls 04OCT2019 18:53

35 (Anhang): Ergebnisse für Patienten mit UE Grad 2 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade 2, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	142	86,6	22	13,4	166	100,0	142	85,5	24	14,5	0,1479	0,83	0,65	1,07		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	80	87,9	11	12,1	94	56,6	78	83,0	16	17,0	0,3648	0,86	0,62	1,19		Convergence criterion (GCONV=1E-8) satisfied.	0,7005
	Female	73	44,5	62	84,9	11	15,1	72	43,4	64	88,9	8	11,1	0,2921	0,82	0,56	1,19		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	58	93,5	4	6,5	62	37,3	52	83,9	10	16,1	0,7925	1,05	0,71	1,57		Convergence criterion (GCONV=1E-8) satisfied.	0,0901
	>= 60 years	102	62,2	84	82,4	18	17,6	104	62,7	90	86,5	14	13,5	0,0367	0,71	0,52	0,98		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	65	83,3	13	16,7	77	46,4	62	80,5	15	19,5	0,6106	0,91	0,63	1,31		Convergence criterion (GCONV=1E-8) satisfied.	0,2929
	North America	67	40,9	60	89,6	7	10,4	72	43,4	66	91,7	6	8,3	0,0758	0,71	0,49	1,04		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	17	89,5	2	10,5	17	10,2	14	82,4	3	17,6	0,9389	1,03	0,50	2,11		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	36	85,7	6	14,3	35	21,1	29	82,9	6	17,1	0,0857	0,63	0,37	1,07		Convergence criterion (GCONV=1E-8) satisfied.	0,3892
	Intermediate (2)	51	31,1	45	88,2	6	11,8	57	34,3	51	89,5	6	10,5	0,9518	0,99	0,65	1,51		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	55	85,9	9	14,1	67	40,4	57	85,1	10	14,9	0,3027	0,81	0,54	1,21		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	6	85,7	1	14,3	7	4,2	5	71,4	2	28,6	0,8558	1,12	0,33	3,78		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas

Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEG2_FOLY_SE_30NOV2018_01297.xls 04OCT2019 18:56

36 (Anhang): Ergebnisse für Patienten mit UE Grad 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade 3, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	105	64,0	59	36,0	166	100,0	100	60,2	66	39,8	0,0193	0,71	0,53	0,95		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	54	59,3	37	40,7	94	56,6	55	58,5	39	41,5	0,0287	0,64	0,43	0,96		Convergence criterion (GCONV=1E-8) satisfied.	0,8062
	Female	73	44,5	51	69,9	22	30,1	72	43,4	45	62,5	27	37,5	0,2200	0,76	0,49	1,18		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	38	61,3	24	38,7	62	37,3	28	45,2	34	54,8	0,7884	0,93	0,55	1,57		Convergence criterion (GCONV=1E-8) satisfied.	0,2319
	>= 60 years	102	62,2	67	65,7	35	34,3	104	62,7	72	69,2	32	30,8	0,0092	0,63	0,44	0,89		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	53	67,9	25	32,1	77	46,4	46	59,7	31	40,3	0,3905	0,83	0,55	1,26		Convergence criterion (GCONV=1E-8) satisfied.	0,3992
	North America	67	40,9	39	58,2	28	41,8	72	43,4	42	58,3	30	41,7	0,0111	0,55	0,34	0,88		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	13	68,4	6	31,6	17	10,2	12	70,6	5	29,4	0,8152	0,91	0,41	2,02		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	23	54,8	19	45,2	35	21,1	17	48,6	18	51,4	0,1276	0,59	0,29	1,17		Convergence criterion (GCONV=1E-8) satisfied.	0,9782
	Intermediate (2)	51	31,1	30	58,8	21	41,2	57	34,3	33	57,9	24	42,1	0,4282	0,81	0,49	1,36		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	45	70,3	19	29,7	67	40,4	44	65,7	23	34,3	0,1170	0,70	0,45	1,09		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	7	100,0			7	4,2	6	85,7	1	14,3	0,4691	1,53	0,48	4,86		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEG3_FOLY_SE_30NOV2018_01297.xls 04OCT2019

37 (Anhang): Ergebnisse für Patienten mit UE Grad 4 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade 4, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	58	35,4	106	64,6	166	100,0	40	24,1	126	75,9	0,9489	1,01	0,66	1,56		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	27	29,7	64	70,3	94	56,6	20	21,3	74	78,7	0,4774	0,80	0,43	1,49		Convergence criterion (GCONV=1E-8) satisfied.	0,6729
	Female	73	44,5	31	42,5	42	57,5	72	43,4	20	27,8	52	72,2	0,4551	1,25	0,69	2,26		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	19	30,6	43	69,4	62	37,3	11	17,7	51	82,3	0,5987	1,24	0,56	2,74		Convergence criterion (GCONV=1E-8) satisfied.	0,5856
	>= 60 years	102	62,2	39	38,2	63	61,8	104	62,7	29	27,9	75	72,1	0,8114	0,94	0,56	1,57		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	34	43,6	44	56,4	77	46,4	17	22,1	60	77,9	0,1903	1,50	0,81	2,78		Convergence criterion (GCONV=1E-8) satisfied.	0,0070
	North America	67	40,9	15	22,4	52	77,6	72	43,4	20	27,8	52	72,2	0,0125	0,38	0,18	0,83		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	9	47,4	10	52,6	17	10,2	3	17,6	14	82,4	0,0897	2,99	0,80	11,27		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	11	26,2	31	73,8	35	21,1	7	20,0	28	80,0	0,6122	0,76	0,26	2,21		Convergence criterion (GCONV=1E-8) satisfied.	0,8801
	Intermediate (2)	51	31,1	21	41,2	30	58,8	57	34,3	16	28,1	41	71,9	0,6030	1,20	0,61	2,36		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	22	34,4	42	65,6	67	40,4	15	22,4	52	77,6	0,8262	0,92	0,45	1,88		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	4	57,1	3	42,9	7	4,2	2	28,6	5	71,4	0,3610	2,19	0,39	12,18		Convergence criterion (GCONV=1E-8) satisfied.	


Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEG4_FOLY_SE_30NOV2018_01297.xls 04OCT2019

19:03

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade 4, Complete Study Duration
STUDY: GO01297

Geographic region (N=330)



Patients at risk										
G-Benda, Western Europe	78	42	32	20	16	13	11	7	4	
G-Benda, North America	67	50	36	31	27	24	20	16	8	5
G-Benda, Other	19	7	4	3	3	3	2	1	1	1
Benda, Western Europe	77	6	3							
Benda, North America	72	5	2							
Benda, Other	17	2	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_ae_km_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_ae_km_sg_COMPL_AEG4_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 16:58

38 (Anhang): Ergebnisse für Patienten mit UE Grad 5 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer) - Subgruppenanalysen

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade 5 (AEs leading to death), Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)


		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	13	7,9	151	92,1	166	100,0	12	7,2	154	92,8	0,0004	0,20	0,08	0,50		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	8	8,8	83	91,2	94	56,6	7	7,4	87	92,6	0,0047	0,21	0,06	0,65		Convergence criterion (GCONV=1E-8) satisfied.	0,6960
	Female	73	44,5	5	6,8	68	93,2	72	43,4	5	6,9	67	93,1	0,0379	0,22	0,05	0,97		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	4	6,5	58	93,5	62	37,3			62	100,0	0,2807	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,0322
	>= 60 years	102	62,2	9	8,8	93	91,2	104	62,7	12	11,5	92	88,5	<.0001	0,14	0,05	0,38		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	7	9,0	71	91,0	77	46,4	6	7,8	71	92,2	0,0249	0,26	0,08	0,88		Convergence criterion (GCONV=1E-8) satisfied.	0,8961
	North America	67	40,9	5	7,5	62	92,5	72	43,4	5	6,9	67	93,1	0,0047	0,12	0,02	0,59		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	1	5,3	18	94,7	17	10,2	1	5,9	16	94,1	0,5924	0,44	0,02	9,27		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	3	7,1	39	92,9	35	21,1	3	8,6	32	91,4	<.0001	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,5712
	Intermediate (2)	51	31,1	3	5,9	48	94,1	57	34,3	4	7,0	53	93,0	0,0831	0,24	0,05	1,28		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	6	9,4	58	90,6	67	40,4	4	6,0	63	94,0	0,1707	0,36	0,08	1,61		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	1	14,3	6	85,7	7	4,2	1	14,3	6	85,7	0,6372	0,52	0,03	8,45		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEG5_FOLY_SE_30NOV2018_01297.xls 04OCT2019 19:04

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade 5 (AEs leading to death), Complete Study Duration
STUDY: GO01297

Age (N=330)



Patients at risk										
G-Benda, < 60 years	62	47	32	31	27	26	19	14	9	5
G-Benda, >= 60 years	102	78	64	51	44	37	30	21	10	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	104	17	8	1	1	1				

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_ae_km_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_ae_km_sg_COMPL_AEG5_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 16:59

Anhang 4-G4: Spezifische Verträglichkeit: Unerwünschte Ereignisse von besonderem Interesse (AESI) – (Induktionsphase)

Für die AESI Hepatitis B (HBV) Reaktivierung, verlängerte Neutropenie und spät einsetzende Neutropenie liegen weder Informationen zum Zeitpunkt des Ereignisses vor, noch dazu, ob es sich jeweils um ein schweres oder schwerwiegendes Ereignis handelt. Für diese AESI werden daher keine Tabellen nach SUE und UE Grad ≥ 3 dargestellt.

39 (Anhang): Ergebnisse für Akute Thrombozytopenie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Acute Thrombocytopenia, Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	10,6		168	100,0				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Sex	Male	91	55,5	11,1		95	56,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 15.313153214 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	NE	NE		Algorithm converged.	NE	NE
	Female	73	44,5			73	43,5																							
Age	< 60 years	62	37,8			63	37,5																		NE					
	>= 60 years	102	62,2	11,0		105	62,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Geographic region	Western Europe	78	47,6	11,3		77	45,8				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE	NE	NE		Algorithm converged.	NE	NE
	North America	67	40,9			73	43,5																							
	Other	19	11,6			18	10,7																							
FLIPI	Low (0-1)	42	25,6			35	20,8																		NE					
	Intermediate (2)	51	31,1			58	34,5																							
	High (>=3)	64	39,0	11,6		68	40,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.239004744 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown	7	4,3			7	4,2																							

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPIATHROM_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:17

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Acute Thrombocytopenia Serious, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: G001297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0		10,6	168	100,0				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Sex	Male	91	55,5		11,1	95	56,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 15.313153214 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	NE	NE		Algorithm converged.	NE	NE
	Female	73	44,5			73	43,5																								
Age	< 60 years	62	37,8			63	37,5																			NE					
	>= 60 years	102	62,2		11,0	105	62,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Geographic region	Western Europe	78	47,6		11,3	77	45,8				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE	NE	NE		Algorithm converged.	NE	NE
	North America	67	40,9			73	43,5																								
	Other	19	11,6			18	10,7																								
FLIPI	Low (0-1)	42	25,6			35	20,8																			NE					
	Intermediate (2)	51	31,1			58	34,5																								
	High (>=3)	64	39,0		11,6	68	40,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.239004744 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown		74,3				74,2																								

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPIATHROMS_FOLY_SE_30NOV2018_01297.xls 07OCT2019 12:22

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Acute Thrombocytopenia Grade >= 3, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda					
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk					
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0		10,6	168	100,0				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Sex	Male	91	55,5		11,1	95	56,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 15.313153214 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	NE	NE		Algorithm converged.	NE	NE
	Female	73	44,5			73	43,5																								
Age	< 60 years	62	37,8			63	37,5																			NE					
	>= 60 years	102	62,2		11,0	105	62,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Geographic region	Western Europe	78	47,6		11,3	77	45,8				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE	NE	NE		Algorithm converged.	NE	NE
	North America	67	40,9			73	43,5																								
	Other	19	11,6			18	10,7																								
FLIPI	Low (0-1)	42	25,6			35	20,8																			NE					
	Intermediate (2)	51	31,1			58	34,5																								
	High (>=3)	64	39,0		11,6	68	40,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.239004744 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown		7 4,3				7 4,2																								

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPIATHROM3_FOLY_SE_30NOV2018_01297.xls 07OCT2019 12:02

40 (Anhang): Ergebnisse für Gastrointestinale Perforation nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: GI Perforation, Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0		0,6	168	100,0				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Sex	Male	91	55,5			95	56,5																			NE					
	Female	73	44,5		1,4	73	43,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.646715143 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Age	< 60 years	62	37,8			63	37,5																			NE					
	>= 60 years	102	62,2		1,0	105	62,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Geographic region	Western Europe	78	47,6		1,3	77	45,8				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 13.073073176 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	NE	NE		Algorithm converged.	NE	NE
	North America	67	40,9			73	43,5																								
	Other	19	11,6			18	10,7																								
FLIPI	Low (0-1)	42	25,6			35	20,8																			NE					
	Intermediate (2)	51	31,1			58	34,5																								
	High (>=3)	64	39,0		1,6	68	40,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown	7	4,3			7	4,2																								

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT739S/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT739S/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPIGIP_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:21

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: GI Perforation Serious, Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)		Benda (N=168)		G-Benda vs. Benda																		Benda vs. G-Benda				
		Patients		Patients		Odds Ratio						Absolute Risk Difference						Relative Risk						Relative Risk				
	Level	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL		Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL		Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	168	100,0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Sex	Male	91	55,5	95	56,5																		NE					
	Female	73	44,5	73	43,5		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.646715143 is greater than the limit of 0.0001. The convergence is questionable.				NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Age	< 60 years	62	37,8	63	37,5																		NE					
	>= 60 years	102	62,2	105	62,5		*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.				NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Geographic region	Western Europe	78	47,6	77	45,8		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 13.073973176 is greater than the limit of 0.0001. The convergence is questionable.				NE		Algorithm converged.	NE	NE	NE	NE	NE		Algorithm converged.	NE	NE
	North America	67	40,9	73	43,5																							
	Other	19	11,6	18	10,7																							
FLIPI	Low (0-1)	42	25,6	35	20,8																		NE					
	Intermediate (2)	51	31,1	58	34,5																							
	High (>=3)	64	39,0	68	40,5		*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.				NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown	7	4,3	7	4,2																							

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPIGIPS_FOLY_SE_30NOV2018_01297.xls 07OCT2019 12:25

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: GI Perforation Grade >= 3, Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0		100,6	168	100,0				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Sex	Male	91	55,5			95	56,5																			NE					
	Female	73	44,5		111,4	73	43,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.646715143 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Age	< 60 years	62	37,8			63	37,5																			NE					
	>= 60 years	102	62,2		111,0	105	62,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Geographic region	Western Europe	78	47,6		111,3	77	45,8				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 13.073973176 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	NE	NE		Algorithm converged.	NE	NE
	North America	67	40,9			73	43,5																								
	Other	19	11,6			18	10,7																								
FLIPI	Low (0-1)	42	25,6			35	20,8																			NE					
	Intermediate (2)	51	31,1			58	34,5																								
	High (>=3)	64	39,0		111,6	68	40,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown	7	4,3			7	4,2																								

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPIGIP3_FOLY_SE_30NOV2018_01297.xls 07OCT2019 12:05

41 (Anhang): Ergebnisse für Infektionen nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients,
Follicular Lymphoma Patients
ENDPOINT: Infections, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																Benda vs. G-Benda				
		Patients		with		Patients		with Event		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	72	43,9	168	100,0	83	49,4	0,80		Convergence criterion (GCONV=1E-8) satisfied.	0,52	1,23	-0,055		Algorithm converged.	-0,162	0,052	0,89		Algorithm converged.	0,71	1,12	0,3164		1,13		Algorithm converged.	0,89	1,42
Sex	Male	91	55,5	33	36,3	95	56,5	40	42,1	0,78		Convergence criterion (GCONV=1E-8) satisfied.	0,43	1,41	-0,058		Algorithm converged.	-0,198	0,082	0,86		Algorithm converged.	0,60	1,23	0,4165	0,8258	1,16		Algorithm converged.	0,81	1,66
	Female	73	44,5	39	53,4	73	43,5	43	58,9	0,80		Convergence criterion (GCONV=1E-8) satisfied.	0,42	1,54	-0,055		Algorithm converged.	-0,216	0,106	0,91		Algorithm converged.	0,68	1,21	0,5055		1,10		Algorithm converged.	0,83	1,47
Age	< 60 years	62	37,8	25	40,3	63	37,5	33	52,4	0,61		Convergence criterion (GCONV=1E-8) satisfied.	0,30	1,25	-0,121		Algorithm converged.	-0,294	0,053	0,77		Algorithm converged.	0,52	1,13	0,1813	0,3491	1,30		Algorithm converged.	0,89	1,91
	>= 60 years	102	62,2	47	46,1	105	62,5	50	47,6	0,94		Convergence criterion (GCONV=1E-8) satisfied.	0,54	1,62	-0,015		Algorithm converged.	-0,151	0,121	0,97		Algorithm converged.	0,72	1,29	0,8243		1,03		Algorithm converged.	0,77	1,38
Geographic region	Western Europe	78	47,6	34	43,6	77	45,8	37	48,1	0,84		Convergence criterion (GCONV=1E-8) satisfied.	0,44	1,57	-0,045		Algorithm converged.	-0,201	0,112	0,91		Algorithm converged.	0,64	1,28	0,5776	0,6807	1,10		Algorithm converged.	0,78	1,55
	North America	67	40,9	31	46,3	73	43,5	36	49,3	0,89		Convergence criterion (GCONV=1E-8) satisfied.	0,46	1,72	-0,030		Algorithm converged.	-0,196	0,135	0,94		Algorithm converged.	0,66	1,33	0,7190		1,07		Algorithm converged.	0,75	1,51
	Other	19	11,6	7	36,8	18	10,7	10	55,6	0,47		Convergence criterion (GCONV=1E-8) satisfied.	0,13	1,74	-0,187		Algorithm converged.	-0,503	0,129	0,66		Algorithm converged.	0,32	1,36	0,2630		1,51		Algorithm converged.	0,73	3,10
FLIPI	Low (0-1)	42	25,6	19	45,2	35	20,8	21	60,0	0,55		Convergence criterion (GCONV=1E-8) satisfied.	0,22	1,37	-0,148		Algorithm converged.	-0,369	0,074	0,75		Algorithm converged.	0,49	1,16	0,1968	0,5822	1,33		Algorithm converged.	0,86	2,04
	Intermediate (2)	51	31,1	23	45,1	58	34,5	31	53,4	0,72		Convergence criterion (GCONV=1E-8) satisfied.	0,34	1,52	-0,084		Algorithm converged.	-0,271	0,104	0,84		Algorithm converged.	0,57	1,24	0,3890		1,19		Algorithm converged.	0,81	1,74
	High (>=3)	64	39,0	27	42,2	68	40,5	28	41,2	1,04		Convergence criterion (GCONV=1E-8) satisfied.	0,52	2,08	0,010		Algorithm converged.	-0,158	0,178	1,02		Algorithm converged.	0,68	1,53	0,9062		0,98		Algorithm converged.	0,65	1,46
	Missing/Unknown	7	4,3	3	42,9	7	4,2	3	42,9	1,00		Convergence criterion (GCONV=1E-8) satisfied.	0,12	8,31	0,000		Algorithm converged.	-0,518	0,518	1,00		Algorithm converged.	0,30	3,35	1,0000		1,00		Algorithm converged.	0,30	3,35

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off:
30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPIINFEC_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:24

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients

ENDPOINT: Infections Serious, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
		Patients		with		Patients		with Event		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	10	6,1	168	100,0	23	13,7	0,41		Convergence criterion (GCONV=1E-8) satisfied.	0,19	0,89	-0,076		Algorithm converged.	-0,140	-0,012	0,45		Algorithm converged.	0,22	0,91	0,0257		2,25		Algorithm converged.	1,10	4,57
Sex	Male	91	55,5	9	9,9	95	56,5	11	11,6	0,84		Convergence criterion (GCONV=1E-8) satisfied.	0,33	2,13	-0,017		Algorithm converged.	-0,106	0,072	0,85		Algorithm converged.	0,37	1,96	0,7106	0,0099	1,17		Algorithm converged.	0,51	2,69
	Female	73	44,5	11	1,4	73	43,5	12	16,4	0,07		Convergence criterion (GCONV=1E-8) satisfied.	<0.01	0,56	-0,151		Algorithm converged.	-0,240	-0,062	0,08		Algorithm converged.	0,01	0,62	0,0156		12,00		Algorithm converged.	1,60	89,92
Age	< 60 years	62	37,8			63	37,5	3	4,8		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 5.0856439 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999	0,1243	>999.99		Algorithm converged.	0,00	NE
	>= 60 years	102	62,2	10	9,8	105	62,5	20	19,0	0,46		Convergence criterion (GCONV=1E-8) satisfied.	0,20	1,04	-0,092		Algorithm converged.	-0,187	0,002	0,51		Algorithm converged.	0,25	1,05	0,0662		1,94		Algorithm converged.	0,96	3,95
Geographic region	Western Europe	78	47,6	6	7,7	77	45,8	11	14,3	0,50		Convergence criterion (GCONV=1E-8) satisfied.	0,18	1,43	-0,066		Algorithm converged.	-0,164	0,032	0,54		Algorithm converged.	0,21	1,38	0,1985	0,7516	1,86		Algorithm converged.	0,72	4,77
	North America	67	40,9	3	4,5	73	43,5	8	11,0	0,38		Convergence criterion (GCONV=1E-8) satisfied.	0,10	1,50	-0,065		Algorithm converged.	-0,152	0,022	0,41		Algorithm converged.	0,11	1,48	0,1721		2,45		Algorithm converged.	0,68	8,85
	Other	19	11,6	1	5,3	18	10,7	4	22,2	0,19		Convergence criterion (GCONV=1E-8) satisfied.	0,02	1,94	-0,170		Algorithm converged.	-0,386	0,047	0,24		Algorithm converged.	0,03	1,92	0,1777		4,22		Algorithm converged.	0,52	34,28
FLIPI	Low (0-1)	42	25,6			35	20,8	2	5,7		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 5.4310946707 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999	0,2491	>999.99		Algorithm converged.	0,00	NE
	Intermediate (2)	51	31,1	5	9,8	58	34,5	8	13,8	0,68		Convergence criterion (GCONV=1E-8) satisfied.	0,21	2,23	-0,040		Algorithm converged.	-0,160	0,081	0,71		Algorithm converged.	0,25	2,04	0,5248		1,41		Algorithm converged.	0,49	4,03
	High (>=3)	64	39,0	4	6,3	68	40,5	13	19,1	0,28		Convergence criterion (GCONV=1E-8) satisfied.	0,09	0,92	-0,129		Algorithm converged.	-0,239	-0,018	0,33		Algorithm converged.	0,11	0,95	0,0401		3,06		Algorithm converged.	1,05	8,89
	Missing/Unknown	7	4,3	1	14,3	7	4,2				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients ENDPOINT:
Infections Grade >=3, Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																Benda vs. G-Benda					
		Patients		with		Patients		with Event		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk					
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	10	6,1	168	100,0	22	13,1	0,43		Convergence criterion (GCONV=1E-8) satisfied.	0,20	0,94	-0,070		Algorithm converged.	-0,133	-0,007	0,47		Algorithm converged.	0,23	0,95	0,0364		2,15		Algorithm converged.	1,05	4,39
Sex	Male	91	55,5	9	9,9	95	56,5	10	10,5	0,93		Convergence criterion (GCONV=1E-8) satisfied.	0,36	2,41	-0,006		Algorithm converged.	-0,093	0,081	0,94		Algorithm converged.	0,40	2,21	0,8862	0,0073	1,06		Algorithm converged.	0,45	2,50
	Female	73	44,5	1	1,4	73	43,5	12	16,4	0,07		Convergence criterion (GCONV=1E-8) satisfied.	<0.01	0,56	-0,151		Algorithm converged.	-0,240	-0,062	0,08		Algorithm converged.	0,01	0,62	0,0156		12,00		Algorithm converged.	1,60	89,92
Age	< 60 years	62	37,8			63	37,5	5	7,9		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 3.538902331 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999	0,0375	>999.99		Algorithm converged.	0,00	NE
	>= 60 years	102	62,2	10	9,8	105	62,5	17	16,2	0,56		Convergence criterion (GCONV=1E-8) satisfied.	0,24	1,30	-0,064		Algorithm converged.	-0,155	0,027	0,61		Algorithm converged.	0,29	1,26	0,1792		1,65		Algorithm converged.	0,79	3,43
Geographic region	Western Europe	78	47,6	6	7,7	77	45,8	9	11,7	0,63		Convergence criterion (GCONV=1E-8) satisfied.	0,21	1,86	-0,040		Algorithm converged.	-0,133	0,053	0,66		Algorithm converged.	0,25	1,76	0,4046	0,4894	1,52		Algorithm converged.	0,57	4,06
	North America	67	40,9	3	4,5	73	43,5	8	11,0	0,38		Convergence criterion (GCONV=1E-8) satisfied.	0,10	1,50	-0,065		Algorithm converged.	-0,152	0,022	0,41		Algorithm converged.	0,11	1,48	0,1721		2,45		Algorithm converged.	0,68	8,85
	Other	19	11,6	1	5,3	18	10,7	5	27,8	0,14		Convergence criterion (GCONV=1E-8) satisfied.	0,02	1,39	-0,225		Algorithm converged.	-0,455	0,005	0,19		Algorithm converged.	0,02	1,47	0,1114		5,28		Algorithm converged.	0,68	40,91
FLIPI	Low (0-1)	42	25,6			35	20,8	2	5,7		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 5.4310946707 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999	0,0891	>999.99		Algorithm converged.	0,00	NE
	Intermediate (2)	51	31,1	5	9,8	58	34,5	5	8,6	1,15		Convergence criterion (GCONV=1E-8) satisfied.	0,31	4,23	0,012		Algorithm converged.	-0,097	0,121	1,14		Algorithm converged.	0,35	3,71	0,8310		0,88		Algorithm converged.	0,27	2,86
	High (>=3)	64	39,0	4	6,3	68	40,5	15	22,1	0,24		Convergence criterion (GCONV=1E-8) satisfied.	0,07	0,75	-0,158		Algorithm converged.	-0,273	-0,043	0,28		Algorithm converged.	0,10	0,81	0,0184		3,53		Algorithm converged.	1,24	10,07
	Missing/Unknown	7	4,3	1	14,3	7	4,2				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE

42 (Anhang): Ergebnisse für Infusionsbedingte Reaktionen (IRR) nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients

ENDPOINT: Infusion Related AEs, Induction Phase Only MODEL:
Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference				Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	109	66,5	168	100,0	111	66,1	1,02		Convergence criterion (GCONV=1E-8) satisfied.	0,65	1,60	0,004		Algorithm converged.	-0,098	0,106	1,01		Algorithm converged.	0,86	1,17	0,9398		0,99		Algorithm converged.	0,85	1,16
Sex	Male	91	55,5	61	67,0	95	56,5	57	60,0	1,36		Convergence criterion (GCONV=1E-8) satisfied.	0,74	2,47	0,070		Algorithm converged.	-0,068	0,208	1,12		Algorithm converged.	0,90	1,39	0,3200	0,1416	0,90		Algorithm converged.	0,72	1,11
	Female	73	44,5	48	65,8	73	43,5	54	74,0	0,68		Convergence criterion (GCONV=1E-8) satisfied.	0,33	1,38	-0,082		Algorithm converged.	-0,230	0,066	0,89		Algorithm converged.	0,72	1,10	0,2814		1,13		Algorithm converged.	0,91	1,39
Age	< 60 years	62	37,8	46	74,2	63	37,5	48	76,2	0,90		Convergence criterion (GCONV=1E-8) satisfied.	0,40	2,02	-0,020		Algorithm converged.	-0,171	0,131	0,97		Algorithm converged.	0,80	1,19	0,7962	0,7140	1,03		Algorithm converged.	0,84	1,26
	>= 60 years	102	62,2	63	61,8	105	62,5	63	60,0	1,08		Convergence criterion (GCONV=1E-8) satisfied.	0,62	1,88	0,018		Algorithm converged.	-0,115	0,151	1,03		Algorithm converged.	0,83	1,28	0,7948		0,97		Algorithm converged.	0,78	1,21
Geographic region	Western Europe	78	47,6	49	62,8	77	45,8	49	63,6	0,97		Convergence criterion (GCONV=1E-8) satisfied.	0,50	1,86	-0,008		Algorithm converged.	-0,160	0,144	0,99		Algorithm converged.	0,78	1,26	0,9161	0,3311	1,01		Algorithm converged.	0,80	1,29
	North America	67	40,9	53	79,1	73	43,5	52	71,2	1,53		Convergence criterion (GCONV=1E-8) satisfied.	0,70	3,32	0,079		Algorithm converged.	-0,064	0,221	1,11		Algorithm converged.	0,92	1,34	0,2816		0,90		Algorithm converged.	0,74	1,09
	Other	19	11,6	7	36,8	18	10,7	10	55,6	0,47		Convergence criterion (GCONV=1E-8) satisfied.	0,13	1,74	-0,187		Algorithm converged.	-0,503	0,129	0,66		Algorithm converged.	0,32	1,36	0,2630		1,51		Algorithm converged.	0,73	3,10
FLIPI	Low (0-1)	42	25,6	33	78,6	35	20,8	24	68,6	1,68		Convergence criterion (GCONV=1E-8) satisfied.	0,60	4,69	0,100		Algorithm converged.	-0,098	0,298	1,15		Algorithm converged.	0,87	1,51	0,3307	0,1855	0,87		Algorithm converged.	0,66	1,15
	Intermediate (2)	51	31,1	38	74,5	58	34,5	39	67,2	1,42		Convergence criterion (GCONV=1E-8) satisfied.	0,62	3,28	0,073		Algorithm converged.	-0,097	0,243	1,11		Algorithm converged.	0,87	1,41	0,4037		0,90		Algorithm converged.	0,71	1,15
	High (>=3)	64	39,0	32	50,0	68	40,5	42	61,8	0,62		Convergence criterion (GCONV=1E-8) satisfied.	0,31	1,24	-0,118		Algorithm converged.	-0,286	0,051	0,81		Algorithm converged.	0,59	1,10	0,1790		1,24		Algorithm converged.	0,91	1,68
	Missing/Unknown	7	4,3	6	85,7	7	4,2	6	85,7	1,00		Convergence criterion (GCONV=1E-8) satisfied.	0,05	19,96	0,000		Algorithm converged.	-0,367	0,367	1,00		Algorithm converged.	0,65	1,53	1,0000		1,00		Algorithm converged.	0,65	1,53

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPIIRR_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:25

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Infusion Related AEs Serious, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference				Relative Risk								Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	8	4,9	168	100,0	2	1,2	4,26		Convergence criterion (GCONV=1E-8) satisfied.	0,89	20,35	0,037		Algorithm converged.	0,000	0,074	4,10		Algorithm converged.	0,88	19,01	0,0716		0,24		Algorithm converged.	0,05	1,13
Sex	Male	91	55,5	3	3,3	95	56,5	1	1,1	3,20		Convergence criterion (GCONV=1E-8) satisfied.	0,33	31,38	0,022		Algorithm converged.	-0,020	0,064	3,13		Algorithm converged.	0,33	29,56	0,3189	0,7670	0,32		Algorithm converged.	0,03	3,01
	Female	73	44,5	5	6,8	73	43,5	1	1,4	5,29		Convergence criterion (GCONV=1E-8) satisfied.	0,60	46,48	0,055		Algorithm converged.	-0,009	0,119	5,00		Algorithm converged.	0,60	41,76	0,1372		0,20		Algorithm converged.	0,02	1,67
Age	< 60 years	62	37,8	4	6,5	63	37,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 4.2239114954 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	0,1227	NE		Algorithm converged.	NE	NE
	>= 60 years	102	62,2	4	3,9	105	62,5	2	1,9	2,10		Convergence criterion (GCONV=1E-8) satisfied.	0,38	11,74	0,020		Algorithm converged.	-0,026	0,066	2,06		Algorithm converged.	0,39	11,00	0,3982		0,49		Algorithm converged.	0,09	2,59
Geographic region	Western Europe	78	47,6	4	5,1	77	45,8	2	2,6	2,03		Convergence criterion (GCONV=1E-8) satisfied.	0,36	11,41	0,025		Algorithm converged.	-0,035	0,086	1,97		Algorithm converged.	0,37	10,47	0,4241		0,51		Algorithm converged.	0,10	2,68
	North America	67	40,9	3	4,5	73	43,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Other	19	11,6	1	5,3	18	10,7				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 4.5566662063 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
FLIPI	Low (0-1)	42	25,6			35	20,8																								
	Intermediate (2)	51	31,1	2	3,9	68	34,5	2	3,4	1,14		Convergence criterion (GCONV=1E-8) satisfied.	0,16	8,42	0,005		Algorithm converged.	-0,066	0,076	1,14		Algorithm converged.	0,17	7,78	0,8957		0,88		Algorithm converged.	0,13	6,02
	High (>=3)	64	39,0	4	6,3	68	40,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 4.5157128231 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown	7	4,3	2	28,6	7	4,2				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPIIRRS_FOLY_SE_30NOV2018_01297.xls 07OCT2019 12:28

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Infusion Related AEs Grade >= 3, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk						Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	18	11,0	168	100,0	10	6,0	1,95		Convergence criterion (GCONV=1E-8) satisfied.	0,87	4,36	0,050		Algorithm converged.	-0,010	0,110	1,84		Algorithm converged.	0,88	3,87	0,1063		0,54		Algorithm converged.	0,26	1,14
Sex	Male	91	55,5	10	11,0	95	56,5	4	4,2	2,81		Convergence criterion (GCONV=1E-8) satisfied.	0,85	9,30	0,068		Algorithm converged.	-0,008	0,144	2,61		Algorithm converged.	0,85	8,03	0,0942	0,3786	0,38		Algorithm converged.	0,12	1,18
	Female	73	44,5	8	11,0	73	43,5	6	8,2	1,37		Convergence criterion (GCONV=1E-8) satisfied.	0,45	4,18	0,027		Algorithm converged.	-0,068	0,123	1,33		Algorithm converged.	0,49	3,65	0,5757		0,75		Algorithm converged.	0,27	2,05
Age	< 60 years	62	37,8	9	14,5	63	37,5	4	6,3	2,50		Convergence criterion (GCONV=1E-8) satisfied.	0,73	8,61	0,082		Algorithm converged.	-0,025	0,188	2,29		Algorithm converged.	0,74	7,04	0,1495	0,6067	0,44		Algorithm converged.	0,14	1,35
	>= 60 years	102	62,2	9	8,8	105	62,5	6	5,7	1,60		Convergence criterion (GCONV=1E-8) satisfied.	0,55	4,66	0,031		Algorithm converged.	-0,040	0,102	1,54		Algorithm converged.	0,57	4,18	0,3928		0,65		Algorithm converged.	0,24	1,75
Geographic region	Western Europe	78	47,6	11	14,1	77	45,8	7	9,1	1,64		Convergence criterion (GCONV=1E-8) satisfied.	0,60	4,49	0,050		Algorithm converged.	-0,050	0,151	1,55		Algorithm converged.	0,63	3,79	0,3356	0,3965	0,64		Algorithm converged.	0,26	1,58
	North America	67	40,9	5	7,5	73	43,5	3	4,1	1,88		Convergence criterion (GCONV=1E-8) satisfied.	0,43	8,20	0,034		Algorithm converged.	-0,044	0,111	1,82		Algorithm converged.	0,45	7,31	0,4010		0,55		Algorithm converged.	0,14	2,22
	Other	19	11,6	2	10,5	18	10,7				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.		NE	NE	NE		NE		Algorithm converged.		NE	NE
FLIPI	Low (0-1)	42	25,6	2	4,8	35	20,8	1	2,9	1,70		Convergence criterion (GCONV=1E-8) satisfied.	0,15	19,57	0,019		Algorithm converged.	-0,066	0,104	1,67		Algorithm converged.	0,16	17,62	0,6712	0,9999	0,60		Algorithm converged.	0,06	6,34
	Intermediate (2)	61	31,1	6	11,8	58	34,5	4	6,9	1,80		Convergence criterion (GCONV=1E-8) satisfied.	0,48	6,78	0,049		Algorithm converged.	-0,061	0,159	1,71		Algorithm converged.	0,51	5,71	0,3862		0,59		Algorithm converged.	0,18	1,96
	High (>=3)	64	39,0	8	12,5	68	40,5	5	7,4	1,80		Convergence criterion (GCONV=1E-8) satisfied.	0,56	5,82	0,051		Algorithm converged.	-0,051	0,154	1,70		Algorithm converged.	0,59	4,93	0,3283		0,59		Algorithm converged.	0,20	1,70
	Missing/Unknown	7	4,3	2	28,6	7	4,2				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.		NE	NE	NE		NE		Algorithm converged.		NE	NE

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPIIRR3_FOLY_SE_30NOV2018_01297.xls 07OCT2019 12:11

43 (Anhang): Ergebnisse für Neoplasie nach UE, SUE, Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Neoplasm, Induction Phase Only
MODEL: Unstratified Analysis STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																Benda vs. G-Benda					
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk					
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	42	4	168	100,0	21	2	2,07		Convergence criterion (GCONV=1E-8) satisfied.	0,37	11,49	0,012		Algorithm converged.	-0,016	0,041	2,05		Algorithm converged.	0,38	11,03	0,4038		0,49		Algorithm converged.	0,09	2,63
Sex	Male	91	55,5	11	1	95	56,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 15.313153214 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	0,3316	NE		Algorithm converged.	NE	NE
	Female	73	44,5	34	1	73	43,5	22	7	1,52		Convergence criterion (GCONV=1E-8) satisfied.	0,25	9,38	0,014		Algorithm converged.	-0,045	0,073	1,50		Algorithm converged.	0,26	0,71	0,6515		0,67		Algorithm converged.	0,11	3,87
Age	< 60 years	62	37,8			63	37,5																								
	>= 60 years	102	62,2	43	9	105	62,5	21	9	2,10		Convergence criterion (GCONV=1E-8) satisfied.	0,38	11,74	0,020		Algorithm converged.	-0,026	0,066	2,06		Algorithm converged.	0,39	11,00	0,3982		0,49		Algorithm converged.	0,09	2,59
Geographic region	Western Europe	78	47,6	22	6	77	45,8	22	6	0,99		Convergence criterion (GCONV=1E-8) satisfied.	0,14	7,19	0,000		Algorithm converged.	-0,050	0,050	0,99		Algorithm converged.	0,14	6,83	0,9896		1,01		Algorithm converged.	0,15	7,01
	North America	67	40,9	23	0	73	43,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 7.89289285 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Other	19	11,6			18	10,7																								
FLIPI	Low (0-1)	42	25,6	12	4	35	20,8				*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Intermediate (2)	51	31,1			58	34,5	23	4		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 5.754388366 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999		>999.99		Algorithm converged.	0,00	NE
	High (>=3)	64	39,0	34	7	68	40,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 5.5491495291 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown	7	4,3			7	4,2																								

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPINEO_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:30

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Neoplasm Serious, Induction Phase Only
MODEL: Unstratified Analysis STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
		Patients		with		Patients		with Event		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	2	1,2	168	100,0	2	1,2	1,02		Convergence criterion (GCONV=1E-8) satisfied.	0,14	7,36	0,000		Algorithm converged.	-0,023	0,024	1,02		Algorithm converged.	0,15	7,19	0,9807		0,98		Algorithm converged.	0,14	6,85
Sex	Male	91	55,5	1	1,1	95	56,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 15.313153214 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	0,1819	NE		Algorithm converged.	NE	NE
	Female	73	44,5	1	1,4	73	43,5	2	2,7	0,49		Convergence criterion (GCONV=1E-8) satisfied.	0,04	5,56	-0,014		Algorithm converged.	-0,060	0,032	0,50		Algorithm converged.	0,05	5,39	0,5679		2,00		Algorithm converged.	0,19	21,58
Age	< 60 years	62	37,8			63	37,5																		1,0000					
	>= 60 years	102	62,2	2	2,0	105	62,5	2	1,9	1,03		Convergence criterion (GCONV=1E-8) satisfied.	0,14	7,45	0,001		Algorithm converged.	-0,037	0,038	1,03		Algorithm converged.	0,15	7,17	0,9766		0,97		Algorithm converged.	0,14	6,77
Geographic region	Western Europe	78	47,6	1	1,3	77	45,8	2	2,6	0,49		Convergence criterion (GCONV=1E-8) satisfied.	0,04	5,48	-0,013		Algorithm converged.	-0,057	0,030	0,49		Algorithm converged.	0,05	5,33	0,5609		2,03		Algorithm converged.	0,19	21,88
	North America	67	40,9	1	1,5	73	43,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.947923778 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Other	19	11,6			18	10,7																							
FLIPI	Low (0-1)	42	25,6			35	20,8																							
	Intermediate (2)	51	31,1			58	34,5	2	3,4		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 5.754388366 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999		>999.99		Algorithm converged.	0,00	NE
	High (>=3)	64	39,0	2	3,1	68	40,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown	7	4,3			7	4,2																							

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Neoplasm Grade >=3, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
		Patients		with		Patients		with Event		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	2	1,2	168	100,0	1	0,6	2,06		Convergence criterion (GCONV=1E-8) satisfied.	0,19	22,96	0,006		Algorithm converged.	-0,014	0,027	2,05		Algorithm converged.	0,19	22,38	0,5565		0,49		Algorithm converged.	0,04	5,33
Sex	Male	91	55,5	1	1,1	95	56,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 15.313153214 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	0,2984	NE		Algorithm converged.	NE	NE
	Female	73	44,5	1	1,4	73	43,5	1	1,4	1,00		Convergence criterion (GCONV=1E-8) satisfied.	0,06	16,30	0,000		Algorithm converged.	-0,038	0,038	1,00		Algorithm converged.	0,06	15,69	1,0000		1,00		Algorithm converged.	0,06	15,69
Age	< 60 years	62	37,8			63	37,5																		1,0000					

	>= 60 years	102	62,2		22,0	105	62,5		11,0	2,08		Convergence criterion (GCONV=1E-8) satisfied.	0,19	23,30	0,010		Algorithm converged.	-0,023	0,043	2,06		Algorithm converged.	0,19	22,36	0,5529		0,49		Algorithm converged.	0,04	5,27
Geographic region	Western Europe	78	47,6		11,3	77	45,8		11,3	0,99		Convergence criterion (GCONV=1E-8) satisfied.	0,06	16,07	0,000		Algorithm converged.	-0,036	0,035	0,99		Algorithm converged.	0,06	15,50	0,9927		1,01		Algorithm converged.	0,06	15,91
	North America	67	40,9		11,5	73	43,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.947923778 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Other	19	11,6			18	10,7																									
FLIPI	Low (0-1)	42	25,6			35	20,8																									
	Intermediate (2)	51	31,1			58	34,5		11,7		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 9.5058621871 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999		>999.99		Algorithm converged.	0,00	NE
	High (>=3)	64	39,0		23,1	68	40,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown	7	4,3			7	4,2																									

44 (Anhang): Ergebnisse für Neutropenie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Neutropenia, Induction Phase Only
MODEL: Unstratified Analysis STUDY: GO01207
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																		Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference				Relative Risk								Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	50	30,5	168	100,0	47	28,0	1,13		Convergence criterion (GCONV=1E-8) satisfied.	0,70	1,81	0,025		Algorithm converged.	-0,073	0,123	1,09		Algorithm converged.	0,78	1,52	0,6150		0,92		Algorithm converged.	0,66	1,28
Sex	Male	91	55,5	26	28,6	95	56,5	23	24,2	1,25		Convergence criterion (GCONV=1E-8) satisfied.	0,65	2,41	0,044		Algorithm converged.	-0,083	0,170	1,18		Algorithm converged.	0,73	1,91	0,5005	0,6271	0,85		Algorithm converged.	0,52	1,37
	Female	73	44,5	24	32,9	73	43,5	24	32,9	1,00		Convergence criterion (GCONV=1E-8) satisfied.	0,50	1,99	0,000		Algorithm converged.	-0,152	0,152	1,00		Algorithm converged.	0,63	1,59	1,0000		1,00		Algorithm converged.	0,63	1,59
Age	< 60 years	62	37,8	17	27,4	63	37,5	14	22,2	1,32		Convergence criterion (GCONV=1E-8) satisfied.	0,59	2,99	0,052		Algorithm converged.	-0,099	0,203	1,23		Algorithm converged.	0,67	2,28	0,5026	0,6270	0,81		Algorithm converged.	0,44	1,50
	>= 60 years	102	62,2	33	32,4	105	62,5	33	31,4	1,04		Convergence criterion (GCONV=1E-8) satisfied.	0,58	1,87	0,009		Algorithm converged.	-0,118	0,136	1,03		Algorithm converged.	0,69	1,53	0,8865		0,97		Algorithm converged.	0,65	1,45
Geographic region	Western Europe	78	47,6	27	34,6	77	45,8	19	24,7	1,62		Convergence criterion (GCONV=1E-8) satisfied.	0,80	3,25	0,099		Algorithm converged.	-0,043	0,242	1,40		Algorithm converged.	0,85	2,30	0,1804	0,0801	0,71		Algorithm converged.	0,43	1,17
	North America	67	40,9	13	19,4	73	43,5	22	30,1	0,56		Convergence criterion (GCONV=1E-8) satisfied.	0,25	1,22	-0,107		Algorithm converged.	-0,249	0,034	0,64		Algorithm converged.	0,35	1,17	0,1504		1,55		Algorithm converged.	0,85	2,83
	Other	19	11,6	10	52,6	18	10,7	6	33,3	2,22		Convergence criterion (GCONV=1E-8) satisfied.	0,59	8,41	0,193		Algorithm converged.	-0,120	0,506	1,58		Algorithm converged.	0,72	3,45	0,2512		0,63		Algorithm converged.	0,29	1,38
FLIPI	Low (0-1)	42	25,6	8	19,0	35	20,8	11	31,4	0,51		Convergence criterion (GCONV=1E-8) satisfied.	0,18	1,47	-0,124		Algorithm converged.	-0,318	0,071	0,61		Algorithm converged.	0,27	1,34	0,2156	0,1787	1,65		Algorithm converged.	0,75	3,65
	Intermediate (2)	51	31,1	19	37,3	58	34,5	17	29,3	1,43		Convergence criterion (GCONV=1E-8) satisfied.	0,64	3,19	0,079		Algorithm converged.	-0,098	0,256	1,27		Algorithm converged.	0,74	2,17	0,3799		0,79		Algorithm converged.	0,46	1,34
	High (>=3)	64	39,0	22	34,4	68	40,5	16	23,5	1,70		Convergence criterion (GCONV=1E-8) satisfied.	0,79	3,65	0,108		Algorithm converged.	-0,046	0,262	1,46		Algorithm converged.	0,85	2,52	0,1736		0,68		Algorithm converged.	0,40	1,18
	Missing/Unknown	7	4,3	1	14,3	7	4,2	3	42,9	0,22		Convergence criterion (GCONV=1E-8) satisfied.	0,02	2,97	-0,286		Algorithm converged.	-0,735	0,163	0,33		Algorithm converged.	0,04	2,48	0,2831		3,00		Algorithm converged.	0,40	22,30

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPINEU_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:33

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Neutropenia Serious, Induction Phase Only
MODEL: Unstratified Analysis STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	84	4,9	168	100,0	31	1,8	2,82		Convergence criterion (GCONV=1E-8) satisfied.	0,73	10,82	0,031		Algorithm converged.	-0,008	0,069	2,73		Algorithm converged.	0,74	10,12	0,1325		0,37		Algorithm converged.	0,10	1,36
Sex	Male	91	55,5	55	5,5	95	56,5	11	1,1	5,47		Convergence criterion (GCONV=1E-8) satisfied.	0,63	47,71	0,044		Algorithm converged.	-0,007	0,096	5,22		Algorithm converged.	0,62	43,82	0,1280	0,3618	0,19		Algorithm converged.	0,02	1,61
	Female	73	44,5	34	4,1	73	43,5	22	2,7	1,52		Convergence criterion (GCONV=1E-8) satisfied.	0,25	9,38	0,014		Algorithm converged.	-0,045	0,073	1,50		Algorithm converged.	0,26	8,71	0,6515		0,67		Algorithm converged.	0,11	3,87
Age	< 60 years	62	37,8	23	3,2	63	37,5	11	1,6	2,07		Convergence criterion (GCONV=1E-8) satisfied.	0,18	23,39	0,016		Algorithm converged.	-0,037	0,070	2,03		Algorithm converged.	0,19	21,84	0,5584	0,7757	0,49		Algorithm converged.	0,05	5,29
	>= 60 years	102	62,2	65	5,9	105	62,5	21	1,9	3,22		Convergence criterion (GCONV=1E-8) satisfied.	0,63	16,33	0,040		Algorithm converged.	-0,013	0,092	3,09		Algorithm converged.	0,64	14,95	0,1611		0,32		Algorithm converged.	0,07	1,57
Geographic region	Western Europe	78	47,6	67	7,7	77	45,8	11	1,3	6,33		Convergence criterion (GCONV=1E-8) satisfied.	0,74	53,90	0,064		Algorithm converged.	0,000	0,128	5,92		Algorithm converged.	0,73	48,05	0,0958	0,4793	0,17		Algorithm converged.	0,02	1,37
	North America	67	40,9	23	3,0	73	43,5	22	2,7	1,09		Convergence criterion (GCONV=1E-8) satisfied.	0,15	7,98	0,002		Algorithm converged.	-0,053	0,058	1,09		Algorithm converged.	0,16	7,52	0,9307		0,92		Algorithm converged.	0,13	6,33
	Other	19	11,6			18	10,7																								
FLIPI	Low (0-1)	42	25,6	24	4,8	35	20,8	30	3,6	0,53		Convergence criterion (GCONV=1E-8) satisfied.	0,08	3,39	-0,038		Algorithm converged.	-0,151	0,075	0,56		Algorithm converged.	0,10	3,14	0,5060	0,0255	1,80		Algorithm converged.	0,32	10,17
	Intermediate (2)	51	31,1	35	5,9	58	34,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.		NE	NE		NE		Algorithm converged.		NE	NE
	High (>=3)	64	39,0	34	4,7	68	40,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.		NE	NE		NE		Algorithm converged.		NE	NE
	Missing/Unknown	74,3				74,2																									

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients ENDPOINT:
Neutropenia Grad >=3, Induction Phase Only
MODEL: Unstratified Analysis STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	59	36,0	168	100,0	60	35,7	1,01		Convergence criterion (GCONV=1E-8) satisfied.	0,65	1,58	0,003		Algorithm converged.	-0,101	0,106	1,01		Algorithm converged.	0,76	1,34	0,9604		0,99		Algorithm converged.	0,74	1,32
Sex	Male	91	55,5	29	31,9	95	56,5	30	31,6	1,01		Convergence criterion (GCONV=1E-8) satisfied.	0,55	1,88	0,003		Algorithm converged.	-0,131	0,137	1,01		Algorithm converged.	0,66	1,54	0,9662	0,9751	0,99		Algorithm converged.	0,65	1,51
	Female	73	44,5	30	41,1	73	43,5	30	41,1	1,00		Convergence criterion (GCONV=1E-8) satisfied.	0,52	1,93	0,000		Algorithm converged.	-0,160	0,160	1,00		Algorithm converged.	0,68	1,47	1,0000		1,00		Algorithm converged.	0,68	1,47
Age	< 60 years	62	37,8	19	30,6	63	37,5	17	27,0	1,20		Convergence criterion (GCONV=1E-8) satisfied.	0,55	2,60	0,037		Algorithm converged.	-0,122	0,195	1,14		Algorithm converged.	0,65	1,97	0,6517	0,6040	0,88		Algorithm converged.	0,51	1,53
	>= 60 years	102	62,2	40	39,2	105	62,5	43	41,0	0,93		Convergence criterion (GCONV=1E-8) satisfied.	0,53	1,62	-0,017		Algorithm converged.	-0,151	0,116	0,96		Algorithm converged.	0,69	1,34	0,7989		1,04		Algorithm converged.	0,75	1,46
Geographic region	Western Europe	78	47,6	33	42,3	77	45,8	25	32,5	1,53		Convergence criterion (GCONV=1E-8) satisfied.	0,79	2,94	0,098		Algorithm converged.	-0,053	0,250	1,30		Algorithm converged.	0,86	1,97	0,2095	0,0042	0,77		Algorithm converged.	0,51	1,16
	North America	67	40,9	13	19,4	73	43,5	28	38,4	0,39		Convergence criterion (GCONV=1E-8) satisfied.	0,18	0,83	-0,190		Algorithm converged.	-0,336	-0,043	0,51		Algorithm converged.	0,29	0,89	0,0187		1,98		Algorithm converged.	1,12	3,49
	Other	19	11,6	13	68,4	18	10,7	7	38,9	3,40		Convergence criterion (GCONV=1E-8) satisfied.	0,88	13,19	0,295		Algorithm converged.	-0,012	0,603	1,76		Algorithm converged.	0,91	3,39	0,0908		0,57		Algorithm converged.	0,30	1,09
FLIPI	Low (0-1)	42	25,6	10	23,8	35	20,8	13	37,1	0,53		Convergence criterion (GCONV=1E-8) satisfied.	0,20	1,42	-0,133		Algorithm converged.	-0,339	0,072	0,64		Algorithm converged.	0,32	1,28	0,2076	0,1938	1,56		Algorithm converged.	0,78	3,12
	Intermediate (2)	51	31,1	22	43,1	58	34,5	23	39,7	1,15		Convergence criterion (GCONV=1E-8) satisfied.	0,54	2,48	0,035		Algorithm converged.	-0,150	0,220	1,09		Algorithm converged.	0,70	1,70	0,7123		0,92		Algorithm converged.	0,59	1,44
	High (>=3)	64	39,0	26	40,6	68	40,5	20	29,4	1,64		Convergence criterion (GCONV=1E-8) satisfied.	0,80	3,38	0,112		Algorithm converged.	-0,050	0,274	1,38		Algorithm converged.	0,86	2,22	0,1804		0,72		Algorithm converged.	0,45	1,16
	Missing/Unknown	7	4,3	1	14,3	7	4,2	4	57,1	0,13		Convergence criterion (GCONV=1E-8) satisfied.	<0.01	1,67	-0,429		Algorithm converged.	-0,878	0,020	0,25		Algorithm converged.	0,04	1,71	0,1580		4,00		Algorithm converged.	0,58	27,41

45 (Anhang): Ergebnisse für Progressive multifokale Leukenzephalopathie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients

ENDPOINT: Progressive multifocal leukoencephalopathy, Induction Phase Only MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPRMLE_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:40

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Progressive multifocal leukoencephalopathy Serious, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPRMLES_FOLY_SE_30NOV2018_01297.xls
07OCT2019 12:39

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Progressive multifocal leukoencephalopathy Grade >= 3, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPRMLE3_FOLY_SE_30NOV2018_01297.xls
07OCT2019 12:21

46 (Anhang): Ergebnisse für Thrombozytopenie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Thrombocytopenia, Induction Phase Only MODEL:
Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	24	14,6	168	100,0	41	24,4	0,53		Convergence criterion (GCONV=1E-8) satisfied.	0,30	0,93	-0,098		Algorithm converged.	-0,182	-0,013	0,60		Algorithm converged.	0,38	0,95	0,0278		1,67		Algorithm converged.	1,06	2,63
Sex	Male	91	55,5	12	13,2	95	56,5	24	25,3	0,45		Convergence criterion (GCONV=1E-8) satisfied.	0,21	0,96	-0,121		Algorithm converged.	-0,232	-0,009	0,52		Algorithm converged.	0,28	0,98	0,0433	0,5179	1,92		Algorithm converged.	1,02	3,60
	Female	73	44,5	12	16,4	73	43,5	17	23,3	0,65		Convergence criterion (GCONV=1E-8) satisfied.	0,28	1,48	-0,068		Algorithm converged.	-0,197	0,060	0,71		Algorithm converged.	0,36	1,37	0,3039		1,42		Algorithm converged.	0,73	2,75
Age	< 60 years	62	37,8	9	14,5	63	37,5	16	25,4	0,50		Convergence criterion (GCONV=1E-8) satisfied.	0,20	1,23	-0,109		Algorithm converged.	-0,248	0,030	0,57		Algorithm converged.	0,27	1,20	0,1372	0,8711	1,75		Algorithm converged.	0,84	3,66
	>= 60 years	102	62,2	15	14,7	105	62,5	25	23,8	0,55		Convergence criterion (GCONV=1E-8) satisfied.	0,27	1,12	-0,091		Algorithm converged.	-0,198	0,016	0,62		Algorithm converged.	0,35	1,10	0,1030		1,62		Algorithm converged.	0,91	2,89
Geographic region	Western Europe	78	47,6	13	16,7	77	45,8	17	22,1	0,71		Convergence criterion (GCONV=1E-8) satisfied.	0,32	1,58	-0,054		Algorithm converged.	-0,178	0,070	0,75		Algorithm converged.	0,39	1,45	0,3964	0,2239	1,32		Algorithm converged.	0,69	2,54
	North America	67	40,9	6	9,0	73	43,5	19	26,0	0,28		Convergence criterion (GCONV=1E-8) satisfied.	0,10	0,75	-0,171		Algorithm converged.	-0,292	-0,049	0,34		Algorithm converged.	0,15	0,81	0,0146		2,91		Algorithm converged.	1,23	6,84
	Other	19	11,6	5	26,3	18	10,7	5	27,8	0,93		Convergence criterion (GCONV=1E-8) satisfied.	0,22	3,96	-0,015		Algorithm converged.	-0,301	0,272	0,95		Algorithm converged.	0,33	2,73	0,9203		1,06		Algorithm converged.	0,37	3,04
FLIPI	Low (0-1)	42	25,6	7	16,7	35	20,8	6	17,1	0,97		Convergence criterion (GCONV=1E-8) satisfied.	0,29	3,20	-0,005		Algorithm converged.	-0,173	0,163	0,97		Algorithm converged.	0,36	2,63	0,9557	0,4432	1,03		Algorithm converged.	0,38	2,78
	Intermediate (2)	51	31,1	11	21,6	58	34,5	18	31,0	0,61		Convergence criterion (GCONV=1E-8) satisfied.	0,26	1,46	-0,095		Algorithm converged.	-0,259	0,069	0,69		Algorithm converged.	0,36	1,33	0,2718		1,44		Algorithm converged.	0,75	2,75
	High (>=3)	64	39,0	6	9,4	68	40,5	15	22,1	0,37		Convergence criterion (GCONV=1E-8) satisfied.	0,13	1,01	-0,127		Algorithm converged.	-0,249	-0,005	0,43		Algorithm converged.	0,18	1,03	0,0575		2,35		Algorithm converged.	0,97	5,69
	Missing/Unknown	7	4,3			7	4,2	2	28,6		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPITHROM_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:35

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Thrombocytopenia Serious, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	3	1,8	168	100,0				*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Sex	Male	91	55,5	3	3,3	95	56,5				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Female	73	44,5			73	43,5																							
Age	< 60 years	62	37,8	1	1,6	63	37,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 11.462723574 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	1,0000	NE		Algorithm converged.	NE	NE
	>= 60 years	102	62,2	2	2,0	105	62,5				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Geographic region	Western Europe	78	47,6	3	3,8	77	45,8				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 5.9559094219 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	North America	67	40,9			73	43,5																							
	Other	19	11,6			18	10,7																							
FLIPI	Low (0-1)	42	25,6			35	20,8																							
	Intermediate (2)	51	31,1			58	34,5																							
	High (>=3)	64	39,0	3	4,7	68	40,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 5.549149524 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown	7	4,3			7	4,2																							

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPITHROMS_FOLY_SE_30NOV2018_01297.xls 07OCT2019 12:35

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Thrombocytopenia Grade >= 3, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference				Relative Risk								Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	17	10,4	168	100,0	26	15,5	0,63		Convergence criterion (GCONV=1E-8) satisfied.	0,33	1,21	-0,051		Algorithm converged.	-0,123	0,021	0,67		Algorithm converged.	0,38	1,19	0,1698		1,49		Algorithm converged.	0,84	2,65
Sex	Male	91	55,5	9	9,9	95	56,5	15	15,8	0,59		Convergence criterion (GCONV=1E-8) satisfied.	0,24	1,41	-0,059		Algorithm converged.	-0,155	0,037	0,63		Algorithm converged.	0,29	1,36	0,2366	0,7992	1,60		Algorithm converged.	0,74	3,46
	Female	73	44,5	8	11,0	73	43,5	11	15,1	0,69		Convergence criterion (GCONV=1E-8) satisfied.	0,26	1,84	-0,041		Algorithm converged.	-0,150	0,068	0,73		Algorithm converged.	0,31	1,70	0,4633		1,37		Algorithm converged.	0,59	3,22
Age	< 60 years	62	37,8	8	12,9	63	37,5	11	17,5	0,70		Convergence criterion (GCONV=1E-8) satisfied.	0,26	1,88	-0,046		Algorithm converged.	-0,171	0,080	0,74		Algorithm converged.	0,32	1,71	0,4806	0,7592	1,35		Algorithm converged.	0,58	3,14
	>= 60 years	102	62,2	9	8,8	105	62,5	15	14,3	0,58		Convergence criterion (GCONV=1E-8) satisfied.	0,24	1,39	-0,055		Algorithm converged.	-0,141	0,032	0,62		Algorithm converged.	0,28	1,35	0,2261		1,62		Algorithm converged.	0,74	3,53
Geographic region	Western Europe	78	47,6	10	12,8	77	45,8	10	13,0	0,99		Convergence criterion (GCONV=1E-8) satisfied.	0,39	2,52	-0,002		Algorithm converged.	-0,107	0,104	0,99		Algorithm converged.	0,44	2,24	0,9753	0,0893	1,01		Algorithm converged.	0,45	2,30
	North America	67	40,9	3	4,5	73	43,5	13	17,8	0,22		Convergence criterion (GCONV=1E-8) satisfied.	0,06	0,80	-0,133		Algorithm converged.	-0,234	-0,033	0,25		Algorithm converged.	0,07	0,84	0,0254		3,98		Algorithm converged.	1,19	13,35
	Other	19	11,6	4	21,1	18	10,7	3	16,7	1,33		Convergence criterion (GCONV=1E-8) satisfied.	0,25	7,01	0,044		Algorithm converged.	-0,208	0,295	1,26		Algorithm converged.	0,33	4,88	0,7347		0,79		Algorithm converged.	0,21	3,06
FLIPI	Low (0-1)	42	25,6	4	9,5	35	20,8	3	8,6	1,12		Convergence criterion (GCONV=1E-8) satisfied.	0,23	5,39	0,010		Algorithm converged.	-0,119	0,138	1,11		Algorithm converged.	0,27	4,63	0,8850	0,8240	0,90		Algorithm converged.	0,22	3,75
	Intermediate (2)	51	31,1	7	13,7	58	34,5	12	20,7	0,61		Convergence criterion (GCONV=1E-8) satisfied.	0,22	1,69	-0,070		Algorithm converged.	-0,210	0,071	0,66		Algorithm converged.	0,28	1,56	0,3456		1,51		Algorithm converged.	0,64	3,54
	High (>=3)	64	39,0	6	9,4	68	40,5	9	13,2	0,68		Convergence criterion (GCONV=1E-8) satisfied.	0,23	2,03	-0,039		Algorithm converged.	-0,146	0,069	0,71		Algorithm converged.	0,27	1,88	0,4882		1,41		Algorithm converged.	0,53	3,74
	Missing/Unknown	7	4,3			7	4,2	2	28,6		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPITHROM3_FOLY_SE_30NOV2018_01297.xls 07OCT2019 12:16

47 (Anhang): Ergebnisse für Tumorlyse-Syndrom (TLS) nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients

ENDPOINT: Tumor Lysis Syndrome, Induction Phase Only
MODEL: Unstratified Analysis STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																Benda vs. G-Benda					
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk					
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	1	0,6	168	100,0	2	1,2	0,51		Convergence criterion (GCONV=1E-8) satisfied.	0,05	5,67	-0,006		Algorithm converged.	-0,026	0,014	0,51		Algorithm converged.	0,05	5,59	0,5834		1,95		Algorithm converged.	0,18	21,32
Sex	Male	91	55,5	1	1,1	95	56,5	1	1,1	1,04		Convergence criterion (GCONV=1E-8) satisfied.	0,06	16,95	0,000		Algorithm converged.	-0,029	0,030	1,04		Algorithm converged.	0,07	16,44	0,9756	0,2984	0,96		Algorithm converged.	0,06	15,09
	Female	73	44,5			73	43,5	1	1,4		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.646715143 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE
Age	< 60 years	62	37,8			63	37,5																			1,0000					
	>= 60 years	102	62,2	1	1,0	105	62,5	2	1,9	0,51		Convergence criterion (GCONV=1E-8) satisfied.	0,05	5,71	-0,009		Algorithm converged.	-0,042	0,023	0,51		Algorithm converged.	0,05	5,59	0,5852		1,94		Algorithm converged.	0,18	21,10
Geographic region	Western Europe	78	47,6	1	1,3	77	45,8	1	1,3	0,99		Convergence criterion (GCONV=1E-8) satisfied.	0,06	16,07	0,000		Algorithm converged.	-0,036	0,035	0,99		Algorithm converged.	0,06	15,50	0,9927		1,01		Algorithm converged.	0,06	15,91
	North America	67	40,9			73	43,5	1	1,4		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 11.644248058 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE
	Other	19	11,6			18	10,7																								
FLIPI	Low (0-1)	42	25,6			35	20,8																								
	Intermediate (2)	51	31,1			58	34,5	2	3,4		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 5.75433883713 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999		>999.99		Algorithm converged.	0,00	NE
	High (>=3)	64	39,0	1	1,6	68	40,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.239004744 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.		NE	NE	NE		NE		Algorithm converged.		NE	NE
	Missing/Unknown	7	4,3			7	4,2																								

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPITLS_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:38

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Tumor Lysis Syndrome Serious, Induction Phase Only
MODEL: Unstratified Analysis STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0			168	100,0	2	1,2		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 13.604227522 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999		>999.99		Algorithm converged.	0,00	NE
Sex	Male	91	55,5			95	56,5	1	1,1		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 14.515820525 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999	1,0000	>999.99		Algorithm converged.	0,00	NE
	Female	73	44,5			73	43,5	1	1,4		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.646715143 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE
Age	< 60 years	62	37,8			63	37,5																								
	>= 60 years	102	62,2			105	62,5	2	1,9		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 9.7534177268 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999		>999.99		Algorithm converged.	0,00	NE
Geographic region	Western Europe	78	47,6			77	45,8	1	1,3		*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE
	North America	67	40,9			73	43,5	1	1,4		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 11.644248058 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE
	Other	19	11,6			18	10,7																								
ELIPI	Low (0-1)	42	25,6			35	20,8																								
	Intermediate (2)	51	31,1			58	34,5	2	3,4		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 5.7543883713 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999		>999.99		Algorithm converged.	0,00	NE
	High (>=3)	64	39,0			68	40,5																								
	Missing/Unknown	7	4,3			7	4,2																								

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPITLSS_FOLY_SE_30NOV2018_01297.xls 07OCT2019 12:37

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Tumor Lysis Syndrome Grade >= 3, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)		Benda (N=168)		G-Benda vs. Benda																		Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk						Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	10	6,0	168	100,0	21	12,2	0,51		Convergence criterion (GCONV=1E-8) satisfied.	0,05	5,67	-0,006		Algorithm converged.	-0,026	0,014	0,51		Algorithm converged.	0,05	5,59	0,5834		1,95		Algorithm converged.	0,18	21,32
Sex	Male	91	55,5	11	11,1	95	56,5	11	11,1	1,04		Convergence criterion (GCONV=1E-8) satisfied.	0,06	16,95	0,000		Algorithm converged.	-0,029	0,030	1,04		Algorithm converged.	0,07	16,44	0,9756	0,2984	0,96		Algorithm converged.	0,06	15,09
	Female	73	44,5			73	43,5	11	11,4		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.646715143 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE
Age	< 60 years	62	37,8			63	37,5																		1,0000					
	>= 60 years	102	62,2	11	11,0	105	62,5	21	11,9	0,51		Convergence criterion (GCONV=1E-8) satisfied.	0,05	5,71	-0,009		Algorithm converged.	-0,042	0,023	0,51		Algorithm converged.	0,05	5,59	0,5852		1,94		Algorithm converged.	0,18	21,10
Geographic region	Western Europe	78	47,6	11	11,3	77	45,8	11	11,3	0,99		Convergence criterion (GCONV=1E-8) satisfied.	0,06	16,07	0,000		Algorithm converged.	-0,036	0,035	0,99		Algorithm converged.	0,06	15,50	0,9927		1,01		Algorithm converged.	0,06	15,91
	North America	67	40,9			73	43,5	11	11,4		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 11.644248058 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE
	Other	19	11,6			18	10,7																							
FLIPI	Low (0-1)	42	25,6			35	20,8																							
	Intermediate (2)	51	31,1			58	34,5	23	13,4		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 5.7543883713 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999		>999.99		Algorithm converged.	0,00	NE
	High (>=3)	64	39,0	11	11,6	68	40,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.239004744 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.		NE	NE	NE		NE		Algorithm converged.		NE
	Missing/Unknown	7	4,3			7	4,2																							

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPITLS3_FOLY_SE_30NOV2018_01297.xls 07OCT2019 12:18

48 (Anhang): Ergebnisse für Kardiale Ereignisse nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients

ENDPOINT: Cardiac Events, Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
		Patients		with		Patients		with Event		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	13	7,9	168	100,0	7	4,2	1,98		Convergence criterion (GCONV=1E-8) satisfied.	0,77	5,10	0,038		Algorithm converged.	-0,014	0,089	1,90		Algorithm converged.	0,78	4,65	0,1582		0,53		Algorithm converged.	0,22	1,28
Sex	Male	91	55,5	6	6,6	95	56,5	3	3,2	2,16		Convergence criterion (GCONV=1E-8) satisfied.	0,52	8,93	0,034		Algorithm converged.	-0,028	0,096	2,09		Algorithm converged.	0,54	8,10	0,2872	0,8474	0,48		Algorithm converged.	0,12	1,86
	Female	73	44,5	7	9,6	73	43,5	4	5,5	1,83		Convergence criterion (GCONV=1E-8) satisfied.	0,51	6,54	0,041		Algorithm converged.	-0,044	0,126	1,75		Algorithm converged.	0,54	5,72	0,3546		0,57		Algorithm converged.	0,17	1,87
Age	< 60 years	62	37,8	5	8,1	63	37,5	1	1,6	5,44		Convergence criterion (GCONV=1E-8) satisfied.	0,62	47,96	0,065		Algorithm converged.	-0,010	0,139	5,08		Algorithm converged.	0,61	42,25	0,1326	0,2359	0,20		Algorithm converged.	0,02	1,64
	>= 60 years	102	62,2	8	7,8	105	62,5	6	5,7	1,40		Convergence criterion (GCONV=1E-8) satisfied.	0,47	4,20	0,021		Algorithm converged.	-0,047	0,090	1,37		Algorithm converged.	0,49	3,82	0,5440		0,73		Algorithm converged.	0,26	2,03
Geographic region	Western Europe	78	47,6	6	7,7	77	45,8	3	3,9	2,06		Convergence criterion (GCONV=1E-8) satisfied.	0,50	8,53	0,038		Algorithm converged.	-0,035	0,111	1,97		Algorithm converged.	0,51	7,61	0,3232	0,3648	0,51		Algorithm converged.	0,13	1,95
	North America	67	40,9	6	9,0	73	43,5	2	2,7	3,49		Convergence criterion (GCONV=1E-8) satisfied.	0,68	17,93	0,062		Algorithm converged.	-0,016	0,140	3,27		Algorithm converged.	0,68	15,64	0,1381		0,31		Algorithm converged.	0,06	1,46
	Other	19	11,6	1	5,3	18	10,7	2	11,1	0,44		Convergence criterion (GCONV=1E-8) satisfied.	0,04	5,38	-0,058		Algorithm converged.	-0,235	0,118	0,47		Algorithm converged.	0,05	4,78	0,5265		2,11		Algorithm converged.	0,21	21,32
FLIPI	Low (0-1)	42	25,6	4	9,5	35	20,8	2	5,7	1,74		Convergence criterion (GCONV=1E-8) satisfied.	0,30	10,10	0,038		Algorithm converged.	-0,079	0,156	1,67		Algorithm converged.	0,32	8,57	0,5408	0,9984	0,60		Algorithm converged.	0,12	3,08
	Intermediate (2)	51	31,1	3	5,9	58	34,5	2	3,4	1,75		Convergence criterion (GCONV=1E-8) satisfied.	0,28	10,91	0,024		Algorithm converged.	-0,056	0,104	1,71		Algorithm converged.	0,30	9,81	0,5495		0,59		Algorithm converged.	0,10	3,37
	High (>=3)	64	39,0	5	7,8	68	40,5	3	4,4	1,84		Convergence criterion (GCONV=1E-8) satisfied.	0,42	8,02	0,034		Algorithm converged.	-0,048	0,116	1,77		Algorithm converged.	0,44	7,11	0,4204		0,56		Algorithm converged.	0,14	2,27
	Missing/Unknown	7	4,3	1	14,3	7	4,2				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPICARD_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:19

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients ENDPOINT:
Cardiac Events Serious, Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																Benda vs. G-Benda				
		Patients		with		Patients		with Event		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	31	18,8	168	100,0	10	6,0	3,11		Convergence criterion (GCONV=1E-8) satisfied.	0,32	30,22	0,012		Algorithm converged.	-0,011	0,036	3,07		Algorithm converged.	0,32	29,24	0,3287		0,33		Algorithm converged.	0,03	3,10
Sex	Male	91	55,5	11	11,1	95	56,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 15.313153269 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	0,4012	NE		Algorithm converged.	NE	NE
	Female	73	44,5	22	27,7	73	43,5	11	11,4	2,03		Convergence criterion (GCONV=1E-8) satisfied.	0,18	22,87	0,014		Algorithm converged.	-0,032	0,060	2,00		Algorithm converged.	0,19	21,58	0,5679		0,50		Algorithm converged.	0,05	5,39
Age	< 60 years	62	37,8			63	37,5																		1,0000					
	>= 60 years	102	62,2	32	32,9	105	62,5	11	11,0	3,15		Convergence criterion (GCONV=1E-8) satisfied.	0,32	30,80	0,020		Algorithm converged.	-0,018	0,058	3,09		Algorithm converged.	0,33	29,20	0,3253		0,32		Algorithm converged.	0,03	3,06
Geographic region	Western Europe	78	47,6	22	22,6	77	45,8				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 7.9991394003 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	North America	67	40,9			73	43,5	11	11,4		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 11.644248058 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE
	Other	19	11,6	15	15,3	18	10,7				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 4.5566662021 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
FLIPI	Low (0-1)	42	25,6	12	12,4	35	20,8	12	12,9	0,83		Convergence criterion (GCONV=1E-8) satisfied.	0,05	13,76	-0,005		Algorithm converged.	-0,077	0,067	0,83		Algorithm converged.	0,05	12,84	0,8961	0,3607	1,20		Algorithm converged.	0,08	18,50
	Intermediate (2)	51	31,1	12	10,0	58	34,5				*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	High (>=3)	64	39,0	11	11,6	68	40,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown	7	4,3			7	4,2																							

POPULATION: Safety Evaluable Patients,
Follicular Lymphoma Patients
ENDPOINT: Cardiac Events Grade >=3,
Induction Phase Only
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
		Patients		with		Patients		with Event		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	4	2,4	168	100,0	10	6,0	4,17		Convergence criterion (GCONV=1E-8) satisfied.	0,46	37,76	0,018		Algorithm converged.	-0,008	0,045	4,10		Algorithm converged.	0,46	36,27	0,2049		0,24		Algorithm converged.	0,03	2,16
Sex	Male	91	55,5	11	1,1	95	56,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 15.313153269 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	0,4688	NE		Algorithm converged.	NE	NE
	Female	73	44,5	3	4,1	73	43,5	11	1,4	3,09		Convergence criterion (GCONV=1E-8) satisfied.	0,31	30,37	0,027		Algorithm converged.	-0,025	0,080	3,00		Algorithm converged.	0,32	28,17	0,3364		0,33		Algorithm converged.	0,04	3,13
Age	< 60 years	62	37,8			63	37,5																		1,0000					
	>= 60 years	102	62,2	4	3,9	105	62,5	11	1,0	4,24		Convergence criterion (GCONV=1E-8) satisfied.	0,47	38,64	0,030		Algorithm converged.	-0,012	0,072	4,12		Algorithm converged.	0,47	36,22	0,2020		0,24		Algorithm converged.	0,03	2,14
Geographic region	Western Europe	78	47,6	3	3,8	77	45,8				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 5.9559094165 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	North America	67	40,9			73	43,5	11	1,4		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 11.644248058 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	1,0000		>999.99		Algorithm converged.	0,00	NE
	Other	19	11,6	1	5,3	18	10,7				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 4.5566662021 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
FLIPI	Low (0-1)	42	25,6	2	4,8	35	20,8	12	2,9	1,70		Convergence criterion (GCONV=1E-8) satisfied.	0,15	19,57	0,019		Algorithm converged.	-0,066	0,104	1,67		Algorithm converged.	0,16	17,62	0,6712	0,4877	0,60		Algorithm converged.	0,06	6,34
	Intermediate (2)	51	31,1	1	2,0	58	34,5				*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	High (>=3)	64	39,0	1	1,6	68	40,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown	7	4,3			7	4,2																								

49 (Anhang): Ergebnisse für Zweitmalignom nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Second malignancies, Induction Phase Only MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
		Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	10	0,6	168	100,0				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Sex	Male	91	55,5			95	56,5																			NE					
	Female	73	44,5	11	1,4	73	43,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.646715143 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Age	< 60 years	62	37,8			63	37,5																			NE					
	>= 60 years	102	62,2	11	1,0	105	62,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Geographic region	Western Europe	78	47,6	11	1,3	77	45,8				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 13.073073176 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	NE	NE		Algorithm converged.	NE	NE
	North America	67	40,9			73	43,5																								
	Other	19	11,6			18	10,7																								
FLIPI	Low (0-1)	42	25,6			35	20,8																			NE					
	Intermediate (2)	51	31,1			58	34,5																								
	High (>=3)	64	39,0	11	1,6	68	40,5				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown		74,3			7	4,2																								

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPIMAL_FOLY_SE_30NOV2018_01297.xls 07OCT2019 11:29

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Second malignancies Serious, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPIMALS_FOLY_SE_30NOV2018_01297.xls
07OCT2019 12:32

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Second malignancies Grade >= 3, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_INDUCT_AEPIMAL3_FOLY_SE_30NOV2018_01297.xls
07OCT2019 12:15

Anhang 4-G4: Spezifische Verträglichkeit: Unerwünschte Ereignisse von besonderem Interesse (AESI) –Time-to-event-Analysen (gesamte Studiendauer)

50 (Anhang): Ergebnisse für Akute Thrombozytopenie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Acute Thrombocytopenia, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297

Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	1	0,6	163	99,4	166	100,0			166	100,0	0,3144	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	1	1,1	90	98,9	94	56,6			94	100,0	0,3095	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9965
	Female	73	44,5			73	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8			62	100,0	62	37,3			62	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9965
	>= 60 years	102	62,2	1	1,0	101	99,0	104	62,7			104	100,0	0,3126	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	1	1,3	77	98,7	77	46,4			77	100,0	0,3204	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	North America	67	40,9			67	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6			19	100,0	17	10,2			17	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6			42	100,0	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	Intermediate (2)	51	31,1			51	100,0	57	34,3			57	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	1	1,6	63	98,4	67	40,4			67	100,0	0,3062	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical

cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPIATHROM_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:07

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Acute Thrombocytopenia Serious, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297

Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	1	0,6	163	99,4	166	100,0			166	100,0	0,3144	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	1	1,1	90	98,9	94	56,6			94	100,0	0,3095	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9965
	Female	73	44,5			73	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8			62	100,0	62	37,3			62	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9965
	>= 60 years	102	62,2	1	1,0	101	99,0	104	62,7			104	100,0	0,3126	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	1	1,3	77	98,7	77	46,4			77	100,0	0,3204	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	North America	67	40,9			67	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6			19	100,0	17	10,2			17	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6			42	100,0	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	Intermediate (2)	51	31,1			51	100,0	57	34,3			57	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	1	1,6	63	98,4	67	40,4			67	100,0	0,3062	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPIATHROMS_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:47


POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Acute Thrombocytopenia Grade >= 3, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	1	0,6	163	99,4	166	100,0			166	100,0	0,3144	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	1	1,1	90	98,9	94	56,6			94	100,0	0,3095	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9965
	Female	73	44,5			73	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8			62	100,0	62	37,3			62	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9965
	>= 60 years	102	62,2	1	1,0	101	99,0	104	62,7			104	100,0	0,3126	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	1	1,3	77	98,7	77	46,4			77	100,0	0,3204	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	North America	67	40,9			67	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6			19	100,0	17	10,2			17	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6			42	100,0	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	Intermediate (2)	51	31,1			51	100,0	57	34,3			57	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	1	1,6	63	98,4	67	40,4			67	100,0	0,3062	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPIATHROM3_FOLY_SE_30NOV2018_01297.xls

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Acute Thrombocytopenia, Complete Study Duration
STUDY: GO01297




Patients at risk										
G-Benda	164	125	97	81	70	62	48	35	20	7
Benda	166	15	6							
Patients censored										
G-Benda	0	38	66	82	93	101	115	128	143	156
Benda	0	151	160							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPIATHROM_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 14:56

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Acute Thrombocytopenia Serious, Complete Study Duration
STUDY: GO01297




Patients at risk										
G-Benda	164	125	97	81	70	62	48	35	20	7
Benda	166	15	6							
Patients censored										
G-Benda	0	38	66	82	93	101	115	128	143	156
Benda	0	151	160							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPIATHROMS_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 16:42

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Acute Thrombocytopenia Grade >= 3, Complete Study Duration
STUDY: GO01297



Patients at risk										
G-Benda	164	125	97	81	70	62	48	35	20	7
Benda	166	15	6							
Patients censored										
G-Benda	0	38	66	82	93	101	115	128	143	156
Benda	0	151	160							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPlATHROM3_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 15:52

51 (Anhang): Ergebnisse für Gastrointestinale Perforation nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: GI Perforation, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297

Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	1	0,6	163	99,4	166	100,0			166	100,0	0,6434	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5			91	100,0	94	56,6			94	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9969
	Female	73	44,5	1	1,4	72	98,6	72	43,4			72	100,0	0,6604	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8			62	100,0	62	37,3			62	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9971
	>= 60 years	102	62,2	1	1,0	101	99,0	104	62,7			104	100,0	0,6212	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	1	1,3	77	98,7	77	46,4			77	100,0	0,6698	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	North America	67	40,9			67	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6			19	100,0	17	10,2			17	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6			42	100,0	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	Intermediate (2)	51	31,1			51	100,0	57	34,3			57	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	1	1,6	63	98,4	67	40,4			67	100,0	0,6604	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPIGIP_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:10

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: GI Perforation Serious, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297

Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	1	0,6	163	99,4	166	100,0			166	100,0	0,6434	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5			91	100,0	94	56,6			94	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9969
	Female	73	44,5	1	1,4	72	98,6	72	43,4			72	100,0	0,6604	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8			62	100,0	62	37,3			62	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9971
	>= 60 years	102	62,2	1	1,0	101	99,0	104	62,7			104	100,0	0,6212	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	1	1,3	77	98,7	77	46,4			77	100,0	0,6698	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	North America	67	40,9			67	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6			19	100,0	17	10,2			17	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6			42	100,0	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	Intermediate (2)	51	31,1			51	100,0	57	34,3			57	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	1	1,6	63	98,4	67	40,4			67	100,0	0,6604	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPIGIPS_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:49

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: GI Perforation Grade >= 3, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297


Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	1	0,6	163	99,4	166	100,0			166	100,0	0,6434	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5			91	100,0	94	56,6			94	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9969
	Female	73	44,5	1	1,4	72	98,6	72	43,4			72	100,0	0,6604	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8			62	100,0	62	37,3			62	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9971
	>= 60 years	102	62,2	1	1,0	101	99,0	104	62,7			104	100,0	0,6212	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	1	1,3	77	98,7	77	46,4			77	100,0	0,6698	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	North America	67	40,9			67	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6			19	100,0	17	10,2			17	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6			42	100,0	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	Intermediate (2)	51	31,1			51	100,0	57	34,3			57	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	1	1,6	63	98,4	67	40,4			67	100,0	0,6604	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPIGIP3_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:37

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: GI Perforation, Complete Study Duration
STUDY: GO01297




Patients at risk									
G-Benda	164	124	96	80	69	61	47	34	20	7
Benda	166	15	6							
Patients censored									
G-Benda	0	39	67	83	94	102	116	129	143	156
Benda	0	151	160							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPIGIP_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 14:59

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: GI Perforation Serious, Complete Study Duration
STUDY: GO01297




Patients at risk									
G-Benda	164	124	96	80	69	61	47	34	20	7
Benda	166	15	6							
Patients censored									
G-Benda	0	39	67	83	94	102	116	129	143	156
Benda	0	151	160							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPIGIPS_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 16:43

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: GI Perforation Grade >= 3, Complete Study Duration
STUDY: GO01297



Patients at risk									
G-Benda	164	124	96	80	69	61	47	34	20	7
Benda	166	15	6							
Patients censored									
G-Benda	0	39	67	83	94	102	116	129	143	156
Benda	0	151	160							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPIGIP3_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 15:57

52 (Anhang): Ergebnisse für Infektionen nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Infections, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	110	67,1	54	32,9	166	100,0	99	59,6	67	40,4	0,0487	0,75	0,56	1,00		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	59	64,8	32	35,2	94	56,6	48	51,1	46	48,9	0,2327	0,78	0,53	1,17		Convergence criterion (GCONV=1E-8) satisfied.	0,5006
	Female	73	44,5	51	69,9	22	30,1	72	43,4	51	70,8	21	29,2	0,0931	0,70	0,46	1,06		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	41	66,1	21	33,9	62	37,3	37	59,7	25	40,3	0,2335	0,76	0,48	1,20		Convergence criterion (GCONV=1E-8) satisfied.	0,8421
	>= 60 years	102	62,2	69	67,6	33	32,4	104	62,7	62	59,6	42	40,4	0,1360	0,76	0,53	1,09		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	50	64,1	28	35,9	77	46,4	44	57,1	33	42,9	0,0908	0,68	0,44	1,07		Convergence criterion (GCONV=1E-8) satisfied.	0,2129
	North America	67	40,9	52	77,6	15	22,4	72	43,4	42	58,3	30	41,7	0,6940	0,92	0,61	1,40		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	8	42,1	11	57,9	17	10,2	13	76,5	4	23,5	0,1063	0,49	0,20	1,19		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	26	61,9	16	38,1	35	21,1	24	68,6	11	31,4	0,1144	0,63	0,35	1,12		Convergence criterion (GCONV=1E-8) satisfied.	0,7309
	Intermediate (2)	51	31,1	36	70,6	15	29,4	57	34,3	36	63,2	21	36,8	0,2482	0,75	0,47	1,22		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	42	65,6	22	34,4	67	40,4	35	52,2	32	47,8	0,2166	0,74	0,45	1,20		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	6	85,7	1	14,3	7	4,2	4	57,1	3	42,9	0,1290	2,83	0,70	11,50		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPIINFEC_FOLY_SE_30NOV2018_01297.xls 04OCT2019 19:12

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients


ENDPOINT: Infections Serious, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	24	14,6	140	85,4	166	100,0	32	19,3	134	80,7	<.0001	0,24	0,13	0,46		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	21	23,1	70	76,9	94	56,6	17	18,1	77	81,9	0,0466	0,48	0,23	1,00		Convergence criterion (GCONV=1E-8) satisfied.	0,0010
	Female	73	44,5	3	4,1	70	95,9	72	43,4	15	20,8	57	79,2	<.0001	0,04	<0.01	0,20		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	6	9,7	56	90,3	62	37,3	5	8,1	57	91,9	0,0013	0,13	0,03	0,49		Convergence criterion (GCONV=1E-8) satisfied.	0,4242
	>= 60 years	102	62,2	18	17,6	84	82,4	104	62,7	27	26,0	77	74,0	0,0003	0,29	0,14	0,58		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	15	19,2	63	80,8	77	46,4	15	19,5	62	80,5	0,0114	0,34	0,14	0,80		Convergence criterion (GCONV=1E-8) satisfied.	0,4928
	North America	67	40,9	7	10,4	60	89,6	72	43,4	11	15,3	61	84,7	0,0043	0,19	0,06	0,63		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	2	10,5	17	89,5	17	10,2	6	35,3	11	64,7	0,0059	0,08	<0.01	0,71		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	2	4,8	40	95,2	35	21,1	4	11,4	31	88,6	0,0001	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,4336
	Intermediate (2)	51	31,1	9	17,6	42	82,4	57	34,3	10	17,5	47	82,5	0,1695	0,49	0,18	1,37		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	10	15,6	54	84,4	67	40,4	18	26,9	49	73,1	<.0001	0,16	0,06	0,41		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	3	42,9	4	57,1	7	4,2			7	100,0	0,1649	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients ENDPOINT:
Infections Grade >=3, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	30	18,3	134	81,7	166	100,0	34	20,5	132	79,5	<.0001	0,25	0,14	0,45		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	25	27,5	66	72,5	94	56,6	16	17,0	78	83,0	0,1149	0,56	0,28	1,15		Convergence criterion (GCONV=1E-8) satisfied.	0,0002
	Female	73	44,5	5	6,8	68	93,2	72	43,4	18	25,0	54	75,0	<.0001	0,04	<0.01	0,15		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	9	14,5	53	85,5	62	37,3	7	11,3	55	88,7	0,0015	0,16	0,05	0,52		Convergence criterion (GCONV=1E-8) satisfied.	0,4928
	>= 60 years	102	62,2	21	20,6	81	79,4	104	62,7	27	26,0	77	74,0	0,0001	0,28	0,14	0,55		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	17	21,8	61	78,2	77	46,4	16	20,8	61	79,2	0,0028	0,29	0,13	0,67		Convergence criterion (GCONV=1E-8) satisfied.	0,4146
	North America	67	40,9	11	16,4	56	83,6	72	43,4	12	16,7	60	83,3	0,0027	0,22	0,08	0,61		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	2	10,5	17	89,5	17	10,2	6	35,3	11	64,7	0,0120	0,10	0,01	0,84		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	3	7,1	39	92,9	35	21,1	3	8,6	32	91,4	0,0052	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,1213
	Intermediate (2)	51	31,1	12	23,5	39	76,5	57	34,3	9	15,8	48	84,2	0,1896	0,52	0,19	1,40		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	12	18,8	52	81,3	67	40,4	22	32,8	45	67,2	<.0001	0,16	0,07	0,37		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	3	42,9	4	57,1	7	4,2			7	100,0	0,1649	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Infections, Complete Study Duration
STUDY: GO01297



Patients at risk									
G-Benda	164	59	25	13	11	9	6	3	2
Benda	166	11	4	1	1				
Patients censored									
G-Benda	0	24	36	41	43	45	48	51	52
Benda	0	61	65	67	67				

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPIINFEC_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 15:01

53 (Anhang): Ergebnisse für Infusionsbedingte Reaktionen (IRR) nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients

ENDPOINT: Infusion Related AEs, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297

Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	111	67,7	53	32,3	166	100,0	110	66,3	56	33,7	0,4815	1,11	0,83	1,49		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	63	69,2	28	30,8	94	56,6	56	59,6	38	40,4	0,1036	1,39	0,93	2,06		Convergence criterion (GCONV=1E-8) satisfied.	0,0728
	Female	73	44,5	48	65,8	25	34,2	72	43,4	54	75,0	18	25,0	0,4140	0,83	0,54	1,29		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	46	74,2	16	25,8	62	37,3	47	75,8	15	24,2	0,4355	1,21	0,75	1,94		Convergence criterion (GCONV=1E-8) satisfied.	0,7974
	>= 60 years	102	62,2	65	63,7	37	36,3	104	62,7	63	60,6	41	39,4	0,6943	1,08	0,74	1,57		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	51	65,4	27	34,6	77	46,4	49	63,6	28	36,4	0,6243	1,11	0,72	1,72		Convergence criterion (GCONV=1E-8) satisfied.	0,2612
	North America	67	40,9	53	79,1	14	20,9	72	43,4	51	70,8	21	29,2	0,1856	1,34	0,87	2,07		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	7	36,8	12	63,2	17	10,2	10	58,8	7	41,2	0,2098	0,53	0,20	1,45		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	33	78,6	9	21,4	35	21,1	24	68,6	11	31,4	0,3108	1,36	0,75	2,44		Convergence criterion (GCONV=1E-8) satisfied.	0,3138
	Intermediate (2)	51	31,1	38	74,5	13	25,5	57	34,3	38	66,7	19	33,3	0,2258	1,36	0,82	2,25		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	34	53,1	30	46,9	67	40,4	42	62,7	25	37,3	0,4088	0,81	0,50	1,33		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	6	85,7	1	14,3	7	4,2	6	85,7	1	14,3	0,7414	0,80	0,21	2,99		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPIIRR_FOLY_SE_30NOV2018_01297.xls

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Infusion Related AEs Serious, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297

Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	8	4,9	156	95,1	166	100,0	2	1,2	164	98,8	0,0520	4,14	0,87	19,54		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	3	3,3	88	96,7	94	56,6	1	1,1	93	98,9	0,2944	3,15	0,33	30,38		Convergence criterion (GCONV=1E-8) satisfied.	0,7730
	Female	73	44,5	5	6,8	68	93,2	72	43,4	1	1,4	71	98,6	0,1031	5,01	0,58	43,06		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	4	6,5	58	93,5	62	37,3			62	100,0	0,0429	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,1207
	>= 60 years	102	62,2	4	3,9	98	96,1	104	62,7	2	1,9	102	98,1	0,4019	2,04	0,37	11,15		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	4	5,1	74	94,9	77	46,4	2	2,6	75	97,4	0,4141	2,01	0,36	11,08		Convergence criterion (GCONV=1E-8) satisfied.	0,2973
	North America	67	40,9	3	4,5	64	95,5	72	43,4			72	100,0	0,0704	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	1	5,3	18	94,7	17	10,2			17	100,0	0,3311	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6			42	100,0	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,1871
	Intermediate (2)	51	31,1	2	3,9	49	96,1	57	34,3	2	3,5	55	96,5	0,9166	1,11	0,16	7,96		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	4	6,3	60	93,8	67	40,4			67	100,0	0,0387	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	2	28,6	5	71,4	7	4,2			7	100,0	0,1413	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPIIRRS_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:39

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Infusion Related AEs Grade >= 3, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297


Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	19	11,6	145	88,4	166	100,0	10	6,0	156	94,0	0,0939	1,92	0,88	4,18		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	11	12,1	80	87,9	94	56,6	4	4,3	90	95,7	0,0701	2,81	0,88	8,98		Convergence criterion (GCONV=1E-8) satisfied.	0,3025
	Female	73	44,5	8	11,0	65	89,0	72	43,4	6	8,3	66	91,7	0,5957	1,33	0,46	3,88		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	9	14,5	53	85,5	62	37,3	4	6,5	58	93,5	0,1460	2,37	0,72	7,84		Convergence criterion (GCONV=1E-8) satisfied.	0,6916
	>= 60 years	102	62,2	10	9,8	92	90,2	104	62,7	6	5,8	98	94,2	0,3501	1,63	0,58	4,54		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	12	15,4	66	84,6	77	46,4	7	9,1	70	90,9	0,2842	1,68	0,65	4,36		Convergence criterion (GCONV=1E-8) satisfied.	0,4455
	North America	67	40,9	5	7,5	62	92,5	72	43,4	3	4,2	69	95,8	0,4061	1,82	0,43	7,69		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	2	10,5	17	89,5	17	10,2			17	100,0	0,1632	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	2	4,8	40	95,2	35	21,1	1	2,9	34	97,1	0,6438	1,75	0,16	19,29		Convergence criterion (GCONV=1E-8) satisfied.	0,9859
	Intermediate (2)	51	31,1	6	11,8	45	88,2	57	34,3	4	7,0	53	93,0	0,3932	1,73	0,48	6,21		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	9	14,1	55	85,9	67	40,4	5	7,5	62	92,5	0,3077	1,78	0,58	5,46		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	2	28,6	5	71,4	7	4,2			7	100,0	0,1413	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPIIRR3_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:39

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Infusion Related AEs, Complete Study Duration
STUDY: GO01297




Patients at risk									
G-Benda	164	37	28	22	19	15	11	6	2	1
Benda	166	9	4							
Patients censored									
G-Benda	0	16	25	31	34	38	42	47	51	52
Benda	0	47	52							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPIIRR_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 15:06

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Infusion Related AEs Serious, Complete Study Duration
STUDY: GO01297




Patients at risk									
G-Benda	164	122	94	78	68	61	48	35	20	7
Benda	166	15	6							
Patients censored									
G-Benda	0	34	62	78	88	95	108	121	136	149
Benda	0	149	158							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPIIRRS_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 16:45

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Infusion Related AEs Grade >= 3, Complete Study Duration
STUDY: GO01297



Patients at risk										
G-Benda	164	115	90	74	66	59	46	33	19	7
Benda	166	15	6							
Patients censored										
G-Benda	0	30	55	71	79	86	99	112	126	138
Benda	0	141	150							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPIIRR3_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 16:05

54 (Anhang): Ergebnisse für Neoplasien nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Neoplasm, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	21	12,8	143	87,2	166	100,0	15	9,0	151	91,0	<.0001	0,19	0,09	0,40		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	14	15,4	77	84,6	94	56,6	9	9,6	85	90,4	<.0001	0,18	0,07	0,46		Convergence criterion (GCONV=1E-8) satisfied.	0,2123
	Female	73	44,5	7	9,6	66	90,4	72	43,4	6	8,3	66	91,7	0,0164	0,23	0,07	0,79		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	2	3,2	60	96,8	62	37,3	2	3,2	60	96,8	0,0011	0,08	0,01	0,56		Convergence criterion (GCONV=1E-8) satisfied.	0,4027
	>= 60 years	102	62,2	19	18,6	83	81,4	104	62,7	13	12,5	91	87,5	0,0002	0,24	0,11	0,54		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	9	11,5	69	88,5	77	46,4	8	10,4	69	89,6	<.0001	0,12	0,04	0,38		Convergence criterion (GCONV=1E-8) satisfied.	0,6970
	North America	67	40,9	11	16,4	56	83,6	72	43,4	6	8,3	66	91,7	0,0127	0,27	0,09	0,80		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	1	5,3	18	94,7	17	10,2	1	5,9	16	94,1	0,2014	0,20	0,01	3,16		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	7	16,7	35	83,3	35	21,1	3	8,6	32	91,4	0,0176	0,18	0,04	0,81		Convergence criterion (GCONV=1E-8) satisfied.	0,3417
	Intermediate (2)	51	31,1	1	2,0	50	98,0	57	34,3	3	5,3	54	94,7	0,0343	0,09	<0.01	1,04		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	11	17,2	53	82,8	67	40,4	8	11,9	59	88,1	0,0004	0,19	0,07	0,52		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	2	28,6	5	71,4	7	4,2	1	14,3	6	85,7	0,8967	1,17	0,11	12,98		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output:
root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/outpu
t/t_s_ttae_sg_COMPL_AEPINEO_FOLY_SE_30NOV2018_01297.xls 04OCT2019 19:16


POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients ENDPOINT: Neoplasm Serious, Complete Study Duration
MODEL: Unstratified Analysis STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	12	7,3	152	92,7	166	100,0	12	7,2	154	92,8	<.0001	0,11	0,04	0,27		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	9	9,9	82	90,1	94	56,6	6	6,4	88	93,6	0,0002	0,14	0,04	0,44		Convergence criterion (GCONV=1E-8) satisfied.	0,0580
	Female	73	44,5	3	4,1	70	95,9	72	43,4	6	8,3	66	91,7	0,0004	0,08	0,02	0,38		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	2	3,2	60	96,8	62	37,3	1	1,6	61	98,4	0,0434	0,12	0,01	1,39		Convergence criterion (GCONV=1E-8) satisfied.	0,9465
	>= 60 years	102	62,2	10	9,8	92	90,2	104	62,7	11	10,6	93	89,4	<.0001	0,12	0,04	0,32		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	7	9,0	71	91,0	77	46,4	7	9,1	70	90,9	0,0001	0,10	0,03	0,37		Convergence criterion (GCONV=1E-8) satisfied.	0,9471
	North America	67	40,9	4	6,0	63	94,0	72	43,4	4	5,6	68	94,4	0,0005	0,09	0,02	0,44		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	1	5,3	18	94,7	17	10,2	1	5,9	16	94,1	0,2014	0,20	0,01	3,16		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	3	7,1	39	92,9	35	21,1	1	2,9	34	97,1	<.0001	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,5189
	Intermediate (2)	51	31,1	1	2,0	50	98,0	57	34,3	3	5,3	54	94,7	0,0343	0,09	<0.01	1,04		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	7	10,9	57	89,1	67	40,4	7	10,4	60	89,6	0,0003	0,14	0,04	0,46		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	1	14,3	6	85,7	7	4,2	1	14,3	6	85,7	0,6660	0,55	0,03	8,78		Convergence criterion (GCONV=1E-8) satisfied.	

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients ENDPOINT: Neoplasm
Grade >= 3, Complete Study Duration
MODEL: Unstratified Analysis STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	13	7,9	151	92,1	166	100,0	12	7,2	154	92,8	<.0001	0,09	0,04	0,23		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	10	11,0	81	89,0	94	56,6	8	8,5	86	91,5	<.0001	0,11	0,04	0,32		Convergence criterion (GCONV=1E-8) satisfied.	0,1082
	Female	73	44,5	3	4,1	70	95,9	72	43,4	4	5,6	68	94,4	0,0047	0,11	0,02	0,57		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	2	3,2	60	96,8	62	37,3	2	3,2	60	96,8	0,0011	0,08	0,01	0,56		Convergence criterion (GCONV=1E-8) satisfied.	0,6744
	>= 60 years	102	62,2	11	10,8	91	89,2	104	62,7	10	9,6	94	90,4	<.0001	0,10	0,04	0,29		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	7	9,0	71	91,0	77	46,4	6	7,8	71	92,2	<.0001	0,09	0,02	0,33		Convergence criterion (GCONV=1E-8) satisfied.	0,9625
	North America	67	40,9	5	7,5	62	92,5	72	43,4	5	6,9	67	93,1	<.0001	0,07	0,02	0,34		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	1	5,3	18	94,7	17	10,2	1	5,9	16	94,1	0,2014	0,20	0,01	3,16		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	3	7,1	39	92,9	35	21,1	2	5,7	33	94,3	0,0001	0,06	<0.01	0,42		Convergence criterion (GCONV=1E-8) satisfied.	0,6174
	Intermediate (2)	51	31,1	1	2,0	50	98,0	57	34,3	2	3,5	55	96,5	0,0531	0,10	<0.01	1,32		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	9	14,1	55	85,9	67	40,4	7	10,4	60	89,6	0,0003	0,15	0,05	0,46		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2	1	14,3	6	85,7	0,1138	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Neoplasm, Complete Study Duration
STUDY: GO01297



Patients at risk										
G-Benda	164	120	89	74	63	54	39	27	16	6
Benda	166	25	13	3	2	2				
Patients censored										
G-Benda	0	38	64	75	85	93	106	116	127	137
Benda	0	138	146	151	151	151				

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPINEO_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 15:14

55 (Anhang): Ergebnisse für Neutropenie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Neutropenia, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	63	38,4	101	61,6	166	100,0	48	28,9	118	71,1	0,8499	1,04	0,70	1,53		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	33	36,3	58	63,7	94	56,6	23	24,5	71	75,5	0,7502	1,09	0,63	1,90		Convergence criterion (GCONV=1E-8) satisfied.	0,6156
	Female	73	44,5	30	41,1	43	58,9	72	43,4	25	34,7	47	65,3	0,8838	0,96	0,55	1,66		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	23	37,1	39	62,9	62	37,3	13	21,0	49	79,0	0,3174	1,43	0,71	2,92		Convergence criterion (GCONV=1E-8) satisfied.	0,2524
	>= 60 years	102	62,2	40	39,2	62	60,8	104	62,7	35	33,7	69	66,3	0,6213	0,89	0,56	1,42		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	31	39,7	47	60,3	77	46,4	21	27,3	56	72,7	0,3927	1,28	0,72	2,27		Convergence criterion (GCONV=1E-8) satisfied.	0,4150
	North America	67	40,9	22	32,8	45	67,2	72	43,4	21	29,2	51	70,8	0,1785	0,64	0,34	1,23		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	10	52,6	9	47,4	17	10,2	6	35,3	11	64,7	0,3518	1,62	0,58	4,52		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	14	33,3	28	66,7	35	21,1	11	31,4	24	68,6	0,1836	0,54	0,22	1,35		Convergence criterion (GCONV=1E-8) satisfied.	0,4931
	Intermediate (2)	51	31,1	22	43,1	29	56,9	57	34,3	16	28,1	41	71,9	0,2541	1,46	0,76	2,81		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	25	39,1	39	60,9	67	40,4	18	26,9	49	73,1	0,7754	1,10	0,59	2,05		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	2	28,6	5	71,4	7	4,2	3	42,9	4	57,1	0,5922	0,61	0,10	3,80		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPINEU_FOLY_SE_30NOV2018_01297.xls 04OCT2019 19:17


POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients ENDPOINT:
Neutropenia Serious, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	6	3,7	158	96,3	166	100,0			166	100,0	0,0242	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	4	4,4	87	95,6	94	56,6			94	100,0	0,0811	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9966
	Female	73	44,5	2	2,7	71	97,3	72	43,4			72	100,0	0,1603	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8			62	100,0	62	37,3			62	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9970
	>= 60 years	102	62,2	6	5,9	96	94,1	104	62,7			104	100,0	0,0243	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	4	5,1	74	94,9	77	46,4			77	100,0	0,0437	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	North America	67	40,9	2	3,0	65	97,0	72	43,4			72	100,0	0,3295	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6			19	100,0	17	10,2			17	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6			42	100,0	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	Intermediate (2)	51	31,1	3	5,9	48	94,1	57	34,3			57	100,0	0,0636	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	2	3,1	62	96,9	67	40,4			67	100,0	0,1525	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	1	14,3	6	85,7	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients ENDPOINT:
Neutropenia Grade >=3, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	56	34,1	108	65,9	166	100,0	41	24,7	125	75,3	0,7761	1,06	0,70	1,62		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	27	29,7	64	70,3	94	56,6	21	22,3	73	77,7	0,8329	0,94	0,52	1,71		Convergence criterion (GCONV=1E-8) satisfied.	0,6371
	Female	73	44,5	29	39,7	44	60,3	72	43,4	20	27,8	52	72,2	0,5576	1,19	0,66	2,15		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	20	32,3	42	67,7	62	37,3	11	17,7	51	82,3	0,3184	1,47	0,68	3,18		Convergence criterion (GCONV=1E-8) satisfied.	0,2834
	>= 60 years	102	62,2	36	35,3	66	64,7	104	62,7	30	28,8	74	71,2	0,7090	0,91	0,55	1,50		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	28	35,9	50	64,1	77	46,4	16	20,8	61	79,2	0,2090	1,50	0,80	2,81		Convergence criterion (GCONV=1E-8) satisfied.	0,1830
	North America	67	40,9	18	26,9	49	73,1	72	43,4	19	26,4	53	73,6	0,0832	0,54	0,26	1,09		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	10	52,6	9	47,4	17	10,2	6	35,3	11	64,7	0,2267	1,86	0,67	5,19		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	11	26,2	31	73,8	35	21,1	8	22,9	27	77,1	0,3420	0,60	0,21	1,74		Convergence criterion (GCONV=1E-8) satisfied.	0,7540
	Intermediate (2)	51	31,1	20	39,2	31	60,8	57	34,3	16	28,1	41	71,9	0,5538	1,22	0,63	2,39		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	23	35,9	41	64,1	67	40,4	14	20,9	53	79,1	0,4485	1,30	0,66	2,59		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	2	28,6	5	71,4	7	4,2	3	42,9	4	57,1	0,5651	0,59	0,09	3,66		Convergence criterion (GCONV=1E-8) satisfied.	

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Neutropenia, Complete Study Duration
STUDY: GO01297



Patients at risk										
G-Benda	164	82	61	50	43	38	30	19	12	5
Benda	166	12	6							
Patients censored										
G-Benda	0	28	43	51	58	63	71	82	89	96
Benda	0	107	112							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPINEU_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 15:15

56 (Anhang): Ergebnisse für Progressive multifokale Leukenzephalopathie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients

ENDPOINT: Progressive multifocal leukoencephalopathy, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0			164	100,0	166	100,0			166	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5			91	100,0	94	56,6			94	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE
	Female	73	44,5			73	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8			62	100,0	62	37,3			62	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE
	>= 60 years	102	62,2			102	100,0	104	62,7			104	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6			78	100,0	77	46,4			77	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE
	North America	67	40,9			67	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6			19	100,0	17	10,2			17	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6			42	100,0	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE
	Intermediate (2)	51	31,1			51	100,0	57	34,3			57	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0			64	100,0	67	40,4			67	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical

cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPRMLE_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:34

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Progressive multifocal leukoencephalopathy Serious, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0			164	100,0	166	100,0			166	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5			91	100,0	94	56,6			94	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE
	Female	73	44,5			73	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8			62	100,0	62	37,3			62	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE
	>= 60 years	102	62,2			102	100,0	104	62,7			104	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6			78	100,0	77	46,4			77	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE
	North America	67	40,9			67	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6			19	100,0	17	10,2			17	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6			42	100,0	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE
	Intermediate (2)	51	31,1			51	100,0	57	34,3			57	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0			64	100,0	67	40,4			67	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPRMLES_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:45

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Progressive multifocal leukoencephalopathy Grade >= 3, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297


Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0			164	100,0	166	100,0			166	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5			91	100,0	94	56,6			94	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE
	Female	73	44,5			73	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8			62	100,0	62	37,3			62	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE
	>= 60 years	102	62,2			102	100,0	104	62,7			104	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6			78	100,0	77	46,4			77	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE
	North America	67	40,9			67	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6			19	100,0	17	10,2			17	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6			42	100,0	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	NE
	Intermediate (2)	51	31,1			51	100,0	57	34,3			57	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0			64	100,0	67	40,4			67	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPRMLE3_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:45

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Progressive multifocal leukoencephalopathy, Complete Study Duration
STUDY: GO01297




Patients at risk									
G-Benda	164	125	97	81	70	62	48	35	20	7
Benda	166	15	6							
Patients censored									
G-Benda	0	39	67	83	94	102	116	129	144	157
Benda	0	151	160							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPRMLE_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 15:23

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Progressive multifocal leukoencephalopathy Serious, Complete Study Duration
STUDY: GO01297




Patients at risk									
G-Benda	164	125	97	81	70	62	48	35	20	7
Benda	166	15	6							
Patients censored									
G-Benda	0	39	67	83	94	102	116	129	144	157
Benda	0	151	160							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPRMLES_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 16:54

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Progressive multifocal leukoencephalopathy Grade >= 3, Complete Study Duration
STUDY: GO01297



Patients at risk									
G-Benda	164	125	97	81	70	62	48	35	20	7
Benda	166	15	6							
Patients censored									
G-Benda	0	39	67	83	94	102	116	129	144	157
Benda	0	151	160							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPRMLE3_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 16:16

57 (Anhang): Ergebnisse für Thrombozytopenie nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients

ENDPOINT: Thrombocytopenia, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297

Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	25	15,2	139	84,8	166	100,0	40	24,1	126	75,9	0,0573	0,61	0,37	1,02		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	13	14,3	78	85,7	94	56,6	23	24,5	71	75,5	0,0803	0,54	0,27	1,09		Convergence criterion (GCONV=1E-8) satisfied.	0,6397
	Female	73	44,5	12	16,4	61	83,6	72	43,4	17	23,6	55	76,4	0,3806	0,72	0,34	1,51		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	9	14,5	53	85,5	62	37,3	15	24,2	47	75,8	0,2230	0,60	0,26	1,38		Convergence criterion (GCONV=1E-8) satisfied.	0,8166
	>= 60 years	102	62,2	16	15,7	86	84,3	104	62,7	25	24,0	79	76,0	0,1481	0,63	0,33	1,19		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	14	17,9	64	82,1	77	46,4	17	22,1	60	77,9	0,5187	0,79	0,38	1,62		Convergence criterion (GCONV=1E-8) satisfied.	0,2058
	North America	67	40,9	6	9,0	61	91,0	72	43,4	18	25,0	54	75,0	0,0179	0,34	0,14	0,87		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	5	26,3	14	73,7	17	10,2	5	29,4	12	70,6	0,9996	1,00	0,29	3,46		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	8	19,0	34	81,0	35	21,1	6	17,1	29	82,9	0,9016	1,07	0,36	3,20		Convergence criterion (GCONV=1E-8) satisfied.	0,2678
	Intermediate (2)	51	31,1	11	21,6	40	78,4	57	34,3	17	29,8	40	70,2	0,4828	0,76	0,36	1,63		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	6	9,4	58	90,6	67	40,4	15	22,4	52	77,6	0,0423	0,39	0,15	1,00		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2	2	28,6	5	71,4	0,1732	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPITHROM_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:31

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Thrombocytopenia Serious, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297

Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	4	2,4	160	97,6	166	100,0			166	100,0	0,0803	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	4	4,4	87	95,6	94	56,6			94	100,0	0,0762	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9959
	Female	73	44,5			73	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	1	1,6	61	98,4	62	37,3			62	100,0	0,3091	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9973
	>= 60 years	102	62,2	3	2,9	99	97,1	104	62,7			104	100,0	0,1526	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	4	5,1	74	94,9	77	46,4			77	100,0	0,0820	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	North America	67	40,9			67	100,0	72	43,4			72	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6			19	100,0	17	10,2			17	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	1	2,4	41	97,6	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	Intermediate (2)	51	31,1			51	100,0	57	34,3			57	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	3	4,7	61	95,3	67	40,4			67	100,0	0,0809	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPITHROMS_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:42


POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Thrombocytopenia Grade >= 3, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	18	11,0	146	89,0	166	100,0	25	15,1	141	84,9	0,2674	0,71	0,38	1,31		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	10	11,0	81	89,0	94	56,6	14	14,9	80	85,1	0,3527	0,68	0,30	1,55		Convergence criterion (GCONV=1E-8) satisfied.	0,9689
	Female	73	44,5	8	11,0	65	89,0	72	43,4	11	15,3	61	84,7	0,5356	0,75	0,30	1,87		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	8	12,9	54	87,1	62	37,3	10	16,1	52	83,9	0,6629	0,81	0,32	2,07		Convergence criterion (GCONV=1E-8) satisfied.	0,7896
	>= 60 years	102	62,2	10	9,8	92	90,2	104	62,7	15	14,4	89	85,6	0,2737	0,64	0,28	1,44		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	11	14,1	67	85,9	77	46,4	10	13,0	67	87,0	0,9106	1,05	0,44	2,52		Convergence criterion (GCONV=1E-8) satisfied.	0,0809
	North America	67	40,9	3	4,5	64	95,5	72	43,4	12	16,7	60	83,3	0,0223	0,25	0,07	0,90		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	4	21,1	15	78,9	17	10,2	3	17,6	14	82,4	0,6694	1,38	0,31	6,20		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	5	11,9	37	88,1	35	21,1	3	8,6	32	91,4	0,8480	1,16	0,26	5,19		Convergence criterion (GCONV=1E-8) satisfied.	0,6487
	Intermediate (2)	51	31,1	7	13,7	44	86,3	57	34,3	11	19,3	46	80,7	0,5667	0,76	0,29	1,96		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	6	9,4	58	90,6	67	40,4	9	13,4	58	86,6	0,4533	0,67	0,24	1,90		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2	2	28,6	5	71,4	0,1732	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPITHROM3_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:42

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Thrombocytopenia, Complete Study Duration
STUDY: GO01297




Patients at risk									
G-Benda	164	109	84	71	62	54	45	32	20	7
Benda	166	11	5							
Patients censored									
G-Benda	0	31	56	68	77	85	94	107	119	132
Benda	0	115	121							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPITHROM_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 15:20

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Thrombocytopenia Serious, Complete Study Duration
STUDY: GO01297




Patients at risk									
G-Benda	164	125	97	81	70	62	48	35	20	7
Benda	166	15	6							
Patients censored									
G-Benda	0	36	64	79	90	98	112	125	140	153
Benda	0	151	160							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPITHROMS_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 16:51

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Thrombocytopenia Grade >= 3, Complete Study Duration
STUDY: GO01297



Patients at risk									
G-Benda	164	116	90	75	65	57	46	33	20	7
Benda	166	13	6							
Patients censored									
G-Benda	0	31	57	71	81	89	100	113	126	139
Benda	0	128	135							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPITHROM3_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 16:11

58 (Anhang): Ergebnisse für Tumorlyse-Syndrom (TLS) nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients

ENDPOINT: Tumor Lysis Syndrome, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297

Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	1	0,6	163	99,4	166	100,0	2	1,2	164	98,8	0,5781	0,51	0,05	5,65		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	1	1,1	90	98,9	94	56,6	1	1,1	93	98,9	0,9754	1,04	0,07	16,70		Convergence criterion (GCONV=1E-8) satisfied.	0,2996
	Female	73	44,5			73	100,0	72	43,4	1	1,4	71	98,6	0,3173	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8			62	100,0	62	37,3			62	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9975
	>= 60 years	102	62,2	1	1,0	101	99,0	104	62,7	2	1,9	102	98,1	0,5790	0,51	0,05	5,66		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	1	1,3	77	98,7	77	46,4	1	1,3	76	98,7	0,9963	1,01	0,06	16,09		Convergence criterion (GCONV=1E-8) satisfied.	0,6079
	North America	67	40,9			67	100,0	72	43,4	1	1,4	71	98,6	0,3420	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6			19	100,0	17	10,2			17	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6			42	100,0	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,1550
	Intermediate (2)	51	31,1			51	100,0	57	34,3	2	3,5	55	96,5	0,1834	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	1	1,6	63	98,4	67	40,4			67	100,0	0,3062	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPITLS_FOLY_SE_30NOV2018_01297.xls

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Tumor Lysis Syndrome Serious, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297

Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0			164	100,0	166	100,0	2	1,2	164	98,8	0,1618	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5			91	100,0	94	56,6	1	1,1	93	98,9	0,3278	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9979
	Female	73	44,5			73	100,0	72	43,4	1	1,4	71	98,6	0,3173	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8			62	100,0	62	37,3			62	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9970
	>= 60 years	102	62,2			102	100,0	104	62,7	2	1,9	102	98,1	0,1614	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6			78	100,0	77	46,4	1	1,3	76	98,7	0,3173	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	North America	67	40,9			67	100,0	72	43,4	1	1,4	71	98,6	0,3420	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6			19	100,0	17	10,2			17	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6			42	100,0	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	1,0000
	Intermediate (2)	51	31,1			51	100,0	57	34,3	2	3,5	55	96,5	0,1834	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0			64	100,0	67	40,4			67	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPITLSS_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:54

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Tumor Lysis Syndrome Grade >= 3, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)


		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	1	0,6	163	99,4	166	100,0	2	1,2	164	98,8	0,5781	0,51	0,05	5,65		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	1	1,1	90	98,9	94	56,6	1	1,1	93	98,9	0,9754	1,04	0,07	16,70		Convergence criterion (GCONV=1E-8) satisfied.	0,2996
	Female	73	44,5			73	100,0	72	43,4	1	1,4	71	98,6	0,3173	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8			62	100,0	62	37,3			62	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,9975
	>= 60 years	102	62,2	1	1,0	101	99,0	104	62,7	2	1,9	102	98,1	0,5790	0,51	0,05	5,66		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	1	1,3	77	98,7	77	46,4	1	1,3	76	98,7	0,9963	1,01	0,06	16,09		Convergence criterion (GCONV=1E-8) satisfied.	0,6079
	North America	67	40,9			67	100,0	72	43,4	1	1,4	71	98,6	0,3420	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6			19	100,0	17	10,2			17	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6			42	100,0	35	21,1			35	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,1550
	Intermediate (2)	51	31,1			51	100,0	57	34,3	2	3,5	55	96,5	0,1834	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	1	1,6	63	98,4	67	40,4			67	100,0	0,3062	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPITLS3_FOLY_SE_30NOV2018_01297.xls

04OCT2019 19:44

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Tumor Lysis Syndrome, Complete Study Duration
STUDY: GO01297




Patients at risk										
G-Benda	164	125	97	81	70	62	48	35	20	7
Benda	166	15	6							
Patients censored										
G-Benda	0	38	66	82	93	101	115	128	143	156
Benda	0	149	158							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPITLS_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 15:20

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Tumor Lysis Syndrome Serious, Complete Study Duration
STUDY: GO01297




Patients at risk									
G-Benda	164	125	97	81	70	62	48	35	20	7
Benda	166	15	6							
Patients censored									
G-Benda	0	39	67	83	94	102	116	129	144	157
Benda	0	149	158							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPITLSS_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 16:52

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Tumor Lysis Syndrome Grade >= 3, Complete Study Duration
STUDY: GO01297



Patients at risk									
G-Benda	164	125	97	81	70	62	48	35	20	7
Benda	166	15	6							
Patients censored									
G-Benda	0	38	66	82	93	101	115	128	143	156
Benda	0	149	158							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPITLS3_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 16:11

59 (Anhang): Ergebnisse für Kardiale Ereignisse nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Cardiac Events, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	22	13,4	142	86,6	166	100,0	10	6,0	156	94,0	0,8175	1,10	0,49	2,49		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	14	15,4	77	84,6	94	56,6	5	5,3	89	94,7	0,9077	1,07	0,35	3,30		Convergence criterion (GCONV=1E-8) satisfied.	0,4108
	Female	73	44,5	8	11,0	65	89,0	72	43,4	5	6,9	67	93,1	0,8130	1,15	0,36	3,71		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	7	11,3	55	88,7	62	37,3	1	1,6	61	98,4	0,0907	5,34	0,62	46,01		Convergence criterion (GCONV=1E-8) satisfied.	0,1793
	>= 60 years	102	62,2	15	14,7	87	85,3	104	62,7	9	8,7	95	91,3	0,4868	0,72	0,29	1,80		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	9	11,5	69	88,5	77	46,4	5	6,5	72	93,5	0,8845	0,91	0,27	3,05		Convergence criterion (GCONV=1E-8) satisfied.	0,4633
	North America	67	40,9	11	16,4	56	83,6	72	43,4	3	4,2	69	95,8	0,3385	1,93	0,49	7,59		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	2	10,5	17	89,5	17	10,2	2	11,8	15	88,2	0,5210	0,51	0,06	4,11		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	8	19,0	34	81,0	35	21,1	2	5,7	33	94,3	0,5364	1,70	0,31	9,30		Convergence criterion (GCONV=1E-8) satisfied.	0,5650
	Intermediate (2)	51	31,1	4	7,8	47	92,2	57	34,3	4	7,0	53	93,0	0,3657	0,49	0,10	2,33		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	8	12,5	56	87,5	67	40,4	3	4,5	64	95,5	0,5699	1,51	0,36	6,22		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	2	28,6	5	71,4	7	4,2	1	14,3	6	85,7	0,8043	1,36	0,12	15,33		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable. Clinical
cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPICARD_FOLY_SE_30NOV2018_01297.xls 04OCT2019 19:09


POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients ENDPOINT:
Cardiac Events Serious, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	6	3,7	158	96,3	166	100,0	2	1,2	164	98,8	0,9535	1,05	0,17	6,36		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	4	4,4	87	95,6	94	56,6	1	1,1	93	98,9	0,5677	0,52	0,05	5,11		Convergence criterion (GCONV=1E-8) satisfied.	0,6404
	Female	73	44,5	2	2,7	71	97,3	72	43,4	1	1,4	71	98,6	0,5578	2,02	0,18	22,28		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	2	3,2	60	96,8	62	37,3			62	100,0	0,7257	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,2584
	>= 60 years	102	62,2	4	3,9	98	96,1	104	62,7	2	1,9	102	98,1	0,9543	0,95	0,15	6,16		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	2	2,6	76	97,4	77	46,4			77	100,0	0,2558	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,1680
	North America	67	40,9	2	3,0	65	97,0	72	43,4	2	2,8	70	97,2	0,0612	0,13	0,01	1,23		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	2	10,5	17	89,5	17	10,2			17	100,0	0,3130	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	2	4,8	40	95,2	35	21,1	1	2,9	34	97,1	0,9322	0,89	0,06	14,18		Convergence criterion (GCONV=1E-8) satisfied.	0,3203
	Intermediate (2)	51	31,1	1	2,0	50	98,0	57	34,3			57	100,0	0,5246	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	3	4,7	61	95,3	67	40,4			67	100,0	0,2979	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2	1	14,3	6	85,7	0,0833				*	WARNING: Iteration limit reached without convergence.	

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients ENDPOINT:
Cardiac Events Grade >=3, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	9	5,5	155	94,5	166	100,0	3	1,8	163	98,2	0,8339	0,85	0,19	3,88		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	6	6,6	85	93,4	94	56,6	2	2,1	92	97,9	0,1590	0,31	0,06	1,72		Convergence criterion (GCONV=1E-8) satisfied.	0,9062
	Female	73	44,5	3	4,1	70	95,9	72	43,4	1	1,4	71	98,6	0,3136	3,02	0,31	29,07		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	2	3,2	60	96,8	62	37,3			62	100,0	0,7257	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,2883
	>= 60 years	102	62,2	7	6,9	95	93,1	104	62,7	3	2,9	101	97,1	0,7677	0,79	0,17	3,78		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	4	5,1	74	94,9	77	46,4	1	1,3	76	98,7	0,6537	1,71	0,16	18,01		Convergence criterion (GCONV=1E-8) satisfied.	0,3707
	North America	67	40,9	3	4,5	64	95,5	72	43,4	2	2,8	70	97,2	0,0612	0,13	0,01	1,23		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	2	10,5	17	89,5	17	10,2			17	100,0	0,3130	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	4	9,5	38	90,5	35	21,1	1	2,9	34	97,1	0,6380	1,77	0,16	19,48		Convergence criterion (GCONV=1E-8) satisfied.	0,3522
	Intermediate (2)	51	31,1	1	2,0	50	98,0	57	34,3	1	1,8	56	98,2	0,1879	0,14	<0.01	3,48		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	3	4,7	61	95,3	67	40,4			67	100,0	0,2979	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	1	14,3	6	85,7	7	4,2	1	14,3	6	85,7	0,5637	0,45	0,03	7,37		Convergence criterion (GCONV=1E-8) satisfied.	

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Cardiac Events, Complete Study Duration
STUDY: GO01297



Patients at risk										
G-Benda	164	117	86	73	63	56	43	30	18	6
Benda	166	17	8	1	1					
Patients censored										
G-Benda	0	32	57	70	80	87	99	112	124	136
Benda	0	142	150	156	156					

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPICARD_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 14:57

60 (Anhang): Ergebnisse für Zweitmalignom nach UE, SUE, UE Grad ≥ 3 aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Second malignancies, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297

Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	18	11,0	146	89,0	166	100,0	13	7,8	153	92,2	<.0001	0,13	0,06	0,29		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	13	14,3	78	85,7	94	56,6	9	9,6	85	90,4	<.0001	0,15	0,06	0,39		Convergence criterion (GCONV=1E-8) satisfied.	0,2110
	Female	73	44,5	5	6,8	68	93,2	72	43,4	4	5,6	68	94,4	0,0002	0,12	0,03	0,46		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	2	3,2	60	96,8	62	37,3	2	3,2	60	96,8	0,0011	0,08	0,01	0,56		Convergence criterion (GCONV=1E-8) satisfied.	0,3231
	>= 60 years	102	62,2	16	15,7	86	84,3	104	62,7	11	10,6	93	89,4	<.0001	0,17	0,07	0,38		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	8	10,3	70	89,7	77	46,4	6	7,8	71	92,2	<.0001	0,10	0,03	0,31		Convergence criterion (GCONV=1E-8) satisfied.	0,8888
	North America	67	40,9	9	13,4	58	86,6	72	43,4	6	8,3	66	91,7	0,0002	0,16	0,05	0,48		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	1	5,3	18	94,7	17	10,2	1	5,9	16	94,1	0,2014	0,20	0,01	3,16		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	6	14,3	36	85,7	35	21,1	3	8,6	32	91,4	0,0003	0,11	0,03	0,46		Convergence criterion (GCONV=1E-8) satisfied.	0,9100
	Intermediate (2)	51	31,1	1	2,0	50	98,0	57	34,3	1	1,8	56	98,2	0,0755	0,12	<0.01	1,95		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	9	14,1	55	85,9	67	40,4	8	11,9	59	88,1	<.0001	0,11	0,04	0,32		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	2	28,6	5	71,4	7	4,2	1	14,3	6	85,7	0,8967	1,17	0,11	12,98		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPIMAL_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:29

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Second malignancies Serious, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297

Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	10	6,1	154	93,9	166	100,0	10	6,0	156	94,0	<.0001	0,07	0,03	0,19		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	8	8,8	83	91,2	94	56,6	6	6,4	88	93,6	<.0001	0,10	0,03	0,33		Convergence criterion (GCONV=1E-8) satisfied.	0,0762
	Female	73	44,5	2	2,7	71	97,3	72	43,4	4	5,6	68	94,4	<.0001	0,05	<0.01	0,26		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	2	3,2	60	96,8	62	37,3	1	1,6	61	98,4	0,0434	0,12	0,01	1,39		Convergence criterion (GCONV=1E-8) satisfied.	0,7842
	>= 60 years	102	62,2	8	7,8	94	92,2	104	62,7	9	8,7	95	91,3	<.0001	0,07	0,02	0,22		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	6	7,7	72	92,3	77	46,4	5	6,5	72	93,5	<.0001	0,07	0,02	0,28		Convergence criterion (GCONV=1E-8) satisfied.	0,8512
	North America	67	40,9	3	4,5	64	95,5	72	43,4	4	5,6	68	94,4	<.0001	0,04	<0.01	0,26		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	1	5,3	18	94,7	17	10,2	1	5,9	16	94,1	0,2014	0,20	0,01	3,16		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	3	7,1	39	92,9	35	21,1	1	2,9	34	97,1	<.0001	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,2202
	Intermediate (2)	51	31,1	1	2,0	50	98,0	57	34,3	1	1,8	56	98,2	0,0755	0,12	<0.01	1,95		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	5	7,8	59	92,2	67	40,4	7	10,4	60	89,6	<.0001	0,07	0,02	0,25		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3	1	14,3	6	85,7	7	4,2	1	14,3	6	85,7	0,6660	0,55	0,03	8,78		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPIMALS_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:41


POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Second malignancies Grade >= 3, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)

		G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio					Interaction Test
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
All	n/a	164	100,0	11	6,7	153	93,3	166	100,0	11	6,6	155	93,4	<.0001	0,06	0,02	0,16		Convergence criterion (GCONV=1E-8) satisfied.	
Sex	Male	91	55,5	9	9,9	82	90,1	94	56,6	8	8,5	86	91,5	<.0001	0,08	0,03	0,25		Convergence criterion (GCONV=1E-8) satisfied.	0,0776
	Female	73	44,5	2	2,7	71	97,3	72	43,4	3	4,2	69	95,8	<.0001	0,05	<0.01	0,33		Convergence criterion (GCONV=1E-8) satisfied.	
Age	< 60 years	62	37,8	2	3,2	60	96,8	62	37,3	2	3,2	60	96,8	0,0011	0,08	0,01	0,56		Convergence criterion (GCONV=1E-8) satisfied.	0,6750
	>= 60 years	102	62,2	9	8,8	93	91,2	104	62,7	9	8,7	95	91,3	<.0001	0,06	0,02	0,18		Convergence criterion (GCONV=1E-8) satisfied.	
Geographic region	Western Europe	78	47,6	6	7,7	72	92,3	77	46,4	5	6,5	72	93,5	<.0001	0,06	0,02	0,23		Convergence criterion (GCONV=1E-8) satisfied.	0,9178
	North America	67	40,9	4	6,0	63	94,0	72	43,4	5	6,9	67	93,1	<.0001	0,04	<0.01	0,22		Convergence criterion (GCONV=1E-8) satisfied.	
	Other	19	11,6	1	5,3	18	94,7	17	10,2	1	5,9	16	94,1	0,2014	0,20	0,01	3,16		Convergence criterion (GCONV=1E-8) satisfied.	
FLIPI	Low (0-1)	42	25,6	3	7,1	39	92,9	35	21,1	2	5,7	33	94,3	0,0001	0,06	<0.01	0,42		Convergence criterion (GCONV=1E-8) satisfied.	0,9111
	Intermediate (2)	51	31,1	1	2,0	50	98,0	57	34,3	1	1,8	56	98,2	0,0755	0,12	<0.01	1,95		Convergence criterion (GCONV=1E-8) satisfied.	
	High (>=3)	64	39,0	7	10,9	57	89,1	67	40,4	7	10,4	60	89,6	<.0001	0,08	0,02	0,26		Convergence criterion (GCONV=1E-8) satisfied.	
	Missing/Unknown	7	4,3			7	100,0	7	4,2	1	14,3	6	85,7	0,1138	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ttae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ttae_sg_COMPL_AEPIMAL3_FOLY_SE_30NOV2018_01297.xls
04OCT2019 19:41

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Second malignancies, Complete Study Duration
STUDY: GO01297




Patients at risk										
G-Benda	164	123	91	75	64	55	40	28	17	6
Benda	166	25	13	3	2	2				
Patients censored										
G-Benda	0	38	65	77	87	95	108	118	129	140
Benda	0	140	148	153	153	153				

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPIMAL_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 15:14

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Second malignancies Serious, Complete Study Duration
STUDY: GO01297




Patients at risk										
G-Benda	164	124	94	79	69	60	45	33	19	7
Benda	166	22	12	2	1	1				
Patients censored										
G-Benda	0	39	66	79	89	97	110	121	135	147
Benda	0	143	151	156	156	156				

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPIMALS_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 16:48

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Second malignancies Grade >= 3, Complete Study Duration
STUDY: GO01297



Patients at risk										
G-Benda	164	125	96	80	69	60	45	33	19	7
Benda	166	23	12	3	2	2				
Patients censored										
G-Benda	0	38	65	79	89	97	110	120	134	146
Benda	0	142	150	155	155	155				

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_COMPL_AEPIMAL3_FOLY_SE_30NOV2018_01297.pdf
07OCT2019 16:06

61 (Anhang): Ergebnisse für Hepatitis-B (HBV) Reaktivierung nach UE aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Hepatitis B reactivation (based on laboratory values), Complete Study Duration MODEL:
Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=166)				G-Benda vs. Benda															Benda vs. G-Benda				
		Patients		with Event		Patients		Event		Odds Ratio					Absolute Risk Difference					Relative Risk						Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	18	10,6	166	100,0	21	12,2	0,50		Convergence criterion (GCONV=1E-8) satisfied.	0,05	5,60	-0,006		Algorithm converged.	-0,026	0,014	0,51		Algorithm converged.	0,05	5,53	0,5766		1,98		Algorithm converged.	0,18	21,58
Sex	Male	91	55,5			94	56,6																			1,0000				
	Female	73	44,5	11	11,4	72	43,4	22	22,8	0,49		Convergence criterion (GCONV=1E-8) satisfied.	0,04	5,48	-0,014		Algorithm converged.	-0,060	0,032	0,49		Algorithm converged.	0,05	5,32	0,5602		2,03		Algorithm converged.	0,19	21,87
Age	< 60 years	62	37,8	11	11,6	62	37,3				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 11.286273606 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	0,0508	NE		Algorithm converged.	NE	NE
	>= 60 years	102	62,2			104	62,7	21	21,9		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 9.7776692757 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999		>999.99		Algorithm converged.	0,00	NE
Geographic region	Western Europe	78	47,6			77	46,4	22	22,6		*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			<0.01		Algorithm converged.	0,00	NE	0,9999		>999.99		Algorithm converged.	0,00	NE
	North America	67	40,9	11	11,5	72	43,4				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.775932355 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Other	19	11,6			17	10,2																							
FLIPI	Low (0-1)	42	25,6			35	21,1																							
	Intermediate (2)	51	31,1	12	12,0	57	34,3				*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	High (>=3)	64	39,0			67	40,4	23	23,0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 6.9349020001 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0,00	NE	0,9999		>999.99		Algorithm converged.	0,00	NE
	Missing/Unknown	7	4,3			7	4,2																							

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_base/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_COMPL_AEPIHEP_FOLY_SE_30NOV2018_01297.xls 21JUL2020 12:11

62 (Anhang): Ergebnisse für verlängerte Neutropenie nach UE aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Prolonged Neutropenia, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297 Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=166)				G-Benda vs. Benda																Benda vs. G-Benda				
		Patients		with Event		Patients		Event		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	31	18,8	166	100,0				*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Sex	Male	91	55,5	30	33,3	94	56,6				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Female	73	44,5			72	43,4																								
Age	< 60 years	62	37,8	11	16,6	62	37,3				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 11.286273606 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	1,0000	NE		Algorithm converged.	NE	NE
	>= 60 years	102	62,2	22	20,0	104	62,7				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Geographic region	Western Europe	78	47,6			77	46,4																								
	North America	67	40,9	34	45,5	72	43,4				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 5.8007505281 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Other	19	11,6			17	10,2																								
FLIPI	Low (0-1)	42	25,6	24	48,8	35	21,1				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Intermediate (2)	51	31,1			57	34,3																								
	High (>=3)	64	39,0	11	16,6	67	40,4				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 12.06438181 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown	7	4,3			7	4,2																								

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_base/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_COMPL_AEPIPNEU_FOLY_SE_30NOV2018_01297.xls 21JUL2020 12:10

63 (Anhang): Ergebnisse für spät einsetzende Neutropenie nach UE aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Late Onset Neutropenia, Complete Study Duration
MODEL: Unstratified Analysis STUDY:
GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)				Benda (N=166)				G-Benda vs. Benda																Benda vs. G-Benda				
		Patients		with Event		Patients		Event		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	164	100,0	13	7,9	166	100,0				*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Sex	Male	91	55,5	7	7,7	94	56,6				*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE		Algorithm converged.	NE	NE	NE	1,0000	NE		Algorithm converged.	NE	NE
	Female	73	44,5	6	8,2	72	43,4				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Age	< 60 years	62	37,8	4	6,5	62	37,3				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 4.1573433727 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	1,0000	NE		Algorithm converged.	NE	NE
	>= 60 years	102	62,2	9	8,8	104	62,7				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 3.4080286713 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
Geographic region	Western Europe	78	47,6	7	9,0	77	46,4				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 3.2621933346 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	North America	67	40,9	4	6,0	72	43,4				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Other	19	11,6	2	10,5	17	10,2				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
FLIPI	Low (0-1)	42	25,6	3	7,1	35	21,1				*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Intermediate (2)	51	31,1	5	9,8	57	34,3				*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	High (>=3)	64	39,0	5	7,8	67	40,4				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 3.804560287 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
	Missing/Unknown	7	4,3			7	4,2																							

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_base/qa/program/t_s_ae.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_sg_COMPL_AEPILONEU_FOLY_SE_30NOV2018_01297.xls 21JUL2020 12:10

Anhang 4-G5: Spezifische Verträglichkeit: UE nach SOC/PT (Induktionsphase)

SOC/PT ohne aufgetretene Ereignisse werden im Folgendem nicht dargestellt.

64 (Anhang): Ergebnisse für UE bei ≥ 10 % der Patienten in einem Studienarm nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

All

			G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																Benda vs. G-Benda				
			Patients		Patients		Patients		Patients with		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	n/a	164	100,0	67	40,9	168	100,0	75	44,6	0,86		Convergence criterion (GCONV=1E-8) satisfied.	0,55	1,32	-0,038		Algorithm converged.	-0,144	0,068	0,92		Algorithm converged.	0,71	1,17	0,486		1,09		Algorithm converged.	0,85	1,4
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	n/a	164	100,0	67	40,9	168	100,0	75	44,6	0,86		Convergence criterion (GCONV=1E-8) satisfied.	0,55	1,32	-0,038		Algorithm converged.	-0,144	0,068	0,92		Algorithm converged.	0,71	1,17	0,486		1,09		Algorithm converged.	0,85	1,4
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	n/a	164	100,0	11	6,7	168	100,0	21	12,5	0,5		Convergence criterion (GCONV=1E-8) satisfied.	0,23	1,08	-0,058		Algorithm converged.	-0,121	0,005	0,54		Algorithm converged.	0,27	1,08	0,08		1,86		Algorithm converged.	0,93	3,74
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	n/a	164	100,0	47	28,7	168	100,0	44	26,2	1,13		Convergence criterion (GCONV=1E-8) satisfied.	0,70	1,83	0,025		Algorithm converged.	-0,071	0,121	1,09		Algorithm converged.	0,77	1,55	0,6144		0,91		Algorithm converged.	0,64	1,3
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	n/a	164	100,0	24	14,6	168	100,0	41	24,4	0,53		Convergence criterion (GCONV=1E-8) satisfied.	0,30	0,93	-0,098		Algorithm converged.	-0,182	-0,013	0,60		Algorithm converged.	0,38	0,95	0,0278		1,67		Algorithm converged.	1,06	2,63
CARDIAC DISORDERS	ALL	n/a	164	100,0	13	7,9	168	100,0	7	4,2	1,98		Convergence criterion (GCONV=1E-8) satisfied.	0,77	5,10	0,038		Algorithm converged.	-0,014	0,089	1,90		Algorithm converged.	0,78	4,65	0,1582		0,53		Algorithm converged.	0,22	1,28
EYE DISORDERS	ALL	n/a	164	100,0	17	10,4	168	100,0	11	6,5	1,65		Convergence criterion (GCONV=1E-8) satisfied.	0,75	3,64	0,038		Algorithm converged.	-0,022	0,098	1,58		Algorithm converged.	0,77	3,28	0,2157		0,63		Algorithm converged.	0,31	1,31
EYE DISORDERS	ALL	n/a	164	100,0	17	10,4	168	100,0	11	6,5	1,65		Convergence criterion (GCONV=1E-8) satisfied.	0,75	3,64	0,038		Algorithm converged.	-0,022	0,098	1,58		Algorithm converged.	0,77	3,28	0,2157		0,63		Algorithm converged.	0,31	1,31
GASTROINTESTINAL DISORDERS	ALL	n/a	164	100,0	111	67,7	168	100,0	140	83,3	0,42		Convergence criterion (GCONV=1E-8) satisfied.	0,25	0,71	-0,157		Algorithm converged.	-0,248	-0,065	0,81		Algorithm converged.	0,72	0,92	0,0012		1,23		Algorithm converged.	1,09	1,4
GASTROINTESTINAL DISORDERS	CONSTIPATION	n/a	164	100,0	28	17,1	168	100,0	36	21,4	0,75		Convergence criterion (GCONV=1E-8) satisfied.	0,44	1,31	-0,044		Algorithm converged.	-0,128	0,041	0,80		Algorithm converged.	0,51	1,24	0,3164		1,26		Algorithm converged.	0,8	1,96
GASTROINTESTINAL DISORDERS	DIARRHOEA	n/a	164	100,0	35	21,3	168	100,0	44	26,2	0,76		Convergence criterion (GCONV=1E-8) satisfied.	0,46	1,27	-0,048		Algorithm converged.	-0,140	0,043	0,81		Algorithm converged.	0,55	1,20	0,3014		1,23		Algorithm converged.	0,83	1,81
GASTROINTESTINAL DISORDERS	NAUSEA	n/a	164	100,0	78	47,6	168	100,0	106	63,1	0,53		Convergence criterion (GCONV=1E-8) satisfied.	0,34	0,82	-0,155		Algorithm converged.	-0,261	-0,050	0,75		Algorithm converged.	0,62	0,92	0,0051		1,33		Algorithm converged.	1,09	1,62
GASTROINTESTINAL DISORDERS	VOMITING	n/a	164	100,0	31	18,9	168	100,0	48	28,6	0,58		Convergence criterion (GCONV=1E-8) satisfied.	0,35	0,97	-0,097		Algorithm converged.	-0,188	-0,006	0,66		Algorithm converged.	0,44	0,98	0,0414		1,51		Algorithm converged.	1,02	2,25
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	n/a	164	100,0	106	64,6	168	100,0	117	69,6	0,8		Convergence criterion (GCONV=1E-8) satisfied.	0,50	1,26	-0,05		Algorithm converged.	-0,151	0,051	0,93		Algorithm converged.	0,80	1,08	0,3325		1,08		Algorithm converged.	0,93	1,25
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ASTHENIA	n/a	164	100,0	22	13,4	168	100,0	22	13,1	1,03		Convergence criterion (GCONV=1E-8) satisfied.	0,55	1,94	0,003		Algorithm converged.	-0,070	0,076	1,02		Algorithm converged.	0,59	1,78	0,9316		0,98		Algorithm converged.	0,56	1,69
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	CHILLS	n/a	164	100,0	21	12,8	168	100,0	16	9,5	1,4		Convergence criterion (GCONV=1E-8) satisfied.	0,70	2,78	0,033		Algorithm converged.	-0,035	0,101	1,34		Algorithm converged.	0,73	2,48	0,3445		0,74		Algorithm converged.	0,4	1,37
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	n/a	164	100,0	63	38,4	168	100,0	57	33,9	1,21		Convergence criterion (GCONV=1E-8) satisfied.	0,78	1,90	0,045		Algorithm converged.	-0,058	0,148	1,13		Algorithm converged.	0,85	1,51	0,3956		0,88		Algorithm converged.	0,66	1,18
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	PYREXIA	n/a	164	100,0	33	20,1	168	100,0	31	18,5	1,11		Convergence criterion (GCONV=1E-8) satisfied.	0,65	1,92	0,017		Algorithm converged.	-0,068	0,102	1,09		Algorithm converged.	0,70	1,69	0,6999		0,92		Algorithm converged.	0,59	1,42
INFECTIONS AND INFESTATIONS	ALL	n/a	164	100,0	72	43,9	168	100,0	83	49,4	0,8		Convergence criterion (GCONV=1E-8) satisfied.	0,52	1,23	-0,055		Algorithm converged.	-0,162	0,052	0,89		Algorithm converged.	0,71	1,12	0,3164		1,13		Algorithm converged.	0,89	1,42
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	n/a	164	100,0	104	63,4	168	100,0	103	61,3	1,09		Convergence criterion (GCONV=1E-8) satisfied.	0,70	1,71	0,021		Algorithm converged.	-0,083	0,125	1,03		Algorithm converged.	0,88	1,22	0,6922		0,97		Algorithm converged.	0,82	1,14
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	n/a	164	100,0	103	62,8	168	100,0	101	60,1	1,12		Convergence criterion (GCONV=1E-8) satisfied.	0,72	1,74	0,027		Algorithm converged.	-0,078	0,132	1,04		Algorithm converged.	0,88	1,24	0,6152		0,96		Algorithm converged.	0,81	1,14
INVESTIGATIONS	ALL	n/a	164	100,0	15	9,1	168	100,0	23	13,7	0,63		Convergence criterion (GCONV=1E-8) satisfied.	0,32	1,26	-0,045		Algorithm converged.	-0,114	0,023	0,67		Algorithm converged.	0,36	1,23	0,1978		1,50		Algorithm converged.	0,81	2,77
INVESTIGATIONS	WEIGHT DECREASED	n/a	164	100,0	6	3,7	168	100,0	18	10,7	0,32		Convergence criterion (GCONV=1E-8) satisfied.	0,12	0,82	-0,071		Algorithm converged.	-0,125	-0,016	0,34		Algorithm converged.	0,14	0,84	0,0191		2,93		Algorithm converged.	1,19	7,19
METABOLISM AND NUTRITION DISORDERS	ALL	n/a	164	100,0	43	26,2	168	100,0	52	31,0	0,79		Convergence criterion (GCONV=1E-8) satisfied.	0,49	1,28	-0,047		Algorithm converged.	-0,144	0,050	0,85		Algorithm converged.	0,60	1,19	0,3415		1,18		Algorithm converged.	0,84	1,66
METABOLISM AND NUTRITION DISORDERS	DECREASED APPETITE	n/a	164	100,0	23	14	168	100,0	32	19,0	0,69		Convergence criterion (GCONV=1E-8) satisfied.	0,39	1,24	-0,05		Algorithm converged.	-0,130	0,029	0,74		Algorithm converged.	0,45	1,20	0,2214		1,36		Algorithm converged.	0,83	2,22
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	ALL	n/a	164	100,0	52	31,7	168	100,0	46	27,4	1,23		Convergence criterion (GCONV=1E-8) satisfied.	0,77	1,97	0,043		Algorithm converged.	-0,055	0,141	1,16		Algorithm converged.	0,83	1,62	0,3883		0,86		Algorithm converged.	0,62	1,21
NERVOUS SYSTEM DISORDERS	ALL	n/a	164	100,0	47	28,7	168	100,0	63	37,5	0,67		Convergence criterion (GCONV=1E-8) satisfied.	0,42	1,06	-0,088		Algorithm converged.	-0,189	0,012	0,76		Algorithm converged.	0,56	1,04	0,0897		1,31		Algorithm converged.	0,96	1,78

NERVOUS SYSTEM DISORDERS	HEADACHE	n/a	164	100,0	19	11,6	168	100,0	30	17,9	0,6		Convergence criterion (GCONV=1E-8) satisfied.	0,32	1,12	-0,063		Algorithm converged.	-0,139	0,013	0,65		Algorithm converged.	0,38	1,11	0,1115		1,54		Algorithm converged.	0,9	2,63
PSYCHIATRIC DISORDERS	ALL	n/a	164	100,0	25	15,2	168	100,0	29	17,3	0,86		Convergence criterion (GCONV=1E-8) satisfied.	0,48	1,55	-0,02		Algorithm converged.	-0,100	0,059	0,88		Algorithm converged.	0,54	1,44	0,6188		1,13		Algorithm converged.	0,69	1,85
PSYCHIATRIC DISORDERS	INSOMNIA	n/a	164	100,0	15	9,1	168	100,0	17	10,1	0,89		Convergence criterion (GCONV=1E-8) satisfied.	0,43	1,86	-0,01		Algorithm converged.	-0,073	0,054	0,90		Algorithm converged.	0,47	1,75	0,7641		1,11		Algorithm converged.	0,57	2,14
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	n/a	164	100,0	59	36	168	100,0	63	37,5	0,94		Convergence criterion (GCONV=1E-8) satisfied.	0,60	1,46	-0,015		Algorithm converged.	-0,119	0,088	0,96		Algorithm converged.	0,72	1,27	0,7734		1,04		Algorithm converged.	0,79	1,38
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	n/a	164	100,0	29	17,7	168	100,0	31	18,5	0,95		Convergence criterion (GCONV=1E-8) satisfied.	0,54	1,66	-0,008		Algorithm converged.	-0,090	0,075	0,96		Algorithm converged.	0,61	1,52	0,8555		1,04		Algorithm converged.	0,66	1,65
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ALL	n/a	164	100,0	44	26,8	168	100,0	47	28,0	0,94		Convergence criterion (GCONV=1E-8) satisfied.	0,58	1,53	-0,011		Algorithm converged.	-0,107	0,084	0,96		Algorithm converged.	0,68	1,36	0,8148		1,04		Algorithm converged.	0,73	1,48
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	PRURITUS	n/a	164	100,0	17	10,4	168	100,0	10	6,0	1,83		Convergence criterion (GCONV=1E-8) satisfied.	0,81	4,12	0,044		Algorithm converged.	-0,015	0,103	1,74		Algorithm converged.	0,82	3,69	0,1476		0,57		Algorithm converged.	0,27	1,22
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	RASH	n/a	164	100,0	13	7,9	168	100,0	17	10,1	0,76		Convergence criterion (GCONV=1E-8) satisfied.	0,36	1,63	-0,022		Algorithm converged.	-0,083	0,040	0,78		Algorithm converged.	0,39	1,56	0,4875		1,28		Algorithm converged.	0,64	2,54
VASCULAR DISORDERS	ALL	n/a	164	100,0	41	25	168	100,0	35	20,8	1,27		Convergence criterion (GCONV=1E-8) satisfied.	0,76	2,12	0,042		Algorithm converged.	-0,049	0,132	1,20		Algorithm converged.	0,81	1,78	0,3674		0,83		Algorithm converged.	0,56	1,24
VASCULAR DISORDERS	HYPOTENSION	n/a	164	100,0	19	11,6	168	100,0	3	1,8	7,21		Convergence criterion (GCONV=1E-8) satisfied.	2,09	24,85	0,098		Algorithm converged.	0,045	0,151	0,49		Algorithm converged.	1,96	21,51	0,0022		0,15		Algorithm converged.	0,05	0,51

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/t_s_ae_soc.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/t_s_ae_soc_sg_SOC01_INDUCT_AAE_FOLY_SE_30NOV2018_01297.xls 07OCT2019 10:45

65 (Anhang): Ergebnisse für UE bei ≥ 10 % der Patienten in einem Studienarm nach SOC/PT und mit statistisch signifikantem Ergebnis für die Gesamtpopulation nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01207
Dichotomous Analysis by Subgroups (Safety)

All

			G-Benda (N=164)		Benda (N=168)						G-Benda vs. Benda																		Benda vs. G-Benda				
			Patients		Patients		Patients		Patients with		Odds Ratio					Absolute Risk Difference					Relative Risk								Relative Risk				
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
GASTROINTESTINAL DISORDERS	ALL	Male	91	55,5	58	63,7	95	56,5	75	78,9	0,47		Convergence criterion (GCONV=1E-8) satisfied.	0,24	0,9	-0,152		Algorithm converged.	-0,28	-0,024	0,81		Algorithm converged.	0,67	0,97	0,0245	0.0000000 00002	1,24		Algorithm converged.	1,03	1,49
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Male	91	55,5	12	13,2	95	56,5	24	25,3	0,45		Convergence criterion (GCONV=1E-8) satisfied.	0,21	0,96	-0,121		Algorithm converged.	-0,232	-0,009	0,52		Algorithm converged.	0,28	0,98	0,0433	0.0000000 00003	1,92		Algorithm converged.	1,02	3,6
GASTROINTESTINAL DISORDERS	NAUSEA	Male	91	55,5	45	49,5	95	56,5	64	56,8	0,74		Convergence criterion (GCONV=1E-8) satisfied.	0,42	1,32	-0,074		Algorithm converged.	-0,217	0,069	0,87		Algorithm converged.	0,66	1,14	0,3151	0,1181	1,15		Algorithm converged.	0,88	1,51
GASTROINTESTINAL DISORDERS	VOMITING	Male	91	55,5	13	14,3	95	56,5	25	26,3	0,47		Convergence criterion (GCONV=1E-8) satisfied.	0,22	0,98	-0,12		Algorithm converged.	-0,234	-0,006	0,54		Algorithm converged.	0,3	0,99	0,048	0.0000000 00001	1,84		Algorithm converged.	1,01	3,37
INVESTIGATIONS	WEIGHT DECREASED	Male	91	55,5	3	3,3	95	56,5	11	11,6	0,26		Convergence criterion (GCONV=1E-8) satisfied.	0,07	0,97	-0,083		Algorithm converged.	-0,157	-0,009	0,28		Algorithm converged.	0,08	0,99	0,0477	0.0000000 00005	2,51		Algorithm converged.	1,01	12,18
VASCULAR DISORDERS	HYPOTENSION	Male	91	55,5	13	14,3	95	56,5	1	1,1	15,67		Convergence criterion (GCONV=1E-8) satisfied.	2	122,43	0,132		Algorithm converged.	0,058	0,207	13,57		Algorithm converged.	1,81	101,65	0,0111	0,2291	9,07		Algorithm converged.	<0.01	0,55
GASTROINTESTINAL DISORDERS	ALL	Female	73	44,5	53	72,6	73	43,5	65	89	0,33		Convergence criterion (GCONV=1E-8) satisfied.	0,13	0,8	-0,164		Algorithm converged.	-0,289	-0,039	0,82		Algorithm converged.	0,69	0,96	0,0137		1,23		Algorithm converged.	1,04	1,44
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Female	73	44,5	12	16,4	73	43,5	17	23,3	0,65		Convergence criterion (GCONV=1E-8) satisfied.	0,28	1,48	-0,068		Algorithm converged.	-0,197	0,06	0,71		Algorithm converged.	0,36	1,37	0,3039		1,42		Algorithm converged.	0,73	2,75
GASTROINTESTINAL DISORDERS	NAUSEA	Female	73	44,5	33	45,2	73	43,5	52	71,2	0,33		Convergence criterion (GCONV=1E-8) satisfied.	0,17	0,66	-0,26		Algorithm converged.	-0,415	-0,106	0,63		Algorithm converged.	0,47	0,85	0,0022		1,58		Algorithm converged.	1,18	2,11
GASTROINTESTINAL DISORDERS	VOMITING	Female	73	44,5	18	24,7	73	43,5	23	31,5	0,71		Convergence criterion (GCONV=1E-8) satisfied.	0,34	1,47	-0,068		Algorithm converged.	-0,214	0,077	0,78		Algorithm converged.	0,46	1,32	0,3598		1,28		Algorithm converged.	0,76	2,16
INVESTIGATIONS	WEIGHT DECREASED	Female	73	44,5	3	4,1	73	43,5	7	9,6	0,4		Convergence criterion (GCONV=1E-8) satisfied.	0,1	1,63	-0,055		Algorithm converged.	-0,136	0,027	0,43		Algorithm converged.	0,12	1,59	0,206		2,33		Algorithm converged.	0,63	8,67
VASCULAR DISORDERS	HYPOTENSION	Female	73	44,5	6	8,2	73	43,5	2	2,7	3,18		Convergence criterion (GCONV=1E-8) satisfied.	0,62	16,3	0,055		Algorithm converged.	-0,018	0,128	3		Algorithm converged.	0,63	14,38	0,1694		0,33		Algorithm converged.	0,07	1,6
GASTROINTESTINAL DISORDERS	ALL	< 60 years	62	37,8	43	69,4	63	37,5	67	90,5	0,24		Convergence criterion (GCONV=1E-8) satisfied.	0,09	0,65	-0,211		Algorithm converged.	-0,347	-0,075	0,77		Algorithm converged.	0,64	0,92	0,0046	0.0000000 00002	1,3		Algorithm converged.	1,09	1,57
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	< 60 years	62	37,8	9	14,5	63	37,5	16	25,4	0,5		Convergence criterion (GCONV=1E-8) satisfied.	0,2	1,23	-0,109		Algorithm converged.	-0,248	0,03	0,57		Algorithm converged.	0,27	1,2	0,1372	0.9999999 99999	1,75		Algorithm converged.	0,84	3,66
GASTROINTESTINAL DISORDERS	NAUSEA	< 60 years	62	37,8	34	54,8	63	37,5	50	79,4	0,32		Convergence criterion (GCONV=1E-8) satisfied.	0,14	0,69	-0,245		Algorithm converged.	-0,404	-0,086	0,69		Algorithm converged.	0,53	0,89	0,0051	0.0000000 00002	1,45		Algorithm converged.	1,12	1,87
GASTROINTESTINAL DISORDERS	VOMITING	< 60 years	62	37,8	12	19,4	63	37,5	23	36,5	0,42		Convergence criterion (GCONV=1E-8) satisfied.	0,19	0,94	-0,172		Algorithm converged.	-0,326	-0,017	0,53		Algorithm converged.	0,29	0,97	0,0393	0.9999999 99999	1,89		Algorithm converged.	1,03	3,45
INVESTIGATIONS	WEIGHT DECREASED	< 60 years	62	37,8	3	4,8	63	37,5	7	11,1	0,41		Convergence criterion (GCONV=1E-8) satisfied.	0,1	1,65	-0,063		Algorithm converged.	-0,157	0,031	0,44		Algorithm converged.	0,12	1,61	0,2123	0,6341	2,3		Algorithm converged.	0,62	8,48
VASCULAR DISORDERS	HYPOTENSION	< 60 years	62	37,8	7	11,3	63	37,5			*	*	Quasi-complete separation of data points detected.				*	relative Hessian			NE		Algorithm converged.	NE	NE	NE	0,1113	NE		Algorithm converged.	NE	NE
GASTROINTESTINAL DISORDERS	ALL	>= 60 years	102	62,2	68	66,7	105	62,5	83	79	0,53		Convergence criterion (GCONV=1E-8) satisfied.	0,28	0,99	-0,124		Algorithm converged.	-0,244	-0,004	0,84		Algorithm converged.	0,71	1	0,0481		1,19		Algorithm converged.	1	1,4
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	>= 60 years	102	62,2	15	14,7	105	62,5	25	23,8	0,55		Convergence criterion (GCONV=1E-8) satisfied.	0,27	1,12	-0,091		Algorithm converged.	-0,198	0,016	0,62		Algorithm converged.	0,35	1,1	0,103		1,62		Algorithm converged.	0,91	2,89
GASTROINTESTINAL DISORDERS	NAUSEA	>= 60 years	102	62,2	44	43,1	105	62,5	56	53,3	0,66		Convergence criterion (GCONV=1E-8) satisfied.	0,38	1,15	-0,102		Algorithm converged.	-0,237	0,033	0,81		Algorithm converged.	0,61	1,08	0,1456		1,24		Algorithm converged.	0,93	1,65
GASTROINTESTINAL DISORDERS	VOMITING	>= 60 years	102	62,2	19	18,6	105	62,5	25	23,8	0,73		Convergence criterion (GCONV=1E-8) satisfied.	0,37	1,43	-0,052		Algorithm converged.	-0,163	0,059	0,78		Algorithm converged.	0,46	1,33	0,3646		1,28		Algorithm converged.	0,75	2,17
INVESTIGATIONS	WEIGHT DECREASED	>= 60 years	102	62,2	3	2,9	105	62,5	11	10,5	0,26		Convergence criterion (GCONV=1E-8) satisfied.	0,07	0,96	-0,075		Algorithm converged.	-0,142	-0,008	0,28		Algorithm converged.	0,08	0,98	0,0459		0,56		Algorithm converged.	1,02	12,4
VASCULAR DISORDERS	HYPOTENSION	>= 60 years	102	62,2	12	11,8	105	62,5	3	2,9	4,53		Convergence criterion (GCONV=1E-8) satisfied.	1,24	16,58	0,089		Algorithm converged.	0,019	0,159	4,12		Algorithm converged.	1,2	14,16	0,0248		0,24		Algorithm converged.	0,07	0,84
GASTROINTESTINAL DISORDERS	ALL	North America	87	40,9	52	77,6	73	43,5	64	87,7	0,49		Convergence criterion (GCONV=1E-8) satisfied.	0,2	1,2	-0,101		Algorithm converged.	-0,226	0,025	0,89		Algorithm converged.	0,76	1,03	0,1226		1,13		Algorithm converged.	0,97	1,32
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	North America	87	40,9	6	9	73	43,5	19	26	0,28		Convergence criterion (GCONV=1E-8) satisfied.	0,1	0,75	-0,171		Algorithm converged.	-0,292	-0,049	0,34		Algorithm converged.	0,15	0,81	0,0146		2,91		Algorithm converged.	1,23	6,84
GASTROINTESTINAL DISORDERS	NAUSEA	North America	87	40,9	40	59,7	73	43,5	49	67,1	0,73		Convergence criterion (GCONV=1E-8) satisfied.	0,36	1,45	-0,074		Algorithm converged.	-0,234	0,085	0,89		Algorithm converged.	0,69	1,15	0,3658		1,12		Algorithm converged.	0,87	1,45
GASTROINTESTINAL DISORDERS	VOMITING	North America	87	40,9	15	22,4	73	43,5	23	31,5	0,63		Convergence criterion (GCONV=1E-8) satisfied.	0,29	1,34	-0,091		Algorithm converged.	-0,237	0,055	0,71		Algorithm converged.	0,41	1,24	0,2314		1,41		Algorithm converged.	0,8	2,46
INVESTIGATIONS	WEIGHT DECREASED	North America	87	40,9	1	1,5	73	43,5	8	11	0,12		Convergence criterion (GCONV=1E-8) satisfied.	0,01	1,01	-0,095		Algorithm converged.	-0,172	-0,017	0,14		Algorithm converged.	0,02	1,06	0,0569		7,34		Algorithm converged.	0,94	57,16
VASCULAR DISORDERS	HYPOTENSION	North America	87	40,9	8	11,9	73	43,5	2	2,7	4,81		Convergence criterion (GCONV=1E-8) satisfied.	0,98	23,55	0,092		Algorithm converged.	0,006	0,178	4,36		Algorithm converged.	0,96	19,8	0,0566		0,23		Algorithm converged.	0,05	1,04

GASTROINTESTINAL DISORDERS	ALL	Western Europe	78	47,6	52	66,7	77	45,8	64	83,1	0,41		Convergence criterion (GCONV=1E-8) satisfied.	0,19	0,87	-0,165		Algorithm converged.	-0,298	-0,031	0,8		Algorithm converged.	0,67	0,97	0,0204	9999999 99999	1,25		Algorithm converged.	1,03	1,5
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Western Europe	78	47,6	13	16,7	77	45,8	17	22,1	0,71		Convergence criterion (GCONV=1E-8) satisfied.	0,32	1,58	-0,054		Algorithm converged.	-0,178	0,07	0,75		Algorithm converged.	0,39	1,45	0,3964	9999999 99999	1,32		Algorithm converged.	0,69	2,54
GASTROINTESTINAL DISORDERS	NAUSEA	Western Europe	78	47,6	36	46,2	77	45,8	47	61	0,55		Convergence criterion (GCONV=1E-8) satisfied.	0,29	1,04	-0,149		Algorithm converged.	-0,304	0,006	0,76		Algorithm converged.	0,56	1,02	0,0667	8000000 000001	1,32		Algorithm converged.	0,98	1,78
GASTROINTESTINAL DISORDERS	VOMITING	Western Europe	78	47,6	14	17,9	77	45,8	23	29,9	0,51		Convergence criterion (GCONV=1E-8) satisfied.	0,24	1,09	-0,119		Algorithm converged.	-0,252	0,014	0,6		Algorithm converged.	0,33	1,08	0,0879	8000000 00003	1,66		Algorithm converged.	0,93	2,99
INVESTIGATIONS	WEIGHT DECREASED	Western Europe	78	47,6	4	5,1	77	45,8	10	13	0,36		Convergence criterion (GCONV=1E-8) satisfied.	0,11	1,21	-0,079		Algorithm converged.	-0,168	0,011	0,39		Algorithm converged.	0,13	1,21	0,1027	0,152	2,53		Algorithm converged.	0,83	7,73
VASCULAR DISORDERS	HYPOTENSION	Western Europe	78	47,6	10	12,8	77	45,8				*	Quasi-complete separation of data points detected.				*	Negative of Hessian not			NE		Algorithm converged.	NE	NE	NE	9999999 999997	NE		Algorithm converged.	NE	NE

| | | |

66 (Anhang): Ergebnisse für SUE bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any SAEs, Induction Phase Only
MODEL: Unstratified Analysis STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

All

			G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda															Benda vs. G-Benda				
			Patients		Patients		Patients		Patients		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	n/a	164	100,0	10	6,1	168	100,0	3	1,8	3,57		(GCONV=1E-8) satisfied.	0,96	13,21	0,043		Algorithm converged.	0,001	0,085	3,41		Algorithm converged.	0,96	12,19	0,0585		0,29		Algorithm converged.	0,08	1,05
INFECTIONS AND INFESTATIONS	ALL	n/a	164	100,0	10	6,1	168	100,0	23	13,7	0,41		(GCONV=1E-8) satisfied.	0,19	0,89	-0,076		Algorithm converged.	-0,140	-0,012	0,45		Algorithm converged.	0,22	0,91	0,0257		2,25		Algorithm converged.	1,10	4,57

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical studies/RO5072759/CDPT7395/GO01297/data analysis/ Output: root/clinical studies/RO5072759/CDPT7395/GO01297/data analysis/A 07OCT2019 11:13

67 (Anhang): Ergebnisse SUE bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT und mit statistisch signifikantem Ergebnis für die Gesamtpopulation nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients ENDPOINT: Any SAEs, Induction Phase Only
MODEL: Unstratified Analysis STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

All

			G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																Benda vs. G-Benda				
			Patients		Patients		Patients		Patients		Odds Ratio						Absolute Risk Difference				Relative Risk								Relative Risk				
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL		Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
INFECTIONS AND INFESTATIONS	ALL	Male	91	55,5	9	9,9	95	56,5	11	11,6	0,84		(GCONV=1E-8) satisfied.	0,33	2,13		-0,017		Algorithm converged.	-0,106	0,072	0,85		Algorithm converged.	0,37	1,96	0,7106	0000000 0000008	1,17		Algorithm converged.	0,51	2,69
INFECTIONS AND INFESTATIONS	ALL	Female	73	44,5	1	1,4	73	43,5	12	10,4	0,07		(GCONV=1E-8) satisfied.	<0.01	0,56		-0,151		Algorithm converged.	-0,24	-0,062	0,08		Algorithm converged.	0,01	0,62	0,0156		12		Algorithm converged.	1,6	89,92
INFECTIONS AND INFESTATIONS	ALL	< 60 years	82	37,8			63	37,5	3	4,8		*	separation of data points detected.					*	WARNING: The relative Hessian convergence criterion of 5.0856439 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0	NE	0,9999	9999999 99999	>999.99		Algorithm converged.	0	NE
INFECTIONS AND INFESTATIONS	ALL	>= 60 years	102	62,2	10	9,8	105	62,5	20	19	0,46		(GCONV=1E-8) satisfied.	0,2	1,04		-0,092		Algorithm converged.	-0,187	0,002	0,51		Algorithm converged.	0,25	1,05	0,0662		1,94		Algorithm converged.	0,96	3,95
INFECTIONS AND INFESTATIONS	ALL	North America	67	40,9	3	4,5	73	43,5	8	11	0,38		(GCONV=1E-8) satisfied.	0,1	1,5		-0,065		Algorithm converged.	-0,152	0,022	0,41		Algorithm converged.	0,11	1,48	0,1721		2,45		Algorithm converged.	0,68	8,85
INFECTIONS AND INFESTATIONS	ALL	Western Europe	78	47,6	6	7,7	77	45,8	11	14,3	0,5		(GCONV=1E-8) satisfied.	0,18	1,43		-0,066		Algorithm converged.	-0,164	0,032	0,54		Algorithm converged.	0,21	1,38	0,1985	0000000 00005	1,86		Algorithm converged.	0,72	4,77
INFECTIONS AND INFESTATIONS	ALL	Other	19	11,6	1	5,3	18	10,7	4	22,2	0,19		(GCONV=1E-8) satisfied.	0,02	1,94		-0,17		Algorithm converged.	-0,386	0,047	0,24		Algorithm converged.	0,03	1,92	0,1777		4,22		Algorithm converged.	0,52	34,28
INFECTIONS AND INFESTATIONS	ALL	Low (0-1)	42	25,6			35	20,8	2	5,7		*	separation of data points detected.					*	WARNING: The relative Hessian convergence criterion of 5.4310946707 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0	NE	0,9999	9999999 99999	>999.99		Algorithm converged.	0	NE
INFECTIONS AND INFESTATIONS	ALL	Intermediate (2)	51	31,1	5	9,8	58	34,5	8	13,8	0,68		(GCONV=1E-8) satisfied.	0,21	2,23		-0,04		Algorithm converged.	-0,16	0,081	0,71		Algorithm converged.	0,25	2,04	0,5248		1,41		Algorithm converged.	0,49	4,03
INFECTIONS AND INFESTATIONS	ALL	High (>=3)	64	39	4	6,3	68	40,5	13	19,1	0,28		(GCONV=1E-8) satisfied.	0,09	0,92		-0,129		Algorithm converged.	-0,239	-0,018	0,33		Algorithm converged.	0,11	0,95	0,0401		3,06		Algorithm converged.	1,05	8,89
INFECTIONS AND INFESTATIONS	ALL	Missing/Unknown	7	4,3	1	14,3	7	4,2				*	separation of data points detected.					*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE

68 (Anhang): Ergebnisse für UE Grad ≥ 3 bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

Age

			G-Benda (N=164)				Benda (N=168)				G-Benda vs. Benda																	Benda vs. G-Benda				
			Patients		Patients		Patients		Patients with		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	n/a	164	100,0	59	36,0	168	100,0	60	35,7	1,01		(GCONV=1E-8) satisfied.	0,65	1,58	0,003		Algorithm converged.	-0,101	0,106	1,01		Algorithm converged.	0,76	1,34	0,9604		0,99		Algorithm converged.	0,74	1,32
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	n/a	164	100,0	6	3,7	168	100,0	13	7,7	0,45		(GCONV=1E-8) satisfied.	0,17	1,22	-0,041		Algorithm converged.	-0,090	0,009	0,47		Algorithm converged.	0,18	1,21	0,1195		2,12		Algorithm converged.	0,82	5,43
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	n/a	164	100,0	43	26,2	168	100,0	41	24,4	1,1		(GCONV=1E-8) satisfied.	0,67	1,81	0,018		Algorithm converged.	-0,075	0,112	1,07		Algorithm converged.	0,74	1,56	0,7038		0,93		Algorithm converged.	0,64	1,35
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	n/a	164	100,0	17	10,4	168	100,0	26	15,5	0,63		(GCONV=1E-8) satisfied.	0,33	1,21	-0,051		Algorithm converged.	-0,123	0,021	0,67		Algorithm converged.	0,38	1,19	0,1698		1,49		Algorithm converged.	0,84	2,65
GASTROINTESTINAL DISORDERS	ALL	n/a	164	100,0	13	7,9	168	100,0	9	5,4	1,52		(GCONV=1E-8) satisfied.	0,63	3,66	0,026		Algorithm converged.	-0,028	0,079	1,48		Algorithm converged.	0,65	3,37	0,3503		0,68		Algorithm converged.	0,3	1,54
INFECTIONS AND INFESTATIONS	ALL	n/a	164	100,0	10	6,1	168	100,0	22	13,1	0,43		(GCONV=1E-8) satisfied.	0,20	0,94	-0,070		Algorithm converged.	-0,133	-0,007	0,47		Algorithm converged.	0,23	0,95	0,0364		2,15		Algorithm converged.	1,05	4,39
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	n/a	164	100,0	19	11,6	168	100,0	6	3,6	3,54		(GCONV=1E-8) satisfied.	1,38	9,10	0,080		Algorithm converged.	0,024	0,137	3,24		Algorithm converged.	1,33	7,92	0,0097		0,31		Algorithm converged.	0,13	0,75
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	n/a	164	100,0	15	9,1	168	100,0	6	3,6	2,72		(GCONV=1E-8) satisfied.	1,03	7,19	0,056		Algorithm converged.	0,003	0,108	2,56		Algorithm converged.	1,02	6,44	0,0456		0,39		Algorithm converged.	0,16	0,98

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable. Clinical cut-off: 30NOV2018

Program: root/clinical studies/RO5072759/CDPT7395/GO01297/data anal Output: root/clinical studies/RO5072759/CDPT7395/GO01297/data analy 07OCT2019 10:59

69 (Anhang): Ergebnisse für UE Grad ≥ 3 bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT und mit statistisch signifikantem Ergebnis für die Gesamtpopulation nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

Age

			G-Benda (N=164)		Benda (N=168)						G-Benda vs. Benda																	Benda vs. G-Benda				
			Patients		Patients		Patients		Patients with		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk				
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Male	91	55,5	9	9,9	95	56,5	2	2,1	5,1		(GCONV=1E-8) satisfied.	1,07	24,3	0,078		Algorithm converged.	0,01	0,146	4,7		Algorithm converged.	1,04	21,16	0,0439	0,500900000 00000001	0,21		Algorithm converged.	0,05	0,96
INFECTIONS AND INFESTATIONS	ALL	Male	91	55,5	9	9,9	95	56,5	10	10,5	0,93		Convergence criterion (GCONV=1E-8) satisfied.	0,36	2,41	-0,006		Algorithm converged.	-0,093	0,081	0,94		Algorithm converged.	0,4	2,21	0,8862	0,007300000 0000000001	1,06		Algorithm converged.	0,45	2,5
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Male	91	55,5	7	7,7	95	56,5	2	2,1	3,87		Convergence criterion (GCONV=1E-8) satisfied.	0,78	19,17	0,056		Algorithm converged.	-0,006	0,118	3,65		Algorithm converged.	0,78	17,13	0,1002	0,533900000 00000004	0,27		Algorithm converged.	0,06	1,28
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Female	73	44,5	10	13,7	73	43,5	4	5,5	2,74		Convergence criterion (GCONV=1E-8) satisfied.	0,82	9,17	0,082		Algorithm converged.	-0,012	0,177	2,5		Algorithm converged.	0,82	7,61	0,1067		0,4		Algorithm converged.	0,13	1,22
INFECTIONS AND INFESTATIONS	ALL	Female	73	44,5	1	1,4	73	43,5	12	16,4	9,07		Convergence criterion (GCONV=1E-8) satisfied.	<0.01	0,56	-0,151		Algorithm converged.	-0,24	-0,062	0,08		Algorithm converged.	0,01	0,62	0,0156		12		Algorithm converged.	1,6	89,92
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Female	73	44,5	8	11	73	43,5	4	5,5	2,12		Convergence criterion (GCONV=1E-8) satisfied.	0,61	7,39	0,055		Algorithm converged.	-0,034	0,143	2		Algorithm converged.	0,63	6,35	0,2397		0,5		Algorithm converged.	0,16	1,59
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	< 60 years	62	37,8	8	12,9	63	37,5	2	3,2	4,52		Convergence criterion (GCONV=1E-8) satisfied.	0,92	22,21	0,097		Algorithm converged.	0,003	0,191	4,06		Algorithm converged.	0,9	18,39	0,0686	0,701999999 99999996	0,25		Algorithm converged.	0,05	1,11
INFECTIONS AND INFESTATIONS	ALL	< 60 years	62	37,8			63	37,5	5	7,9		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 3.538902331 is greater than the limit of 0.0001. The convergence is questionable.			<0.01		Algorithm converged.	0	NE	0,9999	0,037499999 999999999	>999.99		Algorithm converged.	0	NE
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	< 60 years	62	37,8	7	11,3	63	37,5	2	3,2	3,88		Convergence criterion (GCONV=1E-8) satisfied.	0,77	19,47	0,081		Algorithm converged.	-0,009	0,171	3,56		Algorithm converged.	0,77	16,45	0,1045	0,572500000 00000001	0,28		Algorithm converged.	0,06	1,3
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	>= 60 years	102	62,2	11	10,8	105	62,5	4	3,8	3,05		Convergence criterion (GCONV=1E-8) satisfied.	0,94	9,92	0,07		Algorithm converged.	-0,001	0,14	2,83		Algorithm converged.	0,93	8,6	0,0665		0,35		Algorithm converged.	0,12	1,07
INFECTIONS AND INFESTATIONS	ALL	>= 60 years	102	62,2	10	9,8	105	62,5	17	16,2	0,56		Convergence criterion (GCONV=1E-8) satisfied.	0,24	1,3	-0,064		Algorithm converged.	-0,155	0,027	0,61		Algorithm converged.	0,29	1,26	0,1792		1,65		Algorithm converged.	0,79	3,43
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	>= 60 years	102	62,2	8	7,8	105	62,5	4	3,8	2,15		Convergence criterion (GCONV=1E-8) satisfied.	0,63	7,37	0,04		Algorithm converged.	-0,023	0,104	2,06		Algorithm converged.	0,64	6,63	0,226		0,49		Algorithm converged.	0,15	1,56
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	North America	67	40,9	6	9	73	43,5				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
INFECTIONS AND INFESTATIONS	ALL	North America	67	40,9	3	4,5	73	43,5	8	11	0,38		Convergence criterion (GCONV=1E-8) satisfied.	0,1	1,5	-0,065		Algorithm converged.	-0,152	0,022	0,41		Algorithm converged.	0,11	1,48	0,1721		2,45		Algorithm converged.	0,68	8,85
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	North America	67	40,9	4	6	73	43,5				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Western Europe	78	47,6	11	14,1	77	45,8	6	7,8	1,94		Convergence criterion (GCONV=1E-8) satisfied.	0,68	5,55	0,063		Algorithm converged.	-0,035	0,161	1,81		Algorithm converged.	0,7	4,65	0,2179		0,55		Algorithm converged.	0,22	1,42
INFECTIONS AND INFESTATIONS	ALL	Western Europe	78	47,6	6	7,7	77	45,8	9	11,7	0,63		Convergence criterion (GCONV=1E-8) satisfied.	0,21	1,86	-0,04		Algorithm converged.	-0,133	0,053	0,66		Algorithm converged.	0,25	1,76	0,4046	0,4894	1,52		Algorithm converged.	0,57	4,06
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Western Europe	78	47,6	9	11,5	77	45,8	6	7,8	1,54		Convergence criterion (GCONV=1E-8) satisfied.	0,52	4,57	0,037		Algorithm converged.	-0,055	0,13	1,48		Algorithm converged.	0,55	3,96	0,4342	0,071199999 999999999	0,68		Algorithm converged.	0,25	1,81
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Other	19	11,6	2	10,5	18	10,7				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
INFECTIONS AND INFESTATIONS	ALL	Other	19	11,6	1	5,3	18	10,7	5	27,8	0,14		Convergence criterion (GCONV=1E-8) satisfied.	0,02	1,39	-0,225		Algorithm converged.	-0,455	0,005	0,19		Algorithm converged.	0,02	1,47	0,1114		5,28		Algorithm converged.	0,68	40,91
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Other	19	11,6	2	10,5	18	10,7				*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE

INJURY, POISONING AND PROCEDURAL COMPLICATIONS		Low (0-1)	42	25,6	4	9,5	35	20,8				*	Separation of data points detected.				*	relative Hessian			NE		Algorithm converged.	NE	NE	NE	0,326400000 00000002	NE		Algorithm converged.	NE	NE
INFECTIONS AND INFESTATIONS	ALL	Low (0-1)	42	25,6			35	20,8	2	5,7		*	Separation of data points detected.				*	relative Hessian			<0.01		Algorithm converged.	0	NE	0,9999	0,089099999 999999999	>999.99		Algorithm converged.	0	NE
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Low (0-1)	42	25,6	2	4,8	35	20,8				*	Separation of data points detected.				*	relative Hessian			NE		Algorithm converged.	NE	NE	NE	0,512000000 00000001	NE		Algorithm converged.	NE	NE
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	diate (2)	61	31,1	6	11,8	58	34,5	3	5,2	2,44		(GCONV=1E-8) satisfied.	0,58	10,33	0,066		Algorithm converged.	-0,039	0,171	2,27		Algorithm converged.	0,6	8,63	0,2272		0,44		Algorithm converged.	0,12	1,67
INFECTIONS AND INFESTATIONS	ALL	diate (2)	61	31,1	5	9,8	58	34,5	5	8,6	1,15		(GCONV=1E-8) satisfied.	0,31	4,23	0,012		Algorithm converged.	-0,097	0,121	1,14		Algorithm converged.	0,35	3,71	0,831		0,88		Algorithm converged.	0,27	2,86
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	diate (2)	61	31,1	5	9,8	58	34,5	3	5,2	1,99		(GCONV=1E-8) satisfied.	0,45	8,79	0,046		Algorithm converged.	-0,053	0,146	1,9		Algorithm converged.	0,48	7,54	0,3641		0,53		Algorithm converged.	0,13	2,1
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	High (>=3)	64	39	7	10,9	68	40,5	9	4,4	2,66		(GCONV=1E-8) satisfied.	0,66	10,77	0,065		Algorithm converged.	-0,025	0,156	2,48		Algorithm converged.	0,67	9,18	0,1739		0,4		Algorithm converged.	0,11	1,49
INFECTIONS AND INFESTATIONS	ALL	High (>=3)	64	39	4	6,3	68	40,5	15	22,1	0,24		(GCONV=1E-8) satisfied.	0,07	0,75	-0,158		Algorithm converged.	-0,273	-0,043	0,28		Algorithm converged.	0,1	0,81	0,0184		0,53		Algorithm converged.	1,24	10,07
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	High (>=3)	64	39	6	9,4	68	40,5	3	4,4	2,24		(GCONV=1E-8) satisfied.	0,54	9,37	0,05		Algorithm converged.	-0,037	0,136	2,12		Algorithm converged.	0,55	8,14	0,2714		0,47		Algorithm converged.	0,12	1,8
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	/Unknown	7	4,3	2	28,6	7	4,2				*	Separation of data points detected.				*	in computing the link			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
INFECTIONS AND INFESTATIONS	ALL	/Unknown	7	4,3	1	14,3	7	4,2				*	Separation of data points detected.				*	in computing the link			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	/Unknown	7	4,3	2	28,6	7	4,2				*	Separation of data points detected.				*	in computing the link			NE		Algorithm converged.	NE	NE	NE		NE		Algorithm converged.	NE	NE

70 (Anhang): Ergebnisse für Abbruchgründe (UE) nach SOC aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs leading to treatment discontinuation, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)	Benda (N=168)
MedDRA System Organ Class	MedDRA Preferred Term	Patients with events n (%)	Patients with events n (%)2
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	7 (4,3)	11 (6,5)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	4 (2,4)	2 (1,2)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	3 (1,8)	1 (0,6)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	2 (1,2)	0 (0,0)
VASCULAR DISORDERS	ALL	2 (1,2)	1 (0,6)
CARDIAC DISORDERS	ALL	1 (0,6)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	1 (0,6)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	1 (0,6)	0 (0,0)
INFECTIONS AND INFESTATIONS	ALL	1 (0,6)	4 (2,4)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	1 (0,6)	3 (1,8)
INVESTIGATIONS	ALL	0 (0,0)	1 (0,6)
METABOLISM AND NUTRITION DISORDERS	ALL	0 (0,0)	2 (1,2)
NERVOUS SYSTEM DISORDERS	ALL	0 (0,0)	2 (1,2)
RENAL AND URINARY DISORDERS	ALL	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ALL	0 (0,0)	0 (0,0)

71 (Anhang): Ergebnisse für Abbruchgründe (UE) nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs leading to treatment discontinuation, Induction Phase Only
MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

		G-Benda (N=164)	Benda (N=168)
MedDRA System Organ Class	MedDRA Preferred Term	Patients with events n (%)	Patients with events n (%)2
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	5 (3,0)	11 (6,5)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	4 (2,4)	2 (1,2)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	3 (1,8)	3 (1,8)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	2 (1,2)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	1 (0,6)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	1 (0,6)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	1 (0,6)	1 (0,6)
HEPATOBILIARY DISORDERS	CHOLESTASIS	1 (0,6)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	1 (0,6)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND	COLORECTAL CANCER	1 (0,6)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND	RENAL CANCER	1 (0,6)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	1 (0,6)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	1 (0,6)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	1 (0,6)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	1 (0,6)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	0 (0,0)	1 (0,6)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	AUTOIMMUNE HAEMOLYTIC ANAEMIA	0 (0,0)	0 (0,0)

BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	0 (0,0)	1 (0,6)
CARDIAC DISORDERS	ATRIAL FIBRILLATION	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PALATAL OEDEMA	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PANCREATITIS	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	PYREXIA	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	0 (0,0)	1 (0,6)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	0 (0,0)	1 (0,6)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	0 (0,0)	1 (0,6)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	0 (0,0)	1 (0,6)
INFECTIONS AND INFESTATIONS	PNEUMONIA	0 (0,0)	1 (0,6)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	0 (0,0)	1 (0,6)
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	0 (0,0)	0 (0,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	0 (0,0)	1 (0,6)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	0 (0,0)	1 (0,6)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	0 (0,0)	1 (0,6)
NERVOUS SYSTEM DISORDERS	HEADACHE	0 (0,0)	1 (0,6)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	0 (0,0)	1 (0,6)
NERVOUS SYSTEM DISORDERS	SYNCOPE	0 (0,0)	1 (0,6)
RENAL AND URINARY DISORDERS	DYSURIA	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	0 (0,0)	1 (0,6)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	0 (0,0)	1 (0,6)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	LARYNGEAL OEDEMA	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	0 (0,0)	1 (0,6)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	THROAT TIGHTNESS	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	PRURITUS	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	RASH	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPERTENSION	0 (0,0)	1 (0,6)
VASCULAR DISORDERS	PHLEBITIS SUPERFICIAL	0 (0,0)	0 (0,0)

72 (Anhang): Ergebnisse für Abbruchgründe (UE) nach SOC/PT nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (Induktionsphase)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients ENDPOINT: AEs leading to treatment discontinuation, Induction Phase Only MODEL: Unstratified Analysis
STUDY: GO01297
Dichotomous Analysis by Subgroups (Safety)

				G-Benda (N=164)	Benda (N=168)
MedDRA System Organ Class	MedDRA Preferred Term	Level		Patients with events n (%)	Patients with events n (%)2
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	Male	sex	5 (5,5)	8 (8,4)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	Female	sex	4 (5,5)	8 (11,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Male	sex	0 (0,0)	1 (1,1)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Female	sex	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	AUTOIMMUNE HAEMOLYTIC ANAEMIA	Male	sex	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	AUTOIMMUNE HAEMOLYTIC ANAEMIA	Female	sex	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	Male	sex	0 (0,0)	1 (1,1)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	Female	sex	0 (0,0)	0 (0,0)

BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	Male	sex	2 (2,2)	3 (3,2)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	Female	sex	2 (2,7)	1 (1,4)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Male	sex	3 (3,3)	7 (7,4)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Female	sex	3 (4,1)	7 (9,6)
CARDIAC DISORDERS	ALL	Male	sex	1 (1,1)	0 (0,0)
CARDIAC DISORDERS	ALL	Female	sex	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ATRIAL FIBRILLATION	Male	sex	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ATRIAL FIBRILLATION	Female	sex	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	Male	sex	1 (1,1)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	Female	sex	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	Male	sex	1 (1,1)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	Female	sex	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	Male	sex	1 (1,1)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	Female	sex	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PALATAL OEDEMA	Male	sex	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PALATAL OEDEMA	Female	sex	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PANCREATITIS	Male	sex	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PANCREATITIS	Female	sex	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	Male	sex	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	Female	sex	3 (4,1)	1 (1,4)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	Male	sex	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	Female	sex	1 (1,4)	1 (1,4)

GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	Male	sex	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	Female	sex	2 (2,7)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	PYREXIA	Male	sex	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	PYREXIA	Female	sex	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	Male	sex	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	Female	sex	1 (1,4)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	Male	sex	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	Female	sex	1 (1,4)	0 (0,0)
INFECTIONS AND INFESTATIONS	ALL	Male	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ALL	Female	sex	1 (1,4)	6 (8,2)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	Male	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	Female	sex	0 (0,0)	1 (1,4)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	Male	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	Female	sex	0 (0,0)	1 (1,4)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	Male	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	Female	sex	0 (0,0)	1 (1,4)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	Male	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	Female	sex	1 (1,4)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	Male	sex	0 (0,0)	0 (0,0)

INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	Female	sex	0 (0,0)	1 (1,4)
INFECTIONS AND INFESTATIONS	PNEUMONIA	Male	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	Female	sex	0 (0,0)	1 (1,4)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	Male	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	Female	sex	0 (0,0)	1 (1,4)
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	Male	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	Female	sex	0 (0,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Male	sex	2 (2,2)	2 (2,1)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Female	sex	2 (2,7)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Male	sex	2 (2,2)	2 (2,1)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Female	sex	2 (2,7)	0 (0,0)
INVESTIGATIONS	ALL	Male	sex	0 (0,0)	1 (1,1)
INVESTIGATIONS	ALL	Female	sex	0 (0,0)	0 (0,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	Male	sex	0 (0,0)	1 (1,1)
INVESTIGATIONS	BLOOD CREATININE INCREASED	Female	sex	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	ALL	Male	sex	0 (0,0)	1 (1,1)
METABOLISM AND NUTRITION DISORDERS	ALL	Female	sex	0 (0,0)	1 (1,4)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	Male	sex	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	Female	sex	0 (0,0)	1 (1,4)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	Male	sex	0 (0,0)	1 (1,1)

METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	Female	sex	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Male	sex	1 (1,1)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Female	sex	1 (1,4)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	Male	sex	1 (1,1)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	Female	sex	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	Male	sex	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	Female	sex	1 (1,4)	0 (0,0)
NERVOUS SYSTEM DISORDERS	ALL	Male	sex	0 (0,0)	2 (2,1)
NERVOUS SYSTEM DISORDERS	ALL	Female	sex	0 (0,0)	1 (1,4)
NERVOUS SYSTEM DISORDERS	HEADACHE	Male	sex	0 (0,0)	1 (1,1)
NERVOUS SYSTEM DISORDERS	HEADACHE	Female	sex	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	Male	sex	0 (0,0)	1 (1,1)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	Female	sex	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	Male	sex	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	Female	sex	0 (0,0)	1 (1,4)
RENAL AND URINARY DISORDERS	ALL	Male	sex	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	ALL	Female	sex	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	DYSURIA	Male	sex	0 (0,0)	0 (0,0)

RENAL AND URINARY DISORDERS	DYSURIA	Female	sex	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	Male	sex	0 (0,0)	3 (3,2)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	Female	sex	1 (1,4)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	Male	sex	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	Female	sex	1 (1,4)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	Male	sex	0 (0,0)	1 (1,1)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	Female	sex	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	Male	sex	0 (0,0)	1 (1,1)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	Female	sex	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	Male	sex	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	Female	sex	1 (1,4)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	LARYNGEAL OEDEMA	Male	sex	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	LARYNGEAL OEDEMA	Female	sex	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	Male	sex	0 (0,0)	1 (1,1)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	Female	sex	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	THROAT TIGHTNESS	Male	sex	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	THROAT TIGHTNESS	Female	sex	0 (0,0)	0 (0,0)

SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ALL	Male	sex	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ALL	Female	sex	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	PRURITUS	Male	sex	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	PRURITUS	Female	sex	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	RASH	Male	sex	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	RASH	Female	sex	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	ALL	Male	sex	2 (2,2)	1 (1,1)
VASCULAR DISORDERS	ALL	Female	sex	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	Male	sex	1 (1,1)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	Female	sex	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPERTENSION	Male	sex	0 (0,0)	1 (1,1)
VASCULAR DISORDERS	HYPERTENSION	Female	sex	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	Male	sex	1 (1,1)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	Female	sex	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	PHLEBITIS SUPERFICIAL	Male	sex	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	PHLEBITIS SUPERFICIAL	Female	sex	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	Western Europe	region	4 (5,1)	6 (7,8)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	North America	region	3 (4,5)	8 (11,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	Other	region	2 (10,5)	2 (11,1)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Western Europe	region	0 (0,0)	0 (0,0)

BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	North America	region	0 (0,0)	1 (1,4)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Other	region	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	AUTOIMMUNE HAEMOLYTIC ANAEMIA	Western Europe	region	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	AUTOIMMUNE HAEMOLYTIC ANAEMIA	North America	region	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	AUTOIMMUNE HAEMOLYTIC ANAEMIA	Other	region	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	Western Europe	region	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	North America	region	0 (0,0)	1 (1,4)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	Other	region	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	Western Europe	region	1 (1,3)	1 (1,3)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	North America	region	2 (3,0)	3 (4,1)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	Other	region	1 (5,3)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Western Europe	region	3 (3,8)	5 (6,5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	North America	region	1 (1,5)	7 (9,6)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Other	region	2 (10,5)	2 (11,1)
CARDIAC DISORDERS	ALL	Western Europe	region	1 (1,3)	0 (0,0)

CARDIAC DISORDERS	ALL	North America	region	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ALL	Other	region	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ATRIAL FIBRILLATION	Western Europe	region	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ATRIAL FIBRILLATION	North America	region	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ATRIAL FIBRILLATION	Other	region	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	Western Europe	region	1 (1,3)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	North America	region	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	Other	region	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	Western Europe	region	1 (1,3)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	North America	region	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	Other	region	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	Western Europe	region	1 (1,3)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	North America	region	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	Other	region	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PALATAL OEDEMA	Western Europe	region	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PALATAL OEDEMA	North America	region	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PALATAL OEDEMA	Other	region	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PANCREATITIS	Western Europe	region	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PANCREATITIS	North America	region	0 (0,0)	0 (0,0)

GASTROINTESTINAL DISORDERS	PANCREATITIS	Other	region	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	Western Europe	region	2 (2,6)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	North America	region	1 (1,5)	1 (1,4)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	Other	region	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	Western Europe	region	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	North America	region	1 (1,5)	1 (1,4)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	Other	region	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	Western Europe	region	2 (2,6)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	North America	region	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	Other	region	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	PYREXIA	Western Europe	region	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	PYREXIA	North America	region	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	PYREXIA	Other	region	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	Western Europe	region	1 (1,3)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	North America	region	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	Other	region	0 (0,0)	0 (0,0)

HEPATOBILIARY DISORDERS	CHOLESTASIS	Western Europe	region	1 (1,3)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	North America	region	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ALL	Western Europe	region	0 (0,0)	5 (6,5)
INFECTIONS AND INFESTATIONS	ALL	North America	region	1 (1,5)	1 (1,4)
INFECTIONS AND INFESTATIONS	ALL	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	Western Europe	region	0 (0,0)	1 (1,3)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	North America	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	Western Europe	region	0 (0,0)	1 (1,3)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	North America	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	Western Europe	region	0 (0,0)	1 (1,3)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	North America	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	Western Europe	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	North America	region	1 (1,5)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	Other	region	0 (0,0)	0 (0,0)

INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	Western Europe	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	North America	region	0 (0,0)	1 (1,4)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	Western Europe	region	0 (0,0)	1 (1,3)
INFECTIONS AND INFESTATIONS	PNEUMONIA	North America	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	Western Europe	region	0 (0,0)	1 (1,3)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	North America	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	Western Europe	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	North America	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	Other	region	0 (0,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Western Europe	region	2 (2,6)	2 (2,6)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	North America	region	2 (3,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Other	region	0 (0,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Western Europe	region	2 (2,6)	2 (2,6)

INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	North America	region	2 (3,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Other	region	0 (0,0)	0 (0,0)
INVESTIGATIONS	ALL	Western Europe	region	0 (0,0)	0 (0,0)
INVESTIGATIONS	ALL	North America	region	0 (0,0)	1 (1,4)
INVESTIGATIONS	ALL	Other	region	0 (0,0)	0 (0,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	Western Europe	region	0 (0,0)	0 (0,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	North America	region	0 (0,0)	1 (1,4)
INVESTIGATIONS	BLOOD CREATININE INCREASED	Other	region	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	ALL	Western Europe	region	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	ALL	North America	region	0 (0,0)	2 (2,7)
METABOLISM AND NUTRITION DISORDERS	ALL	Other	region	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	Western Europe	region	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	North America	region	0 (0,0)	1 (1,4)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	Other	region	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	Western Europe	region	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	North America	region	0 (0,0)	1 (1,4)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	Other	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Western Europe	region	1 (1,3)	0 (0,0)

NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	North America	region	1 (1,5)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Other	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	Western Europe	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	North America	region	1 (1,5)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	Other	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	Western Europe	region	1 (1,3)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	North America	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	Other	region	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	ALL	Western Europe	region	0 (0,0)	1 (1,3)
NERVOUS SYSTEM DISORDERS	ALL	North America	region	0 (0,0)	2 (2,7)
NERVOUS SYSTEM DISORDERS	ALL	Other	region	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	HEADACHE	Western Europe	region	0 (0,0)	1 (1,3)
NERVOUS SYSTEM DISORDERS	HEADACHE	North America	region	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	HEADACHE	Other	region	0 (0,0)	0 (0,0)

NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	Western Europe	region	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	North America	region	0 (0,0)	1 (1,4)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	Other	region	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	Western Europe	region	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	North America	region	0 (0,0)	1 (1,4)
NERVOUS SYSTEM DISORDERS	SYNCOPE	Other	region	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	ALL	Western Europe	region	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	ALL	North America	region	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	ALL	Other	region	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	DYSURIA	Western Europe	region	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	DYSURIA	North America	region	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	DYSURIA	Other	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	Western Europe	region	1 (1,3)	1 (1,3)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	North America	region	0 (0,0)	1 (1,4)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	Other	region	0 (0,0)	1 (5,6)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	Western Europe	region	1 (1,3)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	North America	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	Other	region	0 (0,0)	0 (0,0)

RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	Western Europe	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	North America	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	Other	region	0 (0,0)	1 (5,6)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	Western Europe	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	North America	region	0 (0,0)	1 (1,4)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	Other	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	Western Europe	region	1 (1,3)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	North America	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	Other	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	LARYNGEAL OEDEMA	Western Europe	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	LARYNGEAL OEDEMA	North America	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	LARYNGEAL OEDEMA	Other	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	Western Europe	region	0 (0,0)	1 (1,3)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	North America	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	Other	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	THROAT TIGHTNESS	Western Europe	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	THROAT TIGHTNESS	North America	region	0 (0,0)	0 (0,0)

RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	THROAT TIGHTNESS	Other	region	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ALL	Western Europe	region	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ALL	North America	region	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ALL	Other	region	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	PRURITUS	Western Europe	region	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	PRURITUS	North America	region	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	PRURITUS	Other	region	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	RASH	Western Europe	region	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	RASH	North America	region	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	RASH	Other	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	ALL	Western Europe	region	1 (1,3)	1 (1,3)
VASCULAR DISORDERS	ALL	North America	region	1 (1,5)	0 (0,0)
VASCULAR DISORDERS	ALL	Other	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	Western Europe	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	North America	region	1 (1,5)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	Other	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPERTENSION	Western Europe	region	0 (0,0)	1 (1,3)
VASCULAR DISORDERS	HYPERTENSION	North America	region	0 (0,0)	0 (0,0)

VASCULAR DISORDERS	HYPERTENSION	Other	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	Western Europe	region	1 (1,3)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	North America	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	Other	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	PHLEBITIS SUPERFICIAL	Western Europe	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	PHLEBITIS SUPERFICIAL	North America	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	PHLEBITIS SUPERFICIAL	Other	region	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	Low (0-1)	flip1Gext	2 (4,8)	2 (5,7)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	Intermediate (2)	flip1Gext	5 (9,8)	9 (15,5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	High (>=3)	flip1Gext	2 (3,1)	5 (7,4)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,7)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)

BLOOD AND LYMPHATIC SYSTEM DISORDERS	AUTOIMMUNE HAEMOLYTIC ANAEMIA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	AUTOIMMUNE HAEMOLYTIC ANAEMIA	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	AUTOIMMUNE HAEMOLYTIC ANAEMIA	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	AUTOIMMUNE HAEMOLYTIC ANAEMIA	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,7)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	Low (0-1)	flip1Gext	2 (4,8)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	Intermediate (2)	flip1Gext	2 (3,9)	3 (5,2)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Low (0-1)	flip1Gext	0 (0,0)	2 (5,7)

BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Intermediate (2)	flip1Gext	4 (7,8)	8 (13,8)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	High (>=3)	flip1Gext	2 (3,1)	4 (5,9)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ALL	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
CARDIAC DISORDERS	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ATRIAL FIBRILLATION	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ATRIAL FIBRILLATION	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ATRIAL FIBRILLATION	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ATRIAL FIBRILLATION	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)

CARDIAC DISORDERS	PALPITATIONS	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PALATAL OEDEMA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PALATAL OEDEMA	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PALATAL OEDEMA	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)

GASTROINTESTINAL DISORDERS	PALATAL OEDEMA	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PANCREATITIS	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PANCREATITIS	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PANCREATITIS	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PANCREATITIS	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	High (>=3)	flip1Gext	2 (3,1)	1 (1,5)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	High (>=3)	flip1Gext	1 (1,6)	1 (1,5)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)

GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	PYREXIA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	PYREXIA	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	PYREXIA	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	PYREXIA	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)

HEPATOBILIARY DISORDERS	CHOLESTASIS	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ALL	Low (0-1)	flip1Gext	0 (0,0)	1 (2,9)
INFECTIONS AND INFESTATIONS	ALL	Intermediate (2)	flip1Gext	1 (2,0)	2 (3,4)
INFECTIONS AND INFESTATIONS	ALL	High (>=3)	flip1Gext	0 (0,0)	3 (4,4)
INFECTIONS AND INFESTATIONS	ALL	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)

INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	Low (0-1)	flip1Gext	0 (0,0)	1 (2,9)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)

INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,7)
INFECTIONS AND INFESTATIONS	PNEUMONIA	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,7)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)

INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	High (>=3)	flip1Gext	1 (1,6)	2 (2,9)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Missing/Unknown	flip1Gext	1 (14,3)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	High (>=3)	flip1Gext	1 (1,6)	2 (2,9)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Missing/Unknown	flip1Gext	1 (14,3)	0 (0,0)
INVESTIGATIONS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INVESTIGATIONS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,7)
INVESTIGATIONS	ALL	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
INVESTIGATIONS	ALL	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)

INVESTIGATIONS	BLOOD CREATININE INCREASED	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,7)
INVESTIGATIONS	BLOOD CREATININE INCREASED	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,7)
METABOLISM AND NUTRITION DISORDERS	ALL	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
METABOLISM AND NUTRITION DISORDERS	ALL	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,7)

METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	High (>=3)	flip1Gext	2 (3,1)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)

NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,7)
NERVOUS SYSTEM DISORDERS	ALL	High (>=3)	flip1Gext	0 (0,0)	2 (2,9)
NERVOUS SYSTEM DISORDERS	ALL	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	HEADACHE	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	HEADACHE	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	HEADACHE	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
NERVOUS SYSTEM DISORDERS	HEADACHE	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,7)

NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
NERVOUS SYSTEM DISORDERS	SYNCOPE	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	ALL	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	DYSURIA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	DYSURIA	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	DYSURIA	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)

RENAL AND URINARY DISORDERS	DYSURIA	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	Intermediate (2)	flip1Gext	1 (2,0)	1 (1,7)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	High (>=3)	flip1Gext	0 (0,0)	2 (2,9)

RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,7)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)

RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	LARYNGEAL OEDEMA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	LARYNGEAL OEDEMA	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	LARYNGEAL OEDEMA	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	LARYNGEAL OEDEMA	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)

RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	THROAT TIGHTNESS	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	THROAT TIGHTNESS	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	THROAT TIGHTNESS	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	THROAT TIGHTNESS	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ALL	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ALL	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	PRURITUS	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	PRURITUS	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)

SKIN AND SUBCUTANEOUS TISSUE DISORDERS	PRURITUS	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	PRURITUS	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	RASH	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	RASH	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	RASH	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	RASH	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	ALL	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)
VASCULAR DISORDERS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	ALL	High (>=3)	flip1Gext	1 (1,6)	1 (1,5)
VASCULAR DISORDERS	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)

VASCULAR DISORDERS	FLUSHING	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPERTENSION	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPERTENSION	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPERTENSION	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
VASCULAR DISORDERS	HYPERTENSION	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	PHLEBITIS SUPERFICIAL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	PHLEBITIS SUPERFICIAL	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	PHLEBITIS SUPERFICIAL	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	PHLEBITIS SUPERFICIAL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)

BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	< 60 years	age60	4 (6,5)	6 (9,5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	>= 60 years	age60	5 (4,9)	10 (9,5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	< 60 years	age60	0 (0,0)	1 (1,6)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	>= 60 years	age60	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	AUTOIMMUNE HAEMOLYTIC ANAEMIA	< 60 years	age60	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	AUTOIMMUNE HAEMOLYTIC ANAEMIA	>= 60 years	age60	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	< 60 years	age60	0 (0,0)	1 (1,6)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	>= 60 years	age60	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	< 60 years	age60	2 (3,2)	1 (1,6)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	>= 60 years	age60	2 (2,0)	3 (2,9)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	< 60 years	age60	3 (4,8)	6 (9,5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	>= 60 years	age60	3 (2,9)	8 (7,6)
CARDIAC DISORDERS	ALL	< 60 years	age60	1 (1,6)	0 (0,0)
CARDIAC DISORDERS	ALL	>= 60 years	age60	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ATRIAL FIBRILLATION	< 60 years	age60	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ATRIAL FIBRILLATION	>= 60 years	age60	0 (0,0)	0 (0,0)

CARDIAC DISORDERS	PALPITATIONS	< 60 years	age60	1 (1,6)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	>= 60 years	age60	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	< 60 years	age60	1 (1,6)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	>= 60 years	age60	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	< 60 years	age60	1 (1,6)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	>= 60 years	age60	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PALATAL OEDEMA	< 60 years	age60	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PALATAL OEDEMA	>= 60 years	age60	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PANCREATITIS	< 60 years	age60	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	PANCREATITIS	>= 60 years	age60	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	< 60 years	age60	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	>= 60 years	age60	3 (2,9)	1 (1,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	< 60 years	age60	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	>= 60 years	age60	1 (1,0)	1 (1,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	< 60 years	age60	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	>= 60 years	age60	2 (2,0)	0 (0,0)

GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	PYREXIA	< 60 years	age60	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	PYREXIA	>= 60 years	age60	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	< 60 years	age60	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	>= 60 years	age60	1 (1,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	< 60 years	age60	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	>= 60 years	age60	1 (1,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ALL	< 60 years	age60	0 (0,0)	1 (1,6)
INFECTIONS AND INFESTATIONS	ALL	>= 60 years	age60	1 (1,0)	5 (4,8)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	>= 60 years	age60	0 (0,0)	1 (1,0)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	< 60 years	age60	0 (0,0)	1 (1,6)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	>= 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	>= 60 years	age60	0 (0,0)	1 (1,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	>= 60 years	age60	1 (1,0)	0 (0,0)

INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	>= 60 years	age60	0 (0,0)	1 (1,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	>= 60 years	age60	0 (0,0)	1 (1,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	>= 60 years	age60	0 (0,0)	1 (1,0)
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	>= 60 years	age60	0 (0,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	< 60 years	age60	3 (4,8)	1 (1,6)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	>= 60 years	age60	1 (1,0)	1 (1,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	< 60 years	age60	3 (4,8)	1 (1,6)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	>= 60 years	age60	1 (1,0)	1 (1,0)
INVESTIGATIONS	ALL	< 60 years	age60	0 (0,0)	0 (0,0)
INVESTIGATIONS	ALL	>= 60 years	age60	0 (0,0)	1 (1,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	< 60 years	age60	0 (0,0)	0 (0,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	>= 60 years	age60	0 (0,0)	1 (1,0)

METABOLISM AND NUTRITION DISORDERS	ALL	< 60 years	age60	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	ALL	>= 60 years	age60	0 (0,0)	2 (1,9)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	< 60 years	age60	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	>= 60 years	age60	0 (0,0)	1 (1,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	< 60 years	age60	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	>= 60 years	age60	0 (0,0)	1 (1,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	< 60 years	age60	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	>= 60 years	age60	2 (2,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	< 60 years	age60	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	>= 60 years	age60	1 (1,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	< 60 years	age60	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	>= 60 years	age60	1 (1,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	ALL	< 60 years	age60	0 (0,0)	1 (1,6)
NERVOUS SYSTEM DISORDERS	ALL	>= 60 years	age60	0 (0,0)	2 (1,9)

NERVOUS SYSTEM DISORDERS	HEADACHE	< 60 years	age60	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	HEADACHE	>= 60 years	age60	0 (0,0)	1 (1,0)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	< 60 years	age60	0 (0,0)	1 (1,6)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	>= 60 years	age60	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	< 60 years	age60	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	>= 60 years	age60	0 (0,0)	1 (1,0)
RENAL AND URINARY DISORDERS	ALL	< 60 years	age60	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	ALL	>= 60 years	age60	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	DYSURIA	< 60 years	age60	0 (0,0)	0 (0,0)
RENAL AND URINARY DISORDERS	DYSURIA	>= 60 years	age60	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	< 60 years	age60	1 (1,6)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	>= 60 years	age60	0 (0,0)	3 (2,9)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	< 60 years	age60	1 (1,6)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	>= 60 years	age60	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	< 60 years	age60	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	>= 60 years	age60	0 (0,0)	1 (1,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	< 60 years	age60	0 (0,0)	0 (0,0)

RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	>= 60 years	age60	0 (0,0)	1 (1,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	< 60 years	age60	1 (1,6)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	>= 60 years	age60	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	LARYNGEAL OEDEMA	< 60 years	age60	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	LARYNGEAL OEDEMA	>= 60 years	age60	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	< 60 years	age60	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	>= 60 years	age60	0 (0,0)	1 (1,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	THROAT TIGHTNESS	< 60 years	age60	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	THROAT TIGHTNESS	>= 60 years	age60	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ALL	< 60 years	age60	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ALL	>= 60 years	age60	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	PRURITUS	< 60 years	age60	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	PRURITUS	>= 60 years	age60	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	RASH	< 60 years	age60	0 (0,0)	0 (0,0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	RASH	>= 60 years	age60	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	ALL	< 60 years	age60	1 (1,6)	1 (1,6)
VASCULAR DISORDERS	ALL	>= 60 years	age60	1 (1,0)	0 (0,0)

VASCULAR DISORDERS	FLUSHING	< 60 years	age60	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	>= 60 years	age60	1 (1,0)	0 (0,0)
VASCULAR DISORDERS	HYPERTENSION	< 60 years	age60	0 (0,0)	1 (1,6)
VASCULAR DISORDERS	HYPERTENSION	>= 60 years	age60	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	< 60 years	age60	1 (1,6)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	>= 60 years	age60	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	PHLEBITIS SUPERFICIAL	< 60 years	age60	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	PHLEBITIS SUPERFICIAL	>= 60 years	age60	0 (0,0)	0 (0,0)

Anhang 4-G5: Spezifische Verträglichkeit: UE nach SOC/PT (gesamte Studiendauer)

73 (Anhang): Ergebnisse für UE bei ≥ 10 % der Patienten in einem Studienarm nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)

All

			G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda					
			Patients		Event		Censored		Patients		Event		Censored		log-rank	Hazard Ratio				Interaction Test
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	Convergence Status	p-value (likelihood ratio)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	n/a	164	100,0	85	51,8	79	48,2	166	100,0	76	45,8	90	54,2	0,4127	0,87	0,63	1,21	Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	n/a	164	100,0	15	9,1	149	90,9	166	100,0	27	16,3	139	83,7	0,0003	0,28	0,13	0,57	Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	n/a	164	100,0	60	36,6	104	63,4	166	100,0	44	26,5	122	73,5	0,6780	1,09	0,73	1,63	Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	n/a	164	100,0	25	15,2	139	84,8	166	100,0	40	24,1	126	75,9	0,0528	0,61	0,37	1,01	Convergence criterion (GCONV=1E-8) satisfied.	
CARDIAC DISORDERS	ALL	n/a	164	100,0	22	13,4	142	86,6	166	100,0	10	6,0	156	94,0	0,8175	1,10	0,49	2,49	Convergence criterion (GCONV=1E-8) satisfied.	
EYE DISORDERS	ALL	n/a	164	100,0	25	15,2	139	84,8	166	100,0	15	9,0	151	91,0	0,8788	0,95	0,47	1,90	Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	ALL	n/a	164	100,0	122	74,4	42	25,6	166	100,0	140	84,3	26	15,7	0,0005	0,63	0,49	0,82	Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	ABDOMINAL PAIN	n/a	164	100,0	11	6,7	153	93,3	166	100,0	18	10,8	148	89,2	0,0101	0,34	0,15	0,79	Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	CONSTIPATION	n/a	164	100,0	31	18,9	133	81,1	166	100,0	36	21,7	130	78,3	0,3057	0,77	0,47	1,26	Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	DIARRHOEA	n/a	164	100,0	45	27,4	119	72,6	166	100,0	48	28,9	118	71,1	0,1028	0,70	0,45	1,08	Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	NAUSEA	n/a	164	100,0	85	51,8	79	48,2	166	100,0	104	62,7	62	37,3	0,0150	0,69	0,51	0,93	Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	VOMITING	n/a	164	100,0	35	21,3	129	78,7	166	100,0	47	28,3	119	71,7	0,0664	0,66	0,42	1,03	Convergence criterion (GCONV=1E-8) satisfied.	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	n/a	164	100,0	118	72,0	46	28,0	166	100,0	118	71,1	48	28,9	0,9174	1,01	0,78	1,32	Convergence criterion (GCONV=1E-8) satisfied.	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ASTHENIA	n/a	164	100,0	24	14,6	140	85,4	166	100,0	22	13,3	144	86,7	0,9541	1,02	0,56	1,84	Convergence criterion (GCONV=1E-8) satisfied.	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	CHILLS	n/a	164	100,0	23	14,0	141	86,0	166	100,0	17	10,2	149	89,8	0,4635	1,27	0,67	2,43	Convergence criterion (GCONV=1E-8) satisfied.	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	n/a	164	100,0	68	41,5	96	58,5	166	100,0	59	35,5	107	64,5	0,5233	1,12	0,79	1,61	Convergence criterion (GCONV=1E-8) satisfied.	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	PYREXIA	n/a	164	100,0	43	26,2	121	73,8	166	100,0	33	19,9	133	80,1	0,9496	1,02	0,63	1,64	Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	ALL	n/a	164	100,0	110	67,1	54	32,9	166	100,0	99	59,6	67	40,4	0,0487	0,75	0,56	1,00	Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	BRONCHITIS	n/a	164	100,0	20	12,2	144	87,8	166	100,0	17	10,2	149	89,8	0,0006	0,40	0,24	0,68	Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	NASOPHARYNGITIS	n/a	164	100,0	17	10,4	147	89,6	166	100,0	7	4,2	159	95,8	0,5043	1,37	0,54	3,51	Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	SINUSITIS	n/a	164	100,0	21	12,8	143	87,2	166	100,0	10	6,0	156	94,0	0,7713	0,88	0,38	2,05	Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	n/a	164	100,0	23	14,0	141	86,0	166	100,0	14	8,4	152	91,6	0,0418	0,57	0,33	0,98	Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	n/a	164	100,0	111	67,7	53	32,3	166	100,0	105	63,3	61	36,7	0,4607	1,12	0,83	1,51	Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	n/a	164	100,0	106	64,6	58	35,4	166	100,0	101	60,8	65	39,2	0,3156	1,17	0,86	1,58	Convergence criterion (GCONV=1E-8) satisfied.	
INVESTIGATIONS	ALL	n/a	164	100,0	24	14,6	140	85,4	166	100,0	26	15,7	140	84,3	0,0459	0,53	0,28	1,00	Convergence criterion (GCONV=1E-8) satisfied.	
INVESTIGATIONS	WEIGHT DECREASED	n/a	164	100,0	8	4,9	156	95,1	166	100,0	18	10,8	148	89,2	0,0115	0,32	0,13	0,81	Convergence criterion (GCONV=1E-8) satisfied.	
METABOLISM AND NUTRITION DISORDERS	ALL	n/a	164	100,0	56	34,1	108	65,9	166	100,0	55	33,1	111	66,9	0,2596	0,80	0,54	1,18	Convergence criterion (GCONV=1E-8) satisfied.	
METABOLISM AND NUTRITION DISORDERS	DECREASED APPETITE	n/a	164	100,0	27	16,5	137	83,5	166	100,0	32	19,3	134	80,7	0,2357	0,73	0,43	1,23	Convergence criterion (GCONV=1E-8) satisfied.	
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	ALL	n/a	164	100,0	73	44,5	91	55,5	166	100,0	53	31,9	113	68,1	0,8269	0,96	0,66	1,39	Convergence criterion (GCONV=1E-8) satisfied.	
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	PAIN IN EXTREMITY	n/a	164	100,0	18	11,0	146	89,0	166	100,0	10	6,0	156	94,0	0,7008	1,17	0,52	2,67	Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	n/a	164	100,0	21	12,8	143	87,2	166	100,0	15	9,0	151	91,0	<.0001	0,19	0,09	0,40	Convergence criterion (GCONV=1E-8) satisfied.	
NERVOUS SYSTEM DISORDERS	ALL	n/a	164	100,0	59	36,0	105	64,0	166	100,0	69	41,6	97	58,4	0,0239	0,66	0,45	0,95	Convergence criterion (GCONV=1E-8) satisfied.	
NERVOUS SYSTEM DISORDERS	HEADACHE	n/a	164	100,0	21	12,8	143	87,2	166	100,0	32	19,3	134	80,7	0,0367	0,55	0,31	0,97	Convergence criterion (GCONV=1E-8) satisfied.	
PSYCHIATRIC DISORDERS	ALL	n/a	164	100,0	33	20,1	131	79,9	166	100,0	30	18,1	136	81,9	0,6069	0,87	0,52	1,47	Convergence criterion (GCONV=1E-8) satisfied.	
PSYCHIATRIC DISORDERS	INSOMNIA	n/a	164	100,0	18	11,0	146	89,0	166	100,0	17	10,2	149	89,8	0,8293	0,93	0,47	1,84	Convergence criterion (GCONV=1E-8) satisfied.	
RENAL AND URINARY DISORDERS	ALL	n/a	164	100,0	17	10,4	147	89,6	166	100,0	18	10,8	148	89,2	0,0901	0,53	0,25	1,11	Convergence criterion (GCONV=1E-8) satisfied.	
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	n/a	164	100,0	89	54,3	75	45,7	166	100,0	72	43,4	94	56,6	0,3208	0,84	0,60	1,18	Convergence criterion (GCONV=1E-8) satisfied.	
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	n/a	164	100,0	52	31,7	112	68,3	166	100,0	35	21,1	131	78,9	0,3419	0,79	0,49	1,28	Convergence criterion (GCONV=1E-8) satisfied.	
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	n/a	164	100,0	21	12,8	143	87,2	166	100,0	20	12,0	146	88,0	0,2944	0,70	0,36	1,37	Convergence criterion (GCONV=1E-8) satisfied.	

SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ALL	n/a	164	100,0	64	39,0	100	61,0	166	100,0	54	32,5	112	67,5	0,3617	0,84	0,57	1,23		Convergence criterion (GCONV=1E-8) satisfied.	
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	PRURITUS	n/a	164	100,0	23	14,0	141	86,0	166	100,0	11	6,6	155	93,4	0,2872	1,50	0,71	3,20		Convergence criterion (GCONV=1E-8) satisfied.	
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	RASH	n/a	164	100,0	20	12,2	144	87,8	166	100,0	18	10,8	148	89,2	0,3762	0,73	0,37	1,46		Convergence criterion (GCONV=1E-8) satisfied.	
VASCULAR DISORDERS	ALL	n/a	164	100,0	46	28,0	118	72,0	166	100,0	37	22,3	129	77,7	0,6929	1,10	0,70	1,72		Convergence criterion (GCONV=1E-8) satisfied.	
VASCULAR DISORDERS	HYPOTENSION	n/a	164	100,0	21	12,8	143	87,2	166	100,0	3	1,8	163	98,2	0,0007	6,44	1,88	21,99		Convergence criterion (GCONV=1E-8) satisfied.	

74 (Anhang): Ergebnisse für UE bei ≥ 10 % der Patienten in einem Studienarm nach SOC/PT und mit statistisch signifikantem Ergebnis für die Gesamtpopulation nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)

All


			G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
			Patients		with Event		Censored		Patients		Event		Censored		log-rank	Hazard Ratio					Interaction Test
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
GASTROINTESTINAL DISORDERS	ALL	Male	91	55,5	65	71,4	26	28,6	94	56,6	75	79,8	19	20,2	0,0408	0,69	0,49	0,99		Convergence criterion (GCONV=1E-8) satisfied.	0,5038
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Male	91	55,5	14	15,4	77	84,6	94	56,6	9	9,6	85	90,4	<.0001	0,18	0,07	0,46		Convergence criterion (GCONV=1E-8) satisfied.	0,2123
NERVOUS SYSTEM DISORDERS	ALL	Male	91	55,5	25	27,5	66	72,5	94	56,6	32	34	62	66	0,0791	0,61	0,35	1,06		Convergence criterion (GCONV=1E-8) satisfied.	0,7636
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Male	91	55,5	7	7,7	84	92,3	94	56,6	9	9,6	85	90,4	0,1027	0,4	0,13	1,24		Convergence criterion (GCONV=1E-8) satisfied.	0,3554
GASTROINTESTINAL DISORDERS	ABDOMINAL PAIN	Male	91	55,5	7	7,7	84	92,3	94	56,6	10	10,6	84	89,4	0,0291	0,3	0,1	0,91		Convergence criterion (GCONV=1E-8) satisfied.	0,683
GASTROINTESTINAL DISORDERS	NAUSEA	Male	91	55,5	48	52,7	43	47,3	94	56,6	53	56,4	41	43,6	0,4478	0,85	0,57	1,28		Convergence criterion (GCONV=1E-8) satisfied.	0,1292
INFECTIONS AND INFESTATIONS	BRONCHITIS	Male	91	55,5	10	11	81	89	94	56,6	9	9,6	85	90,4	0,0187	0,43	0,21	0,88		Convergence criterion (GCONV=1E-8) satisfied.	0,9362
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	Male	91	55,5	14	15,4	77	84,6	94	56,6	10	10,6	84	89,4	0,0417	0,51	0,26	0,98		Convergence criterion (GCONV=1E-8) satisfied.	0,2967
INVESTIGATIONS	WEIGHT DECREASED	Male	91	55,5	4	4,4	87	95,6	94	56,6	11	11,7	83	88,3	0,0301	0,27	0,07	0,96		Convergence criterion (GCONV=1E-8) satisfied.	0,5801
NERVOUS SYSTEM DISORDERS	HEADACHE	Male	91	55,5	9	9,9	82	90,1	94	56,6	13	13,8	81	86,2	0,1996	0,56	0,23	1,37		Convergence criterion (GCONV=1E-8) satisfied.	0,7942
VASCULAR DISORDERS	HYPOTENSION	Male	91	55,5	15	16,5	76	83,5	94	56,6	1	1,1	93	98,9	0,0011	14	1,81	108,08		Convergence criterion (GCONV=1E-8) satisfied.	0,1825
GASTROINTESTINAL DISORDERS	ALL	Female																			
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Female																			
NERVOUS SYSTEM DISORDERS	ALL	Female																			
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Female																			
GASTROINTESTINAL DISORDERS	ABDOMINAL PAIN	Female	73	44,5	4	5,5	69	94,5	72	43,4	8	11,1	64	88,9	0,1591	0,42	0,12	1,46		Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	NAUSEA	Female	73	44,5	37	50,7	36	49,3	72	43,4	51	70,8	21	29,2	0,0049	0,53	0,33	0,83		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	BRONCHITIS	Female	73	44,5	10	13,7	63	86,3	72	43,4	8	11,1	64	88,9	0,0125	0,37	0,17	0,82		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	Female	73	44,5	9	12,3	64	87,7	72	43,4	4	5,6	68	94,4	0,5495	0,75	0,28	1,95		Convergence criterion (GCONV=1E-8) satisfied.	
INVESTIGATIONS	WEIGHT DECREASED	Female	73	44,5	4	5,5	69	94,5	72	43,4	7	9,7	65	90,3	0,192	0,42	0,11	1,62		Convergence criterion (GCONV=1E-8) satisfied.	
NERVOUS SYSTEM DISORDERS	HEADACHE	Female	73	44,5	12	16,4	61	83,6	72	43,4	19	26,4	53	73,6	0,0907	0,53	0,25	1,12		Convergence criterion (GCONV=1E-8) satisfied.	
VASCULAR DISORDERS	HYPOTENSION	Female	73	44,5	6	8,2	67	91,8	72	43,4	2	2,8	70	97,2	0,1986	2,79	0,55	14,14		Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	ALL	< 60 years																			
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	< 60 years																			
NERVOUS SYSTEM DISORDERS	ALL	< 60 years																			
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	< 60 years																			
GASTROINTESTINAL DISORDERS	ABDOMINAL PAIN	< 60 years	62	37,8	8	12,9	54	87,1	62	37,3	7	11,3	55	88,7	0,6522	0,78	0,26	2,34		Convergence criterion (GCONV=1E-8) satisfied.	0,0768
GASTROINTESTINAL DISORDERS	NAUSEA	< 60 years	62	37,8	37	59,7	25	40,3	62	37,3	49	79	13	21	0,0179	0,57	0,36	0,91		Convergence criterion (GCONV=1E-8) satisfied.	0,3581
INFECTIONS AND INFESTATIONS	BRONCHITIS	< 60 years	62	37,8	6	9,7	56	90,3	62	37,3	6	9,7	56	90,3	0,0194	0,32	0,12	0,86		Convergence criterion (GCONV=1E-8) satisfied.	0,5528
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	< 60 years	62	37,8	10	16,1	52	83,9	62	37,3	4	6,5	58	93,5	0,8336	0,9	0,35	2,32		Convergence criterion (GCONV=1E-8) satisfied.	0,2045
INVESTIGATIONS	WEIGHT DECREASED	< 60 years	62	37,8	4	6,5	58	93,5	62	37,3	7	11,3	55	88,7	0,1869	0,41	0,11	1,6		Convergence criterion (GCONV=1E-8) satisfied.	0,6366
NERVOUS SYSTEM DISORDERS	HEADACHE	< 60 years	62	37,8	12	19,4	50	80,6	62	37,3	18	29	44	71	0,1541	0,58	0,27	1,24		Convergence criterion (GCONV=1E-8) satisfied.	0,9411
VASCULAR DISORDERS	HYPOTENSION	< 60 years	62	37,8	7	11,3	55	88,7	62	37,3			62	100	0,0067	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,1389
GASTROINTESTINAL DISORDERS	ALL	>= 60 years																			
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	>= 60 years																			
NERVOUS SYSTEM DISORDERS	ALL	>= 60 years																			
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	>= 60 years																			
GASTROINTESTINAL DISORDERS	ABDOMINAL PAIN	>= 60 years	102	62,2	3	2,9	99	97,1	104	62,7	11	10,6	93	89,4	0,0012	0,12	0,03	0,49		Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	NAUSEA	>= 60 years	102	62,2	48	47,1	54	52,9	104	62,7	55	52,9	49	47,1	0,2052	0,77	0,52	1,15		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	BRONCHITIS	>= 60 years	102	62,2	14	13,7	88	86,3	104	62,7	11	10,6	93	89,4	0,0116	0,45	0,24	0,84		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	>= 60 years	102	62,2	13	12,7	89	87,3	104	62,7	10	9,6	94	90,4	0,0144	0,43	0,22	0,86		Convergence criterion (GCONV=1E-8) satisfied.	
INVESTIGATIONS	WEIGHT DECREASED	>= 60 years	102	62,2	4	3,9	98	96,1	104	62,7	11	10,6	93	89,4	0,028	0,26	0,07	0,95		Convergence criterion (GCONV=1E-8) satisfied.	
NERVOUS SYSTEM DISORDERS	HEADACHE	>= 60 years	102	62,2	9	8,8	93	91,2	104	62,7	14	13,5	90	86,5	0,1292	0,51	0,22	1,23		Convergence criterion (GCONV=1E-8) satisfied.	
VASCULAR DISORDERS	HYPOTENSION	>= 60 years	102	62,2	14	13,7	88	86,3	104	62,7	3	2,9	101	97,1	0,0236	3,95	1,1	14,14		Convergence criterion (GCONV=1E-8) satisfied.	

GASTROINTESTINAL DISORDERS	ALL	North America																				
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	North America																				
NERVOUS SYSTEM DISORDERS	ALL	North America																				
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	North America																				
GASTROINTESTINAL DISORDERS	ABDOMINAL PAIN	North America	67	40,9	5	7,5	62	92,5	72	43,4	10	13,9	62	86,1	0,018	0,23	0,07	0,82		Convergence criterion (GCONV=1E-8) satisfied.		
GASTROINTESTINAL DISORDERS	NAUSEA	North America	67	40,9	44	65,7	23	34,3	72	43,4	48	66,7	24	33,3	0,5502	0,88	0,57	1,35		Convergence criterion (GCONV=1E-8) satisfied.		
INFECTIONS AND INFESTATIONS	BRONCHITIS	North America	67	40,9	6	9	61	91	72	43,4	5	6,9	67	93,1	0,09	0,43	0,16	1,16		Convergence criterion (GCONV=1E-8) satisfied.		
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	North America	67	40,9	15	22,4	52	77,6	72	43,4	9	12,5	63	87,5	0,0821	0,55	0,28	1,09		Convergence criterion (GCONV=1E-8) satisfied.		
INVESTIGATIONS	WEIGHT DECREASED	North America	67	40,9	2	3	65	97	72	43,4	8	11,1	64	88,9	0,0171	0,12	0,02	0,96		Convergence criterion (GCONV=1E-8) satisfied.		
NERVOUS SYSTEM DISORDERS	HEADACHE	North America	67	40,9	14	20,9	53	79,1	72	43,4	18	25	54	75	0,2509	0,65	0,31	1,36		Convergence criterion (GCONV=1E-8) satisfied.		
VASCULAR DISORDERS	HYPOTENSION	North America	67	40,9	10	14,9	57	85,1	72	43,4	2	2,8	70	97,2	0,0544	4,16	0,87	19,83		Convergence criterion (GCONV=1E-8) satisfied.		
GASTROINTESTINAL DISORDERS	ALL	Western Europe																				
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Western Europe																				
NERVOUS SYSTEM DISORDERS	ALL	Western Europe																				
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Western Europe																				
GASTROINTESTINAL DISORDERS	ABDOMINAL PAIN	Western Europe	78	47,6	5	6,4	73	93,6	77	46,4	5	6,5	72	93,5	0,3806	0,54	0,13	2,18		Convergence criterion (GCONV=1E-8) satisfied.	0,599	
GASTROINTESTINAL DISORDERS	NAUSEA	Western Europe	78	47,6	39	50	39	50	77	46,4	47	61	30	39	0,0934	0,68	0,44	1,07		Convergence criterion (GCONV=1E-8) satisfied.	0,0446	
INFECTIONS AND INFESTATIONS	BRONCHITIS	Western Europe	78	47,6	12	15,4	66	84,6	77	46,4	8	10,4	69	89,6	0,0387	0,46	0,22	0,97		Convergence criterion (GCONV=1E-8) satisfied.	0,5821	
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	Western Europe	78	47,6	5	6,4	73	93,6	77	46,4	1	1,3	76	98,7	0,7964	1,26	0,22	7,11		Convergence criterion (GCONV=1E-8) satisfied.	0,187	
INVESTIGATIONS	WEIGHT DECREASED	Western Europe	78	47,6	5	6,4	73	93,6	77	46,4	10	13	67	87	0,0902	0,38	0,12	1,22		Convergence criterion (GCONV=1E-8) satisfied.	0,1997	
NERVOUS SYSTEM DISORDERS	HEADACHE	Western Europe	78	47,6	5	6,4	73	93,6	77	46,4	12	15,6	65	84,4	0,0706	0,39	0,14	1,12		Convergence criterion (GCONV=1E-8) satisfied.	0,46	
VASCULAR DISORDERS	HYPOTENSION	Western Europe	78	47,6	10	12,8	68	87,2	77	46,4			77	100	0,0012	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,0978	
GASTROINTESTINAL DISORDERS	ALL	Other																				
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Other																				
NERVOUS SYSTEM DISORDERS	ALL	Other																				
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Other																				
GASTROINTESTINAL DISORDERS	ABDOMINAL PAIN	Other	19	11,6	1	5,3	18	94,7	17	10,2	3	17,6	14	82,4	0,3022	0,32	0,03	3,1		Convergence criterion (GCONV=1E-8) satisfied.		
GASTROINTESTINAL DISORDERS	NAUSEA	Other	19	11,6	2	10,5	17	89,5	17	10,2	9	52,9	8	47,1	0,0073	0,16	0,03	0,74		Convergence criterion (GCONV=1E-8) satisfied.		
INFECTIONS AND INFESTATIONS	BRONCHITIS	Other	19	11,6	2	10,5	17	89,5	17	10,2	4	23,5	13	76,5	0,0206	0,23	0,06	0,86		Convergence criterion (GCONV=1E-8) satisfied.		
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	Other	19	11,6	3	15,8	16	84,2	17	10,2	4	23,5	13	76,5	0,2336	0,5	0,16	1,58		Convergence criterion (GCONV=1E-8) satisfied.		
INVESTIGATIONS	WEIGHT DECREASED	Other	19	11,6	1	5,3	18	94,7	17	10,2			17	100	0,3173	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.		
NERVOUS SYSTEM DISORDERS	HEADACHE	Other	19	11,6	2	10,5	17	89,5	17	10,2	2	11,8	15	88,2	0,8036	0,77	0,1	5,83		Convergence criterion (GCONV=1E-8) satisfied.		
VASCULAR DISORDERS	HYPOTENSION	Other	19	11,6	1	5,3	18	94,7	17	10,2	1	5,9	16	94,1	0,7589	0,65	0,04	10,72		Convergence criterion (GCONV=1E-8) satisfied.		
GASTROINTESTINAL DISORDERS	ALL	Low (0-1)																				
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Low (0-1)																				
NERVOUS SYSTEM DISORDERS	ALL	Low (0-1)																				
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Low (0-1)																				
GASTROINTESTINAL DISORDERS	ABDOMINAL PAIN	Low (0-1)	42	25,6	3	7,1	39	92,9	35	21,1	3	8,6	32	91,4	0,2456	0,28	0,03	2,74		Convergence criterion (GCONV=1E-8) satisfied.	0,0803	
GASTROINTESTINAL DISORDERS	NAUSEA	Low (0-1)	42	25,6	22	52,4	20	47,6	35	21,1	23	65,7	12	34,3	0,3303	0,74	0,4	1,36		Convergence criterion (GCONV=1E-8) satisfied.	0,8562	
INFECTIONS AND INFESTATIONS	BRONCHITIS	Low (0-1)	42	25,6	2	4,8	40	95,2	35	21,1	6	17,1	29	82,9	0,0003	0,08	0,02	0,41		Convergence criterion (GCONV=1E-8) satisfied.	0,0028	
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	Low (0-1)	42	25,6	8	19	34	81	35	21,1	2	5,7	33	94,3	0,4829	1,54	0,46	5,14		Convergence criterion (GCONV=1E-8) satisfied.	0,247	
INVESTIGATIONS	WEIGHT DECREASED	Low (0-1)	42	25,6	2	4,8	40	95,2	35	21,1	5	14,3	30	85,7	0,0604	0,16	0,02	1,41		Convergence criterion (GCONV=1E-8) satisfied.	0,6857	
NERVOUS SYSTEM DISORDERS	HEADACHE	Low (0-1)	42	25,6	7	16,7	35	83,3	35	21,1	11	31,4	24	68,6	0,0794	0,42	0,15	1,14		Convergence criterion (GCONV=1E-8) satisfied.	0,6495	
VASCULAR DISORDERS	HYPOTENSION	Low (0-1)	42	25,6	4	9,5	38	90,5	35	21,1			35	100	0,1093	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,1197	
GASTROINTESTINAL DISORDERS	ALL	Intermediate (2)																				
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Intermediate (2)																				
NERVOUS SYSTEM DISORDERS	ALL	Intermediate (2)																				

BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Intermediate (2)																			
GASTROINTESTINAL DISORDERS	ABDOMINAL PAIN	Intermediate (2)	51	31,1	6	11,8	45	88,2	57	34,3	5	8,8	52	91,2	0,7261	0,79	0,22	2,88		Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	NAUSEA	Intermediate (2)	51	31,1	25	49	26	51	57	34,3	37	64,9	20	35,1	0,1343	0,67	0,39	1,14		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	BRONCHITIS	Intermediate (2)	51	31,1	9	17,6	42	82,4	57	34,3	6	10,5	51	89,5	0,1296	0,52	0,23	1,22		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	Intermediate (2)	51	31,1	5	9,8	46	90,2	57	34,3	6	10,5	51	89,5	0,002	0,23	0,09	0,61		Convergence criterion (GCONV=1E-8) satisfied.	
INVESTIGATIONS	WEIGHT DECREASED	Intermediate (2)	51	31,1	2	3,9	49	96,1	57	34,3	7	12,3	50	87,7	0,0433	0,15	0,02	1,25		Convergence criterion (GCONV=1E-8) satisfied.	
NERVOUS SYSTEM DISORDERS	HEADACHE	Intermediate (2)	51	31,1	7	13,7	44	86,3	57	34,3	9	15,8	48	84,2	0,7212	0,83	0,3	2,28		Convergence criterion (GCONV=1E-8) satisfied.	
VASCULAR DISORDERS	HYPOTENSION	Intermediate (2)	51	31,1	7	13,7	44	86,3	57	34,3			57	100	0,0077	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	ALL	High (>=3)																			
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	High (>=3)																			
NERVOUS SYSTEM DISORDERS	ALL	High (>=3)																			
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	High (>=3)																			
GASTROINTESTINAL DISORDERS	ABDOMINAL PAIN	High (>=3)	64	39	2	3,1	62	96,9	67	40,4	10	14,9	57	85,1	0,0075	0,15	0,03	0,72		Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	NAUSEA	High (>=3)	64	39	33	51,6	31	48,4	67	40,4	38	56,7	29	43,3	0,2038	0,73	0,45	1,19		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	BRONCHITIS	High (>=3)	64	39	9	14,1	55	85,9	67	40,4	5	7,5	62	92,5	0,2339	0,58	0,24	1,42		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	High (>=3)	64	39	9	14,1	55	85,9	67	40,4	5	7,5	62	92,5	0,4212	0,7	0,29	1,69		Convergence criterion (GCONV=1E-8) satisfied.	
INVESTIGATIONS	WEIGHT DECREASED	High (>=3)	64	39	4	6,3	60	93,8	67	40,4	6	9	61	91	0,5107	0,66	0,18	2,33		Convergence criterion (GCONV=1E-8) satisfied.	
NERVOUS SYSTEM DISORDERS	HEADACHE	High (>=3)	64	39	7	10,9	57	89,1	67	40,4	12	17,9	55	82,1	0,0921	0,44	0,16	1,17		Convergence criterion (GCONV=1E-8) satisfied.	
VASCULAR DISORDERS	HYPOTENSION	High (>=3)	64	39	9	14,1	55	85,9	67	40,4	3	4,5	64	95,5	0,1248	2,76	0,72	10,59		Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	ALL	Missing/Unknown																			
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Missing/Unknown																			
NERVOUS SYSTEM DISORDERS	ALL	Missing/Unknown																			
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Missing/Unknown																			
GASTROINTESTINAL DISORDERS	ABDOMINAL PAIN	Missing/Unknown	7	4,3			7	100	7	4,2			7	100	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	NAUSEA	Missing/Unknown	7	4,3	5	71,4	2	28,6	7	4,2	6	85,7	1	14,3	0,0754	0,29	0,07	1,22		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	BRONCHITIS	Missing/Unknown	7	4,3			7	100	7	4,2			7	100	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	UPPER RESPIRATORY TRACT INFECTION	Missing/Unknown	7	4,3	1	14,3	6	85,7	7	4,2	1	14,3	6	85,7	0,4276	0,37	0,03	4,57		Convergence criterion (GCONV=1E-8) satisfied.	
INVESTIGATIONS	WEIGHT DECREASED	Missing/Unknown	7	4,3			7	100	7	4,2			7	100	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
NERVOUS SYSTEM DISORDERS	HEADACHE	Missing/Unknown	7	4,3			7	100	7	4,2			7	100	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
VASCULAR DISORDERS	HYPOTENSION	Missing/Unknown	7	4,3	1	14,3	6	85,7	7	4,2			7	100	0,3173	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) EAR AND LABYRINTH DISORDERS TINNITUS (N=330)




Patients at risk										
G-Benda, < 60 years	62	47	32	31	27	26	19	14	9	5
G-Benda, >= 60 years	102	77	64	49	41	34	27	19	11	2
Benda, < 60 years	62	3	1							
Benda, >= 60 years	104	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS MUCOSAL INFLAMMATION (N=330)




Patients at risk										
G-Benda, < 60 years	62	45	31	30	27	26	19	14	9	5
G-Benda, >= 60 years	102	74	63	48	41	34	27	19	10	1
Benda, < 60 years	62	4	1							
Benda, >= 60 years	104	10	4							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS THIRST (N=330)




Patients at risk										
G-Benda, < 60 years	62	46	31	30	26	25	18	13	8	5
G-Benda, >= 60 years	102	78	65	50	43	36	29	21	11	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	104	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) INFECTIONS AND INFESTATIONS ATYPICAL PNEUMONIA (N=330)




Patients at risk										
G-Benda, < 60 years	64	49	32	31	27	26	19	14	9	5
G-Benda, >= 60 years	102	78	65	50	43	36	29	21	11	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	105	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) INFECTIONS AND INFESTATIONS INFECTION (N=330)




Patients at risk										
G-Benda, < 60 years	63	47	32	31	27	26	19	14	9	5
G-Benda, >= 60 years	102	78	65	50	43	36	29	21	11	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	107	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) INJURY, POISONING AND PROCEDURAL COMPLICATIONS SKIN LACERATION (N=330)




Patients at risk										
G-Benda, < 60 years	62	46	32	30	26	25	18	13	9	5
G-Benda, >= 60 years	102	78	65	50	43	36	29	21	11	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	104	9	4							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) METABOLISM AND NUTRITION DISORDERS DEHYDRATION (N=330)




Patients at risk										
G-Benda, < 60 years	62	47	32	30	26	25	19	14	9	5
G-Benda, >= 60 years	102	77	64	49	42	35	28	20	10	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	104	10	4							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS MUSCLE SPASMS (N=330)




Patients at risk										
G-Benda, < 60 years	62	47	31	30	26	25	18	13	9	5
G-Benda, >= 60 years	102	74	61	47	40	33	26	19	10	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	104	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS PAIN IN EXTREMITY (N=330)




Patients at risk										
G-Benda, < 60 years	62	42	25	24	20	19	14	10	9	5
G-Benda, >= 60 years	102	72	59	45	39	32	26	19	9	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	104	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) MYELODYSPLASTIC SYNDROME (N=330)




Patients at risk										
G-Benda, < 60 years	62	47	32	31	27	26	19	14	9	5
G-Benda, >= 60 years	102	79	66	51	44	37	29	20	11	2
Benda, < 60 years	62	5	2							
Benda, >= 60 years	104	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) NERVOUS SYSTEM DISORDERS NEURALGIA (N=330)




Patients at risk										
G-Benda, < 60 years	62	45	30	29	25	24	18	13	9	5
G-Benda, >= 60 years	102	78	65	50	43	36	29	21	11	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	104	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) NERVOUS SYSTEM DISORDERS NEUROPATHY PERIPHERAL (N=330)




Patients at risk										
G-Benda, < 60 years	62	47	32	31	27	26	19	14	9	5
G-Benda, >= 60 years	102	77	64	49	42	35	28	20	10	2
Benda, < 60 years	62	3								
Benda, >= 60 years	104	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS RHINITIS ALLERGIC (N=330)




Patients at risk										
G-Benda, < 60 years	62	47	32	30	26	25	18	13	9	5
G-Benda, >= 60 years	102	78	65	50	43	36	29	21	11	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	104	13	6							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) SKIN AND SUBCUTANEOUS TISSUE DISORDERS ERYTHEMA (N=330)




Patients at risk										
G-Benda, < 60 years	62	44	29	27	24	23	16	11	7	3
G-Benda, >= 60 years	102	76	64	49	42	35	29	21	11	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	104	11	4							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) VASCULAR DISORDERS HOT FLUSH (N=330)




Patients at risk										
G-Benda, < 60 years	62	47	32	31	27	26	19	14	9	5
G-Benda, >= 60 years	102	75	62	47	40	33	26	18	8	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	104	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Age (N=330) VASCULAR DISORDERS ORTHOSTATIC HYPOTENSION (N=330)




Patients at risk										
G-Benda, < 60 years	62	46	31	30	26	25	18	13	8	5
G-Benda, >= 60 years	102	78	65	50	43	36	29	21	11	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	104	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) BLOOD AND LYMPHATIC SYSTEM DISORDERS FEBRILE NEUTROPENIA (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	31	24	20	14	13	13	11	5	2
G-Benda, Intermediate (2)	51	35	30	25	24	22	12	8	5	3
G-Benda, High (>=3)	64	48	37	30	27	21	19	12	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS INFLUENZA LIKE ILLNESS (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	23	19	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	36	28	24	23	21	11	7	4	2
G-Benda, High (>=3)	64	48	35	29	25	19	17	10	5	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	8	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS OEDEMA PERIPHERAL (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	31	23	18	12	12	12	10	5	2
G-Benda, Intermediate (2)	51	37	30	26	25	23	13	9	6	4
G-Benda, High (>=3)	64	46	34	27	26	20	18	12	6	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) HEPATOBILIARY DISORDERS (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	23	19	13	13	13	11	6	2
G-Benda, Intermediate (2)	51	36	29	25	24	22	12	8	6	4
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	6	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) INFECTIONS AND INFESTATIONS BRONCHITIS (N=316)




Patients at risk										
G-Benda, Low (0-1)	44	33	22	18	13	13	13	12	6	2
G-Benda, Intermediate (2)	60	36	28	20	17	16	8	6	5	3
G-Benda, High (>=3)	73	51	36	27	24	21	19	13	7	1
Benda, Low (0-1)	41									
Benda, Intermediate (2)	63	6	3							
Benda, High (>=3)	72	4	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) INFECTIONS AND INFESTATIONS PNEUMOCYSTIS JIROVECII PNEUMONIA (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	52	38	30	26	25	23	13	9	6	4
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	36									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	68	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) INFECTIONS AND INFESTATIONS SKIN INFECTION (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	37	30	26	25	23	13	9	6	4
G-Benda, High (>=3)	66	52	40	32	28	22	18	12	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	58	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) INJURY, POISONING AND PROCEDURAL COMPLICATIONS HAND FRACTURE (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	37	29	25	24	23	13	9	6	4
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	35	1								
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) METABOLISM AND NUTRITION DISORDERS HYPERLIPIDAEMIA (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	37	30	25	24	22	12	8	5	3
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	6	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS MUSCULOSKELETAL CHEST PAIN (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	32	23	19	13	13	13	11	6	2
G-Benda, Intermediate (2)	51	37	30	26	25	23	13	9	6	4
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) NERVOUS SYSTEM DISORDERS HYPOAESTHESIA (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	36	29	26	25	23	13	9	6	4
G-Benda, High (>=3)	64	48	35	29	25	19	18	11	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	6	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) NERVOUS SYSTEM DISORDERS POLYNEUROPATHY (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	37	30	26	25	23	13	9	6	4
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	36	2								
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) NERVOUS SYSTEM DISORDERS SCIATICA (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	37	30	25	24	22	13	9	6	4
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	6	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) PSYCHIATRIC DISORDERS INSOMNIA (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	28	18	14	8	8	8	7	4	1
G-Benda, Intermediate (2)	51	32	26	23	23	21	12	9	6	4
G-Benda, High (>=3)	64	46	34	28	24	18	17	11	6	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) SKIN AND SUBCUTANEOUS TISSUE DISORDERS HYPERHIDROSIS (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	36	29	24	23	21	12	8	5	3
G-Benda, High (>=3)	64	48	36	30	27	21	19	12	6	1
Benda, Low (0-1)	35	1								
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) VASCULAR DISORDERS JUGULAR VEIN THROMBOSIS (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	37	30	26	25	23	13	9	6	4
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Geographic region (N=330) GASTROINTESTINAL DISORDERS DRY MOUTH (N=330)




Patients at risk										
G-Benda, Western Europe	78	57	41	32	27	23	19	12	7	
G-Benda, North America	67	49	41	36	33	31	24	21	11	6
G-Benda, Other	19	13	11	9	7	6	3	1	1	1
Benda, Western Europe	77	2	1							
Benda, North America	72	7	2							
Benda, Other	17	3	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Geographic region (N=330) GASTROINTESTINAL DISORDERS NAUSEA (N=330)




Patients at risk										
G-Benda, Western Europe	78	29	20	15	11	10	7	4	2	
G-Benda, North America	67	19	16	12	11	9	6	4		
G-Benda, Other	19	12	10	8	6	5	2	1	1	1
Benda, Western Europe	77	3	1							
Benda, North America	72	4	1							
Benda, Other	17	2	1							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Geographic region (N=330) METABOLISM AND NUTRITION DISORDERS HYPERLIPIDAEMIA (N=330)




Patients at risk										
G-Benda, Western Europe	78	58	42	33	27	23	19	12	7	
G-Benda, North America	67	54	44	38	35	32	25	21	11	5
G-Benda, Other	19	13	11	9	7	6	3	1	1	1
Benda, Western Europe	77	5	2							
Benda, North America	72	7	2							
Benda, Other	17	4	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Geographic region (N=330) RENAL AND URINARY DISORDERS POLLAKIURIA (N=330)




Patients at risk										
G-Benda, Western Europe	78	54	39	30	25	21	17	10	5	
G-Benda, North America	67	54	44	38	35	33	26	22	12	6
G-Benda, Other	19	13	11	9	7	6	3	1	1	1
Benda, Western Europe	77	5	2							
Benda, North America	72	7	1							
Benda, Other	17	3	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Geographic region (N=330) VASCULAR DISORDERS (N=330)




Patients at risk										
G-Benda, Western Europe	78	45	34	27	23	20	16	10	5	
G-Benda, North America	67	36	27	23	22	21	18	15	6	4
G-Benda, Other	19	12	10	8	6	5	2			
Benda, Western Europe	77	4	1							
Benda, North America	72	5	2							
Benda, Other	17	1	1							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Sex (N=330) EYE DISORDERS VISION BLURRED (N=330)




Patients at risk										
G-Benda, Male	91	71	52	41	35	31	24	16	9	4
G-Benda, Female	73	50	41	36	31	27	20	17	9	3
Benda, Male	94	10	4							
Benda, Female	72	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Sex (N=330) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS SWELLING (N=330)




Patients at risk										
G-Benda, Male	91	73	54	44	38	34	27	17	10	4
G-Benda, Female	73	51	42	37	32	28	21	18	10	3
Benda, Male	94	10	4							
Benda, Female	72	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Sex (N=330) IMMUNE SYSTEM DISORDERS HYPOGAMMAGLOBULINAEMIA (N=330)




Patients at risk										
G-Benda, Male	91	73	53	42	36	32	24	14	10	4
G-Benda, Female	73	51	42	36	31	27	20	17	10	3
Benda, Male	94	10	4							
Benda, Female	72	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Sex (N=330) INFECTIONS AND INFESTATIONS SEPSIS (N=330)




Patients at risk										
G-Benda, Male	91	74	53	42	36	32	26	16	10	4
G-Benda, Female	73	51	42	37	32	28	21	18	10	3
Benda, Male	94	10	4							
Benda, Female	72	6	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Sex (N=330) METABOLISM AND NUTRITION DISORDERS HYPERLIPIDAEMIA (N=330)




Patients at risk										
G-Benda, Male	91	74	55	43	37	33	26	16	9	3
G-Benda, Female	73	51	42	37	32	28	21	18	10	3
Benda, Male	94	10	4							
Benda, Female	72	6	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Sex (N=330) NERVOUS SYSTEM DISORDERS DIZZINESS (N=330)




Patients at risk										
G-Benda, Male	91	67	49	39	34	30	24	15	8	2
G-Benda, Female	73	50	40	35	31	27	20	17	9	3
Benda, Male	94	9	4							
Benda, Female	72	4	1							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Sex (N=330) NERVOUS SYSTEM DISORDERS NEUROPATHY PERIPHERAL (N=330)




Patients at risk										
G-Benda, Male	91	74	55	44	38	34	27	17	10	4
G-Benda, Female	73	50	41	36	31	27	20	17	9	3
Benda, Male	94	9	3							
Benda, Female	72	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Sex (N=330) PSYCHIATRIC DISORDERS (N=330)




Patients at risk										
G-Benda, Male	91	59	41	31	26	24	20	13	8	4
G-Benda, Female	73	47	36	32	27	24	17	14	8	2
Benda, Male	94	10	4							
Benda, Female	72	4	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any AEs, Complete Study Duration
STUDY: GO01297

Sex (N=330) SKIN AND SUBCUTANEOUS TISSUE DISORDERS ALOPECIA (N=330)



Patients at risk										
G-Benda, Male	91	74	55	44	38	34	27	17	10	4
G-Benda, Female	73	49	40	35	30	26	19	16	8	1
Benda, Male	94	10	4							
Benda, Female	72	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:09

75 (Anhang): Ergebnisse für SUE bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any SAEs, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: BO21223
Dichotomous Analysis by Subgroups (Safety)

All

			G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
			Patients		with		Censored		Patients		with Event		Censored		rank	Hazard Ratio					Interaction Test
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	n/a	164	100,0	20	12,2	144	87,8	166	100,0	8	4,8	158	95,2	0,2741	1,62	0,68	3,87		Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	FEBRILE NEUTROPENIA	n/a	164	100,0	9	5,5	155	94,5	166	100,0	4	2,4	162	97,6	0,5641	1,44	0,41	5,02		Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	ALL	n/a	164	100,0	10	6,1	154	93,9	166	100,0	4	2,4	162	97,6	0,8406	1,14	0,32	4,05		Convergence criterion (GCONV=1E-8) satisfied.	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	n/a	164	100,0	10	6,1	154	93,9	166	100,0	4	2,4	162	97,6	0,8606	1,12	0,31	4,06		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	n/a	164	100,0	5	3,0	159	97,0	166	100,0	9	5,4	157	94,6	0,0004	0,12	0,03	0,41		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	ALL	n/a	164	100,0	24	14,6	140	85,4	166	100,0	32	19,3	134	80,7	<.0001	0,24	0,13	0,46		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	n/a	164	100,0	11	6,7	153	93,3	166	100,0	3	1,8	163	98,2	0,0817	3,01	0,82	11,05		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	n/a	164	100,0	12	7,3	152	92,7	166	100,0	12	7,2	154	92,8	<.0001	0,11	0,04	0,27		Convergence criterion (GCONV=1E-8) satisfied.	

76 (Anhang): Ergebnisse für SUE bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT und mit statistisch signifikantem Ergebnis für die Gesamtpopulation nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any SAEs, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: BO21223
Dichotomous Analysis by Subgroups (Safety)


All

			G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
			Patients		with		Censored		Patients		with Event		Censored		rank	Hazard Ratio					Test
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
INFECTIONS AND INFESTATIONS	ALL	Male	91	55,5	21	23,1	70	76,9	94	56,6	17	18,1	77	81,9	0,0466	0,48	0,23	1,00		Convergence criterion (GCONV=1E-8) satisfied.	0,0010
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Male	91	55,5	9	9,9	82	90,1	94	56,6	6	6,4	88	93,6	0,0002	0,14	0,04	0,44		Convergence criterion (GCONV=1E-8) satisfied.	0,0580
INFECTIONS AND INFESTATIONS	PNEUMONIA	Male	91	55,5	3	3,3	88	96,7	94	56,6	5	5,3	89	94,7	0,0074	0,13	0,03	0,64		Convergence criterion (GCONV=1E-8) satisfied.	0,7039
INFECTIONS AND INFESTATIONS	ALL	Female	73	44,5	3	4,1	70	95,9	72	43,4	15	20,8	57	79,2	<.0001	0,04	<0.01	0,20		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Female	73	44,5	3	4,1	70	95,9	72	43,4	6	8,3	66	91,7	0,0004	0,08	0,02	0,38		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	Female	73	44,5	2	2,7	71	97,3	72	43,4	4	5,6	68	94,4	0,0213	0,10	0,01	0,79		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	ALL	< 60 years	62	37,8	6	9,7	56	90,3	62	37,3	5	8,1	57	91,9	0,0013	0,13	0,03	0,49		Convergence criterion (GCONV=1E-8) satisfied.	0,4242
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	< 60 years	62	37,8	2	3,2	60	96,8	62	37,3	1	1,6	61	98,4	0,0434	0,12	0,01	1,39		Convergence criterion (GCONV=1E-8) satisfied.	0,9465
INFECTIONS AND INFESTATIONS	PNEUMONIA	< 60 years	62	37,8			62	100,0	62	37,3	1	1,6	61	98,4	0,0008	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,3130
INFECTIONS AND INFESTATIONS	ALL	>= 60 years	102	62,2	18	17,6	84	82,4	104	62,7	27	26,0	77	74,0	0,0003	0,29	0,14	0,58		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	>= 60 years	102	62,2	10	9,8	92	90,2	104	62,7	11	10,6	93	89,4	<.0001	0,12	0,04	0,32		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	>= 60 years	102	62,2	5	4,9	97	95,1	104	62,7	8	7,7	96	92,3	0,0039	0,17	0,05	0,60		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	ALL	North America	67	40,9	7	10,4	60	89,6	72	43,4	11	15,3	61	84,7	0,0043	0,19	0,06	0,63		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	North America	67	40,9	4	6,0	63	94,0	72	43,4	4	5,6	68	94,4	0,0005	0,09	0,02	0,44		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	North America	67	40,9	1	1,5	66	98,5	72	43,4	6	8,3	66	91,7	0,0010	0,04	<0.01	0,38		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	ALL	Western Europe	78	47,6	15	19,2	63	80,8	77	46,4	15	19,5	62	80,5	0,0114	0,34	0,14	0,80		Convergence criterion (GCONV=1E-8) satisfied.	0,4928
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Western Europe	78	47,6	7	9,0	71	91,0	77	46,4	7	9,1	70	90,9	0,0001	0,10	0,03	0,37		Convergence criterion (GCONV=1E-8) satisfied.	0,9471
INFECTIONS AND INFESTATIONS	PNEUMONIA	Western Europe	78	47,6	4	5,1	74	94,9	77	46,4	2	2,6	75	97,4	0,4124	0,43	0,05	3,33		Convergence criterion (GCONV=1E-8) satisfied.	0,0943

INFECTIONS AND INFESTATIONS	ALL	Other	19	11,6	2	10,5	17	89,5	17	10,2	6	35,3	11	64,7	0,0059	0,08	<0.01	0,71		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Other	19	11,6	1	5,3	18	94,7	17	10,2	1	5,9	16	94,1	0,2014	0,20	0,01	3,16		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	Other	19	11,6			19	100,0	17	10,2	1	5,9	16	94,1	0,0455	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	ALL	Low (0-1)	42	25,6	2	4,8	40	95,2	35	21,1	4	11,4	31	88,6	0,0001	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,4336
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Low (0-1)	42	25,6	3	7,1	39	92,9	35	21,1	1	2,9	34	97,1	<.0001	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,5189
INFECTIONS AND INFESTATIONS	PNEUMONIA	Low (0-1)	42	25,6			42	100,0	35	21,1	2	5,7	33	94,3	<.0001	<0.01	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,2331
INFECTIONS AND INFESTATIONS	ALL	Intermediate (2)	51	31,1	9	17,6	42	82,4	57	34,3	10	17,5	47	82,5	0,1695	0,49	0,18	1,37		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Intermediate (2)	51	31,1	1	2,0	50	98,0	57	34,3	3	5,3	54	94,7	0,0343	0,09	<0.01	1,04		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	Intermediate (2)	51	31,1	1	2,0	50	98,0	57	34,3	2	3,5	55	96,5	0,3275	0,29	0,02	3,87		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	ALL	High (>=3)	64	39,0	10	15,6	54	84,4	67	40,4	18	26,9	49	73,1	<.0001	0,16	0,06	0,41		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	High (>=3)	64	39,0	7	10,9	57	89,1	67	40,4	7	10,4	60	89,6	0,0003	0,14	0,04	0,46		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	High (>=3)	64	39,0	4	6,3	60	93,8	67	40,4	5	7,5	62	92,5	0,0303	0,19	0,04	0,90		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	ALL	Missing/Unknown	7	4,3	3	42,9	4	57,1	7	4,2			7	100,0	0,1649	>999.99	0,00	NE		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Missing/Unknown	7	4,3	1	14,3	6	85,7	7	4,2	1	14,3	6	85,7	0,6660	0,55	0,03	8,78		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	Missing/Unknown	7	4,3			7	100,0	7	4,2			7	100,0	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any SAEs, Complete Study Duration
STUDY: GO01297

Age (N=330) NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) MYELODYSPLASTIC SYNDROME (N=330)




Patients at risk										
G-Benda, < 60 years	62	47	32	31	27	26	19	14	9	5
G-Benda, >= 60 years	102	78	65	50	43	36	28	20	11	2
Benda, < 60 years	62	5	2							
Benda, >= 60 years	104	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_ASAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:23

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any SAEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) BLOOD AND LYMPHATIC SYSTEM DISORDERS FEBRILE NEUTROPENIA (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	31	24	20	14	13	13	11	5	2
G-Benda, Intermediate (2)	51	35	30	26	25	23	13	9	6	4
G-Benda, High (>=3)	64	48	36	30	27	21	19	12	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_ASAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:23

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any SAEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	36	30	25	24	22	13	9	6	4
G-Benda, High (>=3)	64	50	37	31	27	21	19	12	6	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_ASAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:23

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any SAEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS HYPERTHERMIA (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	37	30	26	25	23	13	9	6	4
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_ASAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:23

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any SAEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) INFECTIONS AND INFESTATIONS PNEUMOCYSTIS JIROVECII PNEUMONIA (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	37	30	26	25	23	13	9	6	4
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_ASAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:23

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any SAEs, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	19	13	13	13	11	5	2
G-Benda, Intermediate (2)	51	36	29	26	25	23	13	9	6	4
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	6	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_ASAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:23

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any SAEs, Complete Study Duration
STUDY: GO01297

Sex (N=330) INFECTIONS AND INFESTATIONS (N=330)




Patients at risk										
G-Benda, Male	91	66	48	36	31	28	23	14	9	3
G-Benda, Female	73	50	41	36	31	27	20	17	9	3
Benda, Male	94	11	3							
Benda, Female	72	4								

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_ASAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:23

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: Any SAEs, Complete Study Duration
STUDY: GO01297

Sex (N=330) NERVOUS SYSTEM DISORDERS (N=330)



Patients at risk										
G-Benda, Male	91	74	55	44	38	34	27	17	10	4
G-Benda, Female	73	49	40	35	30	27	20	17	8	3
Benda, Male	94	9	4							
Benda, Female	72	6	3							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_ASAE_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:23

77 (Anhang): Ergebnisse für UE Grad ≥ 3 bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)

All

			G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
			Patients		Event		Censored		Patients		Event		Censored		log-rank	Hazard Ratio					Interaction Test
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	n/a	164	100,0	77	47,0	87	53,0	166	100,0	61	36,7	105	63,3	0,8731	0,97	0,68	1,38		Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	n/a	164	100,0	10	6,1	154	93,9	166	100,0	17	10,2	149	89,8	0,0036	0,28	0,11	0,68		Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	FEBRILE NEUTROPENIA	n/a	164	100,0	10	6,1	154	93,9	166	100,0	5	3,0	161	97,0	0,7747	1,18	0,37	3,76		Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	n/a	164	100,0	56	34,1	108	65,9	166	100,0	41	24,7	125	75,3	0,7761	1,06	0,70	1,62		Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	n/a	164	100,0	18	11,0	146	89,0	166	100,0	25	15,1	141	84,9	0,2674	0,71	0,38	1,31		Convergence criterion (GCONV=1E-8) satisfied.	
CARDIAC DISORDERS	ALL	n/a	164	100,0	9	5,5	155	94,5	166	100,0	3	1,8	163	98,2	0,8339	0,85	0,19	3,88		Convergence criterion (GCONV=1E-8) satisfied.	
GASTROINTESTINAL DISORDERS	ALL	n/a	164	100,0	18	11,0	146	89,0	166	100,0	10	6,0	156	94,0	0,8141	1,10	0,49	2,51		Convergence criterion (GCONV=1E-8) satisfied.	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	n/a	164	100,0	11	6,7	153	93,3	166	100,0	6	3,6	160	96,4	0,7842	1,16	0,40	3,39		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	ALL	n/a	164	100,0	30	18,3	134	81,7	166	100,0	34	20,5	132	79,5	<.0001	0,25	0,14	0,45		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	n/a	164	100,0	4	2,4	160	97,6	166	100,0	9	5,4	157	94,6	0,0007	0,11	0,03	0,42		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	n/a	164	100,0	21	12,8	143	87,2	166	100,0	6	3,6	160	96,4	0,0098	3,17	1,26	7,99		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	n/a	164	100,0	16	9,8	148	90,2	166	100,0	6	3,6	160	96,4	0,0352	2,67	1,03	6,89		Convergence criterion (GCONV=1E-8) satisfied.	
METABOLISM AND NUTRITION DISORDERS	ALL	n/a	164	100,0	12	7,3	152	92,7	166	100,0	11	6,6	155	93,4	0,3093	0,62	0,25	1,56		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	n/a	164	100,0	13	7,9	151	92,1	166	100,0	12	7,2	154	92,8	<.0001	0,09	0,04	0,23		Convergence criterion (GCONV=1E-8) satisfied.	

78 (Anhang): Ergebnisse für UE Grad ≥ 3 bei ≥ 5 % der Patienten in einem Studienarm nach SOC/PT und mit statistisch signifikantem Ergebnis für die Gesamtpopulation nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)

All


			G-Benda (N=164)						Benda (N=166)						G-Benda vs. Benda						
			Patients		Event		Censored		Patients		Event		Censored		log-rank	Hazard Ratio					Interaction Test
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL		Convergence Status	p-value (likelihood ratio)
INFECTIONS AND INFESTATIONS	ALL	Male	91	55,5	25	27,5	66	72,5	94	56,6	16	17	78	83	0,1149	0,56	0,28	1,15		Convergence criterion (GCONV=1E-8) satisfied.	0,0002
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Male	91	55,5	11	12,1	80	87,9	94	56,6	2	2,1	92	97,9	0,0398	4,43	0,95	20,6		Convergence criterion (GCONV=1E-8) satisfied.	0,3733
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Male	91	55,5	10	11	81	89	94	56,6	8	8,5	86	91,5	<.0001	0,11	0,04	0,32		Convergence criterion (GCONV=1E-8) satisfied.	0,1082
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Male	91	55,5	5	5,5	86	94,5	94	56,6	7	7,4	87	92,6	0,0778	0,3	0,08	1,2		Convergence criterion (GCONV=1E-8) satisfied.	0,6458
INFECTIONS AND INFESTATIONS	PNEUMONIA	Male	91	55,5	2	2,2	89	97,8	94	56,6	4	4,3	90	95,7	0,0244	0,12	0,02	0,84		Convergence criterion (GCONV=1E-8) satisfied.	0,736
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Male	91	55,5	8	8,8	83	91,2	94	56,6	2	2,1	92	97,9	0,0668	3,92	0,82	18,79		Convergence criterion (GCONV=1E-8) satisfied.	0,439
INFECTIONS AND INFESTATIONS	ALL	Female	73	44,5	5	6,8	68	93,2	72	43,4	18	25	54	75	<.0001	0,04	<0.01	0,15		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Female	73	44,5	10	13,7	63	86,3	72	43,4	4	5,6	68	94,4	0,1101	2,5	0,78	8,03		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Female	73	44,5	3	4,1	70	95,9	72	43,4	4	5,6	68	94,4	0,0047	0,11	0,02	0,57		Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Female	73	44,5	5	6,8	68	93,2	72	43,4	10	13,9	62	86,1	0,0206	0,26	0,08	0,86		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	Female	73	44,5	2	2,7	71	97,3	72	43,4	5	6,9	67	93,1	0,0114	0,09	0,01	0,66		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Female	73	44,5	8	11	65	89	72	43,4	4	5,6	68	94,4	0,2467	2,01	0,6	6,73		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	ALL	< 60 years	62	37,8	9	14,5	53	85,5	62	37,3	7	11,3	55	88,7	0,0015	0,16	0,05	0,52		Convergence criterion (GCONV=1E-8) satisfied.	0,4928
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	< 60 years	62	37,8	9	14,5	53	85,5	62	37,3	2	3,2	60	96,8	0,0626	4	0,84	19,13		Convergence criterion (GCONV=1E-8) satisfied.	0,6909
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	< 60 years	62	37,8	2	3,2	60	96,8	62	37,3	2	3,2	60	96,8	0,0011	0,08	0,01	0,56		Convergence criterion (GCONV=1E-8) satisfied.	0,6744
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	< 60 years	62	37,8	3	4,8	59	95,2	62	37,3	7	11,3	55	88,7	0,0245	0,19	0,04	0,88		Convergence criterion (GCONV=1E-8) satisfied.	0,5378
INFECTIONS AND INFESTATIONS	PNEUMONIA	< 60 years	62	37,8			62	100	62	37,3			62	100	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,997
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	< 60 years	62	37,8	7	11,3	55	88,7	62	37,3	2	3,2	60	96,8	0,0848	3,7	0,76	18,08		Convergence criterion (GCONV=1E-8) satisfied.	0,6555
INFECTIONS AND INFESTATIONS	ALL	>= 60 years	102	62,2	21	20,6	81	79,4	104	62,7	27	26	77	74	0,0001	0,28	0,14	0,55		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	>= 60 years	102	62,2	12	11,8	90	88,2	104	62,7	4	3,8	100	96,2	0,0732	2,74	0,87	8,65		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	>= 60 years	102	62,2	11	10,8	91	89,2	104	62,7	10	9,6	94	90,4	<.0001	0,1	0,04	0,29		Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	>= 60 years	102	62,2	7	6,9	95	93,1	104	62,7	10	9,6	94	90,4	0,0539	0,34	0,11	1,05		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	>= 60 years	102	62,2	4	3,9	98	96,1	104	62,7	9	8,7	95	91,3	0,0012	0,12	0,03	0,47		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	>= 60 years	102	62,2	9	8,8	93	91,2	104	62,7	4	3,8	100	96,2	0,195	2,16	0,66	7,13		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	ALL	North America	67	40,9	11	16,4	56	83,6	72	43,4	12	16,7	60	83,3	0,0027	0,22	0,08	0,61		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	North America	67	40,9	7	10,4	60	89,6	72	43,4			72	100	0,0195	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	

NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	North America	67	40,9	5	7,5	62	92,5	72	43,4	5	6,9	67	93,1	<.0001	0,07	0,02	0,34		Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	North America	67	40,9	3	4,5	64	95,5	72	43,4	8	11,1	64	88,9	0,0108	0,14	0,03	0,74		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	North America	67	40,9	1	1,5	66	98,5	72	43,4	6	8,3	66	91,7	0,001	0,04	<0.01	0,38		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	North America	67	40,9	4	6	63	94	72	43,4			72	100	0,0363	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	ALL	western Europe	78	47,6	17	21,8	61	78,2	77	46,4	16	20,8	61	79,2	0,0028	0,29	0,13	0,67		Convergence criterion (GCONV=1E-8) satisfied.	0,4146
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	western Europe	78	47,6	12	15,4	66	84,6	77	46,4	6	7,8	71	92,2	0,2168	1,86	0,68	5,07		Convergence criterion (GCONV=1E-8) satisfied.	0,0554
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	western Europe	78	47,6	7	9	71	91	77	46,4	6	7,8	71	92,2	<.0001	0,09	0,02	0,33		Convergence criterion (GCONV=1E-8) satisfied.	0,9625
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	western Europe	78	47,6	6	7,7	72	92,3	77	46,4	9	11,7	68	88,3	0,0352	0,29	0,09	0,95		Convergence criterion (GCONV=1E-8) satisfied.	0,2564
INFECTIONS AND INFESTATIONS	PNEUMONIA	western Europe	78	47,6	3	3,8	75	96,2	77	46,4	2	2,6	75	97,4	0,3189	0,32	0,03	3,05		Convergence criterion (GCONV=1E-8) satisfied.	0,1749
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	western Europe	78	47,6	10	12,8	68	87,2	77	46,4	6	7,8	71	92,2	0,3736	1,59	0,57	4,49		Convergence criterion (GCONV=1E-8) satisfied.	0,0989
INFECTIONS AND INFESTATIONS	ALL	Other	19	11,6	2	10,5	17	89,5	17	10,2	6	35,3	11	64,7	0,012	0,1	0,01	0,84		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Other	19	11,6	2	10,5	17	89,5	17	10,2			17	100	0,1632	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Other	19	11,6	1	5,3	18	94,7	17	10,2	1	5,9	16	94,1	0,2014	0,2	0,01	3,16		Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Other	19	11,6	1	5,3	18	94,7	17	10,2			17	100	0,3311	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	Other	19	11,6			19	100	17	10,2	1	5,9	16	94,1	0,3329	<0.01	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Other	19	11,6	2	10,5	17	89,5	17	10,2			17	100	0,1632	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	ALL	Low (0-1)	42	25,6	3	7,1	39	92,9	35	21,1	3	8,6	32	91,4	0,0052	<0.01	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,1213
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Low (0-1)	42	25,6	4	9,5	38	90,5	35	21,1			35	100	0,0944	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,3519
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Low (0-1)	42	25,6	3	7,1	39	92,9	35	21,1	2	5,7	33	94,3	0,0001	0,06	<0.01	0,42		Convergence criterion (GCONV=1E-8) satisfied.	0,6174
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Low (0-1)	42	25,6	2	4,8	40	95,2	35	21,1	4	11,4	31	88,6	0,0329	0,07	<0.01	1,11		Convergence criterion (GCONV=1E-8) satisfied.	0,6653
INFECTIONS AND INFESTATIONS	PNEUMONIA	Low (0-1)	42	25,6			42	100	35	21,1	1	2,9	34	97,1	<.0001	<0.01	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,571
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Low (0-1)	42	25,6	2	4,8	40	95,2	35	21,1			35	100	0,1912	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	0,5206
INFECTIONS AND INFESTATIONS	ALL	Intermediate (2)	51	31,1	12	23,5	39	76,5	57	34,3	9	15,8	48	84,2	0,1896	0,52	0,19	1,4		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Intermediate (2)	51	31,1	6	11,8	45	88,2	57	34,3	3	5,3	54	94,7	0,2311	2,29	0,57	9,23		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Intermediate (2)	51	31,1	1	2	50	98	57	34,3	2	3,5	55	96,5	0,0531	0,1	<0.01	1,32		Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Intermediate (2)	51	31,1	2	3,9	49	96,1	57	34,3	6	10,5	51	89,5	0,0612	0,21	0,04	1,19		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	Intermediate (2)	51	31,1	1	2	50	98	57	34,3	2	3,5	55	96,5	0,3275	0,29	0,02	3,87		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Intermediate (2)	51	31,1	5	9,8	46	90,2	57	34,3	3	5,3	54	94,7	0,3746	1,9	0,45	8,03		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	ALL	High (>=3)	64	39	12	18,8	52	81,3	67	40,4	22	32,8	45	67,2	<.0001	0,16	0,07	0,37		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	High (>=3)	64	39	9	14,1	55	85,9	67	40,4	3	4,5	64	95,5	0,2041	2,36	0,61	9,19		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	High (>=3)	64	39	9	14,1	55	85,9	67	40,4	7	10,4	60	89,6	0,0003	0,15	0,05	0,46		Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	High (>=3)	64	39	5	7,8	59	92,2	67	40,4	6	9	61	91	0,2677	0,48	0,13	1,79		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	High (>=3)	64	39	3	4,7	61	95,3	67	40,4	6	9	61	91	0,0089	0,12	0,02	0,64		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	High (>=3)	64	39	7	10,9	57	89,1	67	40,4	3	4,5	64	95,5	0,241	2,24	0,56	8,89		Convergence criterion (GCONV=1E-8) satisfied.	

INFECTIONS AND INFESTATIONS	ALL	Missing/Unknown	7	4,3	3	42,9	4	57,1	7	4,2			7	100	0,1649	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Missing/Unknown	7	4,3	2	28,6	5	71,4	7	4,2			7	100	0,1413	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Missing/Unknown	7	4,3			7	100	7	4,2	1	14,3	6	85,7	0,1138	<0.01	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Missing/Unknown	7	4,3	1	14,3	6	85,7	7	4,2	1	14,3	6	85,7	0,3545	<0.01	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	
INFECTIONS AND INFESTATIONS	PNEUMONIA	Missing/Unknown	7	4,3			7	100	7	4,2			7	100	NE	NE	NE	NE		Convergence criterion (GCONV=1E-8) satisfied.	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Missing/Unknown	7	4,3	2	28,6	5	71,4	7	4,2			7	100	0,1413	>999.99	0	NE		Convergence criterion (GCONV=1E-8) satisfied.	

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
STUDY: GO01297

Age (N=330) METABOLISM AND NUTRITION DISORDERS HYPOPHOSPHATAEMIA (N=330)




Patients at risk										
G-Benda, < 60 years	62	46	31	30	26	25	18	13	9	5
G-Benda, >= 60 years	102	78	65	50	43	36	29	21	11	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	104	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:19

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
STUDY: GO01297

Age (N=330) NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) MYELODYSPLASTIC SYNDROME (N=330)




Patients at risk										
G-Benda, < 60 years	62	47	32	31	27	26	19	14	9	5
G-Benda, >= 60 years	102	79	66	51	44	37	29	20	11	2
Benda, < 60 years	62	5	2							
Benda, >= 60 years	104	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:19

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
STUDY: GO01297

Age (N=330) VASCULAR DISORDERS HYPERTENSION (N=330)




Patients at risk										
G-Benda, < 60 years	62	47	32	31	27	26	19	14	9	5
G-Benda, >= 60 years	102	77	63	48	41	35	29	21	11	2
Benda, < 60 years	62	3	1							
Benda, >= 60 years	104	11	5							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:19

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) BLOOD AND LYMPHATIC SYSTEM DISORDERS FEBRILE NEUTROPENIA (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	31	24	20	14	13	13	11	5	2
G-Benda, Intermediate (2)	51	35	30	25	24	22	12	8	5	3
G-Benda, High (>=3)	64	48	36	30	27	21	19	12	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:19

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) GASTROINTESTINAL DISORDERS DIARRHOEA (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	37	30	26	25	23	13	9	6	4
G-Benda, High (>=3)	65	49	37	31	27	22	20	13	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	59	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:19

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) GASTROINTESTINAL DISORDERS NAUSEA (N=316)




Patients at risk										
G-Benda, Low (0-1)	43	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	37	30	26	25	23	13	9	6	4
G-Benda, High (>=3)	65	49	37	31	27	21	19	12	6	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	61	7	3							
Benda, High (>=3)	68	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:19

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS HYPERTHERMIA (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	37	30	26	25	23	13	9	6	4
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:19

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) INFECTIONS AND INFESTATIONS PNEUMOCYSTIS JIROVECII PNEUMONIA (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	37	30	26	25	23	13	9	6	4
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:19

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	19	13	13	13	11	5	2
G-Benda, Intermediate (2)	51	34	29	26	25	23	13	9	6	4
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	35	1								
Benda, Intermediate (2)	57	8	3							
Benda, High (>=3)	67	6	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:19

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
STUDY: GO01297

FLIPI (N=316) VASCULAR DISORDERS JUGULAR VEIN THROMBOSIS (N=316)




Patients at risk										
G-Benda, Low (0-1)	42	33	24	20	14	14	14	12	6	2
G-Benda, Intermediate (2)	51	37	30	26	25	23	13	9	6	4
G-Benda, High (>=3)	64	50	38	32	28	22	20	13	7	1
Benda, Low (0-1)	35									
Benda, Intermediate (2)	57	7	3							
Benda, High (>=3)	67	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:19

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
STUDY: GO01297

Geographic region (N=330) NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) BASAL CELL CARCINOMA (N=330)




Patients at risk										
G-Benda, Western Europe	78	58	42	33	27	22	18	12	7	
G-Benda, North America	67	54	44	39	36	33	26	22	12	6
G-Benda, Other	19	13	11	9	7	6	3	1	1	1
Benda, Western Europe	77	5	2							
Benda, North America	72	8	2							
Benda, Other	17	3	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:19

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
STUDY: GO01297

Sex (N=330) INFECTIONS AND INFESTATIONS (N=330)




Patients at risk										
G-Benda, Male	91	66	46	33	28	25	21	14	9	3
G-Benda, Female	73	50	41	36	31	26	19	16	8	3
Benda, Male	94	11	3							
Benda, Female	72	5								

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:19

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
STUDY: GO01297

Sex (N=330) INFECTIONS AND INFESTATIONS SEPSIS (N=330)




Patients at risk										
G-Benda, Male	91	74	53	42	36	32	26	16	10	4
G-Benda, Female	73	51	42	37	32	28	21	18	10	3
Benda, Male	94	10	4							
Benda, Female	72	6	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:19

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs Grade >= 3, Complete Study Duration
STUDY: GO01297

Sex (N=330) VASCULAR DISORDERS HYPERTENSION (N=330)



Patients at risk										
G-Benda, Male	91	74	55	44	38	34	27	17	10	4
G-Benda, Female	73	50	40	35	30	27	21	18	10	3
Benda, Male	94	9	4							
Benda, Female	72	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AEG345_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:19

79 (Anhang): Ergebnisse für Abbruchgründe (UE) nach SOC aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs leading to treatment discontinuation, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety

		G-Benda (N=164)	Benda (N=166)
MedDRA System Organ Class	MedDRA Preferred Term	Patients with events n (%)	Patients with events n (%)2
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	12 (7,3)	16 (9,6)
INFECTIONS AND INFESTATIONS	ALL	6 (3,7)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	5 (3,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	4 (2,4)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	3 (1,8)	0 (0,0)
VASCULAR DISORDERS	ALL	2 (1,2)	0 (0,0)
CARDIAC DISORDERS	ALL	1 (0,6)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	1 (0,6)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	1 (0,6)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	1 (0,6)	0 (0,0)
INVESTIGATIONS	ALL	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	ALL	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	ALL	0 (0,0)	0 (0,0)

80 (Anhang): Ergebnisse für Abbruchgründe (UE) nach SOC/PT aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)


POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs leading to treatment discontinuation, Complete Study Duration
MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety

		G-Benda (N=164)	Benda (N=166)
MedDRA System Organ Class	MedDRA Preferred Term	Patients with events n (%)	Patients with events n (%)2
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	7 (4,3)	4 (2,4)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	6 (3,7)	14 (8,4)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	4 (2,4)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	2 (1,2)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	1 (0,6)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	1 (0,6)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	1 (0,6)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	1 (0,6)	0 (0,0)
INFECTIONS AND INFESTATIONS	CYTOMEGALOVIRUS CHORIORETINITIS	1 (0,6)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENCEPHALITIS VIRAL	1 (0,6)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	1 (0,6)	0 (0,0)
INFECTIONS AND INFESTATIONS	LUNG INFECTION PSEUDOMONAL	1 (0,6)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	1 (0,6)	0 (0,0)
INFECTIONS AND INFESTATIONS	RESPIRATORY TRACT INFECTION	1 (0,6)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND	ACUTE MYELOID LEUKAEMIA	1 (0,6)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND	COLORECTAL CANCER	1 (0,6)	0 (0,0)

NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND	INTESTINAL ADENOCARCINOMA	1 (0,6)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND	MYELODYSPLASTIC SYNDROME	1 (0,6)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND	RENAL CANCER	1 (0,6)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	1 (0,6)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	1 (0,6)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	1 (0,6)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	1 (0,6)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	0 (0,0)	1 (0,6)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	0 (0,0)	1 (0,6)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	0 (0,0)	0 (0,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	HEADACHE	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPERTENSION	0 (0,0)	0 (0,0)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs leading to treatment discontinuation, Complete Study Duration
STUDY: GO01297

Age (N=330) RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS (N=330)




Patients at risk										
G-Benda, < 60 years	62	47	32	31	27	26	19	14	9	5
G-Benda, >= 60 years	102	78	65	50	43	36	29	21	11	2
Benda, < 60 years	62	4	1							
Benda, >= 60 years	104	10	4							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AELDIS_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:24

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs leading to treatment discontinuation, Complete Study Duration
STUDY: GO01297

Sex (N=330) INFECTIONS AND INFESTATIONS (N=330)




Patients at risk										
G-Benda, Male	91	74	52	40	36	32	25	17	10	4
G-Benda, Female	73	50	40	35	30	26	19	16	9	3
Benda, Male	94	10	4							
Benda, Female	72	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AELDIS_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:24

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients
ENDPOINT: AEs leading to treatment discontinuation, Complete Study Duration
STUDY: GO01297

Sex (N=330) RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS (N=330)



Patients at risk										
G-Benda, Male	91	74	55	44	38	34	27	17	10	4
G-Benda, Female	73	51	42	37	32	28	21	18	10	3
Benda, Male	94	9	3							
Benda, Female	72	5	2							

Clinical cut-off: 30NOV2018

Program: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/program/g_km_soc_sg.sas
Output: root/clinical_studies/RO5072759/CDPT7395/GO01297/data_analysis/ACE_CSRFinal/qa/output/g_km_soc_sg_COMPL_AELDIS_FOLY_SE_30NOV2018_01297.pdf
22OCT2019 12:24

81 (Anhang): Ergebnisse für Abbruchgründe (UE) nach SOC/PT nach Subgruppen aus RCT mit dem zu bewertenden Arzneimittel (gesamte Studiendauer)

POPULATION: Safety Evaluable Patients, Follicular Lymphoma Patients ENDPOINT: AEs leading to treatment discontinuation, Complete Study Duration MODEL: Unstratified Analysis
STUDY: GO01297
Time to Event Analysis by Subgroups (Safety)

				G-Benda (N=164)	Benda (N=166)
MedDRA System Organ Class	MedDRA Preferred Term	Level		Patients with events n (%)	Patients with events n (%)2
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	Male	sex	5 (5,5)	8 (8,5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	Female	sex	7 (9,6)	8 (11,1)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Male	sex	0 (0,0)	1 (1,1)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Female	sex	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	Male	sex	0 (0,0)	1 (1,1)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	Female	sex	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	Male	sex	2 (2,2)	3 (3,2)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	Female	sex	5 (6,8)	1 (1,4)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Male	sex	3 (3,3)	7 (7,4)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Female	sex	3 (4,1)	7 (9,7)
CARDIAC DISORDERS	ALL	Male	sex	1 (1,1)	0 (0,0)
CARDIAC DISORDERS	ALL	Female	sex	0 (0,0)	0 (0,0)

CARDIAC DISORDERS	PALPITATIONS	Male	sex	1 (1,1)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	Female	sex	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	Male	sex	1 (1,1)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	Female	sex	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	Male	sex	1 (1,1)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	Female	sex	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	Male	sex	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	Female	sex	3 (4,1)	1 (1,4)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	Male	sex	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	Female	sex	1 (1,4)	1 (1,4)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	Male	sex	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	Female	sex	2 (2,7)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	Male	sex	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	Female	sex	1 (1,4)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	Male	sex	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	Female	sex	1 (1,4)	0 (0,0)
INFECTIONS AND INFESTATIONS	ALL	Male	sex	4 (4,4)	0 (0,0)
INFECTIONS AND INFESTATIONS	ALL	Female	sex	2 (2,7)	6 (8,3)
INFECTIONS AND INFESTATIONS	CYTOMEGALOVIRUS CHORIORETINITIS	Male	sex	1 (1,1)	0 (0,0)

INFECTIONS AND INFESTATIONS	CYTOMEGALOVIRUS CHORIORETINITIS	Female	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENCEPHALITIS VIRAL	Male	sex	1 (1,1)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENCEPHALITIS VIRAL	Female	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	Male	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	Female	sex	0 (0,0)	1 (1,4)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	Male	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	Female	sex	0 (0,0)	1 (1,4)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	Male	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	Female	sex	0 (0,0)	1 (1,4)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	Male	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	Female	sex	1 (1,4)	0 (0,0)
INFECTIONS AND INFESTATIONS	LUNG INFECTION PSEUDOMONAL	Male	sex	1 (1,1)	0 (0,0)
INFECTIONS AND INFESTATIONS	LUNG INFECTION PSEUDOMONAL	Female	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	Male	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	Female	sex	0 (0,0)	1 (1,4)
INFECTIONS AND INFESTATIONS	PNEUMONIA	Male	sex	0 (0,0)	0 (0,0)

INFECTIONS AND INFESTATIONS	PNEUMONIA	Female	sex	1 (1,4)	1 (1,4)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	Male	sex	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	Female	sex	0 (0,0)	1 (1,4)
INFECTIONS AND INFESTATIONS	RESPIRATORY TRACT INFECTION	Male	sex	1 (1,1)	0 (0,0)
INFECTIONS AND INFESTATIONS	RESPIRATORY TRACT INFECTION	Female	sex	0 (0,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Male	sex	2 (2,2)	2 (2,1)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Female	sex	2 (2,7)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Male	sex	2 (2,2)	2 (2,1)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Female	sex	2 (2,7)	0 (0,0)
INVESTIGATIONS	ALL	Male	sex	0 (0,0)	1 (1,1)
INVESTIGATIONS	ALL	Female	sex	0 (0,0)	0 (0,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	Male	sex	0 (0,0)	1 (1,1)
INVESTIGATIONS	BLOOD CREATININE INCREASED	Female	sex	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	ALL	Male	sex	0 (0,0)	1 (1,1)
METABOLISM AND NUTRITION DISORDERS	ALL	Female	sex	0 (0,0)	1 (1,4)

METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	Male	sex	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	Female	sex	0 (0,0)	1 (1,4)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	Male	sex	0 (0,0)	1 (1,1)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	Female	sex	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Male	sex	3 (3,3)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Female	sex	2 (2,7)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ACUTE MYELOID LEUKAEMIA	Male	sex	1 (1,1)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ACUTE MYELOID LEUKAEMIA	Female	sex	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	Male	sex	1 (1,1)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	Female	sex	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	INTESTINAL ADENOCARCINOMA	Male	sex	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	INTESTINAL ADENOCARCINOMA	Female	sex	1 (1,4)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	MYELODYSPLASTIC SYNDROME	Male	sex	1 (1,1)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	MYELODYSPLASTIC SYNDROME	Female	sex	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	Male	sex	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	Female	sex	1 (1,4)	0 (0,0)
NERVOUS SYSTEM DISORDERS	ALL	Male	sex	0 (0,0)	2 (2,1)

NERVOUS SYSTEM DISORDERS	ALL	Female	sex	0 (0,0)	1 (1,4)
NERVOUS SYSTEM DISORDERS	HEADACHE	Male	sex	0 (0,0)	1 (1,1)
NERVOUS SYSTEM DISORDERS	HEADACHE	Female	sex	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	Male	sex	0 (0,0)	1 (1,1)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	Female	sex	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	Male	sex	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	Female	sex	0 (0,0)	1 (1,4)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	Male	sex	0 (0,0)	3 (3,2)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	Female	sex	1 (1,4)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	Male	sex	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	Female	sex	1 (1,4)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	Male	sex	0 (0,0)	1 (1,1)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	Female	sex	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	Male	sex	0 (0,0)	1 (1,1)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	Female	sex	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	Male	sex	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	Female	sex	1 (1,4)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	Male	sex	0 (0,0)	1 (1,1)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	Female	sex	0 (0,0)	0 (0,0)

VASCULAR DISORDERS	ALL	Male	sex	2 (2,2)	1 (1,1)
VASCULAR DISORDERS	ALL	Female	sex	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	Male	sex	1 (1,1)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	Female	sex	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPERTENSION	Male	sex	0 (0,0)	1 (1,1)
VASCULAR DISORDERS	HYPERTENSION	Female	sex	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	Male	sex	1 (1,1)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	Female	sex	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	< 60 years	age60	4 (6,5)	6 (9,7)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	>= 60 years	age60	8 (7,8)	10 (9,6)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	< 60 years	age60	0 (0,0)	1 (1,6)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	>= 60 years	age60	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	< 60 years	age60	0 (0,0)	1 (1,6)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	>= 60 years	age60	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	< 60 years	age60	2 (3,2)	1 (1,6)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	>= 60 years	age60	5 (4,9)	3 (2,9)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	< 60 years	age60	3 (4,8)	6 (9,7)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	>= 60 years	age60	3 (2,9)	8 (7,7)
CARDIAC DISORDERS	ALL	< 60 years	age60	1 (1,6)	0 (0,0)
CARDIAC DISORDERS	ALL	>= 60 years	age60	0 (0,0)	0 (0,0)

CARDIAC DISORDERS	PALPITATIONS	< 60 years	age60	1 (1,6)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	>= 60 years	age60	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	< 60 years	age60	1 (1,6)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	>= 60 years	age60	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	< 60 years	age60	1 (1,6)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	>= 60 years	age60	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	< 60 years	age60	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	>= 60 years	age60	3 (2,9)	1 (1,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	< 60 years	age60	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	>= 60 years	age60	1 (1,0)	1 (1,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	< 60 years	age60	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	>= 60 years	age60	2 (2,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	< 60 years	age60	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	>= 60 years	age60	1 (1,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	< 60 years	age60	0 (0,0)	0 (0,0)

HEPATOBILIARY DISORDERS	CHOLESTASIS	>= 60 years	age60	1 (1,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ALL	< 60 years	age60	0 (0,0)	1 (1,6)
INFECTIONS AND INFESTATIONS	ALL	>= 60 years	age60	6 (5,9)	5 (4,8)
INFECTIONS AND INFESTATIONS	CYTOMEGALOVIRUS CHORIORETINITIS	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	CYTOMEGALOVIRUS CHORIORETINITIS	>= 60 years	age60	1 (1,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENCEPHALITIS VIRAL	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENCEPHALITIS VIRAL	>= 60 years	age60	1 (1,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	>= 60 years	age60	0 (0,0)	1 (1,0)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	< 60 years	age60	0 (0,0)	1 (1,6)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	>= 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	>= 60 years	age60	0 (0,0)	1 (1,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	>= 60 years	age60	1 (1,0)	0 (0,0)

INFECTIONS AND INFESTATIONS	LUNG INFECTION PSEUDOMONAL	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	LUNG INFECTION PSEUDOMONAL	>= 60 years	age60	1 (1,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	>= 60 years	age60	0 (0,0)	1 (1,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	>= 60 years	age60	1 (1,0)	1 (1,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	>= 60 years	age60	0 (0,0)	1 (1,0)
INFECTIONS AND INFESTATIONS	RESPIRATORY TRACT INFECTION	< 60 years	age60	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	RESPIRATORY TRACT INFECTION	>= 60 years	age60	1 (1,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	< 60 years	age60	3 (4,8)	1 (1,6)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	>= 60 years	age60	1 (1,0)	1 (1,0)

INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	< 60 years	age60	3 (4,8)	1 (1,6)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	>= 60 years	age60	1 (1,0)	1 (1,0)
INVESTIGATIONS	ALL	< 60 years	age60	0 (0,0)	0 (0,0)
INVESTIGATIONS	ALL	>= 60 years	age60	0 (0,0)	1 (1,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	< 60 years	age60	0 (0,0)	0 (0,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	>= 60 years	age60	0 (0,0)	1 (1,0)
METABOLISM AND NUTRITION DISORDERS	ALL	< 60 years	age60	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	ALL	>= 60 years	age60	0 (0,0)	2 (1,9)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	< 60 years	age60	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	>= 60 years	age60	0 (0,0)	1 (1,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	< 60 years	age60	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	>= 60 years	age60	0 (0,0)	1 (1,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	< 60 years	age60	1 (1,6)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	>= 60 years	age60	4 (3,9)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ACUTE MYELOID LEUKAEMIA	< 60 years	age60	1 (1,6)	0 (0,0)

NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ACUTE MYELOID LEUKAEMIA	>= 60 years	age60	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	< 60 years	age60	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	>= 60 years	age60	1 (1,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	INTESTINAL ADENOCARCINOMA	< 60 years	age60	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	INTESTINAL ADENOCARCINOMA	>= 60 years	age60	1 (1,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	MYELODYSPLASTIC SYNDROME	< 60 years	age60	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	MYELODYSPLASTIC SYNDROME	>= 60 years	age60	1 (1,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	< 60 years	age60	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	>= 60 years	age60	1 (1,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	ALL	< 60 years	age60	0 (0,0)	1 (1,6)
NERVOUS SYSTEM DISORDERS	ALL	>= 60 years	age60	0 (0,0)	2 (1,9)
NERVOUS SYSTEM DISORDERS	HEADACHE	< 60 years	age60	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	HEADACHE	>= 60 years	age60	0 (0,0)	1 (1,0)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	< 60 years	age60	0 (0,0)	1 (1,6)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	>= 60 years	age60	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	< 60 years	age60	0 (0,0)	0 (0,0)

NERVOUS SYSTEM DISORDERS	SYNCOPE	>= 60 years	age60	0 (0,0)	1 (1,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	< 60 years	age60	1 (1,6)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	>= 60 years	age60	0 (0,0)	3 (2,9)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	< 60 years	age60	1 (1,6)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	>= 60 years	age60	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	< 60 years	age60	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	>= 60 years	age60	0 (0,0)	1 (1,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	< 60 years	age60	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	>= 60 years	age60	0 (0,0)	1 (1,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	< 60 years	age60	1 (1,6)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	>= 60 years	age60	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	< 60 years	age60	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	>= 60 years	age60	0 (0,0)	1 (1,0)
VASCULAR DISORDERS	ALL	< 60 years	age60	1 (1,6)	1 (1,6)
VASCULAR DISORDERS	ALL	>= 60 years	age60	1 (1,0)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	< 60 years	age60	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	>= 60 years	age60	1 (1,0)	0 (0,0)

VASCULAR DISORDERS	HYPERTENSION	< 60 years	age60	0 (0,0)	1 (1,6)
VASCULAR DISORDERS	HYPERTENSION	>= 60 years	age60	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	< 60 years	age60	1 (1,6)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	>= 60 years	age60	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	Western Europe	region	6 (7,7)	6 (7,8)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	North America	region	4 (6,0)	8 (11,1)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	Other	region	2 (10,5)	2 (11,8)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Western Europe	region	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	North America	region	0 (0,0)	1 (1,4)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Other	region	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	Western Europe	region	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	North America	region	0 (0,0)	1 (1,4)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	Other	region	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	Western Europe	region	3 (3,8)	1 (1,3)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	North America	region	3 (4,5)	3 (4,2)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	Other	region	1 (5,3)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Western Europe	region	3 (3,8)	5 (6,5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	North America	region	1 (1,5)	7 (9,7)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Other	region	2 (10,5)	2 (11,8)

CARDIAC DISORDERS	ALL	Western Europe	region	1 (1,3)	0 (0,0)
CARDIAC DISORDERS	ALL	North America	region	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ALL	Other	region	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	Western Europe	region	1 (1,3)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	North America	region	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	Other	region	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	Western Europe	region	1 (1,3)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	North America	region	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	Other	region	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	Western Europe	region	1 (1,3)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	North America	region	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	Other	region	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	Western Europe	region	2 (2,6)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	North America	region	1 (1,5)	1 (1,4)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	Other	region	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	Western Europe	region	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	North America	region	1 (1,5)	1 (1,4)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	Other	region	0 (0,0)	0 (0,0)

GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	Western Europe	region	2 (2,6)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	North America	region	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	Other	region	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	Western Europe	region	1 (1,3)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	North America	region	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	Other	region	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	Western Europe	region	1 (1,3)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	North America	region	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ALL	Western Europe	region	3 (3,8)	5 (6,5)
INFECTIONS AND INFESTATIONS	ALL	North America	region	3 (4,5)	1 (1,4)
INFECTIONS AND INFESTATIONS	ALL	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	CYTOMEGALOVIRUS CHORIORETINITIS	Western Europe	region	0 (0,0)	0 (0,0)

INFECTIONS AND INFESTATIONS	CYTOMEGALOVIRUS CHORIORETINITIS	North America	region	1 (1,5)	0 (0,0)
INFECTIONS AND INFESTATIONS	CYTOMEGALOVIRUS CHORIORETINITIS	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENCEPHALITIS VIRAL	Western Europe	region	1 (1,3)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENCEPHALITIS VIRAL	North America	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENCEPHALITIS VIRAL	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	Western Europe	region	0 (0,0)	1 (1,3)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	North America	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	Western Europe	region	0 (0,0)	1 (1,3)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	North America	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	Western Europe	region	0 (0,0)	1 (1,3)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	North America	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	Western Europe	region	0 (0,0)	0 (0,0)

INFECTIONS AND INFESTATIONS	HERPES ZOSTER	North America	region	1 (1,5)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	LUNG INFECTION PSEUDOMONAL	Western Europe	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	LUNG INFECTION PSEUDOMONAL	North America	region	1 (1,5)	0 (0,0)
INFECTIONS AND INFESTATIONS	LUNG INFECTION PSEUDOMONAL	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	Western Europe	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	North America	region	0 (0,0)	1 (1,4)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	Western Europe	region	1 (1,3)	1 (1,3)
INFECTIONS AND INFESTATIONS	PNEUMONIA	North America	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	Western Europe	region	0 (0,0)	1 (1,3)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	North America	region	0 (0,0)	0 (0,0)

INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	Other	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	RESPIRATORY TRACT INFECTION	Western Europe	region	1 (1,3)	0 (0,0)
INFECTIONS AND INFESTATIONS	RESPIRATORY TRACT INFECTION	North America	region	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	RESPIRATORY TRACT INFECTION	Other	region	0 (0,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Western Europe	region	2 (2,6)	2 (2,6)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	North America	region	2 (3,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Other	region	0 (0,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Western Europe	region	2 (2,6)	2 (2,6)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	North America	region	2 (3,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Other	region	0 (0,0)	0 (0,0)
INVESTIGATIONS	ALL	Western Europe	region	0 (0,0)	0 (0,0)
INVESTIGATIONS	ALL	North America	region	0 (0,0)	1 (1,4)
INVESTIGATIONS	ALL	Other	region	0 (0,0)	0 (0,0)

INVESTIGATIONS	BLOOD CREATININE INCREASED	Western Europe	region	0 (0,0)	0 (0,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	North America	region	0 (0,0)	1 (1,4)
INVESTIGATIONS	BLOOD CREATININE INCREASED	Other	region	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	ALL	Western Europe	region	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	ALL	North America	region	0 (0,0)	2 (2,8)
METABOLISM AND NUTRITION DISORDERS	ALL	Other	region	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	Western Europe	region	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	North America	region	0 (0,0)	1 (1,4)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	Other	region	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	Western Europe	region	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	North America	region	0 (0,0)	1 (1,4)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	Other	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Western Europe	region	3 (3,8)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	North America	region	2 (3,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Other	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ACUTE MYELOID LEUKAEMIA	Western Europe	region	0 (0,0)	0 (0,0)

NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ACUTE MYELOID LEUKAEMIA	North America	region	1 (1,5)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ACUTE MYELOID LEUKAEMIA	Other	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	Western Europe	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	North America	region	1 (1,5)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	Other	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	INTESTINAL ADENOCARCINOMA	Western Europe	region	1 (1,3)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	INTESTINAL ADENOCARCINOMA	North America	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	INTESTINAL ADENOCARCINOMA	Other	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	MYELODYSPLASTIC SYNDROME	Western Europe	region	1 (1,3)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	MYELODYSPLASTIC SYNDROME	North America	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	MYELODYSPLASTIC SYNDROME	Other	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	Western Europe	region	1 (1,3)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	North America	region	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	Other	region	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	ALL	Western Europe	region	0 (0,0)	1 (1,3)

NERVOUS SYSTEM DISORDERS	ALL	North America	region	0 (0,0)	2 (2,8)
NERVOUS SYSTEM DISORDERS	ALL	Other	region	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	HEADACHE	Western Europe	region	0 (0,0)	1 (1,3)
NERVOUS SYSTEM DISORDERS	HEADACHE	North America	region	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	HEADACHE	Other	region	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	Western Europe	region	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	North America	region	0 (0,0)	1 (1,4)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	Other	region	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	Western Europe	region	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	North America	region	0 (0,0)	1 (1,4)
NERVOUS SYSTEM DISORDERS	SYNCOPE	Other	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	Western Europe	region	1 (1,3)	1 (1,3)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	North America	region	0 (0,0)	1 (1,4)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	Other	region	0 (0,0)	1 (5,9)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	Western Europe	region	1 (1,3)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	North America	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	Other	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	Western Europe	region	0 (0,0)	0 (0,0)

RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	North America	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	Other	region	0 (0,0)	1 (5,9)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	Western Europe	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	North America	region	0 (0,0)	1 (1,4)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	Other	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	Western Europe	region	1 (1,3)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	North America	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	Other	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	Western Europe	region	0 (0,0)	1 (1,3)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	North America	region	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	Other	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	ALL	Western Europe	region	1 (1,3)	1 (1,3)
VASCULAR DISORDERS	ALL	North America	region	1 (1,5)	0 (0,0)
VASCULAR DISORDERS	ALL	Other	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	Western Europe	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	North America	region	1 (1,5)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	Other	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPERTENSION	Western Europe	region	0 (0,0)	1 (1,3)

VASCULAR DISORDERS	HYPERTENSION	North America	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPERTENSION	Other	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	Western Europe	region	1 (1,3)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	North America	region	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	Other	region	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	Low (0-1)	flip1Gext	2 (4,8)	2 (5,7)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	Intermediate (2)	flip1Gext	5 (9,8)	9 (15,8)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	High (>=3)	flip1Gext	5 (7,8)	5 (7,5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ALL	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,8)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	ANAEMIA	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,8)

BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	LEUKOPENIA	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	Low (0-1)	flip1Gext	2 (4,8)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	Intermediate (2)	flip1Gext	2 (3,9)	3 (5,3)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	High (>=3)	flip1Gext	3 (4,7)	1 (1,5)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	NEUTROPENIA	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Low (0-1)	flip1Gext	0 (0,0)	2 (5,7)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Intermediate (2)	flip1Gext	4 (7,8)	8 (14,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	High (>=3)	flip1Gext	2 (3,1)	4 (6,0)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	THROMBOCYTOPENIA	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	ALL	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)

CARDIAC DISORDERS	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
CARDIAC DISORDERS	PALPITATIONS	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
GASTROINTESTINAL DISORDERS	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
GASTROINTESTINAL DISORDERS	DIARRHOEA	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)

GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	High (>=3)	flip1Gext	2 (3,1)	1 (1,5)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ALL	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	High (>=3)	flip1Gext	1 (1,6)	1 (1,5)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	FATIGUE	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)

GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	GENERAL PHYSICAL HEALTH DETERIORATION	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
HEPATOBILIARY DISORDERS	CHOLESTASIS	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ALL	Low (0-1)	flip1Gext	1 (2,4)	1 (2,9)
INFECTIONS AND INFESTATIONS	ALL	Intermediate (2)	flip1Gext	2 (3,9)	2 (3,5)
INFECTIONS AND INFESTATIONS	ALL	High (>=3)	flip1Gext	3 (4,7)	3 (4,5)
INFECTIONS AND INFESTATIONS	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)

INFECTIONS AND INFESTATIONS	CYTOMEGALOVIRUS CHORIORETINITIS	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	CYTOMEGALOVIRUS CHORIORETINITIS	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	CYTOMEGALOVIRUS CHORIORETINITIS	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
INFECTIONS AND INFESTATIONS	CYTOMEGALOVIRUS CHORIORETINITIS	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENCEPHALITIS VIRAL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENCEPHALITIS VIRAL	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENCEPHALITIS VIRAL	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENCEPHALITIS VIRAL	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ENDOCARDITIS	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)

INFECTIONS AND INFESTATIONS	ENDOCARDITIS	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
INFECTIONS AND INFESTATIONS	ERYTHEMA INFECTIOSUM	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
INFECTIONS AND INFESTATIONS	HEPATITIS B REACTIVATION	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	HERPES ZOSTER	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)

INFECTIONS AND INFESTATIONS	LUNG INFECTION PSEUDOMONAL	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)
INFECTIONS AND INFESTATIONS	LUNG INFECTION PSEUDOMONAL	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	LUNG INFECTION PSEUDOMONAL	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	LUNG INFECTION PSEUDOMONAL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	Low (0-1)	flip1Gext	0 (0,0)	1 (2,9)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMOCYSTIS JIROVECII PNEUMONIA	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,8)
INFECTIONS AND INFESTATIONS	PNEUMONIA	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)

INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,8)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	PNEUMONIA CYTOMEGALOVIRAL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	RESPIRATORY TRACT INFECTION	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	RESPIRATORY TRACT INFECTION	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
INFECTIONS AND INFESTATIONS	RESPIRATORY TRACT INFECTION	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
INFECTIONS AND INFESTATIONS	RESPIRATORY TRACT INFECTION	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	High (>=3)	flip1Gext	1 (1,6)	2 (3,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ALL	Missing /Unknown	flip1Gext	1 (14,3)	0 (0,0)

INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	High (>=3)	flip1Gext	1 (1,6)	2 (3,0)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	INFUSION RELATED REACTION	Missing /Unknown	flip1Gext	1 (14,3)	0 (0,0)
INVESTIGATIONS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INVESTIGATIONS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,8)
INVESTIGATIONS	ALL	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
INVESTIGATIONS	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,8)
INVESTIGATIONS	BLOOD CREATININE INCREASED	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
INVESTIGATIONS	BLOOD CREATININE INCREASED	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)

METABOLISM AND NUTRITION DISORDERS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,8)
METABOLISM AND NUTRITION DISORDERS	ALL	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
METABOLISM AND NUTRITION DISORDERS	ALL	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,8)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
METABOLISM AND NUTRITION DISORDERS	TUMOUR LYSIS SYNDROME	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)

NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	High (>=3)	flip1Gext	4 (6,3)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ACUTE MYELOID LEUKAEMIA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ACUTE MYELOID LEUKAEMIA	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ACUTE MYELOID LEUKAEMIA	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ACUTE MYELOID LEUKAEMIA	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	COLORECTAL CANCER	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	INTESTINAL ADENOCARCINOMA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	INTESTINAL ADENOCARCINOMA	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)

NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	INTESTINAL ADENOCARCINOMA	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	INTESTINAL ADENOCARCINOMA	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	MYELODYSPLASTIC SYNDROME	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	MYELODYSPLASTIC SYNDROME	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	MYELODYSPLASTIC SYNDROME	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	MYELODYSPLASTIC SYNDROME	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	RENAL CANCER	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,8)
NERVOUS SYSTEM DISORDERS	ALL	High (>=3)	flip1Gext	0 (0,0)	2 (3,0)

NERVOUS SYSTEM DISORDERS	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	HEADACHE	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	HEADACHE	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	HEADACHE	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
NERVOUS SYSTEM DISORDERS	HEADACHE	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,8)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SUBARACHNOID HAEMORRHAGE	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
NERVOUS SYSTEM DISORDERS	SYNCOPE	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
NERVOUS SYSTEM DISORDERS	SYNCOPE	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)

RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	Intermediate (2)	flip1Gext	1 (2,0)	1 (1,8)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	High (>=3)	flip1Gext	0 (0,0)	2 (3,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ALL	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	BRONCHOSPASM	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	Intermediate (2)	flip1Gext	0 (0,0)	1 (1,8)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	COUGH	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)

RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	DYSPNOEA	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	Intermediate (2)	flip1Gext	1 (2,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	HYPOXIA	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	OROPHARYNGEAL PAIN	Missing/Unknown	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	ALL	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)
VASCULAR DISORDERS	ALL	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)

VASCULAR DISORDERS	ALL	High (>=3)	flip1Gext	1 (1,6)	1 (1,5)
VASCULAR DISORDERS	ALL	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	Low (0-1)	flip1Gext	1 (2,4)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	High (>=3)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	FLUSHING	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPERTENSION	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPERTENSION	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPERTENSION	High (>=3)	flip1Gext	0 (0,0)	1 (1,5)
VASCULAR DISORDERS	HYPERTENSION	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	Low (0-1)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	Intermediate (2)	flip1Gext	0 (0,0)	0 (0,0)
VASCULAR DISORDERS	HYPOTENSION	High (>=3)	flip1Gext	1 (1,6)	0 (0,0)

VASCULAR DISORDERS	HYPOTENSION	Missing /Unknown	flip1Gext	0 (0,0)	0 (0,0)